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Abstract 
Background: Chronic spontaneous urticaria (CSU) is characterised by weals, 
angioedema, or both, which occur for six weeks or more. Itchy, red and raised weals in 
CSU are thought to occur as a result of skin mast cell activation, local vasodilatation and 
increased vascular permeability which are the cardinal features of the disease. Serum 
histamine-releasing activity and abnormal basophil function were implicated in the 
pathophysiology of CSU. We hypothesized that severe and/or persistent CSU may be 
associated with serum histamine-releasing activity (HRA), abnormal basophil 
releasability, numbers and phenotype. Furthermore, serum HRA in CSU was 
hypothesized to be associated with higher local concentrations of pro-inflammatory 
mediators (histamine, tryptase) and IL-6 in the skin, local histamine release and, possibly, 
neutrophil infiltration in the dermis. To test this hypothesis, we carried out cutaneous 
microdialysis of autologous serum skin test (ASST) response, a prospective study of 
basophil-related biomarkers in CSU and a retrospective histological study in CSU and 
urticarial vasculitis (UV).  
In cutaneous microdialysis study, 14 CSU patients and 13 healthy subjects were 
evaluated to determine the baseline levels of histamine, tryptase and cytokines and their 
changes in response to skin testing with PBS (pH = 7.4, 20µl), autologous serum (20µl) 
and codeine (0.3mM, 20µl). We demonstrated a slow low-grade local histamine release 
after intradermal injection of autologous serum in two HRA+ CSU patients. There was 
elevated dermal histamine (p=0.0193) but normal tryptase (p=0.1437) and IL-6 
(p=0.1298) concentrations in CSU compared to healthy controls. Dermal histamine 
concentrations were correlated to clinical scores in CSU (r=0.602, p<0.05).   
The prospective observational study was carried out in 22 CSU patients at three time 
points over 6 months to elucidate the relationship between the biomarkers to disease 
severity and disease persistence. Laboratory assessments included serum-induced 
basophil HRA on healthy donor basophils, anti-IgE-induced basophil histamine release 
(BHR) from CSU patients, basophil flow cytometry. Baseline UAS7 correlated with 
serum HRA (r=0.58, p=0.0045), and anti-IgE-induced BHR (r=0.40, p=0.0666). HRA+ 
CSU patients (n=8) had a more severe disease than HRA- CSU patients (n=14) 
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(p=0.0152). Based on the ROC analysis for UAS7 at baseline, a cut-off value of 19 
predicted persistence of CSU in our patient population with 63.16% accuracy (sensitivity 
of 60% and specificity of 66.67%). These results should, however, be interpreted with 
caution in view of a small sample size and the selected patient population from the 
secondary care dermatological setting. There was a persistent (n=3) versus transient 
(n=3) increase in serum HRA in CSU patients over time. Flow cytometric enumeration in 
CSU varied depending on choice of gating strategy for peripheral blood basophils 
(CCR3+CD123+ vs CCR3+CD63+ (p=0.0001), CD63+CD203c+ vs CCR3+CD123+ 
(p=0.0003), CD63+CD203c+ vs CCR3+CD63+ (p=0.0001)). We then examined basophil 
variation using ImageStream® in healthy subjects. ImageStream® studies confirmed the 
difference in basophil percentages detected by CD63+CD203c+ and CCR3+CD63+ 
gating strategies (0.02% vs 0.4% of basophils) in peripheral blood from a healthy donor 
following Ficoll-Paque density gradient centrifugation. In the CD203c+ OR CD63+ 
Boolean gate, we identified a basophil subpopulation with surface alterations that 
comprised 17.7% cells in this gate in peripheral blood sample from a healthy donor. All 
basophils with surface alterations were CD63+cells, 93.75% of which were CCR3+cells 
and 0.78% of which were CD203c+cells in this healthy donor. 
In the retrospective study, we compared clinical and histological findings in CSU 
(n=33) and UV (n=43) patients for the presence of skin autoreactivity or serum HRA and 
eosinophils/neutrophil numbers per high power field (HPF). There were higher numbers 
of neutrophils/HPF in UV than CSU patients by haematoxylin and eosin (H&E) staining 
(p=0.0002) and immunohistochemical detection of myeloperoxidase (p=0.0001). 
Neutrophilic urticaria (more than 25 extravasated neutrophils per five HPF) was noted in 
63.6% of CSU patients including two CSU patients with serum HRA.  
Conclusions: In CSU, disease severity is associated with higher dermal histamine 
concentrations, serum HRA and abnormal basophil releasability. In ASST+ patients, an 
intradermal injection of autologous serum resulted in local in vivo histamine release 
suggesting that the ASST response is a useful experimental model of spontaneous 
wealing in CSU. Whether in vivo local histamine release explains the ASST response in 
CSU patients needs to be established in future studies. Baseline UAS7 is associated with 
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serum HRA and anti-IgE-induced BHR and may predict disease persistence in CSU 
patients. Basophil phenotypic variation was demonstrated by different gating strategies 
which may reflect in vivo basophil activation in CSU. Biological and technical factors 
may contribute to basophil variation in imaging flow cytometry. In the lesional skin 
biopsies, neutrophil counts/HPF, using H&E staining or immunohistochemistry, can be 
useful for the diagnosis of neutrophilic urticaria and to differentiate between CSU and 
UV.  
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Basophil releasability – “the theory wheby biochemical events in basophils influence 
the capacity to release chemical mediators in response to activating stimuli” (Marone et 
al, 1986: p.19).  
Sequential gating – an analysis method of flow cytometric data using sequential 
visualisation of a cell population of interest using dot plots and histograms (Lugli et al., 
2010: p.2).  
Boolean gating – “a specific approach to data processing” in flow cytometry used to 
define a cell population of interest by a combination of gates using Boolean logic (Lugli 
et al, 2010: p.7).  
Frequency distribution is “a collection of observations produced by sorting 
observations into classes and showing their frequency of occurrence in each class” (Witte 
& Witte, 2010). 
Normal or Gaussian Distribution – is a “probability density function of the continuous 
variable which is characterised by a continuous bell-shaped symmetrical frequency 
distribution centered at the mean” (Gardiner, 1997). “The intervals of one, two and three 
standard deviations around the mean contain the probabilities 0.683, 0.954 and 0.997, 
respectively” (Johnson & Tsui, 1998).  
Area-under-the-curve – is an area under the plot of the concentration of solute versus 
time. 
Mean is a measure of central tendency and represents the sum of the observations 
divided by the number of observations (Weiss, 1999) 
Receiver operating characteristic (ROC) curve – is a plot of sensitivity on the y-axis 
against (1-specificity) on the x-axis for varying values of the threshold t (Zou et al., 
2007). 
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Receiver operating characteristic (ROC) analysis is a statistical tool for assessing 
accuracy quantitatively or compare accuracy between tests or predictive models. ROC 
analysis is used to select the optimal threshold under a variety of clinical circumstances, 
balancing the internal tradeoffs that exist between sensitivity and specificity (Zou et al., 
2007). 
ANOVA – “a statistical analysis tool that separates the total variability within the data set 
into random and systematic factors” (such as patient group or disease severity) (Johnson 
& Tsui, 1998). 
Chemotaxis – “a response of motile cells or organisms in which the direction of 
movement is affected by the gradient of a diffusible substance”. (Lackie, 2007: p. 88) 
Brightfield microscopy – a microscopy technique, in which “both the diffracted rays 
(rays that interact with the specimen) and nondiffracted rays (rays that pass undeviated 
through the specimen) are collected by the objective lens and contribute to image 
formation”. (Murphy, 2001: p.112) 
Darkfield microscopy – a microscopy technique, in which only diffracted rays from the 
specimen “are collected by the objective lens and contribute to image formation”. 
(Murphy, 2001: p.112) 
p-value – “the probability that test statistic takes a value equal to or more extreme than 
the value observed by chance, if the null hypothesis H0 is true” (Johnson & Tsui, 1998).  
The power of a statistical test is the probability of rejecting a false null hypothesis 
(Weiss, 1991).  
Type I error – an error that can results from an incorrect rejection of a true null 
hypothesis (Gardiner, 1997) 
Type II error – an error that results from an acceptance of a false null hypothesis 
(Gardiner, 1997).  
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Null hypothesis (H0) – a statistical hypothesis that expresses that no difference or no 
change in the system/to the characteristic of the underlying population from previous 
knowledge is the answer to the research question.  
Alternative (or research) hypothesis (Ha) – a statistical hypothesis that describes the 
response that there is a difference or a change in the system from previous knowledge.  
Median – is a measure of central tendency and represents the middle value in a set of 
measurements expressed in order of magnitude, from smallest to largest (Gardiner, 1997).  
Kd – dissociation constant which is a measure of affinity and estimates ligand 
concentration at which the binding of a ligand to its receptor is half-maximal (Kleinsmith 
&  Kish, 1995) 
In vivo – “Latin: describing biological phenomena that occur or are observed occurring 
within the bodies of living organisms” (Martin, 2010: p.387).  
In vitro – “Latin: describing biological phenomena that are made to occur outside the 
living body (traditionally in a test tube)” (Martin, 2010: p.387).  
Side scatter (SSC) – “90º light scatter by the cell or the particle as they pass through the 
laser beam. SSC is proportional to the granularity of the cell” (Macey, 2001: p.1).  
Forward scatter (FSC) – “light scattered by a cell or a particle in the forward direction 
at low angles (0.5-10º) as they pass through the laser beam” (Macey, 2001: p.1).  
Immunophenotyping - “the classification of normal or abnormal white blood cells 
according to their multiparameter surface antigen characteristics” (Givan, 2001). 
Basophilic cellular sensitivity –a measure of IgE-/FceRI-mediated basophil responses 
which is characterised by “the (allegen) concentration inducing a distinct response” 
(Kleine-Tebbe et al, 2006: p. 82) 
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Basophilic cellular reactivity –a measure of IgE-/FceRI-mediated basophil responses 
which is characterised by “maximum of the basophil response” (Kleine-Tebbe et al, 
2006: p.82).  
Priming – “treatment that does not in itself elicit a response from a system but that 
induces a greater capacity to respond to a second stimulus” (Lackie, 2007: p. 341). 
Degranulation – “release of secretory granule contents by fusion with the plasma 
membrane” (Lackie, 2007: p.117). 
Receiver operating characteristic (ROC) curve – “a graph plotting the sensitivity 
against 1-specificity for a diagnostic test at different cut-off points” (Peacock & Peacock, 
2011: p.504). 
Sensitivity – “the proportion of those who have the disease who are correctly identified 
by the diagnostic test as positive” (Peacock & Peacock, 2011; p.504).  
Specificity – “the proportion of those who do not have the disease who are correctly 
identified by the diagnostic test as negative” (Peacock & Peacock, 2011: p.504).  
NETosis – “a form of cell death that differs from classical apoptosis and necrosis and 
that occurs during the formation of neutrophil extracellular traps” (Mantovani, 2011: 
p.522).  
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CHAPTER 1 
General Introduction 
“If I have seen a little further it is by standing on the shoulders of 
Giants.” 
— ISAAC NEWTON, 1676 
1.1 Chronic spontaneous urticaria – definition and general 
features 
In the latest EAACI/GA2LEN/EDF/WAO guideline, urticaria is defined as a frequent, 
mast cell-driven disease, presenting with weals, angioedema or both (Zuberbier et al, 
2014a) (Figure 1). The term ‘urticaria’ derives from Latin word for stinging nettle. In the 
GA2LEN Task Force report, CSU is a disease with unmet clinical needs (Maurer, 2013a). 
According to the EAACI/GA2LEN/EDF/WAO guideline (the 2013 update), urticaria is 
classified as acute or chronic (Zuberbier et al, 2014a). Acute spontaneous urticaria is 
defined as the occurrence of spontaneous weals, angioedema, or both for less than 6 
weeks. Chronic spontaneous urticaria (CSU) is defined as the occurrence of spontaneous 
weals, angioedema or both for 6 weeks or more due to known and unknown causes 
(Zuberbier et al, 2014a). Chronic urticaria subtypes, as presented in the Table 1, included 
chronic spontaneous urticaria and inducible urticaria. In this classification, inducible 
urticaria includes symptomatic dermographism, cold urticaria, delayed pressure urticaria, 
solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact 
urticaria, aquagenic urticaria.  
Chapter 1 General Introduction 
40 
1.2 A Historical Perspective on Research into Chronic 
Spontaneous Urticaria 
There have been four periods in the evolution of understanding of CSU: first clinical 
description, then insights into disease mechanisms through research in physiology, 
immunology and molecular biology. Each period embraced novel scientific methods, 
clinical innovation and knowledge of previous experience. 
Initially, CSU emerged as an entity following careful clinical observations. The ancient 
Chinese Manuscript “Yellow Emperors Classic of Internal Medicine” and Hippocrates’ 
‘About Diseases’ (460-377 BC) first described urticaria (Maurer, 2014). Heberden 
described the fleeting nature of wealing and a predilection of certain body areas to 
angioedema (1772) (Humphreys, 1997). The term ‘urticaria’ derived from Urtica dioica 
(stinging nettle in Latin) (Maurer, 2014) and was coined by Cullen (1771) who with 
Bateman, distinguished between acute and chronic urticarias (Humphreys, 1997). 
The second period encompassed scientific discoveries of urticaria pathophysiology. 
Histamine’s properties were studied by Dale and Laidlaw and the triple skin reaction to 
histamine was described by Sir Thomas Lewis in 1926 (Czarnetzki, 1989). The role of 
histamine was demonstrated in CSU (Kaplan, 1978). In 1946, Malmros, for the first time, 
described the ability of some patients with heterogeneous conditions, including CSU to 
induce a weal-and-flare reaction upon intradermal injection of patient’s own serum 
(Malmros, 1946). Antihistamines were used to treat urticaria by Curtis in 1947 and 
corticosteroids were used in CSU in 1951 (Shelley, 1983). 
The next period introduced research into the autologous serum skin test (ASST) and work 
on anti-FcεRIα and anti-IgE autoantibodies in CSU (Hide et al, 1993; Grattan et al, 
1986). This period heralded immunomodulatory treatments, including ciclosporin, 
intravenous immunoglobulins and plasmapheresis in CSU (Figure 2). 
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Figure 1. Typical Urticarial Lesions
Figure 1. Extensive wealing on shoulder of a patient with acute spontaneous urticaria. Skin lesions are represented by
confluent weals with surrounding flare. 
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The fourth period encompasses the knowledge of basophil intracellular signalling defects 
delineated using molecular biology (Vonakis & Saini, 2008a) and the introduction of a 
biological agent (omalizumab) in the management of CSU (Spector & Tan, 2007). Each 
period has posed many unresolved questions to be reassessed by new generations of 
clinicians and researchers using careful clinical observation and novel research 
techniques. 
1.3 Clinical Presentations of Chronic Spontaneous Urticaria 
CSU is characterized by daily or almost daily itchy weals on the skin with or without 
angioedema for 6 weeks or more (Zuberbier et al, 2014a). The weals represent swellings 
of the superficial dermis. They are usually itchy with pale centres, surrounded by a red 
flare and resolve over hours without a mark. Swellings of the deep dermis, subcutaneous 
or submucosal tissues are called angioedema. Swellings are often painful rather than 
itchy and may persist up to 72 hours. Weals and angioedema often coexist but may occur 
alone. 
In patients with CSU, continuous wealing and itching may lead to sleep deprivation and 
psychiatric comorbidities (depression), which occurs in up to 45% of patients (Weller et 
al, 2013a) and results in severe impairment in the quality of life to a degree comparable 
to that of patients with severe ischaemic heart disease waiting conorary artery bypass 
surgery (Poon et al, 1999). 
The term urticaria is often used to describe an eruption of weals but the consensus 
definition now also uses it to describe a disease characterized by superficial and deep 
swellings. In line with this concept, urticaria is known to have diverse clinical 
presentations. Recognizing the clinical patterns has important implications for clinical 
evaluation and management without necessarily defining the aetiology. 
These patterns can usually be recognized by history taking, clinical presentation and 
clinical investigations including physical challenge tests (for physical urticarias) and skin 
biopsy (if urticarial vasculitis is suspected). 
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The appearance, distribution and duration of weals, and any associated symptoms, are 
often informative. The duration of individual weals is of particular value: they usually 
last up to 24 hours in CSU, up to one hour in physical urticaria, two hours in contact 
urticaria and for longer than 24 hours in urticarial vasculitis. Patients are often unaware 
of the duration of their weals and it can be helpful to ask them to mark a particular weal 
and observe it until complete fading. 
Weals may occur anywhere on the body but, in some cases, weal distribution may have a 
diagnostic value, especially in patients with contact or physical urticarias. For example, 
weals in cold-exposed areas are more likely to be observed in patients with cold urticaria. 
Contact urticaria starts at the site of contact with the culprit substance but can then 
progress to generalised urticaria in severe cases. 
Weals may vary in colour from pale to red. They may be round, oval or irregular in 
shape, and measure from a few millimetres to many centimetres across. Although weal 
morphology is usually non-specific, the linear weals of dermographic urticaria and the 
pinpoint weals with a surrounding flare in cholinergic and aquagenic urticarias may be 
helpful in diagnosis. In general, the weals of patients with urticarial vasculitis may bruise 
and leave residual pigmentation but they may look clinically indistinguishable from 
spontaneous urticaria. 
Different clinical patterns of urticaria can coexist in the same patient, for example, CSU 
and delayed pressure urticaria (Barlow et al, 1993). 
1.4 Treatments of Chronic Spontaneous Urticaria 
Management of CSU may be difficult. Correct recognition of the different clinical 
patterns helps clinical assessment and treatment. The management of urticaria involves 
recognition of relevant disease associations, treatment of any identifiable external causes 
including infection, avoidance of drug, food and physical triggers and the appropriate use 
of pharmacological therapies. The choice of treatment is influenced by many factors 
including drug licensing, safety, pattern of disease, its severity, pharmaco- economic 
considerations and patient preference. 
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Management of CSU includes nonpharmacological measures and drug therapy with a 
stepwise approach (Zuberbier et al, 2014a). Nonpharmacological measures include 
avoidance of physical triggers, infections and minimizing exposure to nonspecific 
aggravating factors identified by a thorough history that may include overheating, stress, 
alcohol, dietary pseudo-allergens and some drugs, particularly NSAIDs (grade of 
evidence D). Cooling lotions and 1% menthol in aqueous cream can help relieve itching. 
A diet low in pseudo-allergens may be effective in some CSU patients, as was 
demonstrated in a prospective uncontrolled and unblinded study of 140 patients (Magerl 
et al, 2010).  
Current EAACI/GA2LEN/EDF/WAO guideline recommends a step-up management 
algorithm for CSU patients, with the strength of recommendation being based on a 
modified GRADE methodology at the 4th International Consensus Meeting (“Urticaria 
2012”) held in Berlin, Germany in November 2012 (Maurer et al, 2013b; Zuberbier et al, 
2014b). The consensus was achieved by at least 75% agreement between more than 300 
participants according to an open vote (Maurer et al, 2013b). The revised treatment 
algorithm suggested the use of non-sedating antihistamines in standard doses as the first 
level treatment for all CSU patients. If there is no response within two weeks, it is 
recommended to up-dose non-sedating antihistamines up to fourfold daily for up to four 
weeks. If patients do not respond within four weeks, omalizumab, ciclosporin A or 
leukotriene antagonists are recommended as the third-line treatments. Short courses of 
systemic corticosteroids can be used for CSU flare-ups (Zuberbier et al, 2014a).  
Non-sedating H1 antihistamines are the mainstay of the management of CSU (Figure 3) 
with their efficacy confirmed in randomized clinical trials (grade of evidence A, strong 
recommendation). However, some patients respond poorly to the licensed dosages of 
antihistamines and an increase in their daily dosages appears to be a promising strategy in 
a view of a wide therapeutic index and an excellent safety profile. A fourfold increase in 
the daily dose of non-sedating antihistamines have been endorsed by the EAACI for CSU 
patients with suboptimal control at the licensed doses based on wide clinical experience 
and general expert agreement (strength of recommendation D) (Zuberbier et al, 2009b). 
There is accumulating evidence for efficacy and safety of high-dose antihistamines in 
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CSU (Staevska et al, 2010). In real-life clinical practice, surveys of physicians in Spain 
(Ferrer et al, 2009) and Germany (Weller et al, 2013b) about their experience with 
treatment of CSU patients suggested a gradual adoption of high-dose antihistamines in 
the step-up treatment algorithm in CSU. 
The guideline recommends the use of omalizumab, ciclosporin A or leukotriene 
antagonists as third-line treatments in a stepwise management algorithm for patients who 
responded poorly to antihistamines (Zuberbier et al, 2014a). Among these, a combination 
of antileukotrienes and non-sedating antihistamines appears to be the safest option but the 
efficacy of antileukotrienes in CSU remains to be better characterized. 
Among immunomodulatory agents that have been used in CSU, the strongest evidence 
exists for ciclosporin A for which efficacy in CSU has been established in randomized 
controlled trials (Grattan et al, 2000; Vena et al, 2006). Ciclosporin A is a calcineurin 
inhibitor which inhibits T cell proliferation by induction of cell cycle arrest in the G0 or 
early G1 phase and suppresses, at a pretranslational level, the production of IL-2 (Kay, 
1994; Granelli-Piperno et al, 1984). Additionally, ciclosporin A inhibits mediator release 
from mast cells and basophils (Marsland et al, 2005; Hultsch et al, 1990; Stellato et al, 
1992; Kay, 1994). In CSU, treatment with ciclosporin was associated with reduction in 
serum histamine releasing activity and the ASST response to post-treatment serum 
(Grattan et al, 2000). Potential ciclosporin A adverse effects include hypertension, 
nephrotoxicity, hepatotoxicity, hyperkalaemia, hyperlipidaemia, peripheral neuropathy, 
gastrointestinal symptoms (diarrhoea, vomiting and dyspepsia), hirsutism and gingival 
hyperplasia and an increased risk of lymphomas and other malignancies (Jose, 2007) with 
long term use at doses used to prevent transplant rejection. Fewer side effects (mainly 
gastrointestinal and peripheral neuropathy) were reported at low doses (2-3 mg/kg) of 
ciclosporin A  (Kessel & Toubi, 2009). When ciclosporin A is given at higher doses (4-5 
mg/kg), side effects such as hypertension, peripheral neuropathy and increased creatinine 
levels were reported in 20-30% of patients (Kessel & Toubi, 2010). Therefore, careful 
monitoring of blood pressure and serum creatinine levels are required during treatment 
with ciclosporin A. Overall, ciclosporin A has been reported to be an effective treatment 
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for severe CSU, however, there are still some unresolved issues about the optimal dosing 
and the duration of the treatment. 
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The use of omalizumab for the treatment of CSU turned out to be the major advance in 
the management of CSU. Omalizumab (Xolair, Genetech/Novartis), a recombinant 
humanized IgG1κ monoclonal antibody, is used for biological treatment of CSU (Kaplan 
et al, 2008). Omalizumab is non-anaphylactogenic monoclonal antibody because it can 
only bind free IgE but not surface-bound IgE (Fahy, 2006). The binding of omalizumab 
to circulating IgE prevents IgE from interacting with the high- or low-affinity IgE 
receptors (Chang, 2000). The mutually exclusive binding of IgE to omalizumab and 
FcεRI or FcεRII is incompletely understood but is thought to be due overlapping binding 
sites for omalizumab and FcεRI or FcεRII within the Cε3 domain of the IgE constant 
region (Zheng et al, 2008; Chang, 2000).  
The mechanism of action of omalizumab in CSU is incompletely understood. The 
putative mechanisms that may be relevant in CSU include:  
1 binding to free IgE, with the reduction of surface-bound IgE (Chang et al, 2014) and, 
possibly, the reduction in IgE priming effects on mast cells (Kawakami & Galli, 
2002); 
2 down-regulation of the density of high affinity IgE receptors on the surface of mast 
cells and basophils (Beck et al, 2004; Chang & Shiung, 2006); 
3 reduction of the release of mediators, cytokines and chemokines from mast cells and 
basophils (Oliver et al, 2010; Noga et al, 2008); 
4 accummulation of omalizumab-IgE complexes (Hsu et al, 2010; Chang, 2000) which 
may have a role in sequestration of the endogenous autoantigens (Chang et al, 2014); 
5 down-regulation of membrane-bound IgE-producing B cells (Chan et al, 2013) and 
memory B cells and, possibly, a reduction in the continuous generation of IgE-
secreting plasma cells (Chan et al, 2013). 
The mechanisms mediating therapeutic effects of omalizumab in CSU are difficult to 
explain. Treatment with omalizumab induces clinical improvement predominantly within 
the first week of treatment (Casale, 2014). However, it takes a longer time to down-
regulate the expression of the high affinity IgE receptors on the surface of basophils (2 
weeks) or mast cells (10 weeks) (Beck et al, 2004; Casale, 2014).  
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Several multicentre randomized placebo-controlled phase III clinical trials have 
demonstrated the efficacy of omalizumab for treatment of patients with moderate-to-
severe CSU who do not respond to licensed or higher than licensed doses of H1 
antihistamines (Maurer et al, 2013c, Kaplan et al, 2013). In March 2014, Xolair 
(omalizumab) was approved by U.S. Food and Drug Administration (FDA) for the 
indication of CSU in addition to asthma. Omalizumab is licensed for subcutaneous 
injection in adults and children aged 12 or older. The most common side effects involve 
local injection site reactions that occur in approximately 45% of patients (Polosa & 
Casale, 2012). According to the omalizumab Joint Task Force, the frequency of 
omalizumab-associated anaphylaxis was reported to be 0.09% of patients treated for 
asthma (Cox et al, 2007). The pooled analysis of the data from 67 phase I to phase IV 
clinical trials for asthma did not confirm an association between the use of omalizumab 
and risk of malignancy (Busse et al, 2012).  
Short trials of systemic corticosteroids are recommended for CSU flare-ups but they are 
not suitable for long-term management of the disease (Zuberbier et al, 2014a). 
Corticosteroids exert their actions via four mechanisms: genomic mechanism; secondary 
non-genomic effects; membrane-bound glucocorticoid receptor (mGCR)-mediated non-
genomic effects; non-specific, non-genomic effects by interaction with cellular 
membranes (Stahn et al, 2007). Glucocorticoids exert genomic effects by binding to the 
cytosolic glucocorticoid receptors that undergo nuclear translocation and bind to 
glucocorticoid-response elements (GRE) in the promoter region of steroid-sensitive 
genes. GRE affect the transcription of anti-inflammatory proteins (Barnes, 2006). 
Glucocorticoids act on numerous immune cells. Glucocorticoids decrease myelopoiesis 
and release of monocyte precursors (Stahn et al, 2007). Glucocorticosteroids reduce the 
synthesis of pro-inflammatory cytokines (e.g. IL-2, IL-6 and TNF-α) and prostaglandins 
(Stahn et al, 2007). These agents reduce the number of eosinophils and basophils whereas 
they increase the number of circulating neutrophils (Stahn et al, 2007). In bone marrow 
derived mast cells, glucocorticoid treatment suppressed the expression of FcεRIα 
(Benhamou & Mencia-Huerta, 1986). Additionally, glucocorticoids inhibit c-kit-mediated 
mast cell responses such as migration, p38 MAP kinase phosphorylation, TNF-α and IL-6 
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production (Jeong et al, 2003). Furthermore, glucocorticoids can exert rapid effects on 
mast cells, which are likely to occur due to their action on plasma membranes (Oppong et 
al, 2013). Rapid effects of glucocorticoids on mast cells include rapid decrease in 
histamine and calcium release (Zhou et al, 2008). Side effects of longterm glucocorticoid 
use are common and present a significant therapeutic limitation. Potential steroid toxicity 
includes osteoporosis, diabetes, abdominal obesity, glaucoma, hypertension, growth 
retardation in children, skin atrophy and metabolic effects (Barnes, 2006; Oakley & 
Cidlowski, 2013). For CSU exacerbations, prednisolone can be used as 10 mg daily or 
20-25 mg every other day with tapering (Kaplan, 2009). The current guideline 
recommends short courses of corticosteroids for maximum 10 days (Zuberbier et al, 
2014a). 
Treatment-refractory CSU presents a daunting challenge for the clinicians. About 75% of 
patients with refractory CSU tend to respond to the treatment with ciclosporin or 
omalizumab (Kaplan, 2011). For CSU patients with in vitro serum histamine-releasing 
activity, intravenous immunoglobulins and plasmapheresis can be helpful (Grattan, 
2004). Other treatment options such as methotrexate (Perez et al, 2010), miltefosine 
(Magerl et al, 2012) and rituximab (Chakravarty et al, 2011) have been tried in CSU but 
the place of these agents in the algorithm for the management of CSU is yet to be 
established. They may represent potential fourth-line treatments for CSU patients who 
have failed treatment with ciclosporin A or omalizumab. More evidence is needed in 
order to understand how these agents (methotrexate, miltefosine or rituximab) may 
improve stepwise management in CSU. At present, insufficient evidence base, uncertain 
patient selection criteria, poorly defined drug mode of action, potential toxicity and off-
license toxicity limit the use of these agents for treatment of refractory CSU. Future work 
needs to clarify as to when to start these treatments, to define the optimal treatment 
duration and to elucidate the mechanisms mediating their therapeutic effects in CSU. 
A summary of therapeutic targets in CSU is presented in Figure 4. Putative targets for 
therapeutic interventions in CSU include serum histamine-releasing activity, in vivo 
activation of peripheral blood basophils, autoantibody production and dysregulation of T 
and B cell response. Treatment with ciclosporin A resulted in the reduction of serum 
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histamine-releasing activity (Grattan et al, 2000). In vivo basophil and mast cell 
activation may be targeted by treatment with ciclosporin A or omalizumab. Ciclosporin A 
was shown in vitro to inhibit anti-IgE-induced histamine release from peripheral blood 
basophils (Marsland et al, 2005). Omalizumab is known to reduce the density of FceRI 
receptors on the surface of mast cells and basophils (Beck et al, 2004) and may also 
increase intrinsic sensitivity of basophils to anti-IgE-mediated stimulation (MacGlashan 
Jr. & Saini, 2013). T cell-dependent autoantibody production in B cells can be down-
regulated via suppression of T cell co-stimulatory signals by ciclosporin A (Heidt et al, 
2010). More knowledge about the inflammation pathways in CSU would allow the 
identification of novel therapeutic targets in CSU.  
In some patients with a poor response to antihistamines, the diagnosis of CSU should be 
revisited since a lack of efficacy to antihistamines may be a clinical presentation of 
urticarial vasculitis in 15-20% of cases (Tosoni et al, 2009). Therefore, CSU patients non-
responding to antihistamine therapy should be considered for differential diagnosis with 
urticarial vasculitis and a skin biopsy taken. 
1.5 General features of pathophysiology 
CSU is considered as a disease with a complex pathophysiology which presents with 
recurrent wealing due to intermittent activation of skin mast cells by unknown mechanisms 
(Kay et al, 2014a). Several putative factors may contribute to the intermittent activation of 
dermal mast cells in CSU including genetic predisposition, serum histamine-releasing 
factors, intrinsic functional aberration of skin mast cells and the effects of the skin 
microenvironment. Genetic predisposition or intrinsic functional aberrations may cause a 
primary abnormality of skin mast cells in the pathophysiology of CSU but some argue that, 
in this case, the condition would be systemic rather than limited to the skin (Chang et al, 
2014). Alternatively, skin mast cells are thought to be affected by factors present in the 
cutaneous microenvironment (Chang et al, 2014). Two possible mast cell-priming factors 
were suggested in CSU including factors mediating autoreactivity in CSU and monomeric 
IgE (Chang et al, 2014). The autoreactivity in CSU is hypothesized to be mediated by IgG 
autoantibodies against the high-affinity IgE receptor (FcεRI) (Figure 6), IgE or both and by 
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autoantibodies against autoantigens, including IgE autoantibodies against thyroperoxidase 
and, recently reported, IgE autoantibodies against dsDNA (Hide et al, 1993; Altrichter et al, 
2011; Hatada et al, 2013; Chang et al, 2014).  
The role of autoantibodies in CSU. The circumstantial evidence for autoimmunity in CSU is 
based on the association with other autoimmune diseases within the same patient, HLA 
associations and clinical response to immunosuppression but direct and indirect evidence for 
CSU being an autoimmune disease to fulfill Witebsky’s postulates is lacking (Stitt & 
Dreskin, 2013). CSU was noted to be linked to other autoimmune diseases including thyroid 
autoimmunity (Leznoff et al, 1983, O’Donnell et al, 2005). A study by Confino-Cohen et al 
(2013) with more than 12,778 CSU patients revealed that the odds of having one or several 
autoimmune diseases in CSU patients within 10 years of the diagnosis of CSU were 7.7 to 
28.8 times higher than in healthy subjects. In CSU, highly significant HLA-DR4 associations 
were linked to positive autologous serum skin tests and in vitro basophil histamine releasing 
activity of CSU sera (O’Donnell et al, 1999). Treatment with ciclosporin, plasmapheresis and 
intravenous immunoglobulins were reported to be effective in CSU patients (Grattan et al, 
2000; O’Donnell et al, 1998, Grattan et al, 1992). 
CSU is referred to as an autoimmune disease in the current literature (Greaves, 2002; 
Kaplan et al, 2008; Konstantinou et al, 2013), although an animal model has not been 
developed and direct evidence of functional autoantibodies causing CSU in humans is not 
available. In the position paper by the EAACI Task Force, the proposed diagnostic 
criteria for ‘autoimmune’ CSU, based on the agreement of an expert panel, included a 
combination of 1) a positive bioassay (basophil histamine release assay or basophil 
activation marker expression) to demonstrate in vitro functionality and 2) positive 
autoreactivity demonstrated by a positive ASST and 3) a positive immunoassay for 
specific IgG autoantibodies against FcεRI and/or anti-IgE by Western blot or ELISA to 
demonstrate antibody specificity (Konstantinou et al, 2013).  
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The role of anti-FcεRIα autoantibodies in the pathophysiology of CSU is less clear. Their 
involvement in the pathophysiology of CSU was implicated by the original study by Hide 
et al (1993), which was later extended by Kikuchi and Kaplan (2001), showing 
neutralization of serum-induced basophil histamine release by soluble recombinant α-
chains of the high-affinity IgE receptor in some patients. Additional evidence comes from 
the studies showing that serum histamine-releasing activity in CSU is limited to IgG 
fraction and appears to reside in complement fixing IgG1 and IgG3 isotypes (Grattan, 
1991; Kikuchi & Kaplan, 2001; Soundararajan et al, 2005). In the experimental settings, 
anti-FcεRIα autoantibodies were shown to activate peripheral blood basophils and skin 
mast cells in vitro (Niimi et al, 1996). Furthermore, an increased frequency of anti-
FcεRIα autoantibodies was demonstrated in CSU in comparison with other diseases 
(Fiebiger et al, 1995). The presence of anti-FcεRIα antibodies was linked to a more 
severe CSU (Sabroe et al, 1999). The decrease in functional activity of CSU sera 
following the treatment with ciclosporin (Grattan et al, 2000), intravenous 
immunoglobulins (O’Donnell et al, 1998) and plasmapheresis (Grattan et al, 1992) may 
suggest anti-FcεRIα antibodies as a biomarker of therapeutic efficacy rather than 
implying causality.  
On the other hand, anti-FcεRIα antibodies were also detected in healthy subjects by 
immunoassay (Miescher et al, 2001). Anti-FcεRIa autoantibodies, cloned from healthy 
subjects and patients with CSU, demonstrated the same amino acid sequence and were 
able to release histamine from basophils (Pachlopnik et al, 2004) although the differences 
in affinity and titre were not studied. The detection of anti-FcεRIa autoantibodies in 
healthy subjects implies that the presence of anti-FcεRIα autoantibodies may not be a 
sufficient component for the development of CSU. The detection of anti-FcεRIα 
autoantibodies in physical urticarias and urticarial vasculitis (Zuberbier et al, 2000) raises 
the questions about the specificity of these autoantibodies to the CSU pathophysiology. 
Anti-FcεRIα autoantibodies were detected in pemphigus vulgaris, dermatomyositis, SLE 
and bullous pemphigoid but differed in isotype specificity from those in CSU (Fiebiger et 
al, 1995). Anti-FcεRIα autoantibodies in CSU belong to IgG1, IgG3 and, to lesser extent, 
to IgG4 whereas anti-FcεRIα autoantibodies in pemphigus vulgaris, dermatomyositis, 
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SLE and bullous pemphigoid are predominantly of the non-complement fixing IgG2 and 
IgG4 subtypes (Soundararajan et al, 2005, Fiebiger et al, 1998).  
Furthermore, failure to demonstrate functional anti-FcεRIα antibodies in a proportion of 
CSU patients suggests that these antibodies may be unnecessary for the development of 
CSU or that better systems for detection are required. In the prospective study, anti-
FcεRIα autoantibodies, as detected by an enzymatic (nonfunctional) immunoassay, did 
not follow the course of CSU (Eckman et al, 2008), although a selection bias might have 
been introduced in this study by excluding CSU patients with basopenia. Although mouse 
models with humanized high-affinity IgE receptor exist (Fung-Leung et al, 1996), direct 
evidence of wealing upon intradermal injection of anti-FcεRIα antibodies in mouse 
models, as required by Witebsky’s criteria for autoimmune diseases, is currently lacking. 
Since recombinant anti-FcεRIα autoantibodies are not approved for clinical use, the 
evidence of skin mast cell activation by these autoantibodies in vivo in CSU patients or 
healthy subjects is not available.  
Overall, there is indirect evidence to suggest that anti-FcεRIα antibodies mediate serum 
histamine-releasing activity in CSU based on the neutralization experiments in a few 
patients (Hide et al, 1993; Kikuchi & Kaplan, 2001). Although the frequency of these 
antibodies is increased in severe CSU, there is currently insufficient evidence to infer 
causality of these autoantibodies in CSU.  
Several functional and binding assays have been employed for the detection of serum 
histamine-releasing activity and/or anti-FcεRIa autoantibodies. Functional assays (serum-
induced basophil histamine release assay) rely on the detection of histamine-releasing 
activity in patient’s serum on basophils from healthy donors. On the other hand, binding 
assays (immunoblotting, ELISA, immunoenzymometric assay) are based on the detection 
of immunoreactivity of autoantibodies in patient’s serum with relevant targets (Fiebiger 
et al, 1998; Eckman et al, 2008). Comparative studies of functional and binding assays 
for IgG anti-FcεRIα autoantibodies revealed discrepancies between the results of 
immunoblotting, ELISA, immunoenzymometric assays and serum-induced basophil 
histamine release assays in CSU (Altrich et al, 2009; Ferrer et al, 1998). The possible 
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explanations may include biological and methodological reasons. Firstly, this discrepancy 
may be due to the limitations of the methodology. Serum histamine-releasing assay is 
characterized by a considerable variability between the healthy donors, insufficient 
sensitivity, requires pre-selection of donors with the response to tested sera within the 
pre-defined range to reduce variability and the variation of laboratory protocols between 
the research centres, therefore, it is not standardised (MacGlashan Jr., 2013). Binding of 
natural autoantibodies, the lack of reactivity due to conformational change of the blotted 
α-chain of the high affinity IgE receptor and cross reactions of α-chain with IgG 
autoantibodies directed against other autoantibodies or carbohydrates may interfere with 
the results of binding assays (Pachlopnik et al, 2004). Secondly, the biological reasons 
may refer to the chosen cut-offs for positive serum histamine releasing activity in CSU in 
relation to healthy donor basophils and it may differ from the cut-off value relevant in 
vivo in CSU patients. The observation by Kaplan and Joseph (2007) suggests sera from 
CSU patients without serum histamine-releasing activity, as detected by functional 
assays, induces 10 times higher histamine release from healthy donor basophils than sera 
from healthy subjects. Participation of histamine-releasing factors other than 
autoantibodies could be a confounder. Finally, we do not know at present whether the 
presence of anti-FcεRIα autoantibodies is a primary or a secondary event in the context of 
CSU pathophysiology. The experiments to determine whether characterised anti-FcεRIα 
autoantibodies could induce weal and flare responses at physiological concentrations in 
CSU patients have not yet done.  
The possibility of co-expression of anti-FcεRIα and anti-IgE antibodies and, for example, 
genetic or acquired susceptibility of effector cells to the activation with these functional 
antibodies as a predisposing factor for CSU in some patients should be considered. 
Furthermore, the interpretation of the original research twenty years ago was made in the 
context of background knowledge at that time. Even now, with our limited understanding 
of the biology and the role of these antibodies in health and CSU, we cannot fully 
appreciate the complexity of the CSU pathophysiology. For example, naturally occurring 
antibodies have been recently implicated in the apoptosis of granulocytes (von Gunten & 
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Simon, 2012), whether, by analogy, anti-FcεRIα antibodies play a role in basophil 
removal from the circulation is unknown.  
In the literature and expert community in the field of CSU, the opinions about the clinical 
and pathophysiological relevance of anti-FcεRIα antibodies in CSU are rather polarized. 
This only reveals our limited knowledge of the exact molecular mechanisms underlying 
the clinical expression of CSU.  The differences in the methodology, patient selection and 
study designs do not allow for direct comparisons and comprehensive interpretation of 
existing research in this area.  
The variety of autoantibodies to diverse cellular targets involved in the pathophysiology 
of this disease. The most common autoantibodies include antithyroid (O’Donnell et al, 
2005) and antinuclear autoantibodies (Confino-Cohen et al, 2012). The spectrum of 
autoantibodies in CSU include anti-endothelial autoantibodies (Grattan, 1995), anti-
parietal autoantibodies (Mete et al, 2004) and autoantibodies against FcεRII receptors on 
the surface of eosinophils (Pucetti et al, 2005). Recently, anti-dsDNA IgE antibodies 
have been described to have histamine-releasing activity towards basophils in CSU 
patients (Hatada et al, 2013). 
In vivo activation and intrinsic functional aberrations of effector cells in CSU. In the 
peripheral blood, there is a shift in blood differential. Patients with CSU were shown to 
have reduced numbers of circulating basophils and eosinophils. Lymphocyte counts were 
also reported to be lower in patients with CSU compared to healthy controls (Grattan et 
al, 2003). CSU patients with positive autologous serum skin test were divided into two 
groups with normal or reduced (<1500 cells/ml) lymphocyte count in the peripheral blood 
(Garmendia et al, 2006). The pathophysiology of CSU is characterised by in vivo 
activation of the effector cells. Basophil immunophenotyping in CSU revealed increased 
expression of the high affinity IgE receptor FcεRI and basophil activation markers such 
as CD63 and CD69 (Vasagar et al, 2006). Patients with autoreactive CSU are 
characterized by increased expression of CD123 on peripheral blood basophils (Dyke et 
al, 2008). Increased expression of CRTH2 on peripheral blood eosinophils has been 
suggested but needs to be further characterised (Yahara et al, 2010). T lymphocytes in 
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CSU appeared to have an increased expression of CD40L, whether this may be important 
for polyclonal activation of B lymphocytes remains to be established (Loria et al, 2001). 
Furthermore, CSU is characterized by abnormal functional status of effector cells and 
their reactivity to the activation stimuli (Saini, 2009). Two patient subsets were 
recognized based on the response of their peripheral blood basophils to in vitro anti-IgE 
stimulation. Anti-IgE stimulation induced normal or reduced (<10% of total histamine) 
histamine release from peripheral blood basophils in some patients with CSU. In CSU 
abnormal capacity of immune cells for secretion of pro-inflammatory cytokines and 
chemokines was observed. In autoreactive CSU, aberrant functional reactivity of T and B 
lymphocytes in response to activation stimuli was described but needs detailed 
characterization in further studies (Loria et al, 2001).  
Several approaches for the patient classification in CSU were proposed based on different 
pathophysiological parameters (Saini, 2014). The research team from the St John’s 
Institute of Dermatology (London, UK) proposed a classification based on the detection 
of serum histamine-releasing activity in CSU patients (Sabroe et al, 2002). This study 
classified CSU patients into subsets based on the presence of serum histamine-releasing 
activity and anti-FcεRIα and anti-IgE autoantibodies. In this study, serum histamine-
releasing activity was associated with anti-FcεRIα autoantibodies. Another 
pathophysiological classification was proposed by a research team from John Hopkins 
University (Baltimore, USA) and was based on basophil releasability to anti-IgE 
stimulation in CSU patients. In the work by Vonakis and associates (2007), CSU patients 
were subdivided on the basis of basophil functional subsets (responders and non-
responders to anti-IgE stimulation). An observational study in CSU patients revealed that 
basophil functional phenotypes were observed regardless of the presence of anti-FcεRIα 
autoantibodies as detected by an immunoenzymoetric assay (Eckman et al, 2008). The 
authors also reported the lack of relationship between basophil functional subsets and 
serum histamine-releasing activity in CSU patients. Therefore, it was concluded that 
autoantibody-mediated desensitization of the high affinity IgE receptor appeared to be an 
unlikely cause for abnormal basophil releasability to anti-IgE stimulation. Patients’ 
basophils releasing histamine to anti-IgE stimulation show reduced SHIP-1 expression 
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level while non-responding basophils have increased SHIP-2 levels (Vonakis, et al., 
2007). Also, clinical implications of basophil functional phenotypes were suggested in 
the study by Baker and colleagues (2008) but this needs to be further elucidated in well-
designed studies. The direct comparisons between these studies is not possible due to the 
variation in the methodology which was reflected in the correspondence between 
ourselves (Grattan & Borzova, 2009) and the research team from John Hopkins 
University (Eckman et al, 2009). The detection of serum histamine-releasing activity 
relies on basophil releasability assays which are characterized by a considerable 
variability in basophil releasability displayed by different donors (MacGlashan Jr., 2013). 
In the study by Eckman et al (2008), the presence of anti-FcεRIα autoantibodies was 
defined by an immunoenzymometric assay. As for the binding assays, non-specific 
binding was reported due to the conformational changes in blotted α-chains of the high-
affinity IgE receptor (Kaplan & Joseph, 2007). Both methodologies have limitations and 
showed a lack of correlation (Eckman et al, 2009). Hence, the use of both classification 
approaches in the same study population of CSU patients would be of interest may reveal 
the relative contribution of serum histamine-releasing activity and basophil releasability 
to anti-IgE stimulation to disease severity and the clinical course of disease.  
Therefore, the discrepancy seems to be related to differences in patient selection and a 
choice of methodological approaches for detection of anti-FcεRIα autoantibodies 
(Grattan & Borzova, 2009). CSU patients with functional autoantibodies are known to 
have a profound basopenia, therefore, these patients were likely to be excluded from the 
studies using basophil histamine release assays to anti-IgE stimulation for technical 
reasons. As a result, studies into basophil functional subsets or serum histamine-releasing 
activity in CSU may refer to different subpopulations of CSU patients. In addition, the 
results of binding and functional assays for anti-FcεRIα autoantibodies do not 
correspond, possibly, due to the presence of natural FcεRIα autoantibodies (Pachlopnik et 
al, 2004). Consequently, the detection of the immunoreactivity of anti-FcεRIα 
autoantibodies by binding assays does not predict their functionality and, thus, their 
pathogenic potential. 
Chapter 1 General Introduction 
64 
Obviously, functional anti-FcεRIα autoantibodies and basophil functional subsets are 
crucial pathophysiological determinants in CSU. The pathophysiology of CSU is likely to 
depend on both “the seeds” (the presence of autoantibodies) and “the soil” (skin mast 
cells and basophils) (Grattan, 2010) Therefore, a combined methodological approach of 
an anti-IgE basophil histamine release assay on patient’s basophils and a serum-induced 
basophil histamine release assay using basophils from healthy donors would enhance our 
understanding of a complex interaction of functional autoantibodies and their target cells 
(basophils and mast cells) in CSU and would help pathophysiological phenotyping of 
CSU patients. 
Skin autoreactivity in CSU. Autologous serum skin test is characterized by a weal and 
flare response within 30 min of an intradermal injection of autologous serum. Autologous 
serum skin test is a simple cost-effective procedure which is readily available in routine 
clinical practice and recommended by the EAACI task force (Konstantinou et al, 2009). 
CSU associated with a positive autologous serum skin test is considered as autoreactive 
CSU. The frequency of serum autoreactivity in CSU based on cumulative data of 
combined analysis of 50 studies was estimated at 45.6% (Krause et al, 2009). 
A few pointers for autoreactive CSU have emerged over the last 20 years. Four percent of 
CSU patients with a positive autologous serum skin test have a family history of CSU in 
first-degree relatives (Asero, 2002). The frequency of thyroid autoantibodies is higher in 
patients with a positive test. Patients with autoreactive CSU also show a very strong 
association with HLA DRB1*04 (O’Donnell et al, 1999). Patients with serum 
autoreactivity require higher doses of antihistamines on an as needed basis. Patients with 
a positive autologous serum skin test were shown to have high expression of CD123 on 
their basophils (Dyke, et al., 2008) and higher levels of soluble CD154 (Garmendia et al, 
2004) in their serum that those with negative test results. 
CSU patients with a positive autologous serum skin were found to have a longer disease 
duration. In prospective studies, a positive autologous serum skin test appeared to be an 
important predictor for a longer disease duration. A positive autologous serum skin test 
tends to become negative during a spontaneous remission of CSU although a positive 
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autologous serum skin test in patients with concominant autoimmune thyroiditis (Fusari 
et al, 2005) is likely to persist even after a year of resolution of CSU. Further research 
into the natural course of disease and corresponding changes in the autologous serum 
skin test may help a prognosis stratification and thereby a choice of treatment strategy 
depending on the prognosis. 
Serial testing with autologous serum may be helpful for assessing the efficacy of certain 
treatments in CSU. Treatment with ciclosporin was shown to affect the patient’s skin 
response to autologous serum. In a study by DiGioacchino et al (2003), there was a 
significant reduction of the autologous serum skin test score in all patients who underwent 
treatment with ciclosporin. Following treatment, 13 out of 16 patients who developed a 
long-term remission for 9 months and more, showed a negative autologous serum skin test 
during the follow-up. O’Donnell and colleagues (1998) found that patients with a 
conversion to a negative autologous serum skin test within six months after treatment with 
intravenous immunoglobulins developed a complete sustained remission of CSU. This 
was also described in a case report of a patient with severe autoreactive CSU having a 
negative autologous serum skin test six months after therapy with intravenous 
immunoglobulins (Klote et al, 2005) and a positive autologous serum skin test later during 
relapse of disease. Repeated skin testing with autologous serum in some patients with 
severe autoimmune CSU after plasmapheresis revealed significantly reduced skin test 
responses to fresh post-exchange autologous serum compared with stored pre-exchange 
serum (Grattan et al, 1992). These data indicate the possibility of using an autologous 
serum skin test as a treatment efficacy marker and a prognostic factor for a disease 
remission but the optimal timing for post-treatment testing is yet to be established. 
Nevertheless, clinical relevance and the pathophysiological mechanisms underlying 
serum autoreactivity in CSU remain incompletely understood. The positivity of 
autologous serum skin test was related to the presence of functional autoantibodies 
although other circulating pro-inflammatory factors (e.g. IL-18) may play a role in serum 
autoreactivity (Tedeschi et al, 2007) but their contribution is unknown. Ultrastructural 
studies proved mast cell degranulation at the site of intradermal skin testing with 
autologous serum in patients with CSU (Grattan et al, 1990). Histological studies of skin 
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biopsies taken from the site of a positive autologous serum skin test demonstrated a 
mixed proinflammatory cellular infiltrate (Caproni et al, 2005). Some analogies were 
made with a late-phase allergic skin reaction based on histological features of skin biopsy 
specimens (Grattan et al, 1990). Although these two types of skin reactions are similar in 
their clinical and histological presentations, autologous serum skin test and late-phase 
allergic reactions vary in terms of timing and kinetics of their development and the 
composition of their cellular infiltrate (Kaplan, 2010). Moreover, a positive autologous 
serum skin test has been reported in several inflammatory conditions such as asthma 
(Taskapan et al, 2008) and nasal polyposis (Zambetti et al, 2010) using the criteria for 
positivity validated for CSU. However, this is in keeping with the original observation of 
a positive autologous serum skin test by Malmros (1946) in various inflammatory 
diseases, including CSU. 
Further research in the pathophysiology of serum autoreactivity in CSU is crucial for our 
understanding of the mechanisms and clinical significance of a positive autologous serum 
skin test in CSU that will guide its potential use as a prognostic and predictive biomarker 
and a marker of therapeutic efficacy in CSU. 
Skin microenvironment in CSU. Most data on the skin inflammation in CSU comes from 
histological studies suggesting a marked inflammatory infiltrate with increased 
expression of inflammatory mediators and cytokines in the dermis of CSU patients. 
Elevated levels of histamine were noted in the skin of CSU patients (Kaplan et al, 1978) 
(Figure 5). Additionally, expression of CGRP and VEGF was increased in lesional but 
not uninvolved skin in CSU patients compared to healthy subjects (Kay et al, 2014b). 
Furthermore, skin inflammation in CSU is characterised by a dense inflammatory 
infiltrate in the dermis. Skin mast cells demonstrated a threefold increase in the skin of 
CSU patients compared to healthy subjects (Kay et al, 2014a). The inflammatory 
infiltrate in CSU is characterised by significant increases in the intradermal CD3+, 
CD4+, CD8+ and CD25+ T cells, eosinophils, neutrophils, basophils and macrophages 
compared to nonatopic control subjects (Ying et al, 2002). Furthermore, in situ 
hybridization revealed Th0 cytokine profile, with increases in IL-4, IL-5 and IFN-γ 
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mRNA+ cells (Ying et al, 2002). The skin of CSU patients was showed higher 
immunoreactivity to TNF-α and IL-3 compared to healthy controls (Hermes et al, 1999). 
Functional profile of the effector cells in the skin inflammation in CSU can be explored 
in vivo by sampling techniques such as suction blister technique or cutaneous 
microdialysis (Figure 7). Using skin chamber technique, skin mast cell releasability was 
shown to fluctuate with the disease severity in CSU (Brunet et al, 1988). To our 
knowledge, there have been no published reports using cutaneous microdialysis in CSU. 
Cutaneous microdialysis is well-established technique for in vivo sampling of the 
interstitial fluid in the dermis (Clough, 1999). It enables in vivo monitoring of mediator 
release in response to various stimuli under minimally invasive conditions. The use of 
cutaneous microdialysis may provide novel insights into in vivo continuous inflammatory 
events in the skin of CSU patients that are of great interest and would contribute to better 
understanding of a dynamic process of skin pathophysiology in CSU. 
1.6 Discussion of Key Elements 
1.6.1 Mast cells 
Development. Mast cells arise from CD13+CD34+CD117+ hematopoietic progenitor 
cells (Metcalfe et al, 1997). Mast cell progenitors egress from the bone marrow, enter the 
circulation and then migrate to various tissues to differentiate into mature mast cells 
(Wernersson & Pejler, 2014). In the tissues, local growth factors such as stem cell factor 
and IL-3 are important for mast cell differentiation (Gurish & Austen, 2012). The 
lifespan of mast cells in tissues ranges from weeks to months (Voehringer, 2013).  
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Heterogeneity. Mast cells were classified according to their phenotype and tissue 
distribution. In mice, mucosal and connective tissue mast cells have been described as 
distinct subtypes. These mast cell subtypes differ in their granular content of proteases. 
Mucosal mast cells (MCT) contains only tryptase while connective tissue mast cells 
(MCTC) contains tryptase, chymase, cathepsin G, carboxypeptidase A3. Mucosal mast 
cells are located predominantly in the lung, nose and small intestine (Grant & Leonard, 
2002) whereas connective tissue mast cells reside in the skin, blood vessels, 
gastrointestinal submucosa, heart and synovium. 
Morphology. Mast cells are 6-12 µm in diameter with round or ovoid nuclear morphology 
(Voringher, 2013; Stone et al, 2010). By electron microscopy, mast cell morphology is 
characterised by electron dense secretory granules in the cytoplasm. At the ultrastructural 
level, cytoplasmic granules can be distinguished into scroll-, crystal- or particle-
containing granules. Tryptase is known to be located in crystalline structures (Dvorak, 
2005) while chymase is found predominantly in electron-dense areas (Whitaker-Menezes 
et al, 1995).  
Surface markers. Mast cells express numerous receptors including KIT (CD117), FcεRI, 
FcγRI and FcγRIIa (CD32a), C3a and C5a receptors, IL-3R, IL-4R, IL-5R, IL-9R, IL-
10R, GM-CSFR, IFN-γR, CCR3, CCR5, CXCR2, CXCR4, nerve growth factor receptor, 
and Toll-like receptors (Stone et al, 2010), β2-adrenergic receptor, the adenosine receptor 
A2B, and the prostaglandin PGE2 (Gilfillan & Beaven, 2011). 
Distribution. Mast cells are distributed throughout the body in connective tissues and 
mucosal surfaces (Puxeddu et al, 2003) nearby blood vessels and nerve fibres. Mast cells 
predominantly reside in proximity to the body surfaces exposed to the environment, 
including skin, airway and the gastrointestinal tract (Galli et al, 2005). Mucosal mast cells 
are predominantly located in gastrointestinal mucosa and the respiratory tract. By 
contrast, connective tissue mast cells are distributed in gastrointestinal submucosa and 
skin. 
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Mediators and biological effects. Mast cells release various mediators including 
histamine, proteases such as tryptase, chymase and/or carboxypeptidase A3, 
proteoglycans (heparin and chondroitin sulfates), major basic protein, lipid-derived 
mediators, including PGD2, PGE2, LTB4, LTC4, LTD4 and LTE4, PAF and certain 
cytokines, chemokines and growth factors (Wernersson & Pejler, 2014; Galli & Tsai, 
2012). Proteases are the most abundant constituents of the cytoplasmic granules in mast 
cells. The functions of serglycin proteoglycans (such as heparin) include storage of pre-
formed mediators within the secretory granules as well as anticoagulation, inhibition of 
the complement cascade and chemoattraction of eosinophils (Grant & Leonard, 2002). 
Histamine effects include smooth muscle constriction, vasodilatation and increased 
vascular permeability, activation of nociceptive neurons and mucus secretion (Grant &  
Leonard, 2002; Stone et al, 2010). Tryptase is known to activate fibroblasts, degrade 
neuropeptides, cleave C3a, promote eosinophil and neutrophil recruitment and cause mast 
cell degranulation (Grant & Leonard, 2002). LTB4 is a potent bronchoconstrictor and a 
chemoattractant of leukocytes (Stone et al, 2010; Grant & Leonard, 2002). PGD2 is also a 
bronchoconstrictor, it increases vascular permeability and recruits eosinophils and 
basophils into the sites of inflammation, its active metabolite (9α, 11β-PGF2) is known as 
a constrictor of coronary arteries (Stone et al, 2010; Grant & Leonard, 2002). Multiple 
cytokines produced by mast cells include IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, IL-33, 
GM-CSF and TNF-α (Gilfillan & Beaven, 2011). TNF-α is a major cytokine produced by 
mast cells which up-regulates endothelial and epithelial adhesion molecules, attracts 
neutrophils, increases bronchial hyperresponsiveness and has antitumour activity (Stone 
et al, 2010; Grant & Leonard, 2002). Human mast cells also produce several chemokines, 
including CXCL8 (IL-8), CCL2, CCL3 (macrophage inflammatory protein 1α), CCL5 
(Stone et al, 2010; Gilfillan & Beaven, 2011).  
Mechanisms of activation. Mast cells can be activated by the cross-linking of FcεRI 
receptors due to the binding of a multivalent allergen to FcεRI-bound IgE on the surface 
of mast cells.  Mast cells can be also activated via the FcγRI receptor. Other triggers for 
mast cell activation include complement fragments (C3a and C5a), stem cell factor, major 
basic protein, neuropeptides, various cytokines, bacterial peptides and certain venoms 
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and toxins and pharmacological agents (48/80, opioids) (Metcalfe et al, 1997, Grant &  
Leonard, 2002). Upon activation, pre-formed mediators can be released in soluble form 
by compound exocytosis, proteoglycans and proteoglycan-bound compound (chymase, 
carboxypeptidase A3, TNF-α) can be deposited as granule remnants in the surrounding 
tissue (Wernersson & Pejler, 2014). In contrast, piecemeal degranulation occurs by 
gradual vesicular traffic through the cytoplasm (Dvorak, 2005).  
Signalling. The signal transduction pathways via the FcεRI receptor involve ITAMs in 
the cytosolic domains of the β and γ chains that are phosphorylated by the Src family 
kinase Lyn. Then, the tyrosine kinases Syk and Lyn initiate the signalling that involves 
adaptor protein linker of activated T cells with the subsequent activation of phospholipase 
Cγ (PLCγ). Following this, PLCγ cleaves phosphatidylinositol 4,5 biphosphate into 
inositol triphosphate and diacylglycerol which leads to calcium release from the 
endoplasmic reticulum and, subsequently, to mast cell degranulation. Inhibitory 
signalling in mast cells occurs via the FcγRIIb IgG receptor, gp49B1, Siglecs, signal 
regulatory protein-α (SIRPα), human leukocyte immunoglobulin-like receptor, subfamily 
B, member 4 (LILRB4) and CD300a, TGF-β, IL-10, CD200, CD72, and intracellular 
signalling molecules such as LAB (linker for activation of B cells) and RABGEF1 (RAB 
guanine nucleotide exchange factor 1) (Gilfillan & Beaven, 2011; Kalesnikoff & Galli, 
2007).  
Role in health. Under physiological conditions, mast cell functions regulate epithelial 
secretion and permeability, peristalsis and bronchoconstriction and endothelial functions 
including blood flow, coagulation and vascular permeability (Kalesnikoff & Galli, 2005). 
Mast cells are involved in wound healing by promoting the recruitment of inflammatory 
cells to the site of the injury and then by stimulating re-epithelialization and angiogenesis 
(Moon et al, 2010; Wulff & Wilgus, 2013). Mast cells are crucial for recognition of 
pathogens and regulating innate immune responses (Abraham & St. John, 2010). Mast 
cells are responsible for pathogen recognition through pattern recognition receptors and 
Toll-like receptors. Also, mast cells contribute to host resistance to certain parasites 
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(Moon et al, 2010). Mast cells are known to play a role in host defence against toxins 
such as snake and honeybee venoms (Metz et al, 2006).  
Role in disease. Mast cells are implicated in allergic and autoimmune diseases, cancer 
and fibrosis. In autoimmune diseases, for example, mast cell-derived TNF-α is likely to 
contribute to the amplification of local inflammation in rheumatoid arthritis (Kritas et al, 
2013). Mast cells were also shown to facilitate angiogenesis and contribute to tumour 
survival (Kalesnikoff & Galli, 2005).  
Role in allergic inflammation. The role of mast cells in the pathophysiology of allergic 
inflammation includes the elicitation of the early phase and contributions to the late phase 
by recruitment of other cells, tissue infiltration and cell activation in the tissues and 
participating in tissue remodelling that occurs in chronic allergic inflammation (Galli &  
Tsai, 2012).  
Role in CSU. Mast cells are regarded as the key effector cells in eliciting and maintaining 
the inflammation in CSU. In vitro experimental evidence suggests that mast cells can be 
activated by functional autoantibodies against the high-affinity IgE receptor and IgE 
present in patient’s serum (Niimi et al, 1996) although the definitive proof that serum 
histamine-releasing activity towards skin mast cells is attributed to anti-FcεRIα 
antibodies in patient’s serum in vivo is lacking. In CSU patients, mast cell degranulation 
leads to the release of histamine which is a crucial mediator causing clinical 
manifestations of CSU. Evidence for mast cell degranulation in CSU comes from 
electron microscopy studies of the autologous serum skin test response (Grattan et al, 
1990) and immunohistochemical detection of mast cell-derived proteases in the skin of 
CSU patients (Vena et al, 2002). Several lines of evidence suggested diverse effector 
functions of mast cells in the pathophysiology of CSU including leukocyte recruitment 
and control over vascular permeability. In vitro data demonstrated that collection of the 
supernatant of mast cells activated by CSU patients’ sera (with or without functional 
autoantibodies) resulted in up-regulation of adhesion molecules on endothelial cells and 
vascular plasma leakage in an in vitro model (Bossi et al, 2011; Lee et al, 2002). Mast 
cells are known to induce leukocyte recruitment into the site of inflammation. In addition, 
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immunoregulatory functions of mast cells in chronic inflammation have recently been of 
great interest (Metz et al, 2007). There is evidence for a crosstalk between mast cells and 
T-lymphocytes in CSU as demonstrated by a correlation between histamine release and 
IL-2 production (Hidvegi et al, 2003). 
The changes in numbers of mast cells in skin of CSU patients are still debated. Some 
authors suggested that mast cells are increased up to 10-fold in CSU but these data were 
criticized for methodological reasons (Natboni et al, 1983). In general, normal or slightly 
elevated mast cell counts (up to 3 times) were reported in skin biopsy specimens from 
CSU patients (Kay et al, 2014a; Haas et al, 2001). Mast cells undergo phenotypic 
changes during the inflammation in CSU as was shown by their lower threshold for 
activation in the flare-up of the disease compared to the remission of CSU (Jacques et al, 
1992). Mast cells are known to contribute to tissue remodelling in chronic inflammation 
(Maurer et al, 2003). Although increases in serum MMP- 9 (Kessel et al, 2005) and 
VEGF (Kay et al, 2014b) were reported in CSU, their effect on skin matrix composition 
and vessel remodelling in CSU was not studied and this aspect of mast cell biology in 
CSU remains unknown. 
1.6.2 Basophils 
Basophils are the rare granulocytes accounting for less than 1% of circulating leukocytes.  
Development. Basophils develop from CD34+ pluripotent stem cells through a common 
basophil-eosinophil precursor (Prussin & Metcalfe, 2003). Basophils undergo 
differentiation and maturation in the bone marrow before their release into the circulation 
as fully matured cells (Prussin & Metcalfe, 2003).  
Heterogeneity. There is limited evidence regarding basophil heterogeneity. In density 
centrifugation studies, two subpopulations of basophils were distinguished by differences 
in their density. Low-dense basophils differed from basophils with normal density in 
terms of cellular histamine content and higher sensitivity to glucocorticosteroids 
(Bochner, 2000). Alternatively, two basophil subsets were noted with regard to their 
response to anti-IgE stimulation. Releaser and nonreleaser basophils to anti-IgE 
Chapter 1 General Introduction 
74 
stimulation were described in healthy subjects, patients with CSU and asthma (Youseff et 
al, 2007; Vonakis et al, 2007). Additionally, basophil functional plasticity was suggested 
in view of differential activation depending on cytokine stimulation (Siracusa et al, 
2012). Thus, basophils produced more cytokines and chemokines following the 
stimulation with TSLP whereas after IL-3 stimulation basophils produced histamine 
(Siracusa et al, 2012).  
Morphology (including granular content). Basophils are 5-7 μm in diameter. Their 
morphological features include a segmented nucleus with highly condensed chromatin 
and cytoplasmic secretory granules (Prussin and Metcalfe, 2003). In human basophils, 
granules contain pre-formed mediators including histamine, Charcot-Leyden crystal 
protein, major basic protein, cathepsin G. In basophil granules, chondroitin sulphate A is 
the predominant proteoglycan, which is important for the storage of preformed mediators 
(Grant & Leonard, 2002). In healthy subjects, there are negligible amounts of tryptase in 
basophil granules although basophils from allergic patients are known to have detectable 
levels of tryptase upon allergen challenge (Grant & Leonard, 2002).  
Distribution.  Basophils are found in the circulation and can be recruited into tissues in 
inflammation (Ito et al, 2011).  
Mediators and biological effect. Basophils produce a variety of mediators and cytokines 
including histamine, leukotrienes (LTC4, LTD4, LTE4) and PAF, IL-4, IL-13, IL-3, IL-5, 
IL-6, IL-8, IL-10, IL_12, TNF-α, MIP-1α and RANTES (Prussin & Metcalfe, 2003; 
Grant & Leonard, 2002). Histamine a potent vasoactive mediator produced by basophils. 
In addition, histamine has diverse effects mediated by H1-H4 receptors which are 
summarized in the Section 1.6.3 of the thesis. LTC4 is a potent bronchoconstrictor, which 
is synthesized de novo in basophils from arachidonic acid and then converted to LTD4 
and LTE4 (Harvima et al, 2014). Secretion of IL-4 contributes to Th2 differentiation 
(Gibbs, 2011).  
Surface markers. Basophils express numerous receptors including immunoglobulin Fc 
receptors (FcεRI, FcγRII), cytokine receptors (IL-3R, IL-5, GM-CSF), complement 
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receptors (CD11b, CD11c, CD35, CD88), prostaglandin receptors (CRTH2), co-
stimulatory molecules (CD40L), adhesion molecules (VLA-4, VLA-5, all four β2 
integrins, α4β7, L-selectin, PSGL-1 and sialyl Lewis), chemokine receptors (CCR1, 
CCR2, CCR3 and CXCR4) and Toll-like receptors (TLR-2 and TLR-4) (Marone et al, 
2005). Basophil activation markers include CD63, CD203c, CD107a and CD107b, CD13 
and CD69 (MacGlashan Jr., 2009; Yoshimura et al, 2002).  
Mechanism of activation. Basophil activation can occur in response to various stimuli via 
activating receptors such as 2B4, LIR7, leptin receptor, FcεRI, FcγRIIA, CD200R3, 
C3aR, C5aR, LTB4R1, IL-3R, IL-18R, IL-33R, TSLPR (Voeringer, 2013). Allergens 
induce cross-linking of membrane-bound IgE on the surface of basophils whereas non-
IgE-mediated basophil activation can be caused by parasitic antigens, lectins and viral 
superantigens (Gibbs, 2008). Basophil activation via FcεRI, C3a, C5a receptors results in 
histamine release, eicosanoid synthesis and cytokine IL-4 and IL-13 secretion (Prussin & 
Metcalfe, 2003). Signalling through the IL-3 receptor leads to basophil expansion, 
survival and activation in cooperation with other stimuli (Sullivan & Locksley, 2009). 
Additionally, IL-3, nerve growth factors, IL-33 can also induce cytokine release from 
human basophils (Gibbs, 2008). Basophil priming factors include IL-3, NGF, CC 
chemokines (eotaxin, monocyte chemoattractant protein 3, monocyte chemoattractant 
protein 4, RANTES), N-formyl-methionyl-leucyl-phenylalanine, IL-3, IL-5, GM-CSF 
(Prussin & Metcalfe, 2003; Gibbs, 2008). In basophils, granule exocytosis may occur via 
anaphylactic or piecemeal degranulation (Dvorak, 2005).  
Signalling. The signal transduction pathways in basophils are incompletely understood. 
Signalling elements such as Syk and Lyn kinase are important in positive regulation of a 
signal transduction associated with FcεRI activation whereas lipid phosphatases SHIP-1 
and SHIP-2 are negative regulators of signal transduction in basophils (Saini, 2005). 
SHIP expression was shown to be up-regulated via CD300a, CD200R, Siglec-8 and 
FcγRIIb (Gibbs, 2011). Dysregulated SHIP expression in basophils was reported in CSU 
(Vonakis et al, 2007). Signalling by IL-33 via a receptor complex of ST2 receptor and IL-
1 receptor accessory protein is dependent on the adaptor protein MyD88 pathway 
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(Kakkar & Lee, 2008) and appears to be dysregulated in allergic diseases (Saluja et al, 
2014).  
Role in health: Basophils play a role in host defence against ticks (Voehringer, 2013) and 
helminths (Schwartz & Voehringer, 2011). Basophils accumulate in the dermis and 
epidermis at the sites of secondary infestation by ticks and confer tick resistance via yet 
unknown mechanisms (Voehringer, 2013). In mouse Mcpt8 models, depletion of 
basophils led to the loss of tick resistance (Wada et al, 2010). Basophils are accumulated 
in the inflamed tissues during helminth infections and may contribute to protective 
immunity against helminth infections by production of Th2 cytokine, proteases or by 
other yet unidentified mechanisms (Karasuyama et al, 2010). Basophils are also 
implicated in angiogenesis, presumably, via secretion of angiogenic cytokine VEGF and 
the expression of the high affinity urokinase plasminogen activator receptor, known to be 
involved in tissue remodelling and vessel sprouting (Crivellato et al, 2010).  
Role in disease: Basophils are thought to be involved in allergic (eg. asthma), 
autoimmune (eg. lupus nephritis, rheumatoid arthritis,), inflammatory (eg. Crohn disease) 
diseases and haematological malignancies (acute and chronic myeloid leukemia) (Kaveri 
et al, 2010). In SLE, activated basophils are linked to disease severity (Charles et al, 
2010). In myelodisplastic syndromes, basophilia was associated with significantly 
reduced survival (Wimazal et al, 2010). Basophils are also implicated in the 
pathophysiology of skin diseases such as CSU, atopic eczema and allergic contact 
eczema as well as bullous pemphigoid (Borriello et al, 2014). 
Role in allergy and inflammation. Basophils are thought to be important participants in 
allergic inflammation (Schroeder & MacGlashan, 1997). Basophils accumulate in the 
inflamed tissues in allergic diseases (asthma, atopic dermatitis, allergic rhinitis) can 
promote ongoing allergic inflammation by secretion of Th2 cytokines (Falcone et al, 
2011). In atopic eczema, basophils could contribute to the pathophysiology by producing 
angiogenic and tissue remodelling factors (de Paulis et al, 2006). In asthma basophils 
were shown to accumulate in airways of fatal asthma (Kepley et al, 2001). Basophils 
contribute to systemic and local allergic reactions (Voehringer, 2013). Thus, basophils 
Chapter 1 General Introduction 
77 
were implicated in IgG-mediated anaphylaxis that occurs in repeated administration of 
chimeric and humanized monoclonal antibodies (Khodoun et al, 2011). Additionally, 
basophils are recruited to the late-phase allergic reactions in the skin and, to lesser extent, 
in the lungs (Macfarlane et al, 2000).  
The role in CSU. Similar to mast cells, basophils are implicated in the pathogenesis of 
CSU (Saini, 2014). Basopenia is a hallmark feature of severe CSU, which is more 
profound in autoimmune CSU (Grattan et al, 1997a). Propensity of basophils to 
degranulate in response to physiologic stimuli was noted in the experiments with human 
serum (Luquin et al, 2005). Flow cytometry studies revealed in vivo basophil activation 
in the peripheral blood of CSU patients as demonstrated by their increased expression of 
CD69 and CD63 (Vasagar et al, 2006). Prospective evaluations of patient’s basophils, 
using basophil histamine release assays, revealed an increase in basophil releasability to 
anti-IgE stimulation towards the remission of CSU (Kern & Lichtenstein, 1976). 
Research into basophil biology in CSU over the last decade brought out new insights into 
signalling aberrations of basophils associated with CSU. Two subsets of basophils were 
defined based on their response to anti-IgE stimulation. It was shown that the underlying 
defect in non-responding basophils was abnormal SHIP expression (Vonakis et al, 2007). 
Of interest, aberrant SHIP expression in human basophils occurred with no regard to the 
presence of histamine-releasing autoantibodies as defined by immunoenzyme assay 
(Eckman et al, 2008). The discovery of functional defects in peripheral blood basophils in 
CSU opened avenues for targeting basophil signalling with biological treatments. 
Whether newly discovered basophil functions such as contribution to immunoregulation 
(MacGlashan, 2008) or immunological memory (Denzel et al, 2008) are relevant in the 
context of CSU is unknown. 
Differences between basophils and mast cells. Although basophils and mast cells 
phenotypic similarities such as the expression of the high-affinity IgE receptor, 
metachromatic staining, Th2 cytokine expression and histamine release, basophils are 
distinct from mast cells in terms of their origin, response to different secretagogues, 
mediator content, signal transduction pathways and modalities of pharmacological 
control (Schroeder & MacGlashan, 1997; Prussin & Metcalfe, 2003). Basophils and mast 
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cells are believed to originate from different lineages of the haematopoietic system 
(Marone et al, 2002; Prussin & Metcalfe, 2003). Basophils are known to enter the 
bloodstream as fully differentiated cells whereas mast cells circulate as progenitors and 
complete their maturation in tissues under influence of local microenvironment (Li et al, 
2000). Ultrastructurally, basophils are characterised by segmented nuclear morphology 
with condensed chromatin and fewer electron-dense granules as opposed to non-
segmented nucleus and more abundant granules with characteristic patterns in mast cells 
(Li et al, 2000). In cytoplasmic granules, histamine is a common mediator for both cells, 
but they differ in their sulphated proteoglycans, proteases, cytokines. Chondroitin 
sulphate A is a proteoglycan in basophils whereas mast cells contain a mixture of heparin 
and chondroitin sulphate E (Li et al, 2000). In healthy subjects, basophils contain 
negligible amount of tryptase, whereas tryptase is a predominant granule constituent in 
mast cells. In addition, basophils are known to secrete LTC4 but little or no PGD2 
whereas mast cells produce PGD2 but little or no LTC4 (Li et al, 2000). 
1.6.3 Histamine 
The structure and the metabolism of histamine. Histamine (2-(4-imidazolyl)ethylamine) 
is a biogenic amine which acts as a chemical messenger in the human body. The chemical 
structure of histamine comprises an imidazole ring and an ethylamine side chain (Figure 
5). Main cellular sources of histamine include mast cells and basophils, gastric 
enterochromaffin-like cells and histaminergic neurons in the central nervous system 
(MacGlashan Jr., 2003; Panula & Nuutinen, 2013). Histamine is produced by 
decarboxylation of histidine by histidine decarboxylase (HDC). The expression of HDC 
can be modulated by various cytokines including IL-1, RANTES and TNF-α (Wu et al, 
2004; Gutowska-Owsiak et al, 2014). Histamine is metabolized either by histamine N-
methyl-transferase or by diamine oxidase (Figure 5) (Lieberman, 2011). The possible 
alterations of histamine metabolism in CSU are presented in the Figure 5.  
Histamine receptors and their distribution. Histamine acts via four histamine receptor 
subtypes (H1, H2, H3 and H4) that belong to the G-protein-coupled receptor superfamily 
(Bongers et al, 2010). The histamine H1 receptor is mostly found on the endothelial cells 
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in the vascular beds and on smooth muscle cells in the respiratory, gastrointestinal tracts 
and the vasculature (Thurmond et al, 2008). H1 receptors were also reported in various 
hematopoietic cells including neutrophils, eosinophils, monocytes, dendritic cells, T cells 
and B cells (Bongers et al, 2010; Simons & Simons, 2011). In human positron emission 
tomography (PET) studies, high density of H1 receptors was observed in the frontal 
cortex, the temporal cortex, cingulate and hippocampus whereas low density of H1 
receptors was noted in cerebellum and pons (Yanai et al, 1995). The histamine H2 
receptors are expressed on numerous cells including gastric parietal cells, smooth muscle 
cells, neurons and glial cells in the central nervous system and various tissues such as the 
cardiac tissue and the skin (Hil et al, 1997, Lieberman, 2011, Panula & Nuutinen, 2013; 
Greaves & Davies, 1982; Levi et al, 1981). The histamine H3 receptor is mainly 
expressed in the brain (predominantly in basal ganglia), the spinal cord and in the 
peripheral neurons (Hough & Rice, 2011; Panula & Nuutinen, 2013). In cardiac tissue, 
H3 receptors are expressed on sympathetic and sensory nerve endings (Immamura et al, 
1996). The H4 receptor expression is the most prominent in various cells of 
hematopoietic origin including eosinophils, neutrophils, mast cells, basophils, dendritic 
cells and T cells (Zhang et al, 2007; Gibbs & Levi-Schaffer, 2012).  
The pharmacology of histamine. Histamine binding to the histamine receptors results in 
the activation of specific intracellular G-proteins (Thurmond et al, 2008). Histamine 
binding to H1 receptor stabilizes the receptor in the active conformation and leads to 
signal transduction via Gq/G11 proteins with subsequent phospholipase C activation, 
inositol phosphate production and calcium mobilization (Simons & Simons, 2011; 
Thurmond et al, 2008). H2 receptors activate Gαs proteins and increase cyclic AMP 
levels (Simons & Simons, 2011). H3 receptors activate Gαi/o proteins, leading to the 
down-regulation of cyclic AMP production (Thurmond et al, 2008). H4 receptors activate 
signal transduction via Gαi/o proteins resulting in adenylate cyclase inhibition and a 
decrease in cyclic AMP levels (Simons & Simons, 2011).  
Histamine exerts diverse physiological effects in human body. In the skin, an intradermal 
injection of histamine causes the activation of H1 and H2 receptors leading to the 
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immediate weal and flare responses as described by Lewis (1927). The weal formation 
results from increased vascular permeability whereas the initial flare is caused by 
vasodilatation and the surrounding flare – by an axon reflex (Greaves, 2014; Williams, 
1988). Histamine can induce itch by stimulating H1 receptors on free sensory nerve 
endings of the nonmyelinated C fibres in the skin (Metz & Ständer, 2010; Greaves, 
2010). The role of H4 receptors in the itch transmission in humans needs to be 
characterized (Dunford et al, 2007). The activation of H1 receptors also up-regulates 
adhesion molecule expression (ICAM-1, VCAM-1 and P-selectin) on endothelial cells 
(Lo & Fan, 1987).  
In the airways, histamine acts on smooth muscle cells causing bronchoconstriction 
(Dunford & Holgate, 2010). In clinical practice, histamine-induced bronchoconstriction is 
assessed in bronchial histamine challenge tests for measuring bronchial 
hyperresponsiveness in asthma (O’Byrne et al, 2009; de Meer et al, 2004). In nasal 
mucosa, histamine challenge reproduces the symptoms of the early phase of the allergen 
challenge including pruritus, sneezing, rhinorrhoea and nasal blockage (Taylor-Clark, 
2010). The activation of H2 receptors in gastric parietal cells stimulates the proton pump 
H+, K+ ATPase resulting in gastric acid secretion (Thurmond et al, 2008). In the heart, H1 
receptors mediate negative dromotropic effects of histamine whereas activation of H2 
receptors has positive chronotropic and inotropic effects (Matsuda et al, 2004). In the 
central nervous system, H3 receptors are implicated as a neurotransmitter in the sleep-
wake cycle, cognition, memory, appetite and energy regulation (Panula & Nuutinen, 
2013). Presynaptic H3 receptors serve for a presynaptic autoregulation in histaminergic 
neurons whereas those in non-histaminergic neurons play a role in regulation of the 
release of other neurotransmitters such as GABA, glutamate, acetylcholine and 
noradrenaline (Smuda & Bryce, 2011; Panula & Nuutinen, 2013). The activation of H4 
receptors mediate activation and chemotaxis of mast cells, eosinophils, dendritic cells and 
the cytokine secretion from T cells and dendritic cells (Thurmond et al, 2008).  
Role of histamine in CSU. Histamine is considered to be the predominant mediator in 
CSU (Bernstein et al, 2014; Church & Maurer, 2012). Several lines of evidence support 
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this hypothesis. Firstly, dermal histamine concentrations were shown to be increased in 
CSU patients (Kaplan et al, 1978). Secondly, the weals can be reproduced experimentally 
in healthy subjects by an intradermal injection of histamine (Lewis, 1927). Furthermore, 
the efficacy of H1 antihistamines in CSU was demonstrated in double-blind placebo-
controlled studies (Zuberbier et al, 2010; Staevska et al, 2010, Kapp & Pichler, 2006, 
Kaplan et al, 2005).  
Clinically, it is well known that the duration of weals in CSU is approximately 16-18 
hours which is longer than that for histamine-induced weals (Kobza-Black, 1989; 
Greaves, 2014). Additionally, although highly effective for itching, H1 antihistamines 
only incompletely relieve wealing in some CSU patients (Greaves, 2014; Krause & 
Shuster, 1984). Furthermore, histamine-mediated effects in the dermal microvasculature 
are thought to be mediated by H1 and H2 receptors (Greaves et al, 1977) although the 
existing evidence for the efficacy of H2 antihistamines in CSU, as suggested by a 
Cochrane review, is weak and inconclusive (Fedorowicz et al, 2012). Taken together, this 
suggests that histamine is not the only mediator causing the development of weals in 
CSU and other mediators (leukotrienes, platelet-activating factor, calcitonin gene-related 
peptide, vascular endothelial growth factor, kinins, etc) are likely to contribute (Greaves, 
2014; Kay et al, 2014b; Kobza Black, 1989).  
Overall, the precise contribution of histamine to the pathophysiology of CSU is yet to be 
elucidated. Histamine is likely to initiate the weal formation and to induce itching in CSU 
although the persistence of weals is likely to be mediated by other mediators (Greaves, 
2014). At present, several questions regarding the role of histamine in skin remodelling, 
immunoregulation and disease persistence in CSU remain unanswered.  
Role of histamine in allergic inflammation. The importance of histamine in allergic 
inflammation was inferred from the detection of histamine at the sites of allergic 
inflammation in various allergic diseases, the reproduction of the symptoms of allergic 
diseases in the experimental challenge with histamine and from the control of allergic 
symptoms by H1 antihistamines (Bongers et al, 2010). Histamine is implicated in the 
pathophysiology of allergic rhinitis, conjunctivitis, anaphylaxis, urticaria and pruritus 
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although its contribution to chronic asthma and eczema is likely to be less important in 
view of minimal efficacy of H1 antihistamines in these conditions (Howarth et al, 2000; 
Bernstein et al, 2014; Greaves, 2010; Kay, 2002).  
In allergic rhinitis, histamine is thought to play a role in pruritus, sneezing, rhinorrhea 
and, to some extent, in nasal blockage (Holgate et al, 2003, Howarth et al, 2000; Taylor-
Clark, 2010). In anaphylaxis, histamine-mediated events include vasodilatation, increased 
vascular permeability, decreased total vascular resistance, cutaneous and gastrointestinal 
symptoms, flushing, bronchoconstriction, cardiac arrhythmias and hypotension (Winbery 
& Lieberman, 2002). In allergic conjunctivitis, classic histamine-mediated symptoms are 
itching, tearing, conjunctival injection (redness) and chemosis (swelling) (Leonardi, 
2002; Keane-Myers, 2001). In the airways, histamine can induce bronchoconstriction, 
mucosal oedema, recruitment of inflammatory cells and a local release of pro-
inflammatory cytokines, these pharmacological effects of histamine may be relevant in 
the pathophysiology of asthma (Dunford & Holgate, 2010). However, it is pertinent to 
note that histamine is important but not a sole mediator of allergic inflammation 
(Howarth et al, 2000; Kay, 2002). 
Furthermore, histamine plays a role in immunoregulation in chronic allergic 
inflammation by affecting immunological cells such as dendritic cells and T and B 
lymphocytes (Jutel et al, 2009; O’Mahony et al, 2011). For example, histamine affects 
maturation and antigen-presenting activity of dendritic cells. Histamine H1 and H3 
receptors are known to increase antigen-presenting activity, pro-inflammatory cytokine 
secretion in dendritic cells which, in turn, stimulate the development of Th1 cells. By 
contrast, H2 receptors mediate the suppression of antigen-presenting activity and induce 
IL-10 secretion thereby facilitating the development of IL-10-producing T cells or Th2 
cells (Mazzoni et al, 2001). Additionally, histamine may affect polarization of Th1/Th2 
cells. By stimulating H2 receptors, histamine favors Th1-type responses whereas the 
stimulation of H2 receptors down-regulates both Th1 and Th2-type responses (Jutel et al, 
2001). At the sites of local inflammation, histamine may enhance the production of pro-
inflammatory cytokines and chemokines by various cells and may induce the recruitment 
of granulocytes (Meretey et al, 1991; Jeannin et al, 1994). Histamine was shown to 
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induce chemotaxis of eosinophils and mast cells via H4 receptors (Hofstra et al, 2003; 
O’Reilly et al, 2002).  
Antihistamines (1st and 2nd generation). H1 antihistamines act as inverse agonists by 
stabilizing the H1 receptor in the inactive conformation (Simons & Simons, 2011; 
Church & Maurer, 2014). According to the Consensus group on new generation 
antihistamines (CONGA), two generations of H1 antihistamines are currently recognized 
(Holgate et al, 2003). The first generation of H1 antihistamines comprises multiple 
compounds including promethazine, brompheniramine, chlorpheniramine, mepyramine, 
diphenhydramine, clemastine, cyproheptadine and hydroxyzine (Passalacqua et al, 2002). 
The second generation of H1 antihistamines is represented by acrivastine, epinastine, 
ebastine, loratadine, fexofenadine, mizolastine, desloratadine, azelastine, levocetirizine, 
bepotastine, alcaftadine, rupatadine and bilastine (Simons & Simons, 2011; Church & 
Maurer, 2014). Two second-generation H1 antihistamines (astemizole and terfenadine) 
were withdrawn from the market because of their cardiotoxicity. At present, the term 
‘third generation of anthistamines’ should be reserved for future advances in the field 
(Holgate et al, 2003).    
The first-generation H1 antihistamines have low selectivity towards H1 receptors and 
frequently cause anticholinergic effects such as dry mouth, blurred vision and urinary 
retention (Simons & Simons, 2011). Compared to the first-generation H1 antihistamines, 
the second-generation H1 antihistamines are characterized by a more favorable safety 
profile due to their high H1 receptor selectivity and little or no affinity for muscarinic 
cholinergic receptors (Holgate et al, 2003). The first-generation H1 antihistamines can 
easily cross the blood-brain barrier due to their lipophilicity, have higher H1 receptor 
occupancy in the brain and can often cause CNS side effects such as sedation, daytime 
somnolence, impaired REM phases of sleep and reduced cognitive function (Boyle et al, 
2006; Yanai et al, 2011). These side effects lead to the reduced work efficiency, impaired 
ability to operate machinery or driving performance in adults and poor exam performance 
in children (Cockburn et al, 1999; Weiler et al, 2000). The second-generation H1 
antihistamines have less sedative effects because of low or negligible brain penetration 
and their affinity for the P-glycoprotein efflux pump (Lieberman, 2009).  
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Anti-inflammatory effects of antihistamines. The second-generation H1 antihistamines 
were reported to exert various anti-inflammatory effects in vitro and in vivo (Leurs et al, 
2002; Cuss, 1999). Anti-inflammatory effects of the second-generation antihistamines 
include the downregulation of adhesion molecules, the reduction of the leukocyte 
recruitment, the inhibition of the release of mediators and cytokines (Holgate et al, 2003). 
Mast cell stabilizing effects of non-sedating H1 antihistamines are likely to be receptor-
independent. Second-generation H1 antihistamines are hypothesized to inhibit calcium 
ion channels and to reduce calcium ion current into the cells thereby stabilizing the 
membrane of mast cells (Levi-Schaffer & Eliashar, 2009; Church & Maurer, 2014). By 
contrast, the downregulation of leukocyte chemotaxis to the sites of inflammation and the 
inhibition of cytokine production are thought to be receptor-dependent effects that are 
likely to be mediated by the downregulation of the activation of the transcription factor 
NF-κB (Church & Maurer, 2014). Overall, the anti-inflammatory effects of second-
generation H1 antihistamines are difficult to explain and their clinical relevance is yet to 
be established.  
Histamine is known to be an essential mediator of skin inflammation in CSU (Greaves & 
Sabroe, 1996). Elevated levels of histamine were demonstrated in the skin of CSU 
patients (Kaplan et al, 1978). Functional studies in CSU using skin chamber technique 
demonstrated that histamine release in skin paralleled disease activity in CSU (Jacques et 
al, 1992). Effects of functional anti-FcεRIα autoantibodies found in CSU on skin mast 
cells activation were demonstrated in vitro (Niimi et al, 1996) and their contribution to 
activation of skin mast cells in CSU contributes to the pathophysiology of the disease. 
There is limited evidence suggesting abnormal skin metabolism of histamine in CSU 
(Figure 7). Skin mast cells in skin biopsy specimens were shown to have over-expression 
of histidine decarboxylase (Papandopoulou et al, 2005), which may suggest an increased 
generation of histamine from histidine in CSU. Reduced activity of diamine oxidase in 
CSU was shown in plasma (Lessoff et al, 1990) and intestinal mucosa (Guida et al, 2000) 
whether similar changes occur in skin is unknown. The role of genetic polymorphisms of 
histamine-metabolizing enzymes and histamine receptors in skin inflammation in CSU 
(Garcia-Martin et al, 2009) would be of interest but is not yet established. In mouse 
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models, studies into the transporting system of histamine into mast cells revealed a role 
of bidirectional organic cation transporter 3 (OCT3) which was shown to be responsible 
for histamine uptake by mast cells (Ohtsu, 2008). In humans, basophil recovery from 
degranulation was studied in the work by Dvorak (2005). These studies raise fascinating 
questions whether the cellular machinery for histamine uptake and release in human 
basophils and mast cells is affected in CSU but this is an area for future studies. 
1.6.4 IgE and IgE receptor 
IgE structure. The structure of IgE molecule includes two light (L) chains associated with 
two heavy (H) chains (Figure 6A). Each heavy chain contains one variable and four 
constant domains (Cε1-4) (Miescher & Vogel, 2002). Heavy chain C-terminal constant 
domains (Cε2, Cε3 and Cε4) are known to dimerise to form the Fc fragment (Wurzburg 
et al, 2000). In comparison with IgG, IgE molecule has an additional Cε2 constant 
domain (Figure 6A). Two antigen-binding sites are located within the Fab fragment of 
IgE.  
Biological effect of IgE. IgE antibodies recognize allergens in a membrane-bound form 
on B cells or basophils or mast cells and, therefore, play a role in allergic (Drinkwater et 
al, 2014). Monomeric IgE participates in a regulation of mast cell and basophil survival 
(Kawakami & Galli, 2002). IgE antibodies are important in gut immune homeostasis and 
play a role in transepithelial allergen transport (Li et al, 2006). Additionally, IgE 
antibodies have the capacity to up-regulate in vivo antibody response (Heyman, 2002). 
Furthermore, IgE antibodies are involved in protective parasite immunity (Falcone et al, 
2001).  
FcεRI receptor. A tetrameric FcεRI receptor contains four subunits: α, β and two γ chains 
(Figure 6B). The extracellular α chain contains the ligand-binding immunoglobulin-like 
domains D1 and D2. Transmembrane domain β domain amplifies the activation signal. 
Two disulphide-linked γ chains transmit the activation signal to the intracellular 
signalling pathways via two ITAMs.  
In humans, tetrameric FcεRI receptor (abγ2) is expressed on mast cells and basophils 
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whereas trimeric receptor (aγ2) is expressed on monocytes, dendritic cells, macrophages 
and Langerhan’s cells, eosinophils, neutrophils, platelets, bronchial epithelial cells in 
patients with asthma, airway smooth muscle cells (Garman et al, 1998; Wu & Zarrin, 
2014).  
An interaction of IgE and FcεRIα occurs with high affinity (Kd =10-9 - 10-10M) 
(Garman et al, 2001) via contact residues on the top of D2 domain in FcεRIα and the Cε3 
domain in the Fc region of IgE molecule (Turner & Kinet, 1999; Wurzburg & Jardetzky, 
2001). X-ray crystallographic studies showed an asymmetrically bent conformation of 
IgE in its Fc fragment that occurred upon the binding to the receptor (Wat et al, 2002). 
Tetrameric FcεRI receptors on the surface of mast cells and basophils play a role in 
regulating immediate and late-phase allergic reactions, parasite immunity. Antigen-
independent effects IgE alone without antigen are mediated via FcεRI and include 
enhanced mast cell survival and cytokine production (Kraft & Kinet, 2007, Galli & Tsai, 
2012). FcεRI was demonstrated to be involved in parasitic elimination (Miescher et al, 
2002). Additionally, FcεRI was implicated in the regulation of monocyte apoptosis and 
prevention of its differentiation into dendritic cells (Miescher et al, 2002).  
The FcεRII receptor. The low affinity IgE receptor (FcεRII, CD23) is a type II 
transmembrane glycoprotein (Acharya et al, 2010). As demonstrated in Figure 6C, the 
structure of CD23 receptor includes three lectin heads and a three-stranded, a-helical 
coiled-coil “stalk” and a short cytoplasmic tail (Gould et al, 2003). CD23 lectin heads 
display a structural homology to C-type (calcium-dependent) lectins (Gould & Sutton, 
2008). IgE binding to FcεRII occurs via Cε3 domain (Acharya et al, 2010). Single lectin 
domain binds IgE with low affinity (Kd=10-6-10-7 M-1), whereas the multipoint 
interaction of three lectin domains with IgE is characterised by high-affinity binding 
(Kd=10-8-10-9M-1) (Gould & Sutton, 2008).  
The low affinity IgE receptor is expressed on B cells, T cells, NK cells, monocytes, 
macrophages, follicular densritic cells, Langerhans cells, bone marrow stromal cells, 
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neutrophils, eosinophils, platelets, airway and intestinal epithelial cells (Wu & Zarrin, 
2014; Galli & Tsai, 2012). 
On B cells, FcεRII receptor plays a role in positive and negative regulation of IgE 
production and facilitates antigen processing and presentation (Novak et al, 2001). By 
contrast, on macrophages and epithelial cells, the FcεRII mediates the uptake of IgE-
antigen complexes across the intestinal epithelium (Wu & Zarrin, 2014). Furthermore, 
CD23 was shown to participate in cytotoxicity against tumour cells (Karagiannis et al, 
2008). 
Natural/autoimmune anti-IgE. Natural autoantibodies are defined as immunoglobulins 
produced by B cells without external antigen stimulation (Lutz, 2012). Naturally 
occurring anti-IgE autoantibodies can be found in healthy subjects, in patients with CSU, 
atopic dermatitis, asthma and autoimmune diseases such as rheumatoid arthritis, SLE and 
systemic sclerosis (Marone et al, 1999). Natural anti-IgE autoantibodies from some of the 
patients can induce histamine release from basophils and mast cells whereas anti-IgE 
autoantibodies from some patients with allergic diseases are non-anaphylactogenic 
(Stadler et al, 1996). In allergic diseases, IgG anti-IgE autoantibodies mostly belong to 
IgG1 and IgG4 isotypes (Shakib et al, 1994). The biological role of natural anti-IgE 
autoantibodies is unknown.  
Therapeutic anti-IgE. Omalizumab (Xolair®, Genetech) is a monoclonal humanized 
IgG1 antihuman IgE antibody (rhumAb-E25), which binds to the free human IgE with 
higher affinity than the binding affinity between IgE and FcεRI. Fine epitope mapping 
studies revealed that the epitope in the Cε3 domain of IgE recognized by omalizumab 
overlaps with the binding site for the high-affinity IgE receptor (Zheng et al, 2008). This 
non-anaphylactogenic anti-IgE antibody does not bind to surface-bound IgE (D’Amato, 
2006). Pharmacological properties of omalizumab are characterized by a high degree of 
isotype specificity for IgE without binding to other antibody classes (D’Amato, 2006). In 
addition to the reduction in the level of IgE, omalizumab results in rapid the reduction of 
FcεRI expression on basophils and in slower downregulation of FcεRI in mast cells 
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(Beck et al, 2004). Furthermore, omalizumab was shown to increase the intrinsic 
sensitivity of human basophils to anti-IgE stimulation (MacGlashan Jr. & Saini, 2013).  
In CSU, there are several putative mechanisms can mediate the effects of omalizumab 
(Chang et al, 2014). Firstly, by binding free IgE, omalizumab downregulates the 
expression of FcεRI on basophils and mast cells thereby rendering them less sensitive to 
the subsequent stimulation. Secondly, omalizumab binds monomeric IgE and thus 
reduces their priming effects on mast cells, which might be relevant in the context of 
CSU. Additionally, the formation of omalizumab-IgE complexes may sequester 
endogenous autoantigens such as TPO and dsDNA that interact with IgE. Finally, 
omalizumab may reduce the expression of CD23 on B-cells and downregulate IgE-
expressing B lymphoblasts and memory B cells which may result in a reduction of the 
generation of IgE-secreting plasma cells (Chan et al, 2013).  
Another example of therapeutic anti-IgE antibodies is RG7449, which is a novel, 
humanized monoclonal antibody that recognizes the M1 prime segment of membrane IgE 
on B lymphocytes before they produce IgE. RG7449 is developed by Genetech and in 
Phase I/II clinical trials in asthma (Polosa & Casale, 2012).  
Reagent anti-IgE. For research applications, there are several monoclonal anti-IgE 
antibodies including BSW17, Le27 and SUS-11. Monoclonal anti-human IgE antibody 
(BSW17) binds to an epitope located within the C3 and C4 domains of human IgE 
thereby inhibiting the binding of IgE to its high affinity receptor (Stadler et al, 1996). 
Reagent anti-IgE can be anaphylactogenic and non-anaphylactogenic (Rudolf et al, 
2000). Anaphylactogenic anti-IgE antibodies were used in evaluating IgE-mediated 
mediator release mechanisms in human basophils and mast cells in vitro. In the 
experimental settings, antiserum specific for IgE was used to crosslink membrane-bond 
IgE to study the process of ‘immunological activation’ of mast cells and basophils (Walls 
& He, 2008). Basophils and mast cells in vitro demonstrated a variability between 
basophil donors in response to anti-IgE antibodies (Lichtenstein, 1970). Anti-IgE induces 
histamine-release showed a different time course than fMLP or substance P. Anti-IgE 
antibodies induce histamine release as well as the secretion of PGD2 and LTC4 from skin 
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mast cells (Benyon et al, 1989). In in vitro models, the effect of anti-IgE antibodies on 
skin mast cells was characterized by elevations of intracellular cyclic AMP in the 
presence of extracellular calcium (Benyon et al, 1989). In skin mast cells, the kinetics of 
the stimulation with anti-IgE was characterized by relatively slow histamine release that 
reached completion within 6 min after challenge as opposed to rapid histamine release to 
substance P, being completed within 20s (Church et al, 1991). In earlier experiments, it 
was noted that anti-IgE –induced histamine release was more than 20-fold slower that 
that induced by fMLP (Knol et al, 1991).  
1.6.5 Neutrophils 
Neutrophils represent the most abundant type of granulocytes and constitute 40-60% of 
leukocytes in the circulation. In the bone marrow, neutrophils are generated at the rate of 
1010-1011 cells/day (Summers et al, 2010; Rankin, 2010). In peripheral blood, mature 
neutrophils are terminally differentiated cells with a short half-life of 6-8 hours (Summers 
et al, 2010). In healthy individuals, 109 neutrophils/kg body weight are estimated to be 
released daily from the bone marrow into the bloodstream (Rankin, 2010).  
Neutrophils arise from CD34+ hematopoietic stem cell committed to the myeloid lineage. 
In neutrophil granulopoiesis, granulocyte colony-stimulating factor is an essential growth 
factor for myeloid progenitor differentiation and generation of neutrophils (Manz &  
Boettcher, 2014). Neutrophil granulopoiesis is capable of a rapid adjustment from steady-
state conditions to emergency granulopoiesis in response to severe infections (Manz & 
Boettcher, 2014). Overall, neutrophil counts in the circulation are determined as a net 
result of neutrophil granulopoiesis, bone marrow egress, margination and 
extravasation/clearance (Bugl et al, 2012). In human body, neutrophils are distributed in 
the bloodstream, the bone marrow and also as the marginated neutrophil pools in the 
pulmonary vascular bed, liver and spleen (Nauseef & Borregaard, 2014; Pruchniak et al, 
2013). The marginated neutrophil pools can be recruited into the circulation within 
minutes in response to epinephrine or the CXCR4 inhibitor plerixafor (Devi, 2013). 
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Morphologically, mature neutrophils are cells of 12-15µm in diameter with characteristic 
morphological features of nuclear segmentation and cytoplasmic granules, hence, 
neutrophils are also called polymorphonuclear granulocytes. Neutrophils have multi-
lobed nucleus with three to five lobules. Neutrophils contain primary or azurophilic, 
secondary or specific, tertiary or gelatinase granules and secretory vesicles. Azurophilic 
granules contain bactericidal permeability increasing protein, neutrophil elastase, 
cathepsin G, protease 3, azurocidin, myeloperoxidase (Nathan, 2006) which are 
implicated in phagocytosis. Also, azurophilic granules contain alarmins which can 
activate antigen-presenting cells and induce innate and adaptive immune responses 
(Kaplan, 2012). These alarmins in neutrophils include α-defensins, the cathelicidin 
human cationic antimicrobial protein 18 and lactoferrin (Kobayashi et al, 2009). The 
content of specific granules includes cathelicidins (lactoferrin, lipocalin, lysozyme, 
LL37) which mediate antimicrobial activities. Gelatinase granules include MMP8, 
MMP9 and MMP25 (Nathan, 2006), which facilitate neutrophil transmigration. Secretory 
vesicles are characterized by a marker protein CD35 (Kjeldsen et al, 1994) and contain 
CD11b/CD18, complement receptor 1, fMLP receptors, LPS/lipoteichoic acid, receptor 
CD14, FcγRIII CD16 and leukolysin, these neutrophil products are involved in early 
neutrophil-mediated inflammatory response (Cascao et al, 2009).  
Neutrophils are known to express several Fc-receptors such as FcγRI (CD64), FcγRII 
(CD32) and FcγRIII (CD16). Also, neutrophils express various cytokine receptors such 
Type I cytokine receptors (IL-4R, IL-6R, IL-12R, IL-15R, G-CSFR, GM-CSFR), Type II 
cytokine receptors (interferon-α (IFN-α), IFN-β, IFN-γ, IL-10R), IL-1R family (IL-1R, 
IL-1RII, IL-18R) and TNFR family (TNFR1, TNFR2, Fas, LTβR, RANK, TRAIL-R2, 
TRAIL-R3) (Pruchniak et al, 2013, Futosi et al, 2013). Also, neutrophils express 
adhesion molecules such selectins/selectin ligands (L-selectin, PSGL-1) and integrins 
(LFA-1, MAC-1, VLA-4), which plays a role in neutrophil adhesion to bone marrow 
stromal cells and endothelium (Futosi et al, 2013; Summers et al, 2010). Neutrophils 
express numerous G-protein-coupled receptors including formyl-peptide receptors, 
chemoattractant receptors BLT1 and BLT2 for LTB4, receptors for platelet activating 
factor and complement fragment C5a, chemokine receptors (CXCR1, CXCR2), CCR1 
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and CCR2 (Futosi et al, 2013). Neutrophils express membrane-bound receptors (Toll-like 
receptors, C-type lectin receptors) that are important in pattern recognition function at the 
sites of inflammation (Thomas & Schroder, 2013). Human neutrophils express all Toll-
like receptors except TLR3 and TLR7 (Thomas and Schroder, 2013). Syk-coupled C-type 
lectin receptors expressed by neutrophils recognise carbohydrate moieties and include 
Dectin-1, Mincle, C-type lectin domain family 2 (CLEC2) and CLEC5A (Thomas & 
Schroder, 2013).  
Neutrophil were reported to display phenotypic differences in response to physiological 
and pathophysiological conditions. There are distinct neutrophil phenotypes which differ 
in the expression of specific molecular markers. For example, approximately 25% of 
circulating neutrophils express a glycoprotein olfactomedin 4 which is considered to be a 
tumour suppressor (Chen et al, 2011) and a negatively regulator of the activation of 
several granular proteases (cathepsin C, neutrophil elastase, cathepsin G and proteinase 
3) (Chen et al, 2011; Clemmensen et al, 2011). A subset of neutrophils expressing  
surface glycoprotein CD177 (NB1) is thought to be involved in neutrophil transmigration 
(Nourshargh et al, 2010). In cancer, two tumour-associated neutrophil subsets included  
an immunosuppressive and pro-tumorigenic neutrophil phenotype (N2) and an 
immunostimulatory and anti-tumour neutrophil subset (N1). (Beyrau et al, 2012).  
Neutrophil activation results in their effector functions such as phagocytosis, exocytosis 
of cytoplasmic granules, production of reactive oxygen intermediates, chemotactic 
migration, cytokine release and release of neutrophil extracellular traps (Futosi et al, 
2013). Neutrophil activation is a two-stage process. First, neutrophils are primed by 
bacterial products such as lipopolysaccharide, cytokines (TNF-α, GM-CSF, IL-8 and 
IFN-γ), chemokines, contact with activated endothelium or foreign surfaces (Cowburn et 
al, 2008). Neutrophil priming can occur within minutes of stimulation due to the 
mobilization of intracellular granules with pre-formed mediators. As a result, the number 
and sometimes the affinity of surface receptor expression increase without protein 
biosynthesis. By contrast, some priming agents can also induce an activation of 
transcription factors that will result in de novo expression of receptors or cytokines. 
Neutrophil priming facilitates rapid recognition, phagocytosis and killing bacteria or 
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activation by immune complexes via Fcγ receptors. Then, primed neutrophils migrate to 
the sites of infection and inflammation following a chemotactic gradient. At the site of 
infection or inflammation, primed neutrophils recognise pathogens for phagocytosis by 
pattern recognition receptors or, more efficiently, by Fc-receptors or complement 
receptors if the pathogens are opsonised. This results in further neutrophil activation with 
phagocytosis, a respiratory burst, the release of lytic enzymes and antimicrobial products.  
In neutrophils, signalling via G-protein-coupled receptors results in the chemotactic 
migration of neutrophils (Futosi et al, 2013). Triggering via Fcγ-receptors by Ig-
opsonised pathogens requires a synergistic ligation of FcγRIIA and FcγRIIIB and 
involves cytoplasmic ITAM motifs which, in turn, recruits the Syk tyrosine kinase for 
further signalling (Futosi et al, 2013). Signalling via FcγRIIa initiates chemotaxis, 
phagocytosis and bacterial killing whereas FcγRIIIb is involved in the secretion of 
reactive oxygen species in response to immune complexes, but not in phagocytosis or 
killing of serum-opsonized bacteria (Wright et al, 2010). For phagocytosis, cytoplasmic 
granules fuse with plasma membrane with help of SNARE proteins to form the 
phagosome and release their contents including myeloperoxidase in the phagosome 
(Mollinedo et al, 1999). An NADPH-dependent oxidase generates superoxide anions for 
bacterial killing by electron transfer from NADPH to O2 (Cowburn et al, 2008; Mollinedo 
et al, 1999). Following this, superoxide is converted into hydrogen peroxide which, in 
turn, is used by myeloperoxidase in the phagosome to catalize the generation of potent 
antimicrobial products such as hypochlorous acid (Witko-Sarsat et al, 2000). 
Neutrophils are known to generate and secrete cytokines, chemokines, leukotrienes and 
prostaglandins. Neutrophils can synthesize and secrete IL-8, IL-1, IL-1RA, IL-6, IL-12, 
TGF-β, TNF-α, oncostatin M and tumour-necrosis factor-related ligand B-lymphocyte 
stimulator (BlyS) (Mantovani et al, 2011). Neutrophils are also an important source of 
leukotrienes and prostaglandins, in particular, LTB4 and PGE2. LTB4 is a neutrophil 
chemoattractant and a mediator of vascular permeability  (Sadik et al, 2011; Bray, 1982) 
whereas PGE2 has immunosuppressive effects on neutrophils by down-regulating their 
endothelial adhesion and chemotaxis (Agard et al, 2013). 
Chapter 1 General Introduction 
93 
Role in health. In health, neutrophils are the first line in host defence against infections 
including bacteria and fungi (Sadik et al, 2011). Neutrophils are the first cells to arrive at 
the site of infection or inflammation. Neutrophils utilize antimicrobial molecules such as 
myeloperoxidase, neutrophil elastase, cathepsin G and defensins to combat infections. 
Role in disease. In disease, neutrophils are implicated in autoimmunity (Nemeth & 
Moscai, 2012). A signature of autoimmunity is the generation of autoantibodies that can 
be directed against nuclear material such as dsDNA, ribonucleoproteins and histones 
(Bardoel et al, 2014). In the last decade, a new potential source of self-molecules has 
come to light with the discovery of neutrophil extracellular traps (NETs). Indeed, 
molecules released during NETosis are found as autoantigens in many autoimmune 
diseases, including rheumatoid arthritis, systemic lupus erythematosus and vasculitis. 
Neutrophil degranulation may also result in tissue damage while NET formation may 
lead to the exposure to autoantigens (Bardoel et al, 2014).  
Neutrophils have been implicated in cancer pathophysiology (Mantovani et al, 2011). 
Neutrophils are thought to be recruited into tumours and may enhance genetic instability 
and promote angiogenesis. In the context of tumour, neutrophils can be reprogrammed 
into pro-tumoral N2 phenotype under influence by TGF-β whereas downregulation of 
TGF-β may promote N1 phenotype which is associated with cytotoxicity and antitumour 
activity (Mantovani et al, 2011). 
Role in allergy. Neutrophils are known to participate in immune complex –mediated 
hypersensitivity (Jonsson et al, 2013). Neutrophils may modulate the inflammatory 
response via production of pro-inflammatory cytokines (Cassatella, 2003). Neutrophilic 
inflammation in the airways is thought to underlie severe asthma and to mediate steroid 
resistance (Ito et al, 2008). Neutrophils were implicated in IgG-mediated anaphylaxis in 
animal models (Jonsson et al, 2011). 
Role in CSU. Neutrophil accumulation is a common feature of skin inflammation in CSU 
which is seen on histological examination in about 18-50% of cases (Toppe et al, 1998; 
Llamas-Velasco et al, 2012). This two-step process is required as a means for avoiding 
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uncontrolled neutrophil activation due to its significant destructive potential (Condliffe et 
al, 1998). In CSU, neutrophil accumulation was significantly associated with increased 
local expression of IL-3 and TNF-α (Toppe et al, 1998). Local increase in TNF-α may 
create microenvironment for neutrophil priming in CSU (Hermes et al, 2003). New 
insights into neutrophil biology may have pathophysiological relevance in CSU. 
Neutrophil interaction with endothelial cells during transmigration into inflamed tissues 
are a focus of research interest in view of neutrophil capacity to open ‘flood gates’ 
between endothelial cells and thereby contributing to increased vascular permeability 
(DiStasi & Ley, 2009). These data are in keeping with the previous observation of 
neutrophil-mediated oedema reported by Wedmore and Williams (1981). T Signalling via 
FcRγIIaa initiates chemotaxis, phagocytosis and bacterial killing. FcγRIIIb has been 
shown to play an important role in the secretion of ROS in response to immune 
complexes, but no role in phagocytosis or killing serum-opsonized bacteria (Wright et al, 
2010).  
Neutrophil accumulation is a common feature of skin inflammation in CSU which is seen 
on histological examination in about 18-50% of cases (Toppe et al, 1998; Llamas-
Velasco et al, 2012). It is well known that neutrophil activation occurs in two phases 
including priming and then stimulation for neutrophil degranulation. This two-step 
process is required as a means for avoiding uncontrolled neutrophil activation due to its 
significant destructive potential (Condliffe et al, 1998). In CSU, neutrophil accumulation 
was significantly associated with increased local expression of IL-3 and TNF-α (Toppe et 
al, 1998). Local increase in TNF-α may create microenvironment for neutrophil priming 
in CSU (Hermes et al, 2003). New insights into neutrophil biology may have 
pathophysiological relevance in CSU. These data are in keeping with the previous 
observation of neutrophil-mediated oedema reported by Wedmore and Williams (1981). 
The pathophysiological contribution of neutrophils to vascular leakage and oedema 
formation in CSU is unknown and is worth exploring. Another area of interest in 
neutrophil biology stems from the novel data suggesting that neutrophils may provide a 
link between innate and adaptive immunity in inflammation by their crosstalk to B- and 
T-lymphocytes (Mantovani et al, 2011). For example, neutrophils are known as a source 
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of cytokines that may promote B cell activation, including B-cell activating factor 
(BAFF) (Mantovani et al, 2011). The soluble BAFF level was reported to be increased in 
CSU (Kessel et al, 2012) which may raise a question about possible interrelationship 
between neutrophilic CSU and CSU with serum histamine-releasing activity. Overall, 
histological studies in CSU suggest that neutrophilic urticaria is a distinct histological 
phenotype of CSU. However, the clinical significance of neutrophilic urticaria is yet to be 
established as well as neutrophil contribution to the pathophysiology of CSU. 
1.6.6 Eosinophils 
In healthy subjects, eosinophils comprise less than 4% of circulating leukocytes 
(Robinson, Kay & Wardlow, 2002).   
Morphology. Eosinophils are approximately 8-12µm in diameter. Morphologically, 
eosinophils are bi-lobed granulocytes with large spherical or ovoid crystalloid granules 
that contain four primary cationic proteins including eosinophil peroxidase, major basic 
protein eosinophil cationic protein, and eosinophil-derived neurotoxin (Giembycz & 
Lindsay, 1999).  
Development: Eosinophils develop from CD34+IL-5R+ eosinophil progenitor (Fulkerson 
& Rothenberg, 2013). The maturation of eosinophils occurs in bone marrow and they are 
released in the circulation as the fully differentiated cells.  
Heterogeneity: Density-gradient centrifugation studies revealed a subset of hypodense 
eosinophils compared to the majority of normal density eosinophils in the peripheral 
blood (Conesa et al, 2002). The numbers of low-density eosinophils are increased in the 
presence of eosinophilia (Fukuda et al, 1985). The hypodense eosinophils are smaller, 
vacuolated, with more lipid bodies but less MBP (Henderson et al, 1988; Peters et al, 
1988). Low–density eosinophils are hypothesized to be an activated phenotype although 
the evidence is contradictory (Wardlaw & Kay, 2012).   
Distribution. Eosinophils represent approximately 2% of circulating leukocytes in the 
peripheral blood and 8% of leukocytes in the bone marrow (Stone et al, 2010). In healthy 
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subjects, eosinophils are noted in the gastrointestinal tract, thymus, uterus, spleen and 
lymph nodes (Kato et al, 1998). In the inflammation, eosinophils are recruited in the 
inflamed tissues (Kita, 2011).  
Mediators and biological effects: Eosinophils secrete multiple mediators including 
granular proteins, lipid mediators, chemokines, cytokines and growth factors and 
neuropeptides (Kay, 2005; Hogan et al, 2008). In their granules, eosinophils contain 
major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase 
(EPO), eosinophil-derived neurotoxin or eosinophil protein X (EDN or EPX). In 
eosinophils, MBP is the most abundant protein that is located in the crystalloid core of 
the cytoplasmic granules. MBP is cytotoxic by causing the disruption of the integrity of 
lipid bilayers (Abu-Ghazaleh & Gleich, 1992). MBP also causes degranulation of mast 
cells, basophils and neutrophils (Zheutlin et al, 1984). ECP is a zinc-containing protein 
that resides in the granule matrix. ECP is cytotoxic to helminthes, causes degranulation of 
mast cells and basophils and activates Hageman factor, kallikrein and plasminogen (Dahl 
& Venge, 1979). EPO is a heme-containing haloperoxidase which is cytotoxic and, as the 
EPO-H2O2-halide system, plays a role in bacterial killing (Venge, 1990; McEwen, 1992). 
EPO also causes mast cell degranulation (Henderson et al, 1980). EDN effects include 
cytotoxicity, oxidative damage, mutagenesis of DNA and RNA (Venge, 1990). Both EPO 
and EDN are RNAses and possess anti-viral activity (Rothenberg et al, 2013). CLC 
protein (also known as galectin-10) is a lysophospholipase (Rothenberg et al, 2013). 
Lipid mediators include prostaglandins (PGE2 and PGF2), leukotrienes (LTC4 but no or 
minimal amount LTB4), thromboxane B2 and PAF (Weller, 1997). Additionally, 
eosinophils secrete various cytokines including TGF-α, TGF-β, IL-3, IL-5, GM-CSF, IL-
2, IL-4, IL-6, IL-10, IL-16, IFN-γ, TNF-α, VEGF (Weller, 1997). Additionally, 
eosinophils contain multiple enzymes including acid phosphatase, collagenase, 
arylsulfatase B, histaminase, phospholipase D, catalase, non-specific esterases, matrix 
metalloproteinases and vitamin B12-binding protein (Rothenberg et al, 2013).  
Surface markers:  Eosinophils express a variety of surface receptors including 
complement receptors (C3aR, C5aR, CD3 (Mac-1)), Fc-receptors (FcαR, FcγRII, FcεRI, 
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FcεRII (CD23)), chemoattractant receptors (IL-8R, CCR1, CCR3, CCR4, CCR5, CCR6, 
CCR8, CCR9, CXCR2, CXCR3, CXCR4), cytokine receptors (IL-1R, IL-2R, IL-3R, IL-
4R, IL-5R, GM-CSFR α-chain, TNFR), Toll-like receptors (TLR1, TLR2, TLR4, TLR5, 
TLR6, TLR7, TLR8, TLR9, TLR10), receptors for lipid mediators (PAFR, CRTH2, 
PGD1 receptor, PGEP4 receptor, PGEP2 receptor, LTB4 receptor) and some other 
receptors (CD69, FAS (CD95), CD40) (Hogan et al, 2008; Weller, 1997). Additionally, 
eosinophils express several inhibitory receptors such as FcyRIIB, LIR3, Siglec-8 and 
IRp60 (Munitz & Levi-Schaffer, 2007; Hogan et al, 2008).  
Mechanisms of activation: Eosinophil activation can be induced by various triggers and 
may occur via different mechanisms. For example, priming factors include IL-5, IL-3, IL-
33, GM-CSF or Notch ligands (Fulkerson & Rothenberg, 2013).  Several triggers can 
activate eosinophils including secretory IgA and cytokines (IL-5, GM-CSF, IL-3) 
(Gleich, 2000). Eosinophil degranulation may occur via the following mechanisms: 
classical exocytosis, compound exocytosis, piecemeal degranulation and cytolysis (Lee et 
al, 2012). Following degranulation, eosinophils can release cationic proteins, reactive 
oxygen intermediates, lipid mediators, cytokines, chemokines and growth factors as well 
as mitochondrial DNA and antimicrobial agents (Lee et al, 2012).  
Signalling. In eosinophil priming, signal transduction is thought to involve Lyn, JAK2, 
protein tyrosin kinase and p21 ras (Bochner, 2000; Fulkerson & Rothenberg, 2013). IL-5 
mediated signal transduction involves activation of signal transducer and activator of 
transcription 1 (STAT1), STAT3, STAT5 pathways, leading to prolonged eosinophil 
survival (Fulkerson & Rothenberg, 2013). Eosinophil differentiation, degranulation and 
cytokine production is mediated via activation of mitogen-activated protein kinase 
(MAPK)-related pathway (Fulkerson & Rothenberg, 2013). Eosinophil adhesion and 
chemotaxis are known to be dependent on MAPK, the phosphoinositide 3-kinase (PI3K) 
and nuclear factor – κB (NF-κB) (Fulkerson & Rothenberg, 2013).  
Role in health. In health, eosinophils are implicated in tissue homeostasis, adaptive 
immune responses and in host defence against infections, particularly against helminths 
and fungi (Rothenberg, 2007; Kita, 2011). 
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Role in disease. Eosinophils are known to contribute to the pathophysiology of asthma 
and primary hypereosinophilic syndromes (Gleich, 2000). Additionally, eosinophils are 
thought to be involved in tumour immune surveillance (Kay, 2005; Fulkerson & 
Rothenberg, 2013). 
Role in allergy and inflammation: Eosinophils can accumulate in the cutaneous late-
phase reaction and can secrete Th2-type cytokines, which, by autocrine effects, can 
prolong cell survival in the tissues and amplify local allergic inflammation (Kay et al, 
1997). In asthma, eosinophils are implicated in airway hyperreactivity, the damage of 
airway mucosa via the release of basic proteins, lipid mediators and reactive oxygen 
intermediates (Kay, 2005) and in airway remodeling through the secretion of fibrogenic 
factors such as TGF-β, IL-11 and IL-25 (Rothenberg, 2007; Kay et al, 2004). 
How eosinophils contribute to weal formation in CSU? In CSU, eosinophils were shown 
to accumulate in cutaneous inflammatory infiltrate (Ying et al, 2002), particularly in CSU 
patients without serum histamine-releasing activity (Sabroe et al, 1999). In the context of 
CSU pathophysiology, eosinophil activation may be caused by autoantibodies against the 
low affinity IgE receptor (Pucetti et al, 2005) or by mast cell products (Asero et al, 2009). 
On the other hand, eosinophils are known to activate mast cells by MBP and other basic 
products (Gangwar & Levi-Schaffer, 2014). Additionally, eosinophils were a major 
source of VEGF in the skin inflammation in CSU as demonstrated 
immunohistochemically by co-localization of VEGF with ECP in CSU (Tedeschi et al, 
2009). Furthermore, activated eosinophils were implicated in triggering the tissue factor 
pathway of coagulation cascade (Asero et al, 2007). Overall, the precise contribution of 
eosinophils to weal formation in CSU is unknown. The putative role of eosinophils in 
weal formation in CSU may involve mast cell activation by MBP and other basic 
products or indirectly by their contribution to the chronic skin inflammation and, 
possibly, skin remodeling.  
The precise contribution of eosinophils to the pathogenesis of CSU is still incompletely 
understood (Asero et al, 2009). Decreased eosinophil counts in the peripheral blood were 
reported in CSU patients (Grattan et al, 2003). In CSU, eosinophils are characterized by 
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activated phenotype as suggested by an increased expression of CRTH2 on their surface 
in CSU (Yahara et al, 2010). Autoantibodies to CD23 were shown in CSU and can be a 
possible mechanism of eosinophil activation in CSU (Pucetti et al, 2005). CSU is 
associated with increased levels of eotaxin in the peripheral blood (Tedeschi et al, 2012) 
which can induce eosinophil (and basophil) chemotaxis (Bochner & Schleimer, 2001). 
Eosinophil accumulation in skin was demostrated mostly in CSU patients without serum 
histamine-releasing activity. Release of eosinophil granule proteins was shown in the skin 
of patients with CSU and was associated with the duration of weals. Eosinophil 
degranulation was also noted in positive serum skin tests in CSU (Grattan et al, 1997). 
Targeting eosinophil-predominant skin inflammation in CSU with montelukast supports 
the role of eosinophil- derived cysteinyl leukotriene mediators in the pathophysiology of 
chronic urticaria (Criado et al, 2008). 
Several aspects of eosinophil biology may have potential clinical relevance and 
therapeutic implications. For example, experimental evidence suggested that histamine 
induced eosinophil chemotaxis via the production of eotaxin by the endothelial cells 
(Menzies-Gow et al, 2004) and through H4 histamine receptors (Ling et al, 2004) that 
were known to be highly expressed in human eosinophils (Zhang et al, 2007). Whether 
this mechanism is relevant in the context of CSU is unknown and worth exploring. Some 
observations suggest an inhibitory role of eosinophils for mast cell degranulation (Minai-
Fleminger & Levi-Schaffer, 2009). The peculiarities of a crosstalk between mast cells 
and eosinophils in CSU have not been studied and would be of interest. Furthermore, 
eosinophils are known to be a source of PAF, VEGF and MMP- 9 (Hogan et al, 2008) 
which were implicated as a potential participants in the inflammation in CSU (Tedeschi 
et al, 2009; Kessel et al, 2005). Further research in this area may provide exciting insights 
into the pathophysiology of CSU. An increase in eosinophil counts on the treatment with 
PAF inhibitors suggested that the eosinophil count serves as a potential biomarker for its 
therapeutic efficacy (Maiti et al, 2011). 
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1.6.7 Tryptase 
Tryptase is a serine protease which is expressed predominantly in mast cells and, to 
minor extent, in basophils (Hallgren & Pejler, 2006).  
Structural analysis. Crystallography studies of the tryptase structure provided insights 
into its unique biophysical properties. Human β-tryptase was crystallised as a rectangular 
assembly of four monomers with catalytic sites facing a narrow central pore 
(Sommerhoff et al, 1999). The geometry of the central pore allows access to the catalytic 
sites for low molecular weight peptides or flexible side chains of macromolecular 
proteins (Rice & Moore, 2000). Furthermore, the architecture of the central pore renders 
tryptase resistant to endogenous protease inhibitors due to inaccessibility of tryptase 
catalytic sites to macromolecular proteins. The stabilisation of the tetrameric structure of 
tryptase is achieved by ionic interaction of tryptase cationic groove with negatively 
charged glycosaminoglycans of serglycin proteoglycans (Walls, 2000). The cationic 
patches spanning across each dimer of the tetrameric structure are predominantly 
expressed at neutral pH, therefore, in an acidic environment tryptase-heparin complexes 
dissociate into inactive monomers.  
Changes in tryptase molecular weight during its maturation reflect its conformational 
changes and post-translational modification (Schwartz, 2006). The molecular weight of 
tryptase monomers is approximately 30-36kDa. The tetrameric structure of tryptase is 
characterized by the molecular weight of approximately 140kDa. The formation of 
tryptase-heparin complex results in an increase in molecular weight up to 200kDa 
(Schmelz et al, 1999). In in vitro experiments, enzymatic treatment of tryptase monomers 
resulted in the reduction of their molecular weight suggesting a degree of glycosylation 
of tryptase monomers as a post-translational modification. Understanding of the changes 
in the molecular weight of tryptase is crucial for effective recovery of tryptase from 
biological fluids in mechanistic studies.  
Tryptase isoenzymes. An overview of tryptase isoenzymes is important for understanding 
of their antigenic sites and their detection by monoclonal antibodies in diagnostic assays. 
There are five isoenzymes of tryptase: α, β, γ, δ and ε (Schwartz, 2006; Hernandez-
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Hernandez et al, 2012). α-tryptase is processed to the form of pro-enzyme and is 
constitutively secreted by mast cells together with β-protryptase. Mature β tryptase is 
formed from β-protryptase by autoprocessing and then by proteolysis by dipeptidyl-
peptidase I (cathepsin C). Total serum or plasma tryptase is comprised of α- and β-
protryptases and mature β tryptase. Mature β tryptase is released during anaphylactic 
degranulation of mast cells while α- and β-protryptases are considered as a marker of 
mast cell burden. γ-transmembrane tryptase is released by mast cells during anaphylactic 
degranulation and is anchored to the mast cell membrane. δ-tryptase is a truncated protein 
resembling mouse tryptase with low level of expression. ε-tryptase is foetal tryptase, 
which is not present in adults.  
Tryptase substrates. Tryptase preferentially hydrolyses the peptide bonds at the carboxyl 
side of amino acid Arginine and Lysine residues. The tetrameric 3Å crystal structure of 
tryptase also explained its substrate preferences and regulation. For example, tryptase is 
known to hydrolyse neuropeptides such as calcitonin-gene related peptide, vasoactive 
intestinal peptide and PMH (Walls, 2000). Small molecular weight of these peptides 
makes them fit to the central pore with access to catalytic sites. Tryptase can also 
hydrolyze flexible chains of larger proteins including pro-stromelisine, fibronectine, 
fibrinogen. Proteolytic cleavage of the extracellular chain of cell-surface PAR-2 receptor 
results in intracellular signalling on target cells. pH optimum of tryptase differs for 
various substrates and may account for the differences in its proteolytic profile at neutral 
and acidic pH microenviroment. For example, tryptase affinity for fibrinogen is higher in 
acidic environment while peptide proteolysis is more active at neutral pH.  
Biological role. In the skin, tryptase appears to be involved in itch transmission, 
leukocyte recruitment, neuropeptide degradation, extracellular matrix modification and, 
possibly, coagulation as suggested by animal studies (Trivedi et al, 2010; Schwartz, 
2006; Payne and Kam, 2004). 
The role in CSU. In CSU, evidence for local tryptase release in skin stems from suction-
blister fluid studies as well as immunohistochemistry and immunofluorescence (Vena et 
al, 2002). In systemic circulation, tryptase is elevated in active disease and in patients 
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whose serum has the capacity to up-regulate CD63 on basophils from healthy donors 
(Ferrer et al, 2010). A subset of patients with CSU with elevated plasma tryptase levels 
were diagnosed with systemic mastocytosis (Siles et al, 2013).  
Despite recent developments in the field of tryptase research, many questions about the 
role of tryptase in CSU remain unanswered.  The expression, storage and the enzymatic 
profile of skin tryptase in CSU await characterisation. It is unclear whether the local 
tryptase release in the skin precedes the systemic rise in tryptase in CSU and whether this 
reflects disease progression. Additionally, the proteolytic behaviour, the kinetics of 
tryptase release and substrate supply in the context of ongoing mast cell degranulation 
and microvascular leakage in the skin of CSU patients are yet to be elucidated. Further 
research into the effects of tryptase haplotypes and the relative distribution of tryptase 
isoenzymes may help underpin the underlying changes in mast cell load or degranulation 
in CSU. The use of minimally invasive skin sampling techniques and sensitive assays for 
selective detection of tryptase isoenzymes may provide further insights in tryptase 
biology and skin homeostasis in CSU. Tryptase appears to be a promising therapeutic 
target (Rice & Moore, 2000). Tryptase inhibitors were shown to be effective in some 
patients with CSU. The development of selective tryptase inhibitors may advance the 
management of CSU.  
1.6.8 Two mediator hypothesis of inflammation 
It is worth noting that in inflammation several mediators are likely to interact with each 
other as was suggested by a two-mediator hypothesis (Williams, 1977a). According to 
Williams, a vasodilator mediator is likely to potentiate the plasma exudation effects of the 
mediator, which enhances vascular permeability (Williams, 1977a). These synergistic 
interactions were noted between histamine and prostaglandins (Williams, 1977b) or 
CGRP (Brain & Williams, 1985). The in vivo synergistic interactions of mediators are 
likely to account for a longer duration of weals in CSU but the relevant interactions of 
mediators in vivo in CSU await characterization. There is a need for in vivo models of 
wealing in CSU to explore the relative contribution of various mediators to the 
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development of urticarial lesions in the context of persistent dermal inflammation in 
CSU. 
1.7 Hypothesis 
For this thesis, our hypothesis suggested that severe and/or persistent CSU was associated 
with serum histamine-releasing activity, abnormal basophil releasability, altered basophil 
phenotype and absolute numbers in the circulation. We also hypothesized that, at the skin 
level, serum histamine-releasing activity in CSU was associated with higher local 
concentrations of pro-inflammatory mediators (histamine, tryptase) and cytokines, local 
histamine release and, possibly, neutrophil infiltration in the dermis of CSU patients. 
1.8 The Scope of this Thesis 
This PhD dissertation is intended to study different pathophysiological aspects of CSU 
based on three interlinked research projects. 
The first project evaluates skin biochemistry at baseline and in response to skin testing 
with phosphate buffered saline (PBS), autologous serum skin test and codeine in CSU  
patients and healthy controls. The aim of this study is to examine abnormal function of 
skin mast cells and an altered cutaneous microenvironment in CSU. This possibility is 
offered by cutaneous microdialysis which is a minimally invasive research technique for 
sampling of the dermal extracellular fluid in vivo. This pilot project will establish the 
baseline level of inflammatory mediators (histamine and tryptase) and cytokines in CSU 
patients and healthy controls and will explore the pattern of skin response to skin testing 
with PBS, autologous serum and codeine in both groups. 
The second project is designed as a prospective observational study to investigate the 
pathophysiological subsets in CSU and to explore their biomarkers. This project is 
intended to establish and characterize CSU subsets with regards to pathophysiological 
features (functional autoantibodies and basophil function) and to explore their stability 
over time. This project will determine the predictors for disease severity in CSU. As a 
part of this project, the methodology development for imaging flow cytometry studies for 
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peripheral blood basophils in healthy controls using ImageStream technology to link 
immunophenotyping and morphological features of human basophils. The ImageStream 
studies will be presented to provide the rationale for data analysis in the prospective study 
in CSU patients. 
The third project is planned as a retrospective study and was intended to re-evaluate the 
numbers of neutrophils and eosinophils per high power field in lesional skin biopsies 
from patients with CSU and urticarial vasculitis and to explore if there is a potential link 
between the histological presentation of neutrophilic CSU and CSU with serum 
histamine-releasing activity. 
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CHAPTER 2 
Assessment of mediators and cytokines in the skin 
of healthy subjects and patients with chronic 
spontaneous urticaria (CSU) using 
cutaneous microdialysis 
“It is better to know some of the questions than all of the answers.” 
—JAMES THURBER 
Abstract 
Background: The pathophysiology of weal formation in CSU is poorly understood. Serum 
histamine-releasing activity was demonstrated in vitro on human basophils (Hide et al, 
1993) and skin mast cells (Niimi et al, 1996) but the evidence for in vivo serum-induced 
histamine release in the skin of CSU patients is lacking. Elevated histamine levels (Kaplan 
et al, 1978) and cytokine up-regulation (Hermes et al, 1999; Ying et al, 2002) were reported 
in the skin of CSU patients but the relevance of the changes in mediators and cytokines in 
the skin to weal formation in CSU is unknown. We hypothesized that weal formation in 
CSU was mediated by local histamine release caused by circulating serum factors, aberrant 
skin mast cell releasability and altered skin microenvironment. 
The purpose of the study was to evaluate an autologous serum skin test as an 
experimental model for weal formation in CSU and to determine the baseline levels of 
histamine, tryptase and cytokines and the pharmacokinetics of histamine and tryptase 
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release in response to skin testing with phosphate buffered saline (PBS), autologous 
serum and codeine in CSU patients and healthy controls. 
Methods: Cutaneous microdialysis studies were carried out in 14 CSU patients and 13 
healthy controls. Six (two per site) linear microdialysis probes (molecular weight cut-off 
of 3,000 kDa) were inserted into the forearm skin of participants and perfused with sterile 
Ringer’s solution at 3µl/min for in vivo sampling of dermal extracellular fluid. Skin 
testing with PBS (pH = 7.4, 20µl) was carried out along the probes at the site 1, while 
autologous serum (20µl) and codeine (0.3mM, 20µl) were used for skin testing at the 
sites 2-3, respectively. Dialysate sampling was carried out at baseline (30 min), at 40min 
intervals for the first 2 hours and then between 4 and 6 hours after the skin testing 
(Protocol 1). For Protocols 2 and 3, dialysate sampling was carried out at 5 min-intervals 
for 40min and 80 min after skin testing, correspondingly. Dialysate samples were 
analyzed for histamine by ELISA (BioSource, Belgium), for tryptase by double antibody-
sandwich ELISA utilizing polyclonal rabbit anti-tryptase antibodies for capture and the 
mouse AA5 monoclonal antibodies for the detection (University of Southampton, UK), 
for cytokine levels by BD™ Cytometric Bead Array (BD Biosciences, UK). VAS for 
itching and wealing over 24 hours were recorded during the baseline collection. The weal 
area was calculated by skin planimetry using digital analysis with NIH ImageJ software. 
Results: Cutaneous microdialysis was well tolerated by all but two CSU patients. Median 
baseline histamine concentration was higher in CSU patients (2.321 (0.855; 2.784 ng/ml) 
compared to that in healthy controls (0.859 (0.275; 1.327 ng/ml) (Mann-Whitney test, 
p<0.05). There was a moderate correlation between VAS for wealing and baseline 
histamine concentration (Pearson correlation r=0.60, p<0.05) but not for dermal tryptase 
or IL-6 concentrations. Two CSU patients with a positive in vitro serum-induced basophil 
histamine release assay demonstrated a slow low-grade histamine release in response to 
an intradermal injection of autologous serum. The area-under-the-curve analysis for 40 
min after skin testing suggested a tendency for higher AUC40min for PBS and ASST 
stimulation and lower AUC40min for codeine stimulation in CSU patients compared to 
healthy controls. When tested on the arm without microdialysis procedures, the area of 
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the weals was larger after skin testing with autologous serum, but not PBS or codeine, in 
CSU patients than that in healthy controls (two-sample Wilcoxon test, p<0.05). 
Conclusions: The data are consistent with the ASST response being a useful model of 
spontaneous wealing in CSU. We demonstrated for the first time in vivo a slow low-grade 
local histamine release after an intradermal injection of autologous serum in two CSU 
patients with serum histamine-releasing activity. Whether this histamine release explains 
skin autoreactivity to serum observed in some CSU patients needs to be established in 
future studies. In our study, the skin microenvironment in CSU was characterized by 
elevated dermal histamine concentrations but normal tryptase and IL-6 concentrations 
compared to healthy controls. Dermal histamine concentrations were correlated to 
clinical scores in CSU but the underlying mechanisms remained uncertain. Aberrant skin 
mast cell releasability was suggested by AUC40min analysis and needs to be further 
explored in future studies. 
2.1 Background 
Weal formation is associated with vasodilation and vascular hyperpermeability of post-
capillary venules followed by transudation of fluid from dermal microvasulature into 
extracellular space. Multiple mediators were implicated in the wealing in CSU as inferred 
from their capacity to induce weal formation on an intradermal injection in healthy 
subjects. Histamine is the most researched mediator which is known to induce a triple 
Lewis response upon intradermal injection (Greaves & Sabroe, 1996). However, 
histamine is unlikely to solely account for wealing in CSU taking into account a slow 
resolution of weals in CSU than expected for histamine-induced weals as well as partial 
efficacy of anti-histamine treatments in some patients (Krause & Shuster, 1985; Kobza-
Black, 1989). 
Other mediators which may be involved are leukotrienes, prostaglandins, proteases, 
kinins, platelet activating factor and neuropeptides. In human skin, prostaglandins E2, I2 
and D2 are known to induce erythema and oedema that persist over an hour following an 
intradermal injection (Flower et al, 1976). In human skin, leukotrienes C4 and D4 also 
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produced a weal-and-flare reaction upon an intradermal injection (Soter et al, 1983). The 
erythema induced by leukotrienes C4 and D4 persisted for 6 hours oedema for 2 hours 
after an intradermal injection (Soter et al, 1983). Skin testing with leukotriene B4 resulted 
in an initial weal-and-flare reaction followed by a papule lasting for 6 hours (Soter et al, 
1983). When injected in human skin, PAF induced a weal and flare reaction that peaked 
at 5-15 min and resolved in 2-3 hours (Archer, 1984; Krause et al, 2013). Microdialysis 
studies in healthy controls did not reveal histamine release associated with PAF injection 
(Krause et al, 2013). In microdialysis studies, an intradermal delivery of CGRP to human 
skin resulted in prolonged wealing (Weidner et al, 2000). Substance P also induced 
itching, erythema and wealing when injected in human skin (Lembeck & Holzer, 1979). 
However, which mediators are involved in vivo in CSU remains unclear. 
One of the Dale criteria for inflammatory mediators includes recovery of mediators from 
the lesions. Elevated histamine concentrations in the skin have been shown in CSU 
(Kaplan et al, 1978). Exocytosed immunoreactive tryptase was demonstrated in skin 
biopsies from non-lesional skin in CSU patients by immunochemistry studies (Vena et al, 
2002). Elevated tryptase concentration was also shown in suction blister studies in CSU 
(Deleuran et al, 1991). Recently, CGRP and VEGF were also reported in lesional skin in 
CSU (Kay et al, 2014b). Elevated concentrations of MBP were noted in up to 38% of 
CSU patients (Peters et al, 1983). Therefore, multiple mediators were demonstrated in 
vivo in CSU, however, their relative contribution and interactions are yet to be 
established. 
It is worth noting that spontaneous wealing in CSU is a complex phenomenon where 
several mediators are likely to interact with each other as was suggested by a two-
mediator hypothesis (Williams, 1977a). According to Williams, a vasodilator mediator is 
likely to potentiate the plasma exudation effects of the mediator, which enhances vascular 
permeability (Williams, 1977a). These synergistic interactions were noted between 
histamine and prostaglandins (Williams, 1977b) or CGRP (Brain & Williams, 1985). The 
in vivo synergistic interactions of mediators are likely to account for a longer duration of 
weals in CSU but the relevant interactions of mediators in vivo in CSU awaits 
characterization. There is a need for in vivo models of wealing in CSU to explore the 
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relative contribution of various mediators to the development of urticarial lesions in the 
context of persistent dermal inflammation in CSU. 
Serum histamine-releasing activity is a known pathophysiological feature of CSU that is 
observed in 30-50% of patients (Grattan, 2004). The relevance of serum histamine 
releasing factors to the weal development in CSU is suggested by the phenomenon of 
serum autoreactivity that occurs in 45.9% of CSU patients (Krause et al, 2009). An 
intradermal injection of autologous serum is known to induce a cutaneous response that 
resembles a weal-and-flare reaction although a close observation would highlight 
dissimilarities such as absence of pseudopodia, the lack or minimal itching and a slower 
kinetic for weal formation compared to histamine-induced wealing. The relevance of 
serum factors to the development of wealing if inferred from the transfer of the serum-
induced weal response to healthy subjects. However, there are only two observations of 
passive transfer of weal response to date (Grattan, 1981; Pastore et al, 2013) although the 
latter did not use the recipient’s own serum as a control. 
Cutaneous reactions to autologous serum are thought to be mediated by anti-FcεRIα 
antibodies by analogy with neutralization experiments with α-chains of FcεRI receptors 
that block histamine release from basophils from healthy donors (Hide et al, 2013; 
Kaplan, 2004). However, direct proof of the contribution of anti-FcεRIα to the skin 
response to autologous serum in CSU is currently lacking. Anti-FcεRIα antibodies are not 
available for in vivo use. Mice models with humanized FcεRI receptor exist (Hide & 
Greaves, 2013) but the experiments with anti-FcεRIα antibodies are still awaited. To our 
knowledge, an interaction of immunoreactive anti-FcεRIα antibodies and skin mast cells 
has not yet been demonstrated in the skin of CSU patients. Skin priming and kinin 
generation during blood clotting were suggested as non-specific mechanisms that may 
account for skin reactions to autologous serum in CSU. This is a possibility given 
profound skin infiltration with inflammatory cells (Ying et al, 2002; Kay et al, 2014a) 
and enhanced skin sensitivity to kallikrein in CSU patients (Imai, 1989) but the 
demonstration of in vivo weal formation confined to the serum fraction of greater than 
100kDa (Grattan et al, 1991) and in vitro histamine releasing activity towards skin mast 
cells attributed to IgG fractions in serum from CSU patients (Niimi et al, 1996) would 
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argue against kinin sensitivity as the only explanation for serum autoreactivity. 
Additionally, the demonstration of mast cell degranulation autologous serum skin test in 
CSU (Grattan, 1990) suggests that other mechanisms than skin priming may also mediate 
serum autoreactivity. Overall, this justifies the need for further research establishing 
whether autologous serum- induced weal could be an experimental model of wealing in 
CSU and to which extent it reproduces spontaneous wealing in CSU. Research into the 
mechanisms underlying serum reactivity in CSU would not only provide an experimental 
tool to delineate certain aspects of wealing but would also provide insights into the 
clinical significance of autologous serum skin test in CSU which is widely used in 
clinical practice. 
Dysregulated cytokine network are a common feature of inflammatory conditions 
although the data on cytokine expression in the dermis of CSU is limited. CSU patients 
were shown to have an upregulation of TNF-α and IL-3 in the dermis (Hermes et al, 
2003). Also, increased cellular mRNA expression for IL-4, IL-5 and IFN-γ was revealed 
in CSU by in situ hybridization (Ying et al, 2002). Local generation of cytokines in the 
skin of CSU patients is of particular interest in view of their potential effects on skin mast 
cell function. The effects of the cytokine milieu on inflammatory events in situ are 
plausible but has yet to be established. For example, in vitro data suggest that 
recombinant TNF-α can release histamine and tryptase from skin mast cells (van 
Overweld, 1991). Whether cytokines contribute to continuous histamine release or 
perpetuation of the local inflammation in CSU via other mechanisms has yet to be 
elucidated. 
Further research into cytokine network in CSU is needed to enhance our understanding of 
disease-specific cytokine expression patterns at skin level and their effects on skin mast 
cell releasability in CSU. 
Skin mast cell hyperreleasability is regarded as an important determinant of clinical 
manifestations in CSU. In suction blister studies, skin mast cell releasability was shown 
to fluctuate with disease activity in CSU (Jacques et al, 1992). Codeine skin testing was 
used experimentally to explore skin reactivity in CSU (Cohen & Rosenstreich, 1986; 
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Shall & Saihan, 1992) with conflicting results. Taking into account the recent studies, we 
may consider that codeine sensitivity reflects not only cell responsiveness but also mast 
cell density in CSU (Kay et al, 2014a). Nevertheless, skin sensitivity to codeine can be an 
important factor that suggests skin mast cell functional abnormality in CSU. Spontaneous 
histamine release in CSU is poorly understood. The in vivo evidence is lacking while 
experimental data suggest an increased spontaneous histamine release from cultured mast 
cells in CSU patients than that in healthy subjects (Saini et al, 2009). Whether 
spontaneous histamine release is enhanced in vivo in CSU remains to be elucidated. 
Overall, the biochemistry and immunobiology of the dermis of uninvolved and lesional 
skin in CSU is only partially understood. The skin chamber studies and 
immunohistochemistry laid the groundwork for our understanding of biochemical events 
in the dermis in CSU. The advent of newer, less traumatic techniques, like microdialysis, 
holds the promise that the more detailed picture of in vivo biochemical and 
immunological events in the skin associated with wealing will emerge. Further 
understanding of the contribution of various proinflammatory mediators and cytokines to 
the weal formation in CSU is clinically important to allow for better therapeutic targeting 
in this disease. 
Cutaneous microdialysis offers an opportunity of in vivo studying of changes in 
mediators and cytokines in dermal interstitial fluid in CSU (Figure 8). Cutaneous 
microdialysis has been used for dermatological research since the 1990s (Anderson et al, 
1992; Petersen et al, 1996; Church et al, 1997, Groth, 2006). Microdialysis sampling is 
based on the principle of passive diffusion across the microdialysis membrane governed 
by the concentration gradient of the solute (Figure 7) (Chaurasia et al, 2007). While 
described in details in the Methods section below, in brief, microdialysis sampling is 
performed by insertion of the microdialysis probes (small hollow membranes made of 
semipermeable fibre) into the dermis (Schmidt et al, 2008). The microdialysis probes are 
connected to a microdialysis pump which allows their perfusion with a pH-buffered 
perfusate at a constant flow rate. During the perfusion of the microdialysis probes, the 
solute of interest from the extracellular space diffuses into the perfusate into the lumen of 
the microdialysis hollow fibre down the concentration gradient. The size of molecules 
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that can diffuse across the microdialysis membrane is limited by the size of the pores in 
the membrane (a molecular cut-off). Once perfused through the microdialysis membrane 
implanted into the dermis, the perfusate is considered as dialysate which can be analysed 
for the content of mediators and cytokines. 
The advantage of cutaneous microdialysis includes in vivo continuous sampling of 
extracellular fluid from the dermis under minimally invasive conditions. The technique is 
characterized by high temporal and spatial resolution (Clough et al, 2007). Site-specific 
sampling permits studies into skin responses to skin testing with various stimuli or topical 
therapeutic interventions. Methodological difficulties of cutaneous microdialysis involve 
the need for thorough optimisation and validation of the microdialysis experimental 
protocol and analytical procedures for every research application (Andersson, 1995). The 
limitations of the technique are related to the recovery of large or lipophilic molecules 
(Clough, 2005). Very low solute concentrations in low dialysate volumes present 
challenges for sample analysis and require highly sensitive analytical assays (Petersen, 
1997a). 
For the purpose of this study, we define the inflammation in CSU as the local changes in 
mediators and cytokines in the skin, with or without associated skin serum autoreactivity 
and serum histamine releasing activity in the circulation. 
The hypothesis of this research proposes that weal formation in CSU is mediated by local 
histamine release due to circulating serum factors, aberrant skin mast cell releasability 
and altered skin microenvironment. To test this hypothesis, we devised an experimental 
model consisting of skin challenges with PBS, autologous serum and codeine followed 
by monitoring of the local changes in mediators and cytokines using cutaneous 
microdialysis technique. The assessment of baseline levels of mediators and cytokines 
was used to characterize dermal microenvironment in the visibly uninvolved skin in CSU 
patients and healthy subjects. Autologous serum was chosen as a challenge stimulus to 
explore the effect of serum histamine-releasing factors on local histamine release in the 
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skin in CSU patients and healthy controls. Skin challenge with codeine was used to 
assess skin mast cell reactivity to non-immunological stimulation. The concentration of 
codeine solution was chosen following the previous experiments in healthy subjects at the 
University of Southampton (Cole et al, 2001). Skin testing with PBS was used as a 
negative control in the experimental model and also was used to assess the spontaneous 
histamine release in CSU and healthy controls. 
Several methodological components need to be taken into account for an introduction of 
cutaneous microdialysis to a new research application. The pharmacokinetics of the solute 
of interest, the range of its dermal concentrations and an optimal temporal resolution for 
its sampling need to be established before using cutaneous microdialysis for full-scale 
clinical studies (Groth, 2006; Petersen, 1997a). The need for prior knowledge about these 
parameters justifies piloting cutaneous microdialysis in patients with CSU. In addition, 
dermal tolerance of the microdialysis procedure in patients with CSU needs to be 
confirmed to ensure the validity of the microdialysis data in CSU. 
The purpose of this pilot study was to evaluate an autologous serum skin test as an 
experimental model for weal formation in CSU and to explore the pharmacokinetics of 
histamine, tryptase and cytokines at the baseline and in response to intradermal skin testing 
with PBS, autologous serum and codeine in the skin of CSU patients and healthy controls. 
The objectives of the study were: 
● to assess the dermal tolerance of cutaneous microdialysis in CSU; 
● to develop the experimental protocol for cutaneous microdialysis studies into skin 
reactivity to PBS, autologous serum and codeine in CSU patients and healthy 
controls; 
● to establish the baseline values for dermal concentrations of histamine, tryptase and 
cytokines in CSU patients and healthy controls; 
● to explore the kinetics of histamine release in the skin of patients with CSU in 
response to skin testing with PBS, autologous serum and codeine; 
● to choose the optimal outcome measures for future microdialysis studies in CSU. 
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2.2 Materials and Methods 
Cutaneous microdialysis studies in CSU were carried out within the scope of the project 
“Microdialysis study of inflammatory mediators and cytokines in the early and late- 
phase of dermal response to PBS, codeine and autologous serum injections in chronic 
ordinary urticaria patients and healthy controls”. The study was approved by the East 
Norfolk & Waveney Research and Governance Committee (Ref:07/Q0101/42) and the 
Norfolk Research Ethics Committee (Ref: 2006DERM02L(198-12-06)) (Appendix 1). 
2.2.1 Participant Characteristics 
A total of fourteen patients with CSU and thirteen healthy subjects completed the study. 
CSU patients were recruited from Cutaneous Allergy Clinics at the Dermatology 
Department of Norfolk & Norwich University Hospital (Norwich, UK). Healthy 
volunteers were recruited from the hospital staff through noticeboard advertisements. 
Participants were reimbursed for their traveling and meal expenses and loss of income 
incurred by their participation in the study. Healthy volunteers were paid for their 
participation in the study. 
Inclusion criteria for CSU patients were age 18-70 years and continuous CSU. Exclusion 
criteria included pregnancy, lactation; co-morbidity of bronchial asthma treated with 
inhaled corticosteroids at moderate-to-high doses (e.g. beclomethasone dipropionate 
<400µg/day) or allergic rhinitis treated with intranasal corticosteroids; continuous 
treatment with potent topical and/or systemic steroids within one month or systemic 
steroid rescue treatment for less than 3 days within 2 weeks; treatment with ciclosporin 
within 3 months; current treatment with β-adrenoreceptor blockers, allergy to amide local 
anaesthetics, latex allergy, ongoing treatment with oral codeine, current treatment with 
tricyclic antidepressants (doxepin prescribed for urticaria at lower doses than for clinical 
depression was considered as an antihistamine rather than antidepressant) and H2 
blockers prescribed for conditions other than chronic urticaria. Patients on treatment with 
doxepin or H2 antihistamines for their urticaria were asked to discontinue them 2 weeks 
or 72 hours before microdialysis experiments, respectively. Additional exclusion criteria 
for CSU patients included co-existing predominant physical urticarias; CSU with a 
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suspected or confirmed infectious, allergic, drug-induced or physical cause; biopsy-
proven urticarial vasculitis defined by the presence of leukocytoclasia, fibrin deposition, 
endothelial swelling with or without erythrocyte extravasation. Additional exclusion 
criteria for healthy controls were currently active atopic disease (eczema, bronchial 
asthma, hay fever), skin diseases or autoimmune disease, requiring treatment, including 
autoimmune thyroid disease. Healthy subjects were not tested for atopy in this study. 
Of fourteen CSU patients who completed the study, there were hve men and nine women. 
The mean age of patients with CSU was 52.3 years (range 33-68 years). Of thirteen 
healthy controls who completed the study, there were hve men and eight women. The 
mean age of healthy controls was 46.2 years (range 30-60 years). All patients and healthy 
controls provided written informed consent before their participation in the study. 
2.2.2 Experimental Set-up for Microdialysis Studies 
For our microdialysis experiments, we used a high precision CMA 400 microsyringe 
pump (CMA Microdialysis AB, Sweden) to ensure accurate, continuous and pulseless 
perfusion. The pump was subjected to a safety check at the Norfolk & Norwich 
University Hospital. The microdialysis probes were in-house manufactured at the 
Immunopharmacology Unit at the University of Southampton. The probes were 
characterized by a 3,000 kDa cut-off. Linear microdialysis probes were manufactured 
using membranes from the dialysis cartridge Plasmahow ® OP Series Asahi Hollow 
Fiber Plasma Separator. The membrane was glued to nylon connecting tubing (Portex, 
France) using cyanoacrylate glue (Loctite, Ireland). Probe construction was carried out 
wearing sterile gloves at the dedicated area covered with laboratory benchcoat. Before 
the microdialysis experiments, the probes underwent ethylene oxide sterilization at the 
In-Health Decontamination Service (Cardiff, UK). Skin dialysates were collected into 
sterile DNA-free cryotubes (Greiner Bio-One, UK). 
2.2.3 Cutaneous Microdialysis Procedure 
H1 antihistamines were withdrawn for 72 hours, H2 blockers for 72 hours, tricyclic 
antidepressants (e.g. doxepin) 2 weeks before the experiment. Patients were given 1% 
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menthol in aqueous cream to reduce pruritus on an as needed basis. Participants were 
asked to attend the microdialysis procedure having applied local anaesthetic EMLA 
cream to three sites on their forearm and covered with occlusive Tegaderm dressing (3M 
Healthcare Ltd, UK) for 60 minutes before the start of microdialysis (Figure 9). 
The patients and volunteers were provided with verbal and written instructions. Patients 
were asked to avoid strenuous exercise, eating or drinking hot or caffeine containing 
beverages for 8 hours before the microdialysis studies. Visual analogue scales for itching 
and wealing over 24 hours was assessed at baseline. 
Microdialysis studies (see video: Appendix 2 on CD-R) were carried out at the day 
research ward at the Clinical Trials and Research Unit at the Norfolk & Norwich 
University Hospital (Figure 9A). Before the microdialysis experiment, patients and 
volunteers were asked to rest quietly lying in bed for 10 min. Six linear microdialysis 
probes (a molecular weight cut-off of 3,000 kDa) were inserted into non-lesional skin of 
the volar surface of the arm of patients and volunteers under local anaesthesia with 
EMLA cream (Astra AB, UK) (Figure 9B) and a short exposure to an ice cube before the 
probe insertion. The probe insertion was carried out using a 24 gauge guide cannula 
(Figure 9C) which was then removed leaving the microdialysis probe implanted in dermis 
(Figure 9D). The probes run for 20 mm below the surface of the skin. The probes were 
connected to the microdialysis pump via a plastic tubing and were perfused briefly with 
sterile saline solution at a flow rate of 3µl/min to test the probes for leaks, then they were 
disconnected from the pump and the arm was bandaged for 1 hour and 40 min for the 
skin to recover from local anaesthesia and initial trauma caused by probe insertion. 
During the sample collections the microdialysis probes were reattached to the pump and 
perfused with sterile Ringer’s solution at the constant rate of 3µl/min. 
Sterile PBS (pH=7.4) (Tayside Pharmaceuticals, UK) (20µl) was injected, using an 
insulin syringe, at the midpoint along each probe (1mm away from the probe) at the 
microdialysis site 1, autologous serum (20 µl) — at the microdialysis site 2 and codeine 
phosphate (20µ1 of 0.3mM codeine phosphate solution prepared in laminar flow at the 
Pharmacy at the Norfolk & Norwich University Hospital, UK) — at the microdialysis site 
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3 on the non-dominant arm after the baseline perfusion (Figure 9E). At the end of the 
microdialysis experiment, the probes were removed and a sterile dressing was applied. 
2.2.4 Protocol Development for Microdialysis Studies 
Protocol development in this study was related to the technical aspects and design issues 
of the microdialysis procedure. Adjustments to the experimental protocol were needed to 
optimize the procedure for its use in CSU. The protocol design development was focused 
on modifications of sampling strategy to achieve an optimal temporal resolution of 
microdialysis sampling for mediators of interest in skin responses to intradermal testing 
with PBS, autologous serum and codeine in CSU. Optimisation of sample preparation for 
analytical procedures was critical to ensure that the concentration range for the mediators 
of interest in CSU falls within the linear range of the analytical methodologies. 
Modifications in working research hypothesis evolved through protocol development and 
interim analysis of the data. 
Protocol 1 (Figure 10) 
Initially, the protocol was designed to establish the baseline mediator concentrations and 
to assess the early and late phase skin response to intradermal testing with PBS, 
autologous serum and codeine in CSU patients and healthy subjects. For protocol 1, 
microdialysis sampling in patients and healthy controls was carried out at baseline (Time 
period 1), within the first 2 hours (Time period 2), between 4-6 hours (Time period 3) and 
24-26 hours after skin testing (Time period 4). The duration of the baseline collection 
was 30 min, Time periods 2-4 consisted of three 40 min dialysate collections each. Time 
period 1 baseline collection and Time period 2-3 collections after skin testing were 
performed on non-dominant arm while Time period 4 collection was carried out on the 
other arm. Skin testing on the opposite arm before Time period 4 collection was carried 
out using a template of microdialysis sites for the next day microdialysis experiment. The 
sites of skin testing and planned location of the probes were marked with a waterproof 
marker. Undiluted dermal dialysates were analysed for histamine, tryptase and cytokines. 
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Protocol 2 (Figure 11) 
The next step of protocol development was focused on optimising the intervals of 
microdialysis sampling. As illustrated in the Figure 12, Protocol 2 involved 
measurements of skin responses in patients and healthy controls at baseline (Time period 
1), within the first two hours (Time period 2), between 4-6 hours (Time period 3) after 
skin testing. The duration of the baseline collection was 30 min. The collection B within 
Time period 2 included eight 5-min dialysate collections. Collections C and D within 
Time period 2 and all collections within Time period 3 were each of 40 min duration. The 
key differences from Protocol 1 were 5-min dialysate sampling intervals for the first 40 
min after skin testing and limiting the duration of the protocol by 6 hours after skin 
testing. Neat dermal dialysates were analysed for histamine. An introduction of 5 min 
dialysate collections for the first 40 min after skin testing was planned for 
pharmacokinetic profiling of histamine release to intradermal testing with PBS, 
autologous serum and codeine in CSU patients and healthy controls. This protocol 
modification was planned for determining optimal temporal resolution for dialysate 
collections after skin testing. 
Protocol 3 (Figure 11) 
Further protocol development was related to fine-tuning the intervals of microdialysis 
sampling and evaluating the dilution factor for dermal dialysates. Protocol 3 consisted of 
measurements of skin response in CSU patients and healthy controls at baseline (Time 
period 1), within the first 2 hours (Time period 2) and between 4-6 hours (Time period 3) 
after skin testing. The duration of the baseline collection was 30 min. The collections B 
and C within Time period 2 included eight 5-min dialysate collections each. Collection D 
within Time period 2 and all the collections within Time period 3 had duration of 40 min 
each. The main differences from the Protocol 2 were the extension of 5-min dialysate 
sampling for the first 80 min after skin testing. Also, one probe at each microdialysis site 
was allocated for dialysate sampling for analysis of neat dialysates to assess the baseline 
histamine concentration, while the other probe was used for dialysate collection for 
analysis of diluted samples to evaluate the peak histamine concentration after skin 
testing. Fine-tuning of sampling and analytical procedures in Protocol 3 was planned for  
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evaluation of histamine release patterns to codeine and autologous serum in CSU and for 
determining the optimal duration of 5 min sampling after skin testing. Determining the 
range of baseline and peak histamine concentrations was important for estimating the 
optimal dilution of dialysate samples for analytical accuracy. 
The explorative pilot project (Protocol 1) required protocol modification based on the 
data accumulating in the study. Sequential prospective data-driven modifications to the 
study protocol are regarded as an adaptive study design which enhanced the efficiency 
and reduced the costs of the study without compromising its integrity and validity of the 
data (Orloff et al, 2009). An adaptive study design allowed us to improve or modify the 
study design during the study in a pre-planned manner guided by the interim data 
analysis. The adaptive design of our study also enabled us to incorporate the data of the 
Pilot Project (Protocol 1) into the main study (Protocols 2 and 3). However, the outcome 
measures throughout the study did not change, therefore, the data from different protocol 
modifications were pooled for analysis (Figure 12). 
The microdialysis protocols were developed in collaboration with Prof. Martin Church 
and Prof. Geraldine Clough from the Immunopharmacology Group at the University of 
Southampton in view of their extensive expertise in skin mast cell biology and cutaneous 
microdialysis research in allergic inflammation. 
2.2.5 Dialysate Handling and Analysis 
Skin dialysates collected during the microdialysis experiments were snap frozen in liquid 
nitrogen and were stored at -70°C and then sent on dry ice for analysis to the University 
of Southampton by a courier delivery. Dermal dialysates were assessed for histamine by 
Histamine ELISA kit (BioSource, Belgium) in the Protocol 1 and for tryptase by an in-
house double antibody-sandwich ELISA (University of Southampton, UK). 
For histamine analysis of skin dialysates in the Protocol 2 and 3, the Histamine ELISA kit 
was purchased from the Cambridge Biosciences Ltd because of unavailability of the 
previous kit. The detection limit for Histamine ELISA was 0.12 ng/ml. For histamine 
analysis by ELISA, the linearity was observed in the range of concentrations between 
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0.74-8.48ng/ml. Histamine analysis was carried out by Dr Elena Borzova in collaboration 
with Dr Carolanne McGuire (University of Southampton). Histamine analysis in skin 
dialysates collected at 5-min intervals was carried out by Dr Laurie Lau (University of 
Southampton, UK). 
Tryptase measurements were carried out using an in-house double antibody-sandwich 
ELISA utilizing polyclonal rabbit anti-tryptase antibodies for capture and the mouse AA5 
monoclonal antibodies for the detection (University of Southampton, UK). Monoclonal 
AA5 antibodies were purified from hybridoma culture supernatant fluid by protein G 
chromatography. Western blot studies characterized the binding of AA5 mAbs to both 
human recombinant α- and β- tryptase isoforms (Buckley et al, 1997). After coating the 
plate with rabbit anti-tryptase serum, the plate was washed and non-specific binding was 
blocked with bovine serum albumin followed by another washing. The dialysate samples 
were added to the plate for incubation. The plates were washed and then incubated with 
the mouse AA5 monoclonal antibodies. After washing, biotinylated rabbit anti-mouse 
IgG was added and followed by washing and adding avidin-biotin-peroxidase complexes. 
The plate was washed and developed using p-nitrophenyl substrate. Readings of the 
colorimetric reaction was carried out at 450/595nm optical density. The interaction of the 
rabbit anti-mouse IgG and the peroxidase conjugate was enhanced by binding between 
avidin and biotin. The detection limit for the assay was 0.06 ng/ml. The linear region of 
the curve was between 0.75 ng/ml and 64 ng/ml. The tryptase assays of the dialysates 
were carried out by Dr Andrew Walls and Dr Zhou at the University of Southampton. 
Cytokine content in the skin dialysates were analysed using BD Cytometric Bead Array 
Flex Sets measuring IL-5, IL-13, IL-6, IL-3, IFN-γ and TNF-α. Cytometric beads coated 
with specific antibodies allows for the capture of the target protein in the sample on the 
bead surface. In the Flex Set, several particles with discrete fluorescence intensity can be 
discriminated based on their size and fluorescence and, therefore, their use permits 
analysis of multiple target proteins in one sample, i.e. multiplexing. During the flow 
cytometric analysis, each bead population is designated with an alphanumeric position 
relative to other bead population which enables a separate flow cytometric read-out for 
each bead population. The fluorescence readout was carried out using FACS Calibur 
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instrument at the Flow Cytometry facility at the University of Southampton. The data 
were analysed by FCAP Array™ software. The limit of detection of the assays was 20 
pg/ml for selected cytokines. The cytokine assays were carried out by Dr Elena Borzova 
in collaboration with Dr Carolanne McGuire (University of Southampton, UK). 
2.2.6 Planimetry 
Reading of the weal areas was carried out by planimetry using acetate films to record the 
weal perimeter after skin testing with PBS, autologous serum and codeine. The 
planimetry imagery was then digitized and the weal area was calculated using the NIH 
Image J software. 
2.2.7 Data Analysis 
Continuous variables are presented as medians with interquartile ranges. The 
pharmacokinetic parameters included peak concentrations (Cmax), time to reach the peak 
concentration (Tmax) and the area under the curve (AUC) and were calculated using 
LabPilot 5 software (CMA Microdialysis, Sweden). Comparisons between three groups 
were first tested using the Kruskall-Wallis test and then Mann-Whitney U testing was 
used to evaluate the difference between each pair of study groups. Correlations between 
parameters were assessed by Pearson’s correlation coefficient for variables with linear 
relationships and by Spearman’s correlation coefficient for those with non-linear 
relationships. Statistical analysis was carried out using Minitab 16 (Minitab, USA). P-
value <0.05 were considered to be statistically significant. 
2.3 Results 
2.3.1 Dermal Tolerance of Cutaneous Microdialysis Studies in CSU 
Methodological validity of cutaneous microdialysis studies in CSU was supported by 
clinical assessment of microdialysis sites and pharmacokinetic evidence from our 
microdialysis experiments. Cutaneous microdialysis procedures were well tolerated in all 
but two patients with CSU (Figure 13). Figure 13 shows the representative microdialysis 
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experiments in CSU patients and healthy controls suggesting dermal tolerance of 
cutaneous microdialysis procedures in both groups of research participants. 
Fi
gu
re
 1
3. 
Re
pr
es
en
ta
tiv
e 
M
ic
ro
di
al
ys
is 
Ex
pe
rim
en
ts
 in
 C
SU
 P
at
ie
nt
s 
an
d 
H
ea
lth
y 
Su
bj
ec
ts
A.
 R
ep
re
se
nt
at
ive
 m
ic
ro
di
al
ys
is 
ex
pe
rim
en
t 
in
 a
 C
SU
 p
at
ie
nt
B.
 R
ep
re
se
nt
at
ive
 m
ic
ro
di
al
ys
is 
ex
pe
rim
en
t 
in
 a
 h
ea
lth
y 
su
bj
ec
t
Fi
gu
re
 1
3.
 P
ho
to
s o
f m
icr
od
ial
ys
is 
ex
pe
rim
en
ts 
de
m
on
str
at
e 
de
rm
al 
to
ler
an
ce
 o
f m
icr
od
ial
ys
is 
pr
oc
ed
ur
es
 in
 C
SU
 p
at
ien
ts 
(F
ig
ur
e 
13
A)
. I
n 
ou
r p
ilo
t s
tu
dy
,
cu
ta
ne
ou
s m
icr
od
ial
ys
is 
wa
s w
ell
 to
ler
at
ed
 w
ith
ou
t s
po
nt
an
eo
us
 w
ea
lin
g 
to
 th
e 
ins
er
tio
n 
of
 th
e 
m
icr
od
ial
ys
is 
pr
ob
es
 o
r d
ur
ing
 th
e 
ex
pe
rim
en
ts 
in 
all
 (1
2/
14
) b
ut
 2
CS
U 
pa
tie
nt
s. 
Cl
ini
ca
l a
ss
es
sm
en
t o
f t
he
 m
icr
od
ial
ys
is 
sit
es
 su
gg
es
te
d 
th
at
 d
er
m
al 
to
ler
an
ce
 o
f c
ut
an
eo
us
 m
icr
od
ial
ys
is 
in 
m
os
t C
SU
 p
at
ien
ts 
wa
s c
om
pa
ra
bl
e
to
 th
at
 o
f h
ea
lth
y c
on
tro
ls 
(F
ig
ur
e 
13
B)
. 
NM
CP
07
 - 
Le
ft 
Ar
m
AM
SV
11
 - 
Ri
gh
t A
rm
Ab
br
ev
a
tio
n
s:
CS
U 
- C
hr
on
ic 
sp
on
ta
ne
ou
s u
rti
ca
ria
Chapter 2 Assessment of mediators and cytokines in the skin 
129 
However, some methodological considerations regarding cutaneous microdialysis 
experiments arose in a few CSU patients. It was worth noting that skin reactivity to codeine 
may be enhanced in a few CSU patients or healthy volunteers. Acute localized urticaria 
around the microdialysis site was noted in one healthy control (Figure 14). Few patients 
with CSU developed large reactions to skin testing with codeine or autologous serum 
(Figure 15) and/or persistent wealing to microdialysis procedures (Figure 16). Although 
there was an overlap in surrounding flares, the weals did not overlap. Taking into account 
the previous literature (Petersen et al, 1997b), this would not affect the histamine 
concentrations in the adjacent sites. The insertion of the microdialysis probes resulted in 
local wealing in some patients (Figure 17). Spontaneous wealing at the microdialysis sites 
may occur before (Figure 18A) or during the microdialysis experiments (Figure 18B). 
Taping of the microdialysis probes to skin resulted in spontaneous wealing in few patients 
with CSU. In two CSU patients and one healthy control (Figure 19), we observed 
increased dermal histamine or tryptase concentration in skin dialysates at baseline 
comparable to that after skin testing with codeine. This suggested that this dermal 
response was likely to occur as a result of the insertion or the presence of the microdialysis 
probes in the dermis. We are aware of the fact that dermal hyperreactivity to microdialysis 
procedures may occur in a few healthy subjects. We report this dermal response in two out 
of fourteen CSU patients in our study and we would recommend skin biopsy as an 
alternative for these patients. It may be important to include their results in the analysis 
because the exclusion of these patients from the studies may incur selection bias. 
2.3.2 Baseline Dermal Concentrations for Histamine, and Tryptase and IL-
6 wealing in a few Patients with CSU and Healthy Subjects 
In our pilot study, we estimated the baseline dermal concentrations of histamine, and 
tryptase and IL-6 in dialysates from patients with CSU and healthy controls. The median 
for the baseline histamine concentration in CSU patients (n=12) was 2.32 (0.86; 2.78) 
ng/ml while the baseline histamine concentration for healthy controls (n=13) was 0.86 
(0.28; 1.33) ng/ml. Sample analysis revealed that our study was sufficiently powered 
(76.5%) to detect a statistically significant difference in the baseline histamine 
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concentration in CSU patients and healthy controls (unpaired t test, p<0.05). For future 
microdialysis studies, sample size calculation indicated that 12 participants in both groups 
is a sufficient sample size for demonstrating the statistically significant difference in the 
baseline histamine concentrations between CSU patients and healthy controls (Figure 20). 
The mean baseline concentration for tryptase in skin dialysates of patients with CSU 
(n=9) was 2.1 (1.68; 2.77) ng/ml whereas the baseline tryptase concentration in healthy 
controls (n=8) was 0.70 (0.70; 1.72) ng/ml. The difference in the baseline tryptase 
concentrations for both groups was not statistically significant (Mann-Whitney U test, 
p=0.1437) (Figure 21). Sample analysis revealed that our pilot study for tryptase  analysis 
in 9 CSU patients and 8 healthy volunteers was not sufficiently powered (41.4%) to 
detect the minimal significant difference in the baseline dermal tryptase concentrations 
between these two study groups. Baseline IL-6 concentration in CSU patients was 33.08 
(22.961; 82.045) pg/ml whereas in healthy controls it was 12.81 (6.92; 31.11) pg/ml. 
However, the difference was not statistically significant (Figure 22). 
Noteworthy, baseline histamine concentration in skin dialysates tends to be higher in CSU 
patients with a positive autologous serum skin test than those in with a negative autologous 
serum skin test and healthy controls (Table 2, Figure 23A). Also, baseline histamine 
concentrations in skin dialysates in CSU patients with serum histamine-releasing activity 
was significantly higher compared to those without serum histamine-releasing activity 
(Mann-Whitney U test, p=0.0262) and healthy controls (Mann-Whitney U test, p=0.008) 
(Figure 23B). 
There was a moderate correlation between baseline histamine concentrations in skin 
dialysates and clinical indices for wealing in patients with CSU as assessed by visual 
analogue scales (Figure 24A). There was no correlation noted for the baseline tryptase or 
IL-6 concentration and clinical scores for wealing based on visual analogue scales in 
CSU patients (Figure 24B and C). 
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2.3.3 Pharmacokinetic Characteristics of Histamine Release in Response 
to Skin Testing with PBS, Autologous Serum and Codeine in CSU 
Patients and Healthy Controls 
Pharmacokinetic analysis of the concentration-time profiles for histamine concentrations 
in response to different stimuli (PBS, autologous serum and codeine) within 40 min of 
skin testing was carried out on the pooled data from Protocol 2 and 3 (Figure 25). 
Histamine pharmacokinetic analysis was based on eight CSU patients and three healthy 
controls who participated in Protocol 2 and 3. The histamine response profile to skin 
testing with autologous serum was noted in two CSU patients with a positive autologous 
serum skin test and a positive serum-induced basophil histamine release assay (MLP12 
and RPP25) (Figure 26). The peak dermal extracellular histamine concentrations in these 
patients were 17.25 and 31.26 ng/ml, respectively (Table 3). The time to reach the peak 
histamine release after skin testing with autologous serum in these patients (Figure 26 
and Table 3) was 15 min in both patients. Following skin testing with autologous serum, 
dermal extracellular histamine concentrations returned to the baseline levels within 40 
min of skin testing (Figure 26). 
Therefore, our data suggest a relatively slow low-grade histamine release in skin in 
response to skin testing with autologous serum in patients with autoreactive CSU. The 
pattern of histamine release induced by an intradermal injection of autologous serum 
differs considerably from that in response to skin testing with codeine. By contrast, skin 
testing with codeine resulted in the peak histamine concentrations above the linear range 
for Histamine Immunoassay (10 ng/ml for neat samples and 30 ng/ml for diluted 
dialysate samples). Following skin testing with codeine, dermal histamine release peaked 
within 5 min and returned to the baseline values within 20-30 min in most patients and 
healthy controls (Table 3). Therefore, skin testing with codeine results in a rapid, 
pronounced short-term histamine release in skin of CSU patients and healthy subjects. 
Comparison of the box plots for AUC for histamine in response to PBS, autologous 
serum and codeine provided valuable information on the trends in the histamine release 
responses to these stimuli in CSU patients and healthy controls (Figure 25). In general,  
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patients with CSU tended to have higher histamine release to PBS and autologous serum 
but lower histamine release to codeine compared to healthy subjects. However, only 
descriptive pharmacokinetic analysis was possible because the peak concentration for 
histamine release in response to codeine stimulation was above the linear range for the 
histamine assay. 
2.3.4 Protocol Modifications in the Cutaneous Microdialysis Study in CSU 
During the study, there were two modifications of the original protocol which resulted in 
optimisation of cutaneous microdialysis methodology, re-appraisal of the research 
hypothesis and outcome measures. In this section, the interim data analysis will be 
reviewed as a rationale for sequential protocol modifications for our microdialysis 
experiments. An incremental gain and a revision of the research hypothesis will be 
described at each step of the protocol development. Finally, an optimal design for a 
cutaneous microdialysis study in CSU will be discussed based on the results of our study. 
Protocol 1 
An interim analysis of the data from six CSU patients and nine healthy controls 
accumulated during Protocol 1 revealed that the median baseline histamine 
concentrations (IQR) in the dermal interstitial fluid were estimated at 1.83 ng/ml (0.36, 
4.28) in CSU patients and at 0.86 ng/ml (0.20, 1.33) in healthy controls. The coefficient 
of variation for baseline histamine concentration was 121.64% in CSU patients and 
78.72% in healthy controls. There was a histamine release in B collection following 
intradermal testing with codeine in both study groups but no change in histamine 
concentration was observed after skin testing with autologous serum in patients with 
CSU. To ascertain if the 40-min intervals for microdialysis sampling after skin testing 
were suboptimal to detect the changes in mediator levels from the baseline in response to 
skin testing, shorter sampling intervals were proposed to overcome the limitations of the 
current protocol. Therefore, an alternative sampling approach was adopted and included 
sampling at 5-min intervals for the first 40 min after skin testing. The interim study 
results shifted the focus of the research on the early (0-2 hours) and the late phase (4-6 
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hours) biochemical events in skin after skin testing in CSU. Therefore, it was decided to 
proceed with the Time period collections 1-3 of the microdialysis experiments only. 
Protocol 2 
At this stage, the statistical power of the study was still not sufficient (52,3%) for 
detection of the difference in baseline histamine concentration in the dermis of CSU 
patients (median (IQR) — 2.24 ng/ml (0.72-4.28)) and healthy controls (median (IQR) — 
1.04 ng/ml (0.22 — 1.31)). The coefficient of variation for the baseline histamine 
concentration in the pooled patient data from Protocols 1 and 2 was 103.43% in patients 
and 72.4% in healthy controls. An interim analysis at this stage revealed an increase in 
dermal histamine concentrations after skin testing with autologous serum in one patient 
with CSU. In patients and healthy controls, codeine-induced histamine release peaked at 
5 min and returned to normal within 20-25 min of skin testing (Table 1). 
Histamine concentrations after skin testing with autologous serum and codeine reached 
the maximum of the linear dynamic range for the Histamine ELISA assay (Cambridge 
Biosciences Limited, UK). Therefore, for Protocol 3, it was decided to increase the 
duration of 5 min-sampling up to 80 min and to use one microdialysis probe per the 
microdialysis site for analysis of neat samples to detect the baseline concentration of 
histamine and dermal dialysate collected from other probe per the microdialysis site for 
analysis of the diluted samples (DF=3) to look at the peak concentrations of histamine in 
dermis in response to skin testing. The dilution factor (DF=3) for sample dialysates was 
predetermined on the samples from Protocol 1. 
Protocol 3 
Final analysis included the microdialysis data accumulated in the study: 
● baseline histamine concentration for 14 patients and 13 healthy controls; 
● baseline tryptase data for 9 patients and 9 healthy controls; 
● pharmacokinetic analysis for histamine release for 40 min for 4 patients and 3 
healthy controls. 
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Median baseline histamine concentration was 2.32 ng/ml (0.86; 2.78) in patients with 
CSU and 0.86 ng/ml (0.28; 1.33). Two outliers were removed. Data analysis showed a 
statistically significant difference in baseline histamine concentration between patients 
with CSU and healthy controls (Mann-Whitney U test, p<0.05). 
Pharmacokinetic analysis of the data from this stage showed a slow low-grade histamine 
release induced by autologous serum skin test in two CSU patients with serum histamine-
releasing activity. Histamine release in response to autologous serum peaked at 15-20 
min and lasted for up to 40 min. The pattern of histamine release to an intradermal 
injection of codeine was characterized by a fast and pronounced histamine release which 
lasted for 15-20 min. 
2.3.5 Sample analysis 
For protocols 2 and 3, histamine concentrations in skin dialysates collected from each 
microdialysis site in four CSU patients and one healthy control were analysed neat and 
diluted to 1:3. Pearson correlation coefficients between histamine concentrations in neat 
and diluted samples in CSU patients and a healthy control ranged between 83.2-97.9%. 
The dilution factor (DF=3) was established by analysis of skin dialysates obtained from 
one patient (EBP04) and one healthy subject (SCV08) in the Protocol 1 part of the study. 
The Histamine ELISA assay is characterised by high sensitivity of 0.12 ng/ml in plasma 
samples. The log-linear range for Histamine ELISA Kit (Cambridge Biosciences Limited, 
UK) is between 0.74-8.48 ng/ml for neat samples and, therefore, 2.22-25.44 ng/ml for 
diluted samples (DF=3). It is worth noting that histamine concentrations exceed the log-
linear range for this assay in diluted skin dialysates collected at 5 min intervals within 15 
min of skin testing with codeine. From laboratory perspective, these samples need to be 
re-analysed in higher dilutions. However, this approach appears to be impractical for 
microdialysis studies in view of very low dialysate volumes, which do not permit the re-
analysis. 
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2.3.6 Optimal Design of Full-scale Microdialysis Study in CSU 
An optimal study design is crucial for a full-scale microdialysis study in CSU to ensure 
that the obtained results are valid and of biological and clinical relevance. Our pilot study 
confirms that cutaneous microdialysis research is suitable for research in CSU but 
requires protocol modifications. Our study highlighted several design factors that need to 
be considered for a microdialysis study in CSU. Thus, important design variables include 
patient population, a layout of the microdialysis sites, sampling design and the 
performance characteristics of analytical procedures. 
Taking into account sample size calculation, the rate of dermal reactivity to the 
microdialysis procedures in CSU and the costs of the microdialysis experiments, the 
minimum number of study participants should be at least 20 patients and 20 healthy 
controls for sufficient statistical power of the study to detect the differences in baseline 
concentrations of histamine and tryptase between CSU patients and healthy controls. A 
balanced design for patient stratification into patients with positive and negative 
autologous serum skin test can be considered to test the hypothesis of a low-level 
histamine release underlying serum autoreactivity in CSU. Given that serum 
autoreactivity occurs in 45.9% of patients with CSU (Krause et al, 2009), it may be 
needed to balance the patient recruitment until having 10 CSU patients with a positive 
autologous serum skin test and 10 patients with a negative autologous serum skin test 
completed the study. A multi-centre study would facilitate patient accrual. Selection of 
the research centres with an established microdialysis set-up could reduce the costs of the 
study. 
A certain degree of variation in the assessment of skin testing results between different 
centres has been addressed in several recent publications on autologous serum skin test in 
CSU (Konstantinou et al, 2009; Metz et al, 2009). As a suggestion, more stringent criteria 
for a positive autologous serum skin test, such as redness and weal diameter of more than 
5 mm, may be considered for a microdialysis study in CSU in view of technical 
sophistication and the costs of the study to avoid borderline results of skin testing and to 
ensure consistency of patient recruitment in a multi-centre study. Criteria for stopping the 
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microdialysis experiment should include intensive wealing at the areas adjacent to 
microdialysis sites or facial swelling during the experiment. Dermal reactivity to the 
microdialysis procedures should be defined as wealing at the microdialysis sites after the 
probe insertion or during the microdialysis experiment or a release of histamine or 
tryptase at the baseline comparable to that after skin challenge with codeine. A possibility 
of skin biopsy for study participants with dermal reactivity to cutaneous microdialysis 
should be discussed at the recruitment and consent for a skin biopsy, if needed, should be 
obtained before the microdialysis experiment. A prompt analysis of dermal dialysates 
after each experiment can help confirm or exclude dermal reactivity and can inform 
whether further arrangements for skin biopsy are necessary. 
In our study, we could not demonstrate a correlation between the dermal tryptase 
concentrations and the clinical scores (VAS for itching and wealing) or the difference 
between patients with CSU and healthy subjects. First of all, small sample size could be 
an explanation for the lack of correlation as was demonstrated by power calculations. 
However, other methodological and biological reasons could provide alternative 
explanations. The choice of antibodies for the detection of tryptase could have an effect 
on concentration estimates. For example, AA5 monoclonal antibodies used in our study 
appears to bind to the pro and mature forms of α- and β- tryptases with equal affinity. By 
contrast, G5 monoclonal antibodies have greater affinity for mature β-tryptase than for 
the pro or mature forms of α- or β-tryptases. In CSU mast cell density in the skin was 
demonstrated to be about 3 times higher than that in healthy subjects (Kay et al, 2014a) 
as well as ongoing mast cell degranulation. Increased skin mast cell density and ongoing 
mast cell degranulation may contribute to the changes in dermal tryptase concentrations. 
It is possible that a mild degree of mast cell accumulation may not be sufficient to 
stimulate a detectable difference in skin tryptase levels between the groups. In addition, 
the mode of in vivo mast cell degranulation in CSU is poorly understood. A piecemeal 
degranulation of cutaneous mast cells or basophil degranulation in the skin could be an 
alternative explanation for the lack of the difference in tryptase concentrations between 
the groups in our study. Therefore, for future studies, the parallel use of tryptase assays 
using AA5 or G5 monoclonal antibodies on the same dialysate samples would provide 
Chapter 2 Assessment of mediators and cytokines in the skin 
152 
new insights into tryptase isoform distribution in CSU. Other methodological possibilities 
are that tryptase may have been under-represented in the fluid recovered by 
microdialysis, or that availability of only small sample volumes (25µl) may have 
compromised the sensitivity of the assay. This justifies the allocation of larger sample 
volume for tryptase analysis. 
In our study, there was no statistically significant difference (two-sample Wilcoxon test, 
p>0.05) in mean weal area after skin testing with PBS between CSU patients (median 
weal area - 0.23 (0.09-0.34 mm2)) and healthy controls (median weal area — 0.16 (0.01-
0.27 mm2)). The weal area measurements after skin testing with codeine did not reveal 
any statistically significant difference (two-sample Wilcoxon test, p>0.05) between CSU 
patients (median weal area — 1.00 (0.74-1.21mm2) and healthy controls (median weal 
area — 0.74 (0.47-1.36 mm2). However, the median weal area was significantly larger 
(two- sample Wilcoxon test, p<0.05) in autologous serum-induced weals in CSU patients 
(median weal area — 0.40 (0.27-0.54mm2) compared to healthy subjects (median weal 
area — 0.20 (0.07-0.30mm2)). These data indicate the average weal area was within the 
chosen distance (3-5cm) between the microdialysis sites in our study. Although the flares 
did overlap between the microdialysis sites in few patients (Figure 15), this fact did not 
affect the results. In previous microdialysis studies, it was shown that histamine does not 
spread into the flare area (Petersen et al, 1997b). However, larger distance between the 
sites would be important in future studies measuring, for example, neuropeptides which 
are released within the flare area and could be affected by flare overlap. 
In order to assess the variability in the dialysate measurements, a two-way analysis of 
variance model was estimated using duplicates of baseline histamine, tryptase and IL-6 
concentrations from CSU patients and healthy controls. One factor was the subject ID 
and another being the replicate of measurements. The analysis showed that for histamine 
and tryptase there was no significant variation due to replicate measurements in skin 
dialysates in which the tests taken but that there was significant variability between the 
research participants. For IL-6 measurements, there was a significant variation in the 
replicates and the individuals. The variability due to individuals was 3.5 times higher 
than the variability due to the order of measurements. These data highlight the need for 
Chapter 2 Assessment of mediators and cytokines in the skin 
153 
larger microdialysis studies to account for inter-individual variability for all the 
measurements (histamine, tryptase and IL-6 concentrations). These data confirmed the 
reliability and precision of the measurements for histamine and tryptase in the study. This 
is crucial as the baseline measurements were done in dupplicates while the measurements 
for pharmacokinetic profiling were carried out on single samples due to the dialysate 
volume limitations. For cytokine concentrations, the variability in the measurements 
could be, possibly, reduced by using novel BD Cytometric Bead Assays with enhanced 
sensitivity for multiplex cytokine measurements. 
Microdialysis experiment is planned on the forearm of non-dominant arm (Figure 27). 
Predictive skin testing with PBS, codeine and autologous serum on the opposite arm 
could help for adjustment of a layout of the microdialysis sites depending on the extent of 
reaction to codeine and autologous serum. Microdialysis sampling carried out at 5 min 
intervals for 40 min after skin testing is recommended for estimating the concentration 
over the time profile for histamine release after skin testing with PBS, autologous serum 
and codeine in CSU patients and healthy controls. 
Optimal study outcomes may include: 
● Mean baseline histamine and tryptase concentrations in the dermal interstitial fluid of 
CSU patients and healthy controls obtained by cutaneous microdialysis; 
● Pearson’s correlation coefficient for baseline histamine concentration and clinical 
scores (VAS for itching, VAS for wealing and UAS3); 
● The difference in means of AUC(40 min) for histamine release in response to PBS, 
autologous serum and codeine between CSU patients and healthy controls estimated 
by ANOVA; 
● Total histamine content in skin biopsy specimens obtained from study participants 
with dermal reactivity to the microdialysis procedures. 
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2.4 Discussion 
2.4.1 Experimental evaluation of Cutaneous Microdialysis in CSU 
Our pilot study demonstrated that cutaneous microdialysis is a suitable research 
technique in CSU. Methodological, clinical and financial aspects were the main practical 
considerations for cutaneous microdialysis studies in CSU. Firstly, dermal tolerance of 
microdialysis procedures in CSU needed to be established in view of the possibility of 
non-specific wealing response to skin manipulations. Secondly, practical concerns were 
related to patient recruitment to microdialysis studies in view of the need for stopping 
antihistamine treatment for three days before microdialysis. Furthermore, assessment of 
the potential issues with experimental design and data collection in our pilot 
microdialysis study was of particular importance to ensure validity of future full-scale 
microdialysis studies in CSU. Finally, our study offered a possibility to assess the set-up 
and running costs for cutaneous microdialysis research in the setting of a secondary care 
hospital. 
Excellent accrual and high patient compliance were demonstrated in our cutaneous 
microdialysis in CSU. Participant feedback demonstrated high motivation for research in 
patients with CSU due to a significant burden of the disease. In our study, withdrawal of 
antihistamine treatment in most patients resulted in mild-to-moderate worsening of itch 
and wealing but was well tolerated. In severely affected patients, stopping antihistamines 
was associated with severe wealing but no facial swellings were reported. Patients were 
informed about the possibility of withdrawing at any point if they were uncomfortable 
with their wealing and advised against proceeding with the experiments in case of facial 
swellings whilst off antihistamines. Stopping antihistamines for 72 hours before the 
microdialysis studies is a usual practice before autologous serum skin testing in clinical 
settings and 72-hour withdrawal of antihistamines for our study was approved by the 
Norfolk Research Ethics Committee. All patients were highly motivated and willing to 
proceed with the experiments due to the lack of understanding of disease mechanisms 
and limited efficacy of current management. In one patient, mild lip swelling was 
observed at the end of the microdialysis experiment which responded well to a licensed 
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dose of cetirizine. For future microdialysis studies, withdrawal criteria from the study for 
patients during the wash-out period or microdialysis experiments may be considered. 
Financial aspects of an introduction of cutaneous microdialysis to the research facility 
involves the start-up costs of microdialysis pump (the price for the CMA 400 
microdialysis pump - £3,500), running costs of manufacturing and sterilization of the 
microdialysis probes and the costs of analytical assays. Manufacturing costs for each 
probe estimated at £5. For our study, manufacturing of the microdialysis probes was 
carried out at the University of Southampton without charge. Ethylene oxide sterilization 
of the microdialysis probes costed approximately £50 per half-basket. Sample analysis 
may incur the most substantial costs based on selected analytical assay and the number of 
samples according to the study protocol. For example, Protocol 1 yields 30 dialysate 
samples per participant, Protocol 2 -42 dialysate samples per participant and Protocol 3 
— 63 samples per participant. Each Histamine immunoassay kit allows analysis of 84 
samples and is marketed at the price range of £300-£500. Therefore, thorough protocol 
development is also important for financial feasibility of microdialysis studies in CSU. 
Our study showed that cutaneous microdialysis was well tolerated in most patients with 
CSU but the protocol design and technical performance of the technique can be optimised 
for CSU. Methodological concerns are related to wealing response to the probe insertion 
or during the microdialysis experiments in few patients with CSU. Furthermore, 
enhanced response to skin testing with codeine in few patients or healthy controls which 
may affect the microdialysis data from the adjacent microdialysis site and may require 
skin pre-testing with codeine before the experiment for patient selection and optimisation 
of the layout of the microdialysis sites. Post-experiment eligibility criteria for patients 
data to be included in the final analysis may be needed based on the technical aspects of 
cutaneous microdialysis experiments in research participants. It may well be possible that 
exclusion of patients with large or persistent wealing to cutaneous microdialysis may 
introduce bias to the research into skin inflammation in CSU. An option of skin biopsy 
for these patients within the scope of future microdialysis studies may reduce the 
potential bias. Research into mast cell abnormality in these patients may provide some 
insight into skin pathophysiology of this condition. The limitations of cutaneous 
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microdialysis studies in CSU can be improved or overcome by patient stratification, 
predictive skin testing before the experiments, design modifications of microdialysis 
experiments and possibly an option of skin biopsy for patients who are not eligible to 
microdialysis experiments due to non-specific wealing to the microdialysis procedures. 
Cutaneous microdialysis offered a unique opportunity of continuous sampling of the 
extracellular fluid from the skin of patients to look at the local inflammation in the skin in 
CSU. Our pilot study also enabled us to explore the limitations of the technique for this 
novel research application — CSU. Main methodological considerations were related to 
an issue of dermal reactivity to the insertion of the microdialysis probes or their presence 
in the skin during the microdialysis experiments. In our study, dermal reactivity to the 
microdialysis procedures in CSU comprised a local histamine release with or without 
associated non-specific wealing caused by the insertion trauma or by the presence of the 
probes in the skin during the microdialysis experiments. Histamine release due to the 
probe insertion was described in the previous microdialysis studies in healthy subjects. 
Usually, histamine release was noted to subside during the equilibration period after the 
probe insertion. Further methodology research on whether the equilibration period in 
CSU may be of longer duration due to the pre-existing disturbances in the histamine 
metabolism in the skin. Dermal reactivity to the probe insertion was also reported in 
earlier microdialysis studies (Stenken et al, 2010; Linden et al, 2000), however, this 
phenomenon may well be of greater clinical relevance in CSU in a view of a lower skin 
threshold for wealing in this condition. Our data illustrated a good tolerance of cutaneous 
microdialysis in most, but two, CSU patients. However, few CSU patients and healthy 
controls may have skin hyper reactivity to the insertion of the microdialysis probes 
defined as skin wealing at the insertion sites during the experiment or histamine or 
tryptase release at the baseline that is similar to that after skin testing with codeine. In 
these individuals, cutaneous microdialysis may not be a suitable research technique to 
study the skin inflammation. Skin biopsy can be considered as an alternative research 
method to study the skin inflammation in these individuals. Skin hyperreactivity to the 
insertion of the microdialysis procedures in a few individuals was commonly reported in 
the microdialysis studies (Stenken et al, 2010; Sjogren & Anderson, 2000; Petersen, 
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1997a). There is an increasing interest in the recent studies whether skin hyperreactivity 
to the microdialysis procedures can be predicted (Linden et al, 2000). 
An observation of two CSU patients with high levels of dermal extracellular histamine 
concentrations throughout the experiment with or without associated wealing brings to 
our attention an issue of skin threshold for wealing in CSU, even in the evidence of 
histamine release in the dermis. It is possible to assume that histamine release underlying 
serum autoreactivity in CSU was not detected in the previous work due to the insufficient 
sensitivity of histamine assay (Larsen, 2002). 
Our experiments revealed higher levels of the baseline extracellular histamine 
concentration in dermis in patients with CSU compared to healthy controls. Our data also 
suggest the baseline extracellular histamine concentrations in the dermis could be used as 
a candidate biomarker of the intensity of local inflammation in skin in CSU in view of its 
relation to disease severity. This observation can be of practical importance and needs to 
be verified in larger scale microdialysis studies in CSU. As a suggestion, the use of 
urticaria activity score for three days (UAS3) when patients are off antihistamines could 
be a helpful parameter for clinical assessment of disease severity in addition to visual 
analogue scales in future microdialysis studies. 
2.4.2 Histamine Concentrations in the Dermis of Patients with CSU 
Therefore, the data were interpreted with caution in view of limited generalizability. 
Nevertheless, taking into account the usual size of cutaneous microdialysis studies, our 
data on the histamine pharmacokinetics in skin of CSU patients and healthy subjects were 
insightful and of great interest. 
Study results revealed a statistically significant difference in dermal extracellular 
histamine concentrations in CSU patients and healthy controls. These data provided 
additional evidence for the minimal persistent inflammation in visibly unaffected skin in 
patients with CSU. Earlier studies demonstrated an increased level of histamine in the 
skin of CSU patients (Kaplan et al, 1978). Our study confirmed these data on a larger 
group of patients with CSU and showed a tendency for correlation of dermal extracellular 
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histamine concentrations and clinical scores for itching and wealing. This is an important 
finding that needs to be verified in a larger study in CSU. The prospect of developing 
dermal histamine concentrations as a skin biomarker in CSU highlights the clinical 
relevance of these data. 
The pilot study helped refine the research hypothesis based on the accumulating data on 
the pharmacokinetics of histamine release in CSU compared to that in healthy subjects. 
Pharmacokinetic analysis of histamine release to autologous serum and codeine in CSU 
patients revealed two different modes of histamine release: a fast short pronounced 
histamine release to codeine versus a slow low-grade histamine release to autologous 
serum. To our knowledge, this was the first study to report the histamine release 
underlying skin response to autologous serum in CSU. A slow low-grade histamine 
release, but not tryptase release, was described in allergic reactions following a prolonged 
challenge with allergen (Charlesworth et al, 1989). The persistence of functional 
autoantibodies to the high-affinity IgE receptor and/or anti-IgE may present a similar 
prolonged stimulation of the effector cells (mast cells and basophils) in CSU. These data 
drew attention to the activation pathways of mast cells and basophils induced by 
autologous serum in CSU. Hypothetically, a piecemeal degranulation of basophils and, 
possibly, mast cells may be an explanation for the observed pattern of histamine release. 
These findings raise the question about the putative roles of elevated histamine levels in 
the unaffected skin in CSU. There has been recently interest in immunoregulatory effects 
of histamine in inflammatory conditions. H4 receptors are characterized by higher 
affinity towards histamine than H1 and H2 receptors, therefore histamine effects 
mediated via H4 receptors may occur at the local concentrations of histamine lower than 
required for stimulation of H1 and H2 receptors (Fung-Leung et al, 2004). Histamine 
effects mediated via H4 receptors include chemotaxis and cytokine and chemokine 
production by mast cells, eosinophils, dendritic cells and T cells (Jutel et al, 2005; Zhang 
et al, 2007). In mice models, triggering of H4 receptors resuted in mast cell migration 
towards histamine but has no effects on FcεRI-mediated degranulation (Hofstra et al, 
2003). H4 receptors also mediate eosinophil chemotaxis but these effects of histamine are 
considerably weaker than those of CCR3-active eotaxin and eotaxin-2 (Buckland et al, 
Chapter 2 Assessment of mediators and cytokines in the skin 
160 
2003; Ling et al, 2004). H4 mediators also favor Th2-polarization (Schneider et al, 2002; 
Zhang et al, 2007) and mediate attenuation of cytokine production mediated by Toll-like 
receptors on dendritic cells (Zhang et al, 2007). Furthermore, histamine regulates the 
expression of its own receptors on endothelial cells (Shaefer et al, 1999). 
2.4.3 Tryptase Concentrations in the Dermis of Patients with CSU 
Previous reports of dermal tryptase concentrations estimated using cutaneous 
microdialysis are limited. In healthy subjects, tryptase levels in skin dialysates have been 
reported to be below 20 ng/ml, using a fluoroenzyme immunoassay (Pharmacia) (Nielsen 
et al, 2001). In dermal neurogenic inflammation, baseline tryptase concentrations in skin 
dialysates were estimated at 9.84±2.4ng/ml as measured by radioimmunoassay 
(Pharmacia) (Schmelz et al, 1999). In CSU, microdialysis data on dermal tryptase 
concentrations are not available to our knowledge. In suction blister studies tryptase 
levels in visibly unaffected skin of patients with CSU were found to be greater than those 
in the skin of healthy subjects as measured by Pharmacia Tryptase radioimmunoassay 
(Deleruan et al, 1991). In our study, the choice of the double antibody sandwich ELISA 
using AA5 monoclonal antibodies for the detection of tryptase was made taking into 
account sample volume requirements and the sensitivity of the assay. 
In CSU it was observed that there was mild-to-moderate mast cell accumulation in the 
skin as well as ongoing mast cell degranulation. Both of these processes may contribute 
to the changes in dermal tryptase concentrations. α- and β-protryptases are secreted 
constitutively by mast cells and contribute to the total tryptase levels while β-tryptase is 
released upon mast cell degranulation. It is possible that a mild degree of mast cell 
accumulation may not be sufficient to stimulate a detectable difference in skin tryptase 
levels between the groups. In addition, the mode of in vivo mast cell degranulation in 
CSU is poorly understood. A low-grade continuous histamine release, without associated 
tryptase release, was described in the suction blister studies in the late-phase allergic 
reactions similar to that observed in our study. Alternatively, basophil inhltration was 
described in the skin of CSU patients. Basophil degranulation in the skin could result in 
marked histamine release but only minimal tryptase release. 
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Tryptase is thought to be involved in the skin inflammation in CSU, however, its precise 
contribution is poorly understood. Tryptase appears to be involved into microvascular 
leakage (He & Walls, 1998), leukocyte recruitment (Walls, 1995; Compton et al, 1999), 
angiogenesis (Crivellato et al, 2009) and tissue remodeling (Cairns, 1998). The role of 
tryptase was suggested in spreading the signal for mast cell degranulation (He et al, 1998) 
and inducing itch via extracellular proteolysis of PAR-2 receptors (Itoh et al, 2005) 
although the relevance of these processes to CSU is unknown. The presence of 
exocytosed immunoreactive tryptase in the skin of CSU patients was confirmed by 
suction-blister fluid experiments and histological studies although the expression, the 
storage and the relative isoenzyme distribution of skin tryptase in CSU await 
characterisation. In CSU, an ongoing mast cell activation may result in altered kinetics of 
tryptase release whereas microvascular leakage in CSU may affect the proteolytic 
behaviour of tryptase and the substrate supply in the skin. In CSU, serum total tryptase 
levels were shown to be elevated, particularly in patients with symptomatic disease and in 
those with serum capacity to up-regulate CD63 on basophils from healthy donors. It 
remains unclear whether local tryptase release in the skin precedes its systemic rise in 
CSU and whether this may reflect disease progression. Further research into tryptase 
haplotypes and activating mutations underlying hyper-releasable mast cell phenotype 
may explain this observation. 
The potential for therapeutic targeting of β-tryptase in CSU has been indicated by a report 
that the non-selective protease inhibitors, nafamostat mesilate and camostat mesilate had 
clinical efficacy in two CSU patients (Takahagi et al, 2010). A range of tryptase 
inhibitors has been developed including peptidic, dibasic, zinc-mediated inhibitors and 
heparin antagonists (Rice & Moore, 2000). Of the inhibitors of β-tryptase developed for 
clinical use APC 2059, a dibasic tryptase inhibitor, was found to lack of efficacy in 
psoriasis but to be effective in ulcerative colitis (Tremaine et al, 2002) and asthma 
(Krishna et al, 2001). Novel small molecular β-tryptase inhibitors continue to be 
developed using combinatorial libraries. Structure-based library design can provide 
insights into the binding of inhibitors to catalytic sites and inducible pockets in the central 
cavity of the tetrameric scaffold of β-tryptase (Liang et al, 2012). The design and 
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development of potent and highly selective tryptase inhibitors may allow better 
management of CSU in the future. Such innovative therapeutic approaches may provide a 
means for more effective anti-mediator blockade in this disease before embarking on 
immunomodulatory or biological therapies. Topical use of tryptase inhibitors would be an 
attractive approach in CSU, and should help in elucidating the contribution of β tryptase 
in the skin level in CSU. Protease inhibitors such as YC1015, YC1016 and YC1017 have 
been developed as topical formulations for atopic eczema, and their effects on dermal 
tryptase levels in CSU may be worth exploring. However, the potential concerns would 
include the risk of protein sensitization or skin irritation with topical use of β-tryptase 
inhibitors as well as the extent to which they may also inhibit other serine proteases. 
2.4.4 Histamine Release to Codeine and Autologous Serum in CSU 
Notably, both patterns of histamine release to codeine and autologous serum skin test 
with different pharmacokinetic profiles were characterised by the area under the curve for 
histamine of similar magnitude for both stimuli (autologous serum and codeine). This 
suggested the possibility of different modes of degranulation of mast cells and basophils 
to autologous serum and codeine of CSU patients. Mast cell degranulation in response to 
skin testing with autologous serum was shown by electron microscopy. Basophil 
accumulation in skin of patients with CSU was noted in histological studies, their 
degranulation was proved by extracellular deposition of BB1 antibodies. Piecemeal 
degranulation of basophils was described in various skin inflammatory conditions 
(Dvorak, 2005) and may serve as a possible explanation for a slow low-grade histamine 
release observed in response to autologous serum in some patients with autoreactive 
CSU. 
Higher histamine release to PBS may suggest non-specific wealing due to ‘twitchy’ mast 
cells in CSU. Enhanced histamine release in response to skin testing with autologous 
serum demonstrated the phenomenon of serum autoreactivity which is observed in 45.9% 
of CSU patients (Krause et al, 2009). According to the available literature (Cohen et al, 
1986; Shall & Saihan, 1992), skin responsiveness to codeine may well be a two-phase 
phenomenon. Initially, predisposed individuals with a tendency for intermittent wealing 
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display high sensitivity and responsiveness to codeine skin testing while patients with 
clinical expression of chronic wealing (CSU) show high sensitivity but decreased skin 
responsiveness to codeine. This may reflect disease progression and gradual depletion of 
cellular pools of histamine due to continuous degranulation of mast cells and basophils. 
2.4.5 Methodological issues with the detection of histamine, tryptase and 
cytokines 
In our study, histamine release to codeine was characterised by considerable inter-
individual variability beyond the dilution factor used for dialysate samples in our study. 
Accurate detection of both the ceiling and floor values for histamine release in response to 
codeine stimulation is critical for pharmacokinetic analysis of histamine release modes in 
CSU. Histamine ELISA (Biosource, Belgium) used in our study is highly sensitive to 
detect baseline extracellular histamine concentrations in skin dialysates but the dynamic 
range is not sufficient for the detection of the peak histamine concentrations in response to 
codeine. Therefore, there is a need for further development of analytical approaches to the 
histamine detection in dermal dialysate samples from patients with CSU and healthy 
subjects. For this purpose, an optimal analytical assay should be characterised by high 
sensitivity (low detection limit), a wide linear dynamic range for at least two log-decades 
(nanogram to microgram range) and low sample volume requirements. 
This pilot study allowed us to refine the research hypothesis and focus our research 
questions. For future microdialysis studies, the working hypothesis could suggest that 1) 
the baseline extracellular histamine concentration in dermis reflects the intensity of local 
inflammation in CSU and 2) skin reactivity in CSU is mediated by aberrant modes of 
histamine release in response to skin testing with PBS, autologous serum and codeine. 
Several potential causes for raised extracellular histamine concentration at baseline can be 
explored including abnormal activity of histidine decarboxylase or histamine-metabolising 
enzymes. Local factors that can affect the enzyme activity could be explored such as 
cytokine effects on histidine decarboxylase or substrate inhibition of histamine-
metabolising enzymes. In addition, parallel microdialysis and histological studies on the 
same patient in CSU could shed some light on contribution of local mast cell accumulation 
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noted in CSU (Kay et al, 2014a) to increased dermal histamine concentration in unaffected 
skin. Aberrant skin mast cell releasability is a likely mechanism underlying aberrant modes 
of histamine release in response to PBS, autologous serum and codeine. Signaling defects 
or activating mutations resulting in hyperreleasable skin mast cell phenotype would be 
worth exploring with laser capture dissection microscopy of skin biopsies in parallel with 
functional responses assessed by cutaneous microdialysis. 
Based on our data, the baseline extracellular histamine concentrations, Tmax, T1/2 and 
AUC can be selected as optimal outcome measures for a full-scale microdialysis study in 
CSU to answer these questions. The use of the peak histamine concentration (Cmax) as an 
outcome measure showed a few pitfalls. The peak histamine concentrations in response 
to codeine were characterised by a high inter-individual variability which was in keeping 
with the results reported in other microdialysis studies (Krause et al, 2013). In our study, 
the concentration ranges for histamine release in response to skin testing with codeine 
was beyond the linear range of the immunoassay which did not permit an accurate 
detection of Cmax in response to codeine stimulation. The use of analytical methodologies 
with a wide dynamic range (nanogram-miligram range) would improve the validity of 
Cmax as an outcome measure for the microdialysis studies in CSU. 
Therefore, other analytical approaches with high sensitivity but a wide dynamic range of 
at least two log-decades have to be considered for the detection of histamine in skin 
dialysates. Accurate detection of both baseline and peak histamine concentrations in skin 
dialysates is important for estimating the concentration over time profiles for histamine 
release to different stimuli. Clinical relevance of this pharmacokinetic analysis is 
highlighted by an observation of different modes of histamine release after skin testing 
with codeine and autologous serum in CSU. Therefore, further research into the 
pharmacokinetic characteristics of histamine release in response to codeine and 
autologous serum in CSU may provide fascinating insights into the pathophysiology of 
serum autoreactivity and abnormal codeine sensitivity in CSU. 
Recent advances in the analytical detection of histamine in biological samples include the 
development of Förster resonance energy transfer (FRET)-based assay which is based on 
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methylaloamine dehydrogenase conversion of histamine, transfer of reducing equivalence 
to amicyanin and measurement of resultant change in amicyanin absorption by 
fluorescence (Gustiananda et al, 2012). This method is characterised by high sensitivity 
(13nM) and a wide linear detection range (13nM-225µM). However, the method was 
reported for samples of 100µL, which would be a limitation of its use for skin dialysate 
samples in our study design. Histamine assays using Luminex technology permit 
histamine detection within the range of 0.4-40 ng/ml with sensitivity of 0.2 ng/ml but this 
linear range may not be sufficient, without sample dilutions, to detect the peak histamine 
concentration in response to codeine stimulation. Alternative methods for histamine 
detection in biological samples may include surface plasmon resonance immunosensor (Li 
et al, 2006) or high performance liquid chromatographic method (Siegel et al, 1990). 
Recently, an analyzer HistaReader 510, based on glass microfiber-based technology, was 
developed for histamine analysis by Reflab (University of Copenhagen, Denmark). The 
method is characterised by sensitivity of 5 ng/ml and a dynamic range between 0 to 150 
ng/ml. A high throughput capacity of HistaReader 510 makes it an attractive method for 
analysis of skin dialysates in healthy subjects and patients with CSU. This method was 
used for microdialysis studies in healthy subjects (Krause et al, 2013). However, the 
baseline values in healthy subjects and CSU patients fall below the detection limit of the 
HistaReader analyzer. By contrast, immunoassays are characterised by high sensitivity for 
histamine detection. For example, the sensitivity of Histamine ELISA Kit (Cambridge 
Biosciences, UK) is 0.12 ng/ml, which is appropriate for the baseline levels of histamine. 
There may be a rationale for using both techniques for skin dialysate analysis in CSU. In 
the future microdialysis studies, dialysate collection by each probe per a microdialysis site 
can be allocated either for histamine analysis for the baseline concentration by 
immunoassay (high sensitivity) or for peak concentration analysis by the HistaReader 
technology (a wide dynamic range). 
In our study, we could not demonstrate correlation between the dermal tryptase 
concentrations and the clinical scores (VAS for itching and wealing) or the difference 
between CSU patients and healthy subjects. First of all, small sample size could be an 
explanation for the lack of correlation as was demonstrated by power calculations. 
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However, other methodological and biological reasons could provide alternative 
explanations. The choice of antibodies for the detection of tryptase could have an effect 
on concentration estimates. For example, AA5 monoclonal antibodies used in our study 
appears to bind to the pro and mature forms of α- and β- tryptases with equal affinity. By 
contrast, G5 monoclonal antibodies have greater affinity for mature β-tryptase than for 
the pro forms of α- or β-tryptases. For future studies, the parallel use of tryptase assays 
using AA5 or G5 monoclonal antibodies on the same dialysate samples would provide 
new insights into tryptase isoform distribution in CSU. Other methodological possibilities 
are that tryptase may have been under-represented in the fluid recovered by 
microdialysis, or that availability of only small sample volumes (25µl) may have 
compromised the sensitivity of the assay. 
We did not detect any difference in IL-6 concentration in skin dialysates between CSU 
patients and healthy controls. IL-6 is known to be increased in several inflammatory 
conditions as well as in response to the minimal trauma of microdialysis probe insertion 
(Krause et al, 2013; Stenken et al, 2010; Sjogren and Anderson, 2009). Our results 
suggest neither the increase in IL-6 in CSU patients at baseline compared to healthy 
controls, nor its correlation with disease severity. However, these results should be 
interpreted with caution as the analysis of variability indicated significant variation 
between individuals and sample replicates for IL-6 measurements in our study. Previous 
data suggest that IL-6 is consistently recovered and measured in skin dialysates (Krause 
et al, 2013; Sjogren et al, 2012; Clough et al, 2007) using both CBA bead-based 
immunoassays and microarrays although the direct comparisons between the studies are 
not possible due to the differences in the microdialysis set-up and the kits used for 
cytokine analysis. In our study, we attempted to measure IL-4, IL-5, IL-6, TNF-α and IL-
13 in skin dialysates from both groups of study participants. TNF-α and IL-13 were 
detectable at low levels in few patients while IL-4 and IL-5 were not detectable in the 
samples. This is consistent with previous studies (Stenken et al, 2010, Clough et al, 
2007). The possible reasons for poor recovery of these cytokines could be insufficient 
sensitivity of the assays, cytokine binding to the receptors and microdialysis membrane, 
impermeability of the membrane for certain cytokines. It is unknown whether cytokine 
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detection could be improved by the use of novel bead-based immunoassays with 
enhanced sensitivity for cytokines (BD Biosciences) or by addition of the antibody- 
coated beads to the perfusate for microdialysis sampling (Clough et al, 2013). 
2.4.6 Strengths and limitations of the study 
The pilot study resulted in the detection of the differences between dermal histamine 
concentrations in CSU patients and healthy controls as well as the demonstration for the 
first time of in vivo histamine release in the skin of CSU patients in response to skin 
testing with autologous serum. The major strength of this study is its controlled study 
design. The use of histamine analysis assays with high sensitivity and reliability was 
another strength of the study which allowed us to detect dermal histamine release at the 
lower range of nanoscale measurements that was, probably, missed in an earlier 
microdialysis study in CSU (Larsen, 2002). Microdialysis studies provide stronger 
evidence for mediator participation in dermal responses compared to the circumstantial 
evidence derived from blockade of the response by antihistamines (Clough & Church, 
2002). Protocol development through adaptive design was also a strength of the study 
which permitted the use of the same outcome measures from different stages of protocol 
development. 
The exploratory nature of this pilot study defined the study limitations such as small 
participant numbers per each protocol modification and limited generalisability of the 
results. Also, the limitations of the experimental model have to be understood as no 
model can fully capture and reproduce the complexity of a biological phenomenon. Lack 
of histamine calibration can be considered as another limitation of this study but some 
authors argue that histamine calibration cannot be carried out in the inflammatory 
conditions due to altered solute recovery by plasma extravasation after skin testing 
(Petersen, 1997a). This study did not use codeine titration which limited the interpretation 
of observed histamine release in dermal response to the stimulation with autologous 
serum and its relevance to the skin autoreactivity. Analytical limitations included the lack 
of the detection of most cytokines except IL-6 in skin dialysates. Also, the peak 
concentrations of histamine in response to codeine were above the log-linear range for 
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both neat and diluted samples (DF=3) and, therefore, could not be accurately estimated 
by the analytical approaches in this pilot study. Overall, the pilot study was successful 
and led to the development of optimal study protocol for a definitive confirmatory study. 
2.4.7 Optimal Study Design for a Microdialysis Study in CSU 
The development of an optimal protocol design (Figure 27) for a full-scale microdialysis 
study in CSU was related to refinement of post-experiment exclusion criteria, clinical 
criteria for stopping a microdialysis experiment, a layout of the microdialysis sites, 
predictive skin testing and analytical procedures for skin dialysates. A multi-centre study 
was suggested by sample size calculations for several candidate outcome measures such 
as the baseline concentrations of histamine or tryptase in skin dialysates and AUC(40 min) 
for histamine release in response to PBS, autologous serum and codeine. The suggested 
study design will address the issues that arose during the pilot project. Whether or not this 
study design is successful for a multi-centre microdialysis study in CSU in real-life 
research setting will depend on sufficient attention to patient recruitment, technical 
training support for clinical investigators and analytical performance of the assays for 
sample analysis as well as close monitoring of the progress throughout the study. 
2.4.8 Unresolved questions for future studies 
Although our knowledge advanced over the last two decades, there are numerous 
unresolved questions about the pathophysiology of CSU. For example, what is the 
relative contribution of histamine and other mediators such as VEGF, CGRP and PAF to 
weal formation in CSU? Answers to these questions would optimize the use of existing 
anti-mediator treatments in CSU as well as enhance the development of combined 
therapeutic agents targeting several mediators. 
It is important to know what are the molecular mechanisms mediating the 
proinflammatory effects of persistent increase in dermal histamine concentration in the 
skin of CSU patients? In particular, the relevance of histamine effects mediated via H4 
histamine receptors is of practical significance in view of potential targeting of these 
effects with H4 histamine antagonists. In addition, whether histamine metabolism is 
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perturbed in CSU would justify further research in enzymes involved in histamine 
synthesis and catabolism in the skin. This would provide novel insights into biochemical 
abnormalities which are likely to contribute to elevated histamine levels in the skin of 
CSU patients. 
It would be interesting to know the functional profile of skin mast cells in CSU at a single 
cell level. The use of laser capture dissection microscopy on skin biopsies combined with 
molecular technologies would shed some light on the signaling mechanisms underlying 
skin mast cell releasability in CSU. 
What is the relevance of the effects of anti-FcεRIα antibodies on skin mast cells to the 
phenomenon of skin autoreactivity? Whether anti-FcεRIα antibodies induces a weal- and-
flare response in the skin, can be studied in mouse models with humanized high-affinity 
IgE receptor (Hide & Greaves, 2013). In such studies, in vivo dynamic visualization of an 
interaction between anti-FcεRIα antibodies and cutaneous mast cells using imaging 
techniques in situ would be of particular interest by analogy with the dynamic 
visualization of capture of luminal IgE by perivascular mast cells recently demonstrated 
in mouse models (Cheng et al, 2013). 
Furthermore, studies into the effects of patients’ serum on purified neutrophils would be 
an exciting line of research for future studies. Whether serum histamine-releasing 
activity, as detected by in vitro basophil assays, would also demonstrate neutrophil 
chemotactic effects is yet to be established. However, this suggestion is not unlikely 
taking into account a significant overlap in molecular weight of serum histamine-
releasing factors in CSU and serum neutrophil chemotactic activity in cold-induced 
urticaria (Grattan et al, 1991; Soter, 1983). If this turns out to be right, this would provide 
an overlooked mechanism in CSU and may expand our understanding of underlying 
mechanisms in CSU associated with serum histamine-releasing activity. 
Microdialysis studies in CSU open an avenue for entry to the field of skin proteomics. 
Shotgun proteomic approach was applied to skin dialysate samples obtained in would 
healing (Gill et al, 2011). The skin proteome in CSU remains to be defined. This would 
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provide a more comprehensive picture of contributing mediators as well as other 
biochemical changes in the skin of CSU patients. This data would provide the 
groundwork for the network analysis which may reveal yet unknown biochemical 
interactions in CSU as demonstrated by network analysis in late-phase allergic reactions 
in the skin (Benson et al, 2006). 
The concept of skin threshold for wealing and the reasons for its lowering in CSU needs 
further research. Careful codeine titration in active disease and in remission coupled with 
microdialysis sampling would provide some insights into the minimal histamine release 
required for weal formation in CSU. Another interesting area of future research would 
concern histamine receptors, their density, polymorphism and affinity to histamine in 
CSU. Whether aberrant sensitivity of histamine receptors contributes to weal formation in 
CSU is worth exploring. 
Finally, the use of microdialysis studies could help elucidate the effects of topical 
medications in CSU such as Syk inhibitors and potentially protease inhibitors in the 
future. Further microdialysis studies into therapeutic modulation of skin priming and 
responsiveness in CSU would open up new opportunities for rational therapy in CSU. 
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CHAPTER 3 
Pathophysiological Subsets 
in CSU and their Biomarkers:  
A prospective observational study 
“Surprise is the greatest gift which life can grant us.” 
—BORIS PASTERNAK 
Abstract 
Background: CSU is a common disease which is characterized by recurrent wealing for 
6 weeks or more. CSU is a heterogeneous condition encompassing several 
pathophysiological phenotypes. CSU associated with serum histamine-releasing activity 
is thought to be mediated by functional autoantibodies against the high-affinity IgE 
receptor and IgE itself on the surface of basophils and dermal mast cells (Hide et al, 
1993) although the definitive proof for functional autoantibodies as a causative factor in 
CSU is still lacking (Kaplan & Greaves, 2009). Conversely, patient subsets based on 
basophil histamine releasability to anti-IgE stimulation appeared to be unrelated to the 
presence or absence of serum histamine-releasing activity or anti-FcεRIα autoantibodies 
(Vonakis et al, 2007). Furthermore, in vivo basophil priming in CSU patients, suggested 
by flow cytometric studies, demonstrated the lack of relationship with serum histamine-
releasing activity and anti-FcεRIa autoantibodies (Vasagar et al, 2006). From a clinical 
perspective, there is a need for greater understanding of the contribution of these 
pathophysiological factors to disease severity and the clinical course of CSU. Therefore, 
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we hypothesize that disease severity and a persistent course of the disease in CSU 
patients are associated with serum histamine-releasing activity, aberrant basophil 
releasability to anti-IgE stimulation and phenotypic changes in peripheral blood 
basophils. 
The aim of this observational study was to carry out prospective longitudinal assessments 
of clinical and pathophysiological parameters in CSU patients and to elucidate their 
relation to disease severity and the persistent course of disease. 
Materials and Methods: The study was designed as a prospective observational 
longitudinal study with data collection at three time points over the study period of 6 
months. Twenty two patients (M:F ratio – 5:18) recruited in the study and were treated 
with their usual antihistamine with or without antileukotrienes throughout the study. 
Serum histamine-releasing activity was detected by a serum-induced basophil histamine 
release assay (RefLab, Denmark). Basophil functional subsets were defined by anti-IgE-
induced basophil histamine release assays (Medway School of Pharmacy, UK). Basophil 
flow cytometry studies were carried out using a lyse-no-wash protocol with the 
microbead technology on FACS Canto™ II at the Norfolk & Norwich University 
Hospital. Acquired data were analyzed using Kaluza® software (version 1.1.). 
Results: Based on basophil releasability assays, CSU patients were classified into 
basophil responders (n=8), non-responders (n=7) to anti-IgE stimulation and a subset of 
patients (n=7) with total cellular histamine below the level of detection by 
spectrofluorimetry at all points of a dose-response curve. In addition, CSU patients were 
divided into those with (n=8) and without (n=14) serum histamine-releasing activity. 
Patients with serum histamine-releasing activity were clustered in the subset with total 
cellular histamine below the level of detection by spectrofluorimetry (chi-squared test, 
p=0.004). 
At baseline, CSU patients with total cellular histamine below the level of detection 
demonstrated a more severe disease compared to basophil responders (Mann-Whitney U 
Test, p=0.055) or non-responders (Mann-Whitney U test, p=0.025) to anti-IgE 
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stimulation. The baseline UAS7 score was significantly higher in CSU patients with 
serum histamine-releasing activity compared to those without serum histamine-releasing 
activity (Mann-Whitney U test, p=0.0152). Baseline UAS7 correlated with serum 
histamine releasing activity (Spearman correlation r=0.58, p=0.0045), and with anti-IgE-
induced BHR (Spearman correlation r=0.40, p=0.0666). In our study, 9 patients had a 
persistent CSU and 10 patients had a clinical improvement. Based on the ROC analysis 
for UAS7 at baseline, the cut-off value of 19 predicted the persistent course of CSU with 
63.16% accuracy (sensitivity of 60% and specificity of 66.67%). In longitudinal analysis, 
we showed persistent (n=3) versus transient (n=3) increase in serum histamine-releasing 
activity in CSU patients over time. The use of different gating strategies for flow 
cytometric basophil enumeration in the same sample from each CSU patient resulted in 
statistically significant differences in absolute counts depending on the basophil 
phenotype (CCR3+CD123+ vs CCR3+CD63+ (p=0.0001), CD63+CD203c+ vs 
CCR3+CD123+ (p=0.0003), CD63+CD203c+ vs CCR3+CD63+ (p=0.0001)). There was 
no correlation between absolute basophil counts detected by different gating strategies 
with disease severity. There was no difference in absolute basophil counts between CSU 
patients with a persistent disease or a clinical improvement. 
Conclusions: Pathophysiological phenotyping of CSU patients revealed the lack of 
relationship between serum histamine-releasing activity and basophil releasability to anti-
IgE stimulation. CSU patients with serum histamine-releasing activity had a more severe 
disease. Disease severity in CSU predicted the persistent course of disease. Serial testing 
for serum histamine-releasing activity may be helpful for monitoring inflammation in 
CSU patients. Increased absolute counts of CCR3+CD63+ basophil subpopulation 
compared to CCR3+CD123+ or CD63+CD203c basophil subpopulations may reflect in 
vivo basophil priming in CSU. Flow cytometric enumeration in CSU varied depending on 
the choice of gating strategy for peripheral blood basophils. 
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3.1 Introduction 
3.1.1 The Pathophysiological Classification of CSU patients 
CSU is a heterogeneous condition encompassing several pathophysiological subsets 
(Sabroe et al, 2002; Vonakis et al, 2007). A comprehensive patient classification into 
distinct pathophysiological phenotypes in CSU may help a better assessment of the 
underlying inflammation and a selection of targeted treatment. Several approaches for the 
patient classification in CSU were proposed based on different pathophysiological 
parameters (Saini, 2014). 
The research team from the St John’s Institute of Dermatology (London, UK) proposed a 
classification based on the detection of serum histamine-releasing activity in CSU 
patients (Sabroe et al, 2002). This study classified CSU patients into subsets based on the 
presence of serum histamine-releasing activity and anti-FcεRIα and anti-IgE 
autoantibodies. In this study, serum histamine-releasing activity was associated with anti-
FcεRIα autoantibodies. In general, serum histamine-releasing activity is detected in 30-
50% of CSU patients (Kaplan & Greaves, 2009; Grattan, 2004). In CSU, serum 
histamine-releasing activity was shown to be confined to IgG serum fraction 
(Soundararajan et al, 2005; Kikuchi & Kaplan, 2001). The inhibition of serum-induced 
BHR by recombinant α-chains in CSU patients was first demonstrated by Hide et al 
(1993), and then extended in studies by Kikuchi and Kaplan (2002). This led to an 
interpretation that CSU with serum histamine-releasing activity may be mediated by 
functional autoantibodies against the α chains of the high-affinity IgE receptors or IgE 
itself on the surface of basophils and mast cells in 30-50% of patients (Grattan, 2004) 
although the direct proof of this theory is still lacking (Kaplan & Greaves, 2009). 
Furthermore, this theory does not explain the CSU pathophysiology in about 50-70% of 
patients without serum histamine-releasing activity (Saini, 2014). In addition, serum 
histamine-releasing activity is not specific for CSU and was also observed in cold 
urticaria and urticarial vasculitis (Gruber et al, 1988). Therefore, the clinical and the 
pathophysiological relevance of these findings is incompletely understood and merits 
further research. 
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Another pathophysiological classification was proposed by a research team from John 
Hopkins University (Baltimore, USA) and was based on basophil releasability to anti-IgE 
stimulation in CSU patients. In the work by Vonakis et al (2007), CSU patients were 
subdivided on the basis of basophil functional subsets (responders and non-responders to 
anti-IgE stimulation). An observational study in CSU patients revealed that basophil 
functional phenotypes were observed regardless of the presence of anti-FcεRIα 
autoantibodies as detected by an immunoenzymometric assay (Eckman et al, 2008). The 
authors also reported the lack of relationship between basophil functional subsets and 
serum histamine-releasing activity in CSU patients. Therefore, it was concluded that 
autoantibody-mediated desensitization of the high-affinity IgE receptor appeared to be an 
unlikely cause for abnormal basophil releasability to anti-IgE stimulation. Patients’ 
basophils releasing histamine to anti-IgE stimulation show reduced SHIP-1 expression 
level while non-responding basophils have increased SHIP-2 levels (Vonakis et al, 2007). 
Also, clinical implications of basophil functional phenotypes were suggested in the study 
by Baker et al (2008) but this needs to be further elucidated in well-designed studies. 
Based on the previous work, both mechanisms, serum histamine-releasing activity and 
basophil releasability to anti-IgE stimulation, are thought to contribute to the disease 
severity. The direct comparisons between these studies is not possible due to the variation 
in the methodology which was reflected in the correspondence between ourselves 
(Grattan & Borzova, 2009) and the research team from John Hopkins University 
(Eckman et al, 2009). The detection of serum histamine-releasing activity relies on 
basophil releasability assays which are characterized by a considerable variability in 
basophil releasability displayed by different donors (MacGlashan Jr., 2013). In the study 
by Eckman et al (2007), the presence of anti-FcεRIα autoantibodies was defined by an 
immunoenzymometric assay. As for the binding assays, non-specific binding was 
reported due to the conformational changes in blotted α-chains of the high-affinity IgE 
receptor (Kaplan & Joseph, 2007). Both methodologies have limitations and showed a 
lack of correlation (Eckman et al, 2009). In addition, methodological concerns were 
raised that CSU patients with basopenia might have been excluded from the functional 
studies using basophils from CSU patients. This may have resulted in the recruitment of 
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different patient populations between the studies. Hence, the use of both classification 
approaches in the same study population of CSU patients may reveal the relative 
contribution of serum histamine-releasing activity and basophil releasability to anti-IgE 
stimulation to disease severity and the clinical course of disease. The interrelationship 
between these classification approaches in CSU patients, although currently unclear, may 
be potentially important for identifying underlying pathophysiology linked to severe 
and/or persistent CSU. 
3.1.2 In vivo basophil priming in CSU 
Another phenomenon of interest in the pathophysiology of CSU is in vivo priming of 
peripheral blood basophils in CSU as suggested by Vasagar et al (2006). In practice, 
activated basophils can be recognized by up-regulation of surface activation markers 
using flow cytometric analysis. Currently, several surface activation markers have been 
described for human basophils including CD63, CD203c, CD107a, CD107b, CD164 and 
CD13 (MacGlashan Jr., 2010a; Valent, 2010). CD63 (gp53) is a lysosomal membrane 
glycoprotein which belongs to a transmembrane-4 superfamily (Valent, 2010) and is 
expressed by basophils, mast cells, platelets and macrophages (Nieuwenhuis, et al., 1997; 
Metzelaar et al, 1991; Valent, 2010). In basophils, CD63 is located in the membranes of 
the cytoplasmic granules and is considerably up-regulated by fusion of granules with the 
plasma membrane upon anaphylactic degranulation of basophils (MacGlashan Jr., 
2010b). CD203c (neural cell surface differentiation antigen ENPP3) is ectonucleotide 
pyrophosphatase 3 which is involved in the cleavage of deoxynucleotides and nucleotide 
sugars (Bollen et al, 2000). CD203c is a glycosylated type II transmembrane protein 
which is constitutively expressed on mature basophils, basophil and mast cell precursors 
(Buehring et al, 1999). The CD203c expression on resting basophils is relatively low 
which may hinder the identification of peripheral blood basophils using this marker 
(Sturm et al, 2010). CD203c is significantly upregulated on basophil degranulation via 
unknown mechanisms that differ from CD63-linked activation pathway (Sturm et al, 
2010). The lysosome-associated membrane surface markers CD107a (LAMP1) and 
CD107b (LAMP2) are transmembrane lysosomal glycoproteins that were identified as 
novel basophil activation markers (Hennersdorf et al, 2005; Valent, 2010). CD13 is type 
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II transmembrane glycoprotein which is expressed on plasma membranes of most 
myeloid cells including basophils. CD13 belongs to zinc-binding metalloproteinases and 
is also known as aminopeptidase N. This marker was also reported as a novel basophil 
activation marker (Hennersdorf et al, 2005). Surface marker CD69 belongs to a 
transmembrane C-type lectin domain family 2 and is known as a very early activation 
marker for lymphocytes, especially for T cells (Hartnell et al, 1993). CD69 is expressed 
on lymphocytes, NK cells, basophils, eosinophils, platelets (Yoshimura et al, 2002). The 
kinetics of upregulation of basophil activation markers differs depending on the 
activating receptor and the mode of degranulation (MacGlashan Jr., 2010b; Hennersdorf 
et al, 2005). 
Several gating strategies have been devised based on the combination of surface marker 
expression for identification of peripheral blood basophils. For example, a gating strategy 
is based on CD63 and CD203c on circulating basophils was described by Ebo et al 
(2012). The combination of these basophil surface markers was used in HistaFlow test 
(Ebo et al, 2012). Surface marker CCR3 (CD193) is a CC chemokine receptor-3 for 
eotaxin, eotaxin 2, MCP 3, MCP-4 and RANTES and is expressed on basophils, 
eosinophils, mast cells and T-lymphocytes (Pease and Williams, 2006). CCR3 (CD193) 
was characterized by less interindividual variability in its expression on basophils than 
other markers such as IgE or CD123 (Hausmann et al, 2011). Basophils can be also 
identified based on dual expression of CCR3 and CD63 (Eberlein et al, 2010). The 
combination of these markers is employed in the Flow CAST® assay (Bühlmann 
Laboratories AG, Switzerland). In addition, a combination of CCR3 and CD123 was also 
used for basophil enumeration in healthy subjects (Amundsen et al, 2012). CRTH2 
(chemoattractant receptor-homologous molecule expressed on Th2 cells) represents the 
second receptor for prostaglandin D2 and is expressed on basophils, eosinophils and T 
lymphocytes (Boumiza et al, 2005). For basophil identification, CRTH2 is used in 
combination with CD3 to differentiate basophils from Th2 lymphocytes (Boumiza et al, 
2005). CCR3-based gating has been actively developed and advocated as a sensitive and 
reliable approach to basophil gating compared to other gating strategies such as 
CD123/HLA-DR and anti-IgE-based gating (Hausmann et al, 2006). CD123 is IL-3 
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receptor α chain and has a high level of expression on human basophils. Another gating 
strategy for peripheral blood basophil relies on CD123 expression but the lack of HLA-
DR expression (Ebo et al, 2006). However, HLA-DR expression on circulating basophils 
was described in SLE (Charles et al, 2010). IgE is commonly used as a basophil surface 
marker in combination with CD63 or CD203c for gating for peripheral blood basophils 
(de Weck et al, 2002). The IgE density varies among individuals but generally results in 
reliable basophil identification (MacGlashan Jr. et al, 2013). Several novel surface 
markers for human basophils were described such as CD164 (Chirumbolo, 2011; 
Wolanczyk-Medrala et al, 2011) but the information about the gating strategies using 
these markers was not available at the time when this study commenced. At present, 
comparisons of each basophil activation markers has been carried out in CSU but the use 
of gating expression based on two surface markers can provide further insights in 
basophil phenotypes and absolute counts as defined by selected gating strategy. This 
approach may provide novel information on the in vivo basophil immunephenotype and 
ultimately on in vivo basophil priming in CSU. 
Activation status of peripheral blood basophils was noted in CSU (Vasagar et al, 2006), 
asthma (Ono et al, 2010) and venom allergy (Gober et al, 2007). In this study by Vasagar 
et al (2006), flow cytometric analysis demonstrated up-regulation of CD63 and CD69 but 
not CD203c on the surface of peripheral blood basophils in CSU patients. Recent 
research has shown significant up-regulation of FcεRIα on the surface of peripheral blood 
basophils in CSU (Lourenco et al, 2008). Basophil activation markers CD63 and CD203c 
on peripheral blood basophils from CSU patients were up-regulated regardless of ASST 
results while increased CD123 expression was associated only with skin autoreactivity in 
CSU patients (Lourenco et al, 2008). Of interest, Ono et al (2010) described CD203c 
expression on circulating basophils in asthma exacerbations. Among the patients allergic 
to insect venom, baseline CD63 expression was significantly higher in patients with 
systemic reactions during immunotherapy (Gober et al, 2007). In these patients, up-
regulation of CD69 and CD203c was noted following a sting challenge (Gober et al, 
2007). In patients with asthma, circulating basophils were characterized by higher levels 
of CD69 expression than basophils from healthy subjects (Yoshimura et al, 2002). 
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Furthermore, basophils recovered by bronchoalveolar lavage fluid from patients with 
asthma showed higher levels of CD69 expression than peripheral blood basophils from 
the same patients (Yoshimura et al, 2002). Overall, basophils with a vast number of 
receptors on their surface have a capacity of sensing the microenvironment in circulation 
as well as during their maturation. The resulting basophil phenotype in the circulation in 
patients with various diseases may reflect occurring inflammatory changes in the 
microenvironment. Therefore, flow cytometric immunophenotyping of peripheral 
basophils in CSU may be informative for disease-specific changes in peripheral blood 
basophil phenotype. 
3.1.3 Factors associated with disease severity and the clinical course in 
CSU 
Several pathophysiological parameters have been assessed in relation to disease severity 
in CSU in cross-sectional and longitudinal studies. CSU patients with serum histamine-
releasing activity tended to have a more severe disease (Sabroe et al, 2002). 
Autoantibodies against the high affinity IgE receptors were also noted to occur at 
increased frequencies in patients with a more severe disease (Sabroe et al, 2002). The 
relationship between basophil functional subsets and disease severity in CSU patients 
was less clear. Some evidence exist that CSU patients with basophil responder phenotype 
had a more severe itching and higher frequency of patient visits to the emergency 
departments than basophil non-responders but both patient subsets did not differ in 
disease severity (Baker et al, 2008). In prospective observations, basophil numbers were 
also shown to fluctuate in parallel with disease severity and the effect of treatment with 
antihistamines or steroids (Grattan et al, 2003). Basophil releasability to anti-IgE 
stimulation was reported to increase towards the remission of the disease (Eckman et al, 
2009) while serum histamine-releasing activity fluctuated with the treatment-induced 
changes in disease severity by ciclosporin (Grattan et al, 2000) and plasmapheresis 
(Grattan et al, 1992). In a systematic review, plasma levels of prothrombin fragment 1+2, 
D-dimers and C-reactive protein were evaluated as markers for disease severity 
(Takahagi et al, 2010). To our knowledge, longitudinal studies into the level of serum 
histamine-releasing activity in relation to disease severity have not been undertaken. 
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The natural history of CSU ranges from a spontaneous remission to a persistent course 
over years. Factors associated with a longer disease duration include the severe disease, 
the presence of angioedema, co-existence of CSU with physical urticarias and skin 
autoreactivity (Maurer et al, 2011). A systematic review of factors associated with 
disease duration confirmed a disease severity as an important predictor for a persistent 
course of disease (Rabelo-Filardi et al, 2013). There is a considerable variation in CSU 
duration between different studies into the natural course of disease which is likely to 
reflect the differences in patient selection and the period of observation. Nevertheless, 
there is generally considered that CSU in most patients would continue for longer than 
one year and in considerable number of patients for more than 5 years as reported in a 
GA2LEN Task Force report on unmet clinical needs in CSU (Maurer et al, 2013a). 
Although a persistent clinical course occurs only in a subset of CSU patients, its impact 
on patient’s wellbeing and healthcare costs makes it crucial to identify patients at risk of 
a persistent disease. 
3.1.4 The hypothesis of the study 
For this thesis, we hypothesize that disease severity and the persistent course of CSU is 
associated with serum histamine-releasing activity, aberrant basophil releasability to anti-
IgE stimulation and in vivo basophil priming in the circulation. To test this hypothesis, 
we designed a prospective longitudinal observational study with the assessments of 
clinical and pathophysiological parameters at three time points throughout the 
observational period. 
3.1.5 The rationale for the choice of biomarkers in the study 
In this study, we used previously published UAS7 score (range 0-49) to assess disease 
severity in CSU patients. However, during this study, clinical guidelines recommended 
UAS7 score (range 0-42) for clinical assessments of disease severity in CSU patients 
(Zuberbier et al, 2009). There is no current definition for the persistent CSU. In our 
study, we defined a persistent disease if UAS7 score at the Visit 3 was greater or equal to 
that at the Visit 1 whereas a clinical improvement was defined if UAS7 score at Visit 3 in 
the study was less that that at Visit 1. 
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Serum histamine-releasing activity was chosen, with an understanding of its limitations, 
as an integral functional parameter reflecting the activity of histamine-releasing 
autoantibodies and potentially other factors such as chemokines, cytokines on peripheral 
blood basophils from healthy subjects. From a clinical point of view, the use of serum 
histamine-releasing activity was chosen because it was considered as an important 
determinant of disease severity in the previous research by Sabroe et al (2002). Basophil 
releasability assays to anti-IgE stimulation were used to apply the patient classification 
approach described in the previous work by Vonakis et al (2007). It was reasoned that the 
use of both classification approaches would reveal the details of an interaction of serum 
histamine-releasing factors and the effector cells, basophils, in the same patient. In vivo 
basophil priming was assessed in CSU patients to extend the findings published by 
Vasagar et al (2006). In this thesis, we used the detection of basophil phenotypes as 
defined by three previously published gating strategies (CCR3+CD123+ (Amundsen et 
al, 2012), CD63+CD203c+ (Ebo et al, 2002), CCR3+CD63+ (Eberlein et al, 2010) in the 
same whole blood sample from each CSU patient in the study. The choice and the 
interpretation of these pathophysiological parameters in CSU were carried out in the 
context of background knowledge and published evidence supporting their association 
with pathophysiological subsets and/or disease severity in CSU. 
We did not measure the anti-FcεRIα autoantibodies in view of the limitations reported in 
the literature which were not, to our knowledge, resolved. These limitations include non-
specific binding to IgG2 and carbohydrate moieties when blotted α-chains were used for 
the assay (Kaplan & Joseph, 2007). Also, the sensitivity of the autoantibody detection 
varies considerably between the binding assays which makes interpretation and direct 
comparisons difficult. Also, there are no assays at the moment that can distinguish 
functional from non-functional autoantibodies in CSU. 
Furthermore, since there is no consensus on how to define peripheral blood basophils and 
the availability of several gating strategies for basophil studies, we selected well-
researched basophil surface markers CD203c, CD63, CCR3, CD123 for our flow 
cytometric panel based on their applicability to the project aims. First, the gating strategy 
based on CD203c and CD63 was selected as a combination of markers representative of 
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different modes of basophil activation as was suggested by HistaFlow assay (Ebo et al, 
2012) and then demonstrated in the study by MacGlashan Jr. (2010b). CD123 was 
selected based on the previous data on its up-regulation in CSU with skin autoreactivity 
(Lourenco et al, 2008). Surface marker HLA-DR was selected as a part of the gating 
strategy based on CD123 and HLA-DR, however, this analysis was not carried out later 
in view of the possibility of HLA-DR up-regulation in CSU by analogy with SLE 
(Charles et al, 2010). CCR3 surface marker was included in the panel based on the initial 
published data on CCR3-based gating strategies for basophil identification. A dual gating 
strategy based on CCR3 and CD63 expression was applied later following new 
developments in basophil flow cytometry such as the release of Flow CAST® assay 
(Bühlmann Laboratories, Switzerland) employing both surface markers. 
3.1.6 The aims of the study 
The aims of the study included: 
1 to classify CSU patients based on serum histamine-releasing activity and basophil 
releasability to anti-IgE stimulation and to evaluate the relationship between CSU 
pathophysiological subsets and disease severity; 
2 to assess the natural course of disease in CSU patients and to determine the clinical 
and pathophysiological factors predicting the clinical course of CSU; 
3 to determine absolute counts for basophil subpopulations in CSU patients identified 
by three flow cytometric gating strategies and to explore their association with 
disease severity or a clinical course of disease. 
3.2 Materials and Methods 
3.2.1 Study Design 
The study was designed as a prospective observational longitudinal study with data 
collection at three time points over the study period (Figure 28). In the prospective study, 
there was one run-in and three follow-up visits for prospective assessment of clinical 
parameters and the biomarker levels in CSU patients at three time points over the study 
period. We allowed flexibility of 4 weeks between run-in and follow-up visits and 5 
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working days for the assessment visits for logistic reasons. Patients recruited to the study 
were treated with their usual antihistamine with the intention of staying on the same 
treatment throughout the study. Dose variation of antihistamine was allowed. 
CSU exacerbations were treated according to standard clinical practice. The study 
protocol allowed short-term treatment with steroids for urticaria exacerbations if they 
were given within two weeks before the next scheduled study visit, the study visit should 
be deferred by up to 1 month provided patients went back to the original medication. 
Beyond this, patients would be withdrawn from the study. 
As per protocol, if a clinical decision were made that patients need additional long-term 
second- or third- line treatment within the first three weeks of the observational periods, 
patients would be withdrawn from the study. If the decision was made within three weeks 
before the next scheduled visit, the assessment visit would be brought forward and 
patients would be offered a final assessment during a week of clinical work-up required 
before starting the second-line treatment. 
3.2.2 Study Settings 
The clinical study was performed at the Dermatology Department of Norfolk & Norwich 
University Hospital (Norwich, UK). Basophil releasability studies were carried out at 
Medway School of Pharmacy, University of Kent (Chatham Maritime, UK). A serum-
induced basophil histamine release assay was carried our at the “RefLab” Laboratory at 
the Univeristy of Copenhagen (Copenhagen, Denmark). Flow cytometry studies were 
performed at the Pathology Department, Norfolk & Norwich University Hospital 
(Norwich, UK). 
3.2.3 Study Population 
CSU patients were recruited from the Urticaria Clinics at the Dermatology Department of 
Norfolk & Norwich University Hospital from December 2008 till August 2011. 
Inclusion criteria for CSU patients were: 
Chapter 3 Pathophysiological Subsets in CSU 
184 
1 More than 18 years of age. 
2 Continuous CSU. 
3 Treatment with antihistamines with or without antileukotrienes. 
4 Autologous serum skin test performed as a part of clinical routine work-up for CSU 
patients within one month before recruitment. 
5 Willingness and capacity to give informed consent. 
Exclusion criteria were: 
1 Co-existing predominant physical urticarias. 
2 CSU with a confirmed infectious, allergic, drug-induced or physical cause. 
3 Biopsy-proven urticarial vasculitis defined by the presence of leukocytoclasia, fibrin 
deposition, endothelial swelling with or without red blood cell extravasation. 
4 Current long-term treatment with steroids, ciclosporin or methotrexate. 
5 Treatment with ciclosporin or methotrexate for urticaria or any other clinical reason 
within the last month before recruitment. 
Criteria for patient withdrawal from the study: 
1 The need for long-term steroid treatment on clinical grounds. 
2 The need for a second- or third-line treatment (e.g. ciclosporin) on clinical grounds. 
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3.2.4 Study Procedures 
3.2.4.1 Clinical Activity Scores 
Patients assessed their disease activity by visual analogue scales referring to itching and 
wealing over the last week at each follow-up appointment. Patients recorded their 
symptoms daily in the self-assessments sheets. CSU activity was also assessed by UAS7 
score which scores the number of weals (o=no weals, 1=1-10 small weals, 2=11-50 small 
weals (diameter <3cm) or 1-10 big weals (diameter > 3cm), 3=>50 small weals or 11-50 
big weals, 4=almost covered) and the intensity of itching (0=none, 1=mild, 2=moderate, 
3=severe) based on a patient’s self-assessment sheet. The weekly score UAS7 was 
calculated as a sum of daily scores for itching and wealing over the last week before the 
blood collection. The weekly urticaria activity score ranged from 0 to 49. The number of 
weals on the day of the blood collection was assessed. Clinical assessment was performed 
by Dr Elena Borzova at the Dermatology Department of Norfolk & Norwich University 
Hospital. 
3.2.4.2 Serum-induced BHR assay 
For serum-induced basophil histamine release, basophils from healthy donors were 
incubated with 40µl patient’s serum diluted 1:4 or 1:8 for 60 min at 37°C. Serum and 
released histamine was removed and the cells lysed using 20µl of 7% perchloric acid. 
After lysis of the cells 200µl PIPES were added and the samples were centrifuged at 
2000g for 10 min and the histamine content in the filtrate was measured using the glass 
fibre method. Histamine release was expressed as a percentage of total histamine content. 
Serum-induced BHR assays were performed by Prof. Per Skov at the Reflab, University 
of Copenhagen, Denmark. Serum-induced BHR was carried out as previously described 
(Platzer et al, 2005). 
For serum-induced BHR, the selection criteria for blood-bank buffy coats included anti-
IgE induced BHR over 30% of the total cellular histamine. Then, three pools of pre-
defined serum samples from CSU patients were tested on the selected buffy coat. For the 
serum pool 1, serum-induced BHR was required to fall within the range of 45-60% of 
total cellular histamine; for the serum pool 2 – within the range of 30-40%; and for the 
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serum pool 3 – within the range of 20-30%. In addition, a pool of serum samples from 
healthy non-allergic patients was tested to confirm that selected buffy coat did not 
respond with histamine release. The test was considered negative if serum-induced BHR 
was below 16.5 %. In the study by Platzer et al (2005), this cut-off value of 16.5% was 
used to discriminate between CSU patients with positive and negative ASST and yielded 
negative results in non-CSU patients and healthy controls. 
3.2.4.3 Basophil purification and basophil histamine release assays 
Basophils from whole blood of CSU patients were purified by Ficoll density 
centrifugation. Basophil absolute counts and purity was determined by Alcian blue 
staining. Purified basophils were resuspended in HEPES-buffered Tyrode’s solution (400 
µl per tube) containing 1mmol/L of CaCl2 and after a warming period (15min at 37°C) 
cells were stimulated with various titrations of anti-IgE or fMLP. Controls consisted of 
cells incubated with buffer alone. Basophils were stimulated for 15 min and reactions 
were terminated by adding ice-cold calcium-free HEPES buffer, followed by 
centrifugation and immediate transfer of supernatants into new vials. Histamine content 
in the supernatants, together with the cell pellets, which were diluted accordingly and 
lysed with perchloric acid (4%), was measured by spectrofluorimetry. BHR was 
considered positive if 10% or greater of the total cellular histamine was released to anti-
IgE stimulation after correction for spontaneous histamine release. Total cellular 
histamine in the enriched basophil preparations was determined as a sum of histamine 
levels in supernatants and cell pellets in each experiment. Patient’s basophil releasability 
studies were carried out by Dr Bernhard Gibbs at the Medway School of Pharmacy, 
University of Kent, UK. 
3.2.4.4 Flow cytometry Basophil studies 
For flow cytometric basophil studies, blood samples were drawn by venipuncture in 
Vacutainer tubes with sodium citrate (Beckton Dickinson, UK). The samples were 
incubated for 15 min at 37°C. Then, 100µl of patient’s whole blood was dispensed into 
BD Trucount™ tubes with 100 µl of FACS Flow solution (Beckton Dickinson, UK) with 
100 µl of anti-IgE solution (Sigma Aldridge, UK) or PBS. Then, the samples were mixed 
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by inversion and incubated in waterbath for 20 min at 37°C. After this, the samples were 
placed on ice and the following antibodies were added to the samples: 20µl of CCR3-PE, 
10µl of CD203c-APC, 20µl of CD63-FITC, 5µl of CD45-APC/Cy7, 20µl of CD123-
PerCP/Cy5 (Table 4; Appendix 4, Figure 3). The samples were mixed by inversion 
followed by incubation on ice for 30 min in the dark. Next, 2ml of Pharmlyse solution 
(Beckton Dickinson, UK) was added to the sample followed by 10 min incubation at 
room temperature. Samples were analysed by Miss Cheryl Barker on FACS Canto II flow 
cytometer at the Pathology Department, Norfolk and Norwich University Hospital 
(Norwich, UK). 
For data analysis, three gating strategies were applied on the same sample. As gating 
controls, fluorescence minus one (FMO) samples were used for each marker to set the gates 
for positive cell populations at 99th percentile (Appendix 4, Figure 4). Then, Boolean gates 
for each combination of two markers (CD63+CD203c+; CCR3+CD123+; CCR3+CD63+ 
gates) were constructed using Boolean logic by adding the gates defined for each marker 
by FMO samples as illustrated in Figure 5 (Appendix 4). The absolute basophil count using 
BD TruCount™ tubes was estimated according to the manufacturer’s recommendations. 
For absolute count, a reverse pipetting technique was used to dispense whole blood 
samples. Flow cytometry data were analysed by Dr Elena Borzova (University of East 
Anglia) using Kaluza® Flow Analysis software (Beckman Coulter, Inc.). 
As a part of the preparation for this study, a research visit to the Department of 
Immunology, Allergology and Rheumatology at the University of Antwerpen 
(Antwerpen, Belgium) (Head of the Department - Prof. Ebo) was undertaken by Dr 
Borzova in 2007 to study the technique and the details of the gating strategy and the data 
analysis. Additionally, a research visit to the Department of Hematology at the Medical 
University of Vienna (Vienna, Austria) (Head of the Department - Prof. Valent) was 
carried out by Dr. Borzova in 2008 to learn the technique for sample preparation and the 
technique of basophil flow cytometric studies in healthy subjects and allergic patients. 
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3.2.4.5 Statistics 
Two by three contingency table was created to determine patient distribution based on 
serum histamine-releasing activity and basophil releasability to anti-IgE stimulation at 
baseline. Distributional differences across CSU subsets based on serum histamine-
releasing activity and basophil releasability to anti-IgE stimulation were tested by the chi-
squared test. Continuous variables are presented as medians and the interquartile ranges. 
Mann-Whitney U test was used to compare continuous variables between the groups: 
CSU patients with or without serum histamine-releasing activity, basophil responders vs 
non-responders to anti-IgE stimulation, improving vs persistent disease course. Pearson’s 
or Spearman’s correlation tests were used to analyze variable correlations. Receiver-
operating characteristic curves were constructed to determine the optimal threshold for 
differentiating between CSU patients with a persistent disease and a clinical 
improvement. P<0.05 was considered statistically significant. The analysis was 
performed by STATA statistical package, version 11/SE (StataCorp LP, USA). 
3.3 Results 
3.3.1 Study Population 
Patient characteristics were presented in Figure 29. Of twenty two patients recruited to 
the study, nineteen patients completed the study (Table 5). The age of patients ranged 
from 19 and 68 years (mean – 49.2 years), the duration of CSU varied from 5 months to 
42 years (mean – 8.2 years) (Table 5). The mean duration of patient’s participation in the 
study was 174.05 ± 32.45 days (Figure 29B and C). 
3.3.2 Pathophysiological Phenotypes of CSU and their relation to disease 
severity 
The raw data for basophil histamine release assays in CSU patients are presented in the 
Appendix 4. 
Based on basophil releasability assays, the subjects were classified into responders (n=8) 
and non-responders (n=7) to anti-IgE stimulation as previously described (Vonakis B.M. 
et al, 2007). Additionally, we identified a group of patients (n=7) with total cellular  
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histamine below the level of detection by spectrofluorimetry at all points of a dose-
response curve. CSU patients were divided into those with (n=8) and without (n=14) serum 
histamine-releasing activity. The distribution of patient across both classification 
approaches are presented in Figure 30A. The results for individual patients are presented in 
Figure 1 (Appendix 4). As expected, CSU patients with serum histamine-releasing activity 
were predominantly clustered in the pathophysiological subset with total cellular histamine 
below the level of detection by spectrofluorimetry (Figure 30B). By contrast, CSU patients 
without serum histamine-releasing activity were mainly distributed between CSU subsets 
with responding or not-responding basophils to anti-IgE stimulation. The difference in 
distribution of CSU patients with or without serum histamine-releasing activity between 
basophil releasability subsets was statistically significant (Chi-squared test, p=0.004). 
Basophil responders were defined by histamine release above 10% of total cellular 
histamine to anti-IgE stimulation (0.1ng/ml). Basophil non-responders were defined by 
BHR below 10% of total cellular histamine. A subset with total cellular histamine below 
the level of detection by spectrofluorimetry was defined by the lack of detection of 
histamine at each point of dose-response curve for histamine release (the level of 
detection – 1ng/ml). The characteristic dose-response curve for a CSU patient with 
basophil response to anti-IgE stimulation was presented in Figure 22 (Appendix 4). In 
Figure 20 (Appendix 4), a dose response curve for histamine release to anti-IgE 
stimulation revealed that basophils do not respond to anti-IgE stimulation. By contrast, a 
flat curve for histamine release on the x-axis in Figure 11 (Appendix 4) suggested 
histamine concentration below the level of detection by spectrofluorimetry. 
We examined the relation of CSU pathophysiological subsets to disease severity to 
understand if these pathophysiological subsets provide clinically meaningful information. At 
baseline, CSU patients with total cellular histamine below the level of detection demonstrated 
a more severe disease compared to basophil responders (p=0.055) or non-responders 
(p=0.025) to anti-IgE stimulation (Figure 31A). The baseline UAS7 score was significantly 
higher in CSU patients with serum histamine-releasing activity compared to those without 
serum histamine-releasing activity (Figure 31B). There was no difference in disease severity 
between basophil responders and non-responders to anti-IgE stimulation (p=0.560). 
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To further assess the interrelationships between these pathophysiological parameters and 
disease severity in CSU patients, we examined the correlations of UAS7 score with 
serum histamine-releasing activity and anti-IgE-induced BHR at baseline. We noted a 
moderate correlation between UAS7 and serum histamine releasing activity (Figure 
32A), between UAS7 and basophil releasability to anti-IgE stimulation (Figure 32B). Of 
interest, there was a lack of correlation between serum histamine-releasing activity and 
anti-IgE-induced BHR in CSU patients (Figure 32C). 
3.3.3 Natural course of disease in CSU patients 
During follow-up, the persistent course of CSU was observed in 10 patients whereas 9 
patients displayed a clinical improvement of CSU over the period of observation in our 
study. Based on the ROC analysis, baseline UAS7 was predictive of the persistent course 
of disease whereas serum histamine-releasing activity and anti-IgE-induced BHR were 
not informative as predictors for disease persistence in our study population. The ROC 
analysis for UAS7 suggested that the cut-off value of 19 allowed 63.16% accuracy in 
predicting the persistent course of disease, with sensitivity of 60% and specificity of 
66.67% (Figure 33A). The disease profiling in CSU patients based on the ROC analysis 
is demonstrated in Figure 33B.  
This means that, in our study, the use of a UAS7 score equal or above 19 (using the scale 
of 49 in total) at baseline correctly identified CSU patients with persistent disease in 60% 
of cases. Furthermore, baseline UAS value of 19 or higher correctly excluded patients 
with improving CSU in 66.67% of cases.  Overall, the accuracy of prediction of the 
course of the disease based on baseline UAS7 score using the threshold of 19 was noted 
to be 63.16%.  
However, ROC analysis results must be interpreted with caution in view of the 
limitations of ROC analysis in small samples. It is important to underscore that the 
threshold UAS7 value and the accuracy of prediction obtained in our study is relevant 
only to the studied patient population which is a small size sample from a secondary care 
dermatological setting. These data need to be validated in larger patient samples and also 
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in samples from different clinical settings to explore whether a similar threshold would 
apply. We would expect the cut-off UAS7 threshold at baseline for predicting persistent 
CSU to vary depending on the sample size and the frequency of severe disease in the 
study population. Whether the accuracy of prediction of CSU course at baseline could be 
improved by using a UAS7 score in combination with inflammatory biomarkers in the 
skin or in the circulation, is uncertain, but its potential is worth exploring in further 
studies.  
In persistent CSU, disease was more severe at baseline than in CSU patients with a 
clinical improvement over the observation period (Figure 34). There was no difference in 
serum-induced BHR or anti-IgE-induced BHR between CSU patients with persistent or 
improving disease (Appendix 4, Figure 5). 
3.3.4 Longitudinal Changes of Serum Histamine-releasing activity and 
disease severity in CSU patients 
Analysis of longitudinal data identified two groups of patients with different patterns of 
serum histamine-releasing activity over time. Three CSU patients were characterized by a 
persistent increase in serum histamine-releasing activity above 16.5% at all time points 
over the period of observation (Figures 35A-C). By contrast, three CSU patients had a 
transient increase of serum histamine-releasing activity above 16.5% at one or two time 
points only over the period of observation (Figures 35D-F). 
Fi
gu
re
 3
2. 
C
or
re
la
tio
ns
 b
et
w
ee
n 
Se
ru
m
 H
ist
am
in
e-
Re
le
as
in
g 
A
ct
iv
ity
 a
nd
 B
as
op
hi
l
Re
le
as
ab
ilit
y 
to
 A
nt
i-I
gE
 S
tim
ul
at
io
n 
w
ith
 D
ise
as
e 
Se
ve
rit
y 
In
 C
SU
B.
 C
or
re
la
tio
n 
be
tw
ee
n 
UA
S7
 a
nd
 a
nt
i-I
gE
-
in
du
ce
d 
BH
R 
fro
m
 C
SU
 p
at
ie
nt
’s 
ba
so
ph
ils
at
 b
as
el
in
e
A.
 C
or
re
la
tio
n 
be
tw
ee
n 
UA
S7
 a
nd
 s
er
um
hi
st
am
in
e-
re
le
as
in
g 
ac
tiv
ity
 
in
 C
SU
 p
at
ie
nt
s 
at
 b
as
el
in
e
Fi
gu
re
 3
2.
 A
t b
as
eli
ne
, U
AS
7 
in 
CS
U 
pa
tie
nt
s s
ho
we
d 
a 
co
rre
lat
ion
 w
ith
 se
ru
m
 h
ist
am
ine
-re
lea
sin
g 
ac
tiv
ity
 (S
pe
ar
m
an
 c
or
re
lat
ion
 r=
0.
58
, p
=0
.0
04
5)
 (F
ig
ur
e
32
A)
.T
he
re
 w
as
 n
eg
at
ive
 c
or
re
lat
ion
 b
et
we
en
 b
as
eli
ne
 U
AS
7 
sc
or
es
 a
nd
 a
nt
i-I
gE
-in
du
ce
d 
BH
R 
fro
m
 p
er
ip
he
ra
l b
loo
d 
ba
so
ph
ils
 in
 C
SU
 p
at
ien
ts 
(S
pe
ar
m
an
co
rre
lat
ion
 r=
0.
40
, p
=0
.0
66
6)
 (F
ig
ur
e 
30
B)
. N
ot
ew
or
th
y, 
th
er
e 
wa
s n
o 
co
rre
lat
ion
 b
et
we
en
 se
ru
m
 h
ist
am
ine
-re
lea
sin
g 
ac
tiv
ity
 a
nd
 a
nt
i-I
gE
-in
du
ce
d 
BH
R 
in 
CS
U
pa
tie
nt
s (
Fig
ur
e 
32
C)
. T
he
 a
na
lys
is 
wa
s c
ar
rie
d 
ou
t o
n 
22
 C
SU
 p
at
ien
ts 
wh
o 
co
m
pl
et
ed
 th
e 
ba
se
lin
e 
vis
it i
n 
th
e 
stu
dy
. I
n 
ou
r s
tu
dy
, U
AS
7 
sc
or
e 
ra
ng
ed
 fr
om
 0
 to
49
.S
er
um
 h
ist
am
ine
-re
lea
sin
g 
ac
tiv
ity
 w
as
 a
ss
es
se
d 
on
 p
er
ip
he
ra
l b
loo
d 
ba
so
ph
ils
 fr
om
 h
ea
lth
y d
on
or
s a
t R
efl
ab
 (U
niv
er
sit
y o
f C
op
en
ha
ge
n,
 D
en
m
ar
k)
. F
or
ba
so
ph
il r
ele
as
ab
ilit
y a
ss
ay
s, 
ce
lls
 w
er
e 
sti
m
ula
te
d 
wi
th
 a
nt
i-I
gE
 a
nt
ib
od
ies
 (S
ig
m
a-
Al
dr
id
ge
, U
K)
 a
t 0
.1
ng
/m
l.  
An
ti-
Ig
E-
ind
uc
ed
 B
HR
 in
 p
er
ip
he
ra
l b
loo
d
ba
so
ph
ils
 fr
om
 C
SU
 p
at
ien
ts 
wa
s a
ss
es
se
d 
by
 D
r B
er
nh
ar
d 
Gi
bb
s f
ro
m
 M
ed
wa
y S
ch
oo
l o
f P
ha
rm
ac
y (
Ch
at
ha
m
 M
ar
itim
e,
 U
K)
.  
Sp
ea
rm
an
 c
or
re
lat
ion
 r=
 0
.5
8,
 p
=0
.0
04
5.
Sp
ea
rm
an
 c
or
re
lat
ion
 r=
-0
.4
0,
 p
=0
.0
66
6
UAS7 Score
40 30 20 10 0
0
10
20
30
40
50
Se
ru
m
-
In
du
ce
d 
BH
R
 
(%
 o
f t
o
ta
l c
e
llu
la
r 
hi
st
a
m
in
e
)
n
=
22
UAS7 Score
0
10
20
30
40
50
60
70
a
n
ti-
Ig
E-
 
in
du
ce
d 
BH
R
 
(%
 o
f t
o
ta
l c
e
llu
la
r 
hi
st
a
m
in
e
) 
n
=
22
Ab
br
ev
a
tio
n
s:
CS
U 
- C
hr
on
ic 
sp
on
ta
ne
ou
s u
rti
ca
ria
 
BH
R 
- B
as
op
hil
 h
ist
am
ine
 re
lea
se
UA
S7
 - 
Ur
tic
ar
ia 
ac
tiv
ity
 sc
or
e 
ov
er
 7
 d
ay
s
40 30 20 10 0
C.
 C
or
re
la
tio
n 
be
tw
ee
n 
se
ru
m
 h
ist
am
in
e-
re
le
as
in
g 
ac
tiv
at
y 
an
d 
an
ti-
Ig
E-
in
du
ce
d 
BH
R
fro
m
 C
SU
 p
at
ie
nt
’s 
ba
so
ph
ils
 a
t b
as
el
in
e
Sp
ea
rm
an
 c
or
re
lat
ion
 r=
-0
.2
3,
 p
=0
.3
09
2
Serum-Induced BHR
(% of total cellular histamine) 
a
n
ti-
Ig
E 
-
 
in
du
ce
d 
BH
R
 
(%
 o
f t
o
ta
l c
e
llu
la
r 
hi
st
a
m
in
e
) 
n
=
22
-
20
0
20
40
60
50 40 30 20 10 0
Fi
gu
re
 3
3. 
Th
e 
C
lin
ic
al
 C
ou
rs
e 
of
 C
SU
 in
 th
e 
Pr
os
pe
ct
ive
 S
tu
dy
 
B.
 T
he
 d
ise
as
e 
co
ur
se
 p
ro
fil
in
g 
in
 C
SU
 p
at
ie
nt
s
in
 th
e 
pr
os
pe
ct
ive
 s
tu
dy
A.
 R
OC
 a
na
lys
is 
gr
ap
h 
fo
r d
isc
rim
in
at
in
g 
be
tw
ee
n
pa
tie
nt
s 
wi
th
 p
er
sis
te
nt
 C
SU
 a
nd
 th
os
e 
wi
th
sp
on
ta
ne
ou
s 
im
pr
ov
em
en
t o
f C
SU
1.
00
0.
75
0.
50
0.
25
0.
00
1 
-
 
Sp
e
ci
fic
ity
Sensitivity
Ar
e
a
 
u
n
de
r 
RO
C 
cu
rv
e
 
=
 
0.
75
00
0.
00
0.
25
0.
50
0.
75
1.
00
40 30 20 10 0
Vi
si
ts
UAS7 Score
1
2
3
Pe
rs
ist
en
t C
SU
 (n
=9
)
Im
pr
ov
ing
 C
SU
 (n
=1
0)
St
an
da
rd
 e
rro
r 
Fi
gu
re
 3
3.
 In
 o
ur
 st
ud
y, 
UA
S7
 a
pp
ea
re
d 
to
 b
e 
a 
pr
ed
ict
or
 o
f d
ise
as
e 
co
ur
se
 o
ve
r t
he
 p
er
iod
 o
f o
bs
er
va
tio
n.
 T
he
 R
OC
 g
ra
ph
 d
em
on
str
at
ed
 th
e 
re
cip
ro
ca
l
re
lat
ion
sh
ip
 b
et
we
en
 se
ns
itiv
ity
 a
nd
 sp
ec
ific
ity
 o
f a
ll p
os
sib
le 
UA
S7
 va
lue
s (
Fig
ur
e 
33
B)
. S
en
sit
ivi
ty 
an
d 
sp
ec
ific
ity
 in
 d
isc
rim
ina
tin
g 
CS
U 
pa
tie
nt
s w
ith
pe
rs
ist
en
t c
ou
rs
e 
of
 d
ise
as
e 
fro
m
 th
os
e 
wi
th
 im
pr
ov
ing
 C
SU
 w
as
 b
as
ed
 o
n 
th
e 
di
se
as
e 
co
ur
se
 (F
ig
ur
e 
33
A)
. T
he
 R
OC
 a
na
lys
is 
fo
r U
AS
7 
su
gg
es
te
d 
th
at
 th
e
cu
t-o
ff 
va
lue
 o
f 1
9 
yie
ld
ed
 th
e 
hig
he
st 
ac
cu
ra
cy
 fo
r p
re
di
ct
ion
 o
f d
ise
as
e 
se
ve
rit
y (
se
ns
itiv
ity
 - 
60
%
, s
pe
cifi
cit
y -
 6
6.
67
%
). 
Pa
tie
nt
s w
ith
 p
er
sis
te
nt
 C
SU
(d
es
ig
na
te
d 
in 
bl
ue
 o
n 
Fig
ur
e 
33
B)
 w
er
e 
de
fin
ed
 if 
th
eir
 U
AS
7 
sc
or
e 
at
 V
isi
t 3
 w
as
 la
rg
er
 o
r e
qu
al 
th
an
 th
at
 a
t V
isi
t 1
. P
at
ien
ts 
wi
th
 im
pr
ov
ing
 C
SU
 w
er
e 
de
fin
ed
if t
he
ir 
UA
S7
 sc
or
e 
at
 V
isi
t 3
 w
as
 le
ss
 th
an
 th
at
 a
t V
isi
t 1
 (d
es
ig
na
te
d 
in 
re
d 
on
 F
ig
ur
e 
33
B)
. U
AS
7 
wi
th
 sc
or
e 
ra
ng
e 
of
 0
 to
 4
9 
wa
s u
se
d 
in 
th
is 
stu
dy
.
Ab
br
ev
a
tio
n
s:
CS
U 
- C
hr
on
ic 
sp
on
ta
ne
ou
s u
rti
ca
ria
 
UA
S7
 - 
Ur
tic
ar
ia 
ac
tiv
ity
 sc
or
e 
ov
er
 7
 d
ay
s
RO
C 
- R
ec
eiv
er
 o
pe
ra
tin
g 
cu
rv
e 
Fi
gu
re
 3
4. 
Ba
se
lin
e 
U
A
S7
 S
co
re
 in
 P
at
ie
nt
s 
w
ith
 P
er
sis
te
nt
 a
nd
 Im
pr
ov
in
g 
C
SU
 
A.
 B
as
el
in
e 
UA
S7
 in
 p
at
ie
nt
s 
wi
th
 p
er
sis
te
nt
 
or
 im
pr
ov
in
g 
CS
U
UAS7 Score
Fi
gu
re
 3
4.
 In
 o
ur
 st
ud
y, 
19
 C
SU
 c
om
pl
et
ed
 th
re
e 
vis
its
 in
 th
e 
ob
se
rv
at
ion
al 
stu
dy
 a
nd
 w
er
e 
inc
lud
ed
 in
 th
e 
lon
gi
tu
di
na
l a
na
lys
is 
of
 th
e 
cli
nic
al 
co
ur
se
 o
f t
he
di
se
as
e.
 O
f t
he
se
, 9
 p
at
ien
ts 
ha
d 
im
pr
ov
ing
 C
SU
 a
nd
 1
0 
pa
tie
nt
s h
ad
 p
er
sis
te
nt
 C
SU
. A
t b
as
eli
ne
, p
at
ien
ts 
wi
th
 p
er
sis
te
nt
 C
SU
 h
ad
 h
ig
he
r U
AS
7 
sc
or
es
th
an
 th
os
e 
wi
th
 im
pr
ov
ing
 C
SU
 (M
an
n-
W
hit
ne
y U
 te
st,
 p
=0
.0
18
). 
Th
e 
UA
S7
 sc
or
e 
ra
ng
ed
 fr
om
 0
 to
 4
9.
Re
d 
ba
r r
ep
re
se
nt
s m
ed
ian
 va
lue
s.
Pa
irw
ise
 c
om
pa
ris
on
s b
et
we
en
 C
SU
 su
bg
ro
up
s i
n 
re
lat
ion
 to
 th
e 
cli
nic
al 
co
ur
se
 o
f
dis
ea
se
 w
as
 c
ar
rie
d 
ou
t b
y M
an
n-
W
hit
ne
y U
 te
st.
 
Im
pr
ov
in
g 
CS
U
Pe
rs
is
te
n
t C
SU
n
=
9
n
=
10
40 30 20 10 0
p=
0.
01
8
Ab
br
ev
a
tio
n
s:
CS
U 
- C
hr
on
ic 
sp
on
ta
ne
ou
s u
rti
ca
ria
UA
S7
 - 
Ur
tic
ar
ia 
ac
tiv
ity
 sc
or
e 
ov
er
 7
 d
ay
s
BD
 - 
Be
ct
on
 D
ick
ins
on
FA
CS
  -
 F
luo
re
sc
en
ce
-a
ct
iva
te
d 
ce
ll s
or
tin
g
Fi
gu
re
 3
5. 
Lo
ng
itu
di
na
l C
ha
ng
es
 in
 S
er
um
 H
ist
am
in
e-
Re
le
as
in
g 
A
ct
iv
ity
 
an
d 
D
ise
as
e 
Se
ve
rit
y 
in
 C
SU
 P
at
ie
nt
s 
A.
 P
at
ien
t T
BP
03
B.
 P
at
ien
t D
BP
23
C.
 P
at
ien
t B
HP
24
D.
 P
at
ien
t D
PP
16
E.
 P
at
ien
t B
SP
19
F. 
Pa
tie
nt
 D
M
P2
1
Pe
rs
ist
en
t p
at
te
rn
 o
f s
er
um
hi
st
am
in
e-
re
le
as
in
g 
ac
tiv
ity
 
in
 C
SU
 P
at
ie
nt
s
Tr
an
sie
nt
 p
at
te
rn
 o
f s
er
um
 
hi
st
am
in
e-
re
le
as
in
g 
ac
tiv
ity
 
in
 C
SU
 P
at
ie
nt
s
Fi
gu
re
 3
5.
 L
on
gi
tu
di
na
l m
ea
su
re
m
en
ts 
 re
ve
ale
d
tra
ns
ien
t o
r p
er
sis
te
nt
 in
cr
ea
se
 in
 se
ru
m
 h
ist
am
ine
-
re
lea
sin
g 
ac
tiv
ity
 in
 C
SU
 p
at
ien
ts.
  C
SU
 p
at
ien
ts
wi
th
 a
 p
er
sis
te
nt
 in
cr
ea
se
 in
 se
ru
m
 h
ist
am
ine
-
re
lea
sin
g 
ac
tiv
ity
 sh
ow
ed
 se
ru
m
-in
du
ce
d 
BH
R
as
sa
y o
ve
r 1
6.
5%
 a
t a
ll t
im
e 
po
int
s o
f o
bs
er
va
tio
n
(F
ig
ur
e 
35
A-
C)
. T
he
 p
at
ien
t g
ro
up
 w
ith
 a
 tr
an
sie
nt

inc
re
as
e 
in 
se
ru
m
 h
ist
am
ine
-re
lea
sin
g 
ac
tiv
ity

de
m
on
str
at
ed
 se
ru
m
-in
du
ce
d 
BH
R 
ab
ov
e 
16
.5
%
on
ly 
at
 o
ne
 o
r t
wo
 o
bs
er
va
tio
n 
tim
e 
po
int
s (
Fig
ur
e
35
D-
F)
. F
or
 se
ru
m
-in
du
ce
d 
BH
R 
as
sa
y, 
a
di
ag
no
sti
c 
cu
t-o
ff 
of
 1
6.
5%
 w
as
 u
se
d 
to
 d
et
ec
t
se
ru
m
 h
ist
am
ine
-re
lea
sin
g 
ac
tiv
ity
 in
 C
SU
 p
at
ien
ts
(P
lat
ze
r e
t a
l, 2
00
5)
. S
er
um
-in
du
ce
d 
BH
R 
as
sa
y
wa
s c
ar
rie
d 
ou
t a
t t
he
 R
ef
La
b 
(U
niv
er
sit
y o
f
Co
pe
nh
ag
en
, D
en
m
ar
k)
. 
Ab
br
ev
a
tio
n
s:
BH
R 
- B
as
op
hil
 h
ist
am
ine
 re
lea
se
CS
U 
- C
hr
on
ic 
sp
on
ta
ne
ou
s u
rti
ca
ria
UA
S7
 - 
Ur
tic
ar
ia 
ac
tiv
ity
 sc
or
e 
ov
er
 7
 d
ay
s 
Chapter 3 Pathophysiological Subsets in CSU 
201 
3.3.5 Flow cytometric enumeration of basophil subpopulations in CSU 
patients 
Flow cytometric quantification of basophil phenotypes in peripheral blood of CSU 
patients revealed statistically significant differences in absolute basophil counts detected 
by flow cytometric gating strategies (CCR3+CD123+ vs CCR3+CD63+ (p=0.0001), 
CD63+CD203c+ vs CCR3+CD123+ (p=0.0003), CD63+CD203c+ vs CCR3+CD63+ 
(p=0.0001)) in the same sample from each CSU patient (Figure 36). Enumeration of 
CCR3+CD63+ basophils by microbead technology (Figures 36A, B) yielded significantly 
higher absolute counts compared to CCR3+CD123+ or CD63+CD203c+ basophil 
subpopulations in the same peripheral blood sample from each CSU patient suggesting 
that absolute basophils counts depend on the gating strategy used to define peripheral 
blood basophil phenotype in CSU patients. 
Of interest, there was no correlation between absolute basophil counts detected by 
CCR3+CD123+ and CCR3+CD63+ gating strategies in peripheral blood samples from 
CSU patients (Spearman correlation r=0.15, p=0.5269) (Figure 37A). By contrast, there 
was moderate correlation between absolute basophil counts determined by 
CD63+CD203c+ and CCR3+CD63+ gating strategies (Spearman correlation r=0.57, 
p=0.0085) and by CD63+CD203c+ and CCR3+CD123+ gating strategies (Spearman 
correlation r=0.63, p=0.0029) (Figure 37 B-C). 
We examined whether basophil phenotype and absolute counts defined by different gating 
strategies were associated with the pathophysiological subsets, disease severity or a 
clinical course of CSU. We did not detect any differences in absolute basophil counts 
detected by three gating strategies between CSU pathophysiological subsets which was in 
keeping with previous data (Vonakis et al, 2007). There was a lack of correlation between 
baseline UAS7 and absolute basophil counts determined by three gating strategies 
(Appendix 4, Figure 6). Also, there was no difference in absolute basophil counts between 
CSU patients with persistent or improving disease (Appendix 4, Figure 7). 
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3.4 Discussion 
3.4.1 The pathophysiological phenotyping in CSU 
We reported a prospective observational study in CSU patients with a focus on the 
pathophysiological phenotyping and the relation of the pathophysiological subsets to 
disease severity and a clinical course of CSU. We confirmed and extended the studies on 
the pathophysiological phenotyping in CSU patients by Eckman et al (2008) and Sabroe 
et al (2002). The observation of basophil responders and nonresponders to anti-IgE 
stimulation in CSU was previously reported by Eckman et al (2008) and was also 
confirmed by our study. We found that these basophil functional profiles were not related 
to serum histamine-releasing activity in CSU patients which was also consistent with the 
previous findings (Eckman et al, 2008). In addition, we demonstrated that serum 
histamine-releasing activity was predominantly clustered in the subset of CSU patients 
with total cellular histamine below the level of detection by spectrofluorimetry. The 
distribution of serum histamine-releasing activity in a CSU subset other than basophil 
responders and non-responders to anti-IgE stimulation suggested that serum histamine-
releasing activity and aberrant basophil releasability to anti-IgE stimulation were likely to 
operate via independent disease pathways in CSU. This was also demonstrated by the 
lack of correlation between serum histamine-releasing activity and anti-IgE-induced BHR 
in CSU patients and may explain the previous discrepancies between the studies. 
However, we can interpret these results with caution as we cannot exclude the possibility 
that the levels of serum histamine-releasing factors, which are relevant in vivo, may be 
lower compared to the in vitro settings and below the levels of detection with existing 
diagnostic methodology. As reported by Kaplan and Joseph (2007), serum from CSU 
patients, classified as not having serum histamine-releasing activity, still induces BHR 
from healthy donor basophils 10 times higher than sera from healthy subjects. 
Furthermore, it remains unknown whether basophil functional defects or serum 
histamine-releasing activity are primary or secondary events in the pathophysiology of 
CSU. In general, our findings on the pathophysiological phenotyping in CSU patients 
highlighted the pathophysiological heterogeneity of the disease and need to be validated 
in larger study populations of CSU patients. 
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From clinical perspective, we confirmed our hypothesis that a more severe CSU was 
associated with serum histamine-releasing activity. The association of serum histamine-
releasing activity with disease severity was in keeping with the previous work by Sabroe 
et al (2002) and indicated the clinical relevance of serum histamine-releasing activity as a 
marker for a more severe CSU. With regards to basophil functional subsets, CSU patients 
with total cellular histamine below the level of detection by spectrofluorimetry had a 
more severe disease than basophil responders or non-responders to anti-IgE stimulation. 
This may suggest that studies employing only basophil releasability assays from CSU 
patients may exclude a subset of CSU patients with basopenia and severe disease. 
Longitudinal analysis of serum histamine-releasing activity in CSU patients demonstrated 
persistent vs transient increases of serum histamine-releasing activity in CSU patients. 
There are several possible explanations as to which factors may mediate serum 
histamine-releasing activity in CSU patients including anti-FcεRIα autoantibodies, 
complement components, cytokines and, possibly, yet unknown factors but the reasons 
for the observed persistent or transient patterns of serum histamine-releasing activity in 
CSU are poorly understood. At present, a large multicenter cross-sectional study in 
chronic autoimmune urticaria (PURIST study) is ongoing in Europe to identify and 
characterize novel biomarkers for chronic autoimmune urticaria in line with the proposal 
of diagnostic criteria by the EAACI Task Force position paper on autoimmune urticaria 
(Konstantinou et al, 2013). The results of this study are awaited and will likely provide 
some insights into this subset of CSU patients associated with serum histamine-releasing 
activity. 
3.4.2 Natural history in CSU 
Natural history of CSU is less well studied with only few observational studies reported 
in the literature (Toubi et al, 2004; Takahagi et al, 2010). Our study suggested a variable 
course of disease in CSU patients with a disease persistence in some patients and a 
clinical improvement in others. In our study, baseline UAS7 score was confirmed as a 
predictor for a persistent course of CSU which was consistent with the conclusions of the 
recent systematic review (Rabelo-Filardi et al, 2013). We determined, for the first time, 
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the sensitivity and specificity of UAS7 score as predictor for persistent CSU. Our 
contention that serum histamine-releasing activity could be a predictor for disease 
persistence was not supported by this study. Neither serum histamine-releasing activity, 
nor anti-IgE-induced BHR predicted CSU persistence in our study. It is plausible that a 
persistent disease is associated with the underlying inflammation by analogy with asthma 
(Panattieri et al, 2008), however, we could not identify the pathophysiological predictors 
for a persistent course of CSU. The possible explanations could be that the association is 
more obvious in patient subpopulations which are likely to be treated with 
immunomodulatory or biological agents. These patient subpopulations were not included 
in our observational study. Another possibility could be that pathophysiological factors 
other than serum histamine-releasing activity or basophil releasability to anti-IgE 
stimulation may be responsible for disease persistence. For example, skin priming and 
remodeling associated with chronic wealing was suggested in the recent study by Kay et 
al (2014a) and may well be a contributing factor for a disease persistence in CSU. 
Furthermore, there are only a few longitudinal observations in CSU exploring the 
dynamics of serum histamine-releasing activity over the clinical course of disease (Tanus 
et al, 1996). In longitudinal study, we demonstrated, for the first time, a persistent and a 
transient increase in serum histamine-releasing activity in some CSU patients over the 
observation period. Our data suggested that serial testing for serum histamine-releasing 
activity could be useful in CSU patients to differentiate between CSU patients with 
transient or persistent increase in serum histamine-releasing activity. The biological 
significance and the underlying causes for the transient or persistent production of serum 
histamine-releasing factors in CSU are unknown and may represent an interesting area 
for future research in CSU. 
3.4.3 Flow cytometric analysis of circulating basophils in CSU 
In flow cytometric analysis, we tested three previously published gating strategies for the 
identification of peripheral blood basophils in CSU patients (Ebo et al, 2012; Eberlein et 
al, 2009; Amundsen et al, 2012). Flow cytometric enumeration of peripheral blood 
basophils yielded significantly different absolute counts of basophil subpopulations 
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depending on the gating strategy. Thus, our study revealed significantly higher absolute 
counts of CCR3+CD63+ basophils compared to other basophil subpopulations defined by 
dual expression of CCR3 and CD123 or CD63 and CD203c. There may be biological 
reasons for the observed variation in basophil phenotypes in CSU. The in vivo basophil 
priming was suggested by the increased expression of basophil activation markers in 
CSU patients as determined by flow cytometry (Vasagar et al, 2006). In the study by 
Vasagar et al (2006), peripheral blood basophils demonstrated up-regulation of CD63 and 
CD69 but not CD203c. In our study, CCR3+CD63+ basophil subpopulation appeared to 
be a predominant basophil phenotype in CSU patients. The biological relevance of this 
subpopulation is unknown although CCR3+CD63+ subpopulation may reflect basophil 
responses in the context of the inflammation in CSU. The biological rationale for this 
assumption lies in the fact that expression of CCR3 receptors may be up-regulated in 
response to eotaxin which is known to be an inducible chemokine in the context of the 
inflammation (Iikura et al, 2001). The eotaxin levels were reported to be elevated in CSU 
patients (Tedeschi et al, 2012) and may represent a putative mechanism for basophil 
recruitment into the skin. In addition, CD63 up-regulation is noted to be up-regulated in a 
graded fashion in response to activation stimuli (MacGlashan Jr., 1995). Hence, it is 
conceivable that CCR3+CD63+ basophil subpopulation may be a primed basophil 
phenotype undergoing chemotaxis to the inflamed skin in CSU although this assumption 
needs a rigorous in vitro testing using cutting edge chemotaxis assays (Toetsch et al, 
2009). In the future, comparative studies into basophil subpopulations in healthy subjects, 
patients with CSU and other inflammatory conditions may provide a biological 
interpretation as to whether these basophil subpopulations represent a disease-specific 
basophil phenotype or a non-specific phenomenon in the context of inflammation. 
Another important question is whether the observed basophil phenotypes in CSU 
represent a spectrum of peripheral blood basophils at the different stages of activation or 
whether they reflect basophil heterogeneity in CSU. Based on he previous work by 
Vasagar et al (2006), basophil phenotypes in CSU are likely to represent a primed 
activated state. Further studies may shed some light on molecular, functional and 
morphological characteristics of this subpopulation in comparison to different activation 
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states of peripheral blood basophils. However, it is important to consider the differences 
between in vivo and in vitro basophil activation as was demonstrated in sting challenge in 
venom-allergic patients by Gober et al (2007). On the other hand, we cannot completely 
rule out the possibility of CCR3+CD63+ basophil subpopulation being phenotypically 
distinct from the remainder of the peripheral blood basophils. Functional basophil 
heterogeneity has been reported (Siracusa et al, 2012) but whether or not this is relevant 
to CSU is unknown. Classically, cellular heterogeneity relies on the distinct phenotypic 
signature and cellular behavior of a given cell subpopulation with a particular biological 
function and, possibly, clinical contribution (Altschuler & Wu, 2010; Prussin et al, 2010). 
In our study, we explored the association of this basophil subpopulation with disease 
severity or persistence but no differences were detected. Thus, we could not discern the 
clinically relevant contribution of the observed basophil phenotypes in CSU. In the 
future, this question can be addressed by single cell measurements using cutting edge 
technologies such as imaging flow cytometry, advanced microscopy and single cell PCR 
analysis. These multi-dimensional studies would allow more accurate interpretation of 
the observed variation in basophil phenotypes and may provide some insights into 
whether these different phenotypes represent the spectrum of the activation states or 
phenotypically distinct subpopulations. 
Alternatively, several methodological reasons may also account for differences in flow 
cytometric assessments of circulating basophils in the peripheral blood using 
conventional flow cytometry. Firstly, there is a lack of consensus on flow cytometric 
definition of peripheral blood basophils with a wide range of surface markers being used 
for basophil identification. Different basophil markers are characterized by a variation of 
their surface expression on resting basophils which may affect the performance of these 
markers for basophil identification. Secondly, there is a considerable variation in the 
approaches to gating and data analysis. The use of different gating strategies may result 
in a considerable inter-laboratory variation. The lack of standardization of gating 
strategies hinders the comparisons between the studies as well as collaborations between 
the laboratories. Our data demonstrated that the choice of gating strategy affects the 
basophil immunophenotyping and absolute counts. Furthermore, the FMO gating is 
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widely accepted as a technical approach to distinguish a positive population for a given 
marker. However, for markers with continuous expression this approach may not result in 
the accurate capture of biologically relevant populations. Search for basophil surface 
markers with discrete expression may enhance basophil identification in flow cytometry 
studies. Then, automated gating approaches based on the cluster recognition of cellular 
populations with continuous marker expression may be a more optimal approach to 
basophil flow cytometry research in the future. Even though flow cytometric cell 
enumeration by a single platform methodology is characterized by a statistical superiority 
compared to cell counting in microscopic slides or counting chambers, the limitations of 
flow cytometric absolute counts for low-frequency cell populations in whole blood are 
well recognized. For example, studies into flow cytometric WBC differential 
demonstrated insufficient accuracy of basophil detection in healthy subjects (Roussel et 
al, 2010). In the future, extended flow cytometric panels and standardized gating 
strategies may enhance basophil identification in healthy subjects and patients with 
various allergic or inflammatory conditions in which basophil phenotype or absolute 
counts can be affected. 
3.4.4 The strengths and limitations of the study 
This study was designed to address the specific question as to whether serum histamine-
releasing activity, anti-IgE-induced basophil releasability and basophil phenotypes are 
related to CSU severity or persistence. The study design of prospective longitudinal 
assessments was the strength of the study which allowed a more accurate disease 
profiling at three time points over the period of observation. Novel insights were gained 
by the use of a combination of two classification systems based on serum histamine-
releasing activity and anti-IgE-induced BHR and their relationship to disease severity and 
persistence although we recognize the methodological limitations of both classification 
approaches. 
Several limitations of this study need to be reported. Firstly, as with all observational 
studies into the natural history of disease, it was a nonrandomized and uncontrolled 
study. We employed certain techniques such as extended inclusion/exclusion criteria to 
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identify a well-defined subgroup of CSU patients in the observational study. 
Nevertheless, our CSU patient population may not be fully representative of a general 
patient population as we cannot rule out a referral bias to the secondary care settings and 
a selection bias inherent to the observational nonrandomized studies. In the future, the 
observed associations need to be confirmed in randomized controlled studies to provide a 
greater degree of certainty. Secondly, the rate of persistent CSU in a general patient 
population may differ from that in our study due to the exclusion of CSU patients on 
immunomodulatory or biological treatments. Another limitation arises from a small 
sample size of the study. Although we could detect statistically significant associations in 
this study, the results need to be validated in larger clinical studies. Finally, although the 
biological variability of serum histamine-releasing activity and anti-IgE-induced BHR in 
health and disease was beyond the scope of this study into a natural history of CSU, 
parallel assessments of the pathophysiological variables (serum histamine-releasing 
activity and anti-IgE-induced BHR) in healthy subjects would have strengthened a 
biological interpretation of the data on pathophysiological phenotyping in CSU. Overall, 
we believe that this study provided some insights into the natural history of disease, the 
markers for disease severity and the predictors of disease persistence. The observed 
clinical patterns and pathophysiological associations provided preliminary data for 
randomized controlled studies in CSU patients with a rational approach to disease 
phenotyping, monitoring of inflammation and, perhaps, an early therapeutic intervention 
in patients with a persistent disease. 
3.4.5 Clinical implications of the study 
The importance of pathophysiological heterogeneity in CSU is underscored by the 
clinical need for discerning the main pathophysiological pathways in CSU which can be 
targeted therapeutically. Furthermore, the identification of CSU patient subpopulations 
that may be responsive to different treatments underlines the importance of the 
pathophysiological phenotyping of the disease. Our study confirms the argument by 
Eckman et al (2007) that serum histamine-releasing activity and anti-IgE-induced BHR 
are unrelated and seem to operate in different patient subgroups. Whether this translates 
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into differential treatment efficacy in these patient subgroups needs to be established in 
clinical trials. 
Our data may provide the groundwork for further optimization of the diagnostic work-up 
in CSU patients. Testing for serum histamine-releasing activity in CSU is used in clinical 
practice and recommended by EAACI Task Force on autoimmune CSU (Konstantinou et 
al, 2013) although the clinical meaning of the test results needs to be further elucidated. 
Our longitudinal study, for the first time, described the transient and persistent increase in 
serum histamine-releasing activity in CSU patients over the period of observation. 
Different longitudinal patterns of serum histamine-releasing activity in CSU patients may 
suggest the need for serial testing for serum histamine-releasing activity in CSU patients. 
The results of the ongoing multicenter PURIST study into the features of CSU with 
serum histamine-releasing activity may provide further insights into an optimal 
combination of diagnostic approaches to this condition. 
Our data emphasize that disease severity at presentation may predict the persistent 
clinical course in CSU patients. If this data are validated in larger patient populations 
from different clinical settings, the prediction of the persistent CSU based on UAS7 at 
presentation could guide a clinical decision-making for an early start of 
immunomodulatory or biological treatments in CSU patients with severe disease. 
Prognostic criteria for severe and persistent CSU will need to be explored in clinical 
interventional studies while the definitions for a persistent disease and a clinical 
remission in CSU need to be developed in clinical guidelines. From a healthcare 
perspective, early treatment and prevention of severe and persistent CSU in the future 
may reduce healthcare visits and costs that were previously estimated for the 
management of CSU patients (Weller et al, 2012; Delong et al, 2008, Zazzali et al, 2012). 
Our flow cytometry data may provide valuable information for ongoing research into 
WBC differential counting by flow cytometry. Multi-parameter flow cytometry has been 
applied for WBC count and differential (Cherian et al, 2010; Roussel et al, 2010; van de 
Geijn et al, 2011) in an attempt to supersede the current reference method of manual 
microscopy. However, the accuracy of basophil enumeration was insufficient in WBC 
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differential by flow cytometry (Roussel et al, 2010). For the first time, we demonstrated 
that absolute basophil counts in CSU varied depending on the choice of the gating 
strategy. These data need to be validated in healthy subjects and in patients with various 
allergic or inflammatory diseases before an introduction of extended flow cytometric 
panels for basophil identification can be recommended for flow cytometric WBC 
differential. 
3.4.6 Unanswered questions and future studies 
Although our knowledge about the natural history and the pathophysiology of CSU 
advances, several unanswered questions remain. 
Firstly, the interrelationship and the relative contribution of serum histamine-releasing 
activity and anti-IgE induced basophil releasability in CSU patients are of great 
theoretical and clinical interest. To further understand how these factors account for the 
variance in disease severity in CSU, we need to design an intermediate study with the 
recruitment of at least 20 CSU patients per predictor in the regression equation. 
Furthermore, a comparative study into the variability of these two parameters in CSU 
patients and healthy subjects would enhance a biological interpretation of 
pathophysiological phenotyping in CSU patients. Larger longitudinal studies are needed 
to better characterize the subset of CSU patients with persistent disease and to validate 
the baseline predictors for disease persistence. 
The causes of aberrant basophil responsiveness to anti-IgE stimulation are yet to be fully 
understood. For basophil responders to anti-IgE stimulation, the priming and 
degranulating factors in the circulation need to be further explored. The biological 
significance of decreased responsiveness of basophils to anti-IgE stimulation in some 
CSU patients is yet to be elucidated. Signaling via different activation and inhibitory 
receptors in peripheral blood basophils in CSU needs to be better characterized. Such 
integral functional characterization of peripheral blood basophils in CSU may help 
uncover yet unidentified signaling defects in CSU in addition to those reported by 
Vonakis et al (2007). What is the biological significance of different patterns of basophil 
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releasability to anti-IgE stimulation in CSU? Do they represent the stages of the disease? 
Do basophils re-circulate after their migration into the inflamed skin in CSU? If they do, 
what are their phenotypic features and functional characteristics on re-circulation? These 
questions remain unanswered at present but draw an attention of scientists to these novel 
dimensions of inflammation in CSU. 
What are the underlying mechanisms responsible for the variability of the clinical course 
in CSU? Although there is currently no evidence for pathophysiological determinants for 
persistent CSU, research into genetic predisposition, epigenetic mechanisms, skin 
remodelling, abnormal mast cell releasability in the context of pro-inflammatory skin 
microenvironment in the dermis of CSU patients with a persistent disease would be of 
great interest. Clinico-histopathological correlations in persistent CSU may also shed 
some light on the relevance of skin remodeling and the pattern of inflammatory 
infiltration in the dermis to the persistent disease. Research into immunomodulatory and 
biological treatments in CSU may help answer the question as to whether the persistent 
course of CSU can be therapeutically altered or prevented. 
In clinical practice, absolute basophil counts in CSU patients will need to take into 
account basophil subpopulations as demonstrated by flow cytometric 
immunophenotyping in our study. Morphological and functional characteristics of 
basophil subpopulations using advanced microscopy, imaging flow cytometry and single-
cell PCR would enhance our understanding of basophil subpopulations in health and 
CSU. Flow cytometric assessments of absolute basophil counts using a volumetric 
approach may result in higher precision of enumeration of basophil subpopulations in 
future studies. Monitoring changes in basophil subpopulations in CSU over the course of 
disease may yield novel insights into basophil biology in CSU. If basophil 
subpopulations can be novel therapeutic targets in CSU needs to be explored in future 
studies. Some lessons about basophil biology can be learned from the effects of 
biological agents such as omalizumab or Syk inhibitors on basophil phenotype and 
functional characteristics. 
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The mechanisms and causes for in vivo basophil priming are an interesting area of future 
research. For example, the effects of eotaxin on peripheral blood basophils in the context 
of CSU may represent an important line of future research. An interaction of β-
chemokines with peripheral blood basophils from CSU patients and healthy subjects 
needs to be examined in in vitro using basophil activation tests and chemotaxis assays. 
The use of extended immunophenotyping panels and quantitative assessments of basophil 
surface receptors would allow better understanding of in vivo priming of circulating 
basophils in CSU. In particular, the in vivo expression profile of chemokine receptors in 
circulating basophils in CSU would also be of interest. Also, the use of novel basophil 
markers such as CD164 may enhance basophil identification in CSU. Furthermore, 
comparative studies would allow better assessments of the variability of marker 
expression such as HLA-DR on basophils in CSU patients and healthy subjects to 
understand if HLA-DR expression is affected in CSU by analogy with SLE (Charles, 
2010). 
Overall, translating this pathophysiological insights into clinically relevant information as 
markers for disease severity, predictors for a persistent course and treatment targets in 
CSU would certainly enhance the management of CSU patients and may allow a more 
targeted approach to treatment in CSU patient subgroups. 
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CHAPTER 4 
Imaging Flow Cytometry Studies in Peripheral Blood 
Basophils in Healthy Subjects 
“Curiosity is the ambition to go beyond.” 
—BARBARA M. BENEDICT 
4.1 Abstract 
Background: Human basophil heterogeneity has been suggested in terms of cellular 
density, ultrastructural morphology, immunophenotype, functional responses to anti-IgE 
stimulation and chemotactic stimulation with C5a. We hypothesised that the variation in 
basophil phenotypes in our flow cytometric studies in CSU patients may result from 
phenotypically and, possibly, morphologically different basophil subpopulations in the 
peripheral blood. In this study, we used innovative ImageStream® technology to assess 
basophil variation in healthy subjects by a combination of immunophenotyping and 
morphometric analysis at a single cell level. This study was undertaken to examine the 
differences in peripheral blood basophil phenotypes in healthy subjects that may explain 
basophil phenotypic variation in our prospective observational study in CSU using 
conventional flow cytometry. 
The aim of the study was to develop methodology to characterise the immunophenotypic 
and morphological variation in peripheral blood basophils and differences in the basophil 
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yield based on different gating strategies in healthy subjects using ImageStream® 
technology.  
Methods: For imaging flow cytometry studies, basophils were enriched by Ficoll-Paque 
density centrifugation (1.084 g/ml). After surface staining with a four-colour panel, 
samples were fixed using 0.025% glutaraldehyde solution. Data were acquired using 
ImageStreamX imaging flow cytometer (Amnis Corporation, USA). Four fluorescence 
images, the brightfield and the darkfield images were acquired at 40× magnification. Data 
analysis was carried out using IDEAS software 4.0 (Amnis Corporation, USA).  
Results: The use of CD63+CD203c+ gating strategy allowed the detection of 0.02% of 
basophils whereas CCR3+CD63+ gating strategy identified 0.4% of basophils in the 
same peripheral blood sample from a healthy donor following Ficoll-Paque density 
gradient centrifugation. Visual inspection of cells within a Boolean gate constructed 
using Boolean logic CD203c+ OR CD63+ resulted in the identification of a basophil 
subpopulation with surface alterations that comprised 17.7% cells in this gate. In this 
healthy subject, single marker-based gating resulted in 0.1% of CD203c-positive cells, 
1.42% CD63-positive cells and 0.89% CCR3-positive cells in the same sample. When 
single marker-based gates were tested for the percentages of basophil subpopulation with 
surface alterations in the same sample, all basophils with surface alterations were CD63-
positive, 93.75% of which were CCR3-positive and 0.78% of which were CD203c-
positive. We demonstrated that pre-analytical sample handling at 4°C resulted in 0.03% 
of basophils with surface alterations in the sample whereas sample handling at 37°C 
resulted in 0.16% basophils with surface alterations in the same sample from a different 
healthy donor. In this healthy donor, 8.41% of CD203c-positive basophils demonstrated 
characteristic staining with PAC-1, suggestive of platelet-basophil adhesion.  
Conclusions: ImageStream® imaging flow cytometry is a useful research tool to study 
basophil phenotypic and morphological variation. The results of our ImageStream® 
basophil studies in healthy subjects suggest that the differences in the basophil yield 
between different gating strategies (CD63+CD203c+ versus CCR3+CD63+) may arise 
from biological (basophil phenotypic variation, a relative contribution of basophil 
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subpopulation with surface alterations), technical (pre-analytical handling at different 
temperatures) reasons as well as effect of confounding factors (platelet-basophil 
adhesion). These results may indicate the putative factors contributing to basophil 
phenotypic variation observed in our prospective observational study in CSU using flow 
cytometry.  
4.2 Introduction 
Progress in understanding of basophil immunobiology has historically been defined by 
advances in research methodology. Since the discovery of basophils by Ehrlich (1879), 
metachromatic staining with basic dyes (toluidine blue, methylene blue, methylene violet, 
brilliant cresyl blue, neutral red, safranin and azure) has been the main method used for 
basophil identification. Further research into differential staining of human basophils 
with basic dyes and basophil biochemistry was accelerated in the 1950s. The direct 
chamber count of basophils was introduced into basophil research by Moore and James 
(1953) and has been widely used for studies examining variation in basophil counts in 
allergic and inflammatory conditions. Basophil functional studies using metachromatic 
staining were developed by Shelley and Juhlin (1962) and their studies resulted in a 
descriptive atlas of various stages of basophil granulation and degranulation. An 
introduction of basophil mediator release assays was an important milestone in the 1970s, 
and these tests remain benchmark assays for basophil functional studies to date (de Weck 
et al, 2008; Ebo et al, 2008). Serum-induced basophil histamine release assay was 
introduced for the detection of serum histamine-releasing activity in CSU in the 1990s 
and is used currently (Platzer et al, 2005). 
Ultrastructural analysis of basophils was introduced to the field in the late 1960s and then 
extensively developed in 1970s-1990s (Dvorak & Ishizaka, 1995). The development of 
antibodies to several basophil surface markers  (2D7, CD63, CD203c) as well as basophil 
intracellular marker BB1 in the 1990s allowed immunohistochemistry and flow 
cytometric studies in basophil research (Buckley et al, 2002). The advances in basophil 
purification in 1990s-2000s were marked by the wide use of density gradient media for 
basophil enrichment, basophil cell sorting and commercial kits for negative 
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immunomagnetic basophil purification (Gibbs & Ennis, 2001). Currently, innovative 
technologies in the field of basophil research include live basophil allergen arrays 
developed as a bioassay based on the combination of protein arrays with live human 
basophils (Falcone et al, 2009). Future prospects in basophil research include innovative 
technologies (imaging flow cytometry) (Zuba-Surma et al, 2007) and single cell gene 
expression profiling (Livak et al, 2013) which offer novel possibilities of 
immunophenotyping, functional and morphometric analysis of human basophils at a 
single-cell level. 
Basophil variations in phenotype in healthy subjects were described in terms of density, 
response to anti-IgE stimulation and chemotactic stimulation with C5a. Different patterns 
of granulation in mature and immature basophils were noted in the 1960s (Thornnard-
Neumann, 1963). Comparative studies of basophil precursors and mature basophils were 
described in the 1970s (Parwaresch & Lennert, 1979) and then extended in 1970-1990s 
(Dvorak & Ishizaka, 1995). For example, basophil precursors tend to be larger in size, 
sensitive to metachromatic staining with basic dyes at lower pH and have less granulation 
compared to their mature counterparts (Parwaresch & Lennert, 1979). During activation, 
basophil phenotypes included fully granulated, intermediate and degranulated basophils 
(Dvorak, 1991). Density gradient studies revealed hypodense and hyperdense basophils 
(Lennart & Skeel, 1985). Additionally, chemotaxis of human basophils to the 
complement component C5a and other chemotactic agents was first described in two 
patients with myeloid leukemia and high basophil counts by Kay and Austen (1972) and 
it was noted in the later studies that only approximately 10% of basophils in peripheral 
blood respond to a chemotactic stimulation with C5a or lymphocyte-derived chemotactic 
factors (Lett-Brown et al, 1976; Lett-Brown & Leonard, 1977). Basophil functional 
heterogeneity in response to anti-IgE stimulation was described in CSU (Vonakis et al, 
2007) and asthma (Youssef et al, 2007). Together, our observations and work by other 
researchers suggest re-visiting basophil phenotypic variation in health and disease and a 
re-assessment of its biological significance and, possibly, clinical contributions in allergic 
and inflammatory diseases including CSU. 
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In the context of inflammation, basophil phenotype is characterised by up-regulation of 
surface and intracellular markers (Bochner, 2000). For phenotypic analysis, surface 
activation markers include CD63, CD203c, CD107a/D107b, CD13 and CD69 
(Hennersdorf et al, 2005). CD63, a member of the tetraspan family, is a highly 
glycosylated lysosomal-associated membrane protein (LAMP-3) which resides in 
cytoplasmic granules in basophils (Valent, 2010). Its up-regulation is linked, but not 
identical, to histamine release (MacGlashan Jr., 1995). CD63 and CD69, but not CD203c, 
were reported to be up-regulated on circulating basophils from CSU patients (Vasagar et 
al, 2006). CD69 was also up-regulated in asthma (Yoshimura et al, 2002) and venom 
allergy (Gober et al, 2007), however, the biological function of this activation marker is 
currently unknown. CD203c is an ectoenzyme which is expressed in peripheral blood 
basophils although the basal level on the resting basophils is low. CD203c expression 
increases in asthma exacerbation (Ono et al, 2010), but is unaffected in CSU patients 
(Vasagar et al, 2006). Basophil surface markers CD107a (also known as LAMP-1) and 
CD107b (also known as LAMP-2) belong to the family of lysosomal membrane proteins 
(Hennersdorf et al, 2005) and their up-regulation occurs via the same pathway as that for 
CD63 (Hennersdorf et al, 2005). The novel basophil markers CD107a/CD107b, CD13 
and CD164 have not been studied in the context of CSU. The basophil intracellular 
granule-specific marker BB1 is the highly basic protein basogranulin (McEuen et al, 
2001), however, the intracellular expression of BB1 antigen and its release has not been 
studied in CSU. This highlights the need for a better characterisation of basophil 
phenotypic variation in CSU.  
Why are basophils important in CSU? Basophils have been implicated in the 
pathophysiology of CSU since the 1960s (Robinson & Pennington, 1966). There are 
several lines of evidence suggesting that basophil numbers and function are affected in 
CSU. The numbers of circulating basophils appear to be inversely related to the severity 
of CSU, and basopenia, defined by metachromatic staining, was noted to be a feature of 
severe disease (Grattan et al, 2003). Peripheral blood basophils in CSU patients are 
characterised by an abnormal sensitivity to serum from CSU patients and healthy donors 
in in vitro studies (Liquin et al, 2005). Interestingly, basopenia detected by 
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metachromatic staining appears to be related to serum histamine-releasing activity in 
CSU (Grattan, 1997) while in vivo basophil priming and an aberrant basophil response to 
anti-IgE stimulation are unrelated to the presence or absence of serum histamine-
releasing activity (Vasagar et al, 2006; Eckman et al, 2008). Distinct basophil functional 
subsets based on their histamine release to anti-IgE stimulation have been described in 
CSU. Basophil functional subsets were shown to be a stable feature in CSU patients but 
their clinical significance is poorly understood (Eckman et al, 2008; Baker et al, 2008). In 
longitudinal observations, basophil histamine release to anti-IgE stimulation improves 
towards the remission of the disease (Eckman et al, 2008). These findings suggest that 
basophils participate in the CSU disease process via yet unknown mechanisms. Taken 
together, these data led to the hypothesis that basophils, together with mast cells, are the 
effector cells of the inflammation in CSU, although direct proof of their involvement in 
weal formation in CSU is still lacking. Overall, basophils appear to be important in the 
pathophysiology of CSU, however, their precise contribution to weal formation, chronic 
skin inflammation and disease persistence remains unclear. Basophils in CSU may be 
targeted therapeutically (Marsland et al, 2005), particularly with advent of the biological 
treatments (MacGlashan Jr. et al, 2011; MacGlashan Jr. & Saini, 2013). Therefore, 
understanding basophil biology and function in CSU may lead to advances in their 
development as a biomarker or a therapeutic target.  
Our prospective study also demonstrated phenotypic basophil variation in CSU patients 
(Chapter 3). In our study, variation in basophil phenotype depended on the choice of 
gating strategy used for basophil identification. We hypothesised that basophil 
phenotypic and, possibly, morphological variation at a single cell level may contribute to 
the differences in basophil phenotypes observed in our flow cytometric studies in CSU 
depending on the chosen gating strategy. To test this hypothesis, we used the innovative 
ImageStream® imaging flow cytometry to study basophil phenotypic and morphological 
variation in healthy subjects using the same gating strategies as in our flow cytometric 
study in CSU patients.  
ImageStream® imaging flow cytometry (developed by Amnis Corporation and then by 
EMD-Millipore) is an innovative research technology (McGrath et al, 2008) that allows 
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multiparameter immunophenotyping to be combined with morphometric analysis of 
basophils in the same sample at the single cell level. Analysis of cells in the suspension 
by imaging flow cytometry offers an advantage for CSU research because peripheral 
blood basophils in CSU are primed and their threshold for activation during cell sorting 
may be lowered. In imaging flow cytometry, analysis of cells in suspension is achieved 
by using a charge coupled device (CCD) camera that works in Time Delay integration 
mode to ensure optimal imaging of cells in flow. Furthermore, basophil research in CSU 
is hindered by low basophil counts in some patients. The ImageStreamX imaging flow 
cytometer is characterised by a maximum acquisition rate of 1,000 cells/min that makes it 
a high-throughput technology suitable for rare cell analysis including basophil research in 
CSU. Furthermore, ImageStream technology offers cell gating based on both 
fluorescence and morphological features. The capability of visualizing the morphology of 
gated cell populations identified by different gating strategies on the dot plot is missing in 
flow cytometry and can be used for morphometric analysis of basophil subpopulations in 
CSU.   
The limitations of imaging flow cytometry include longer acquisition periods for rare cell 
research and the requirement for high-speed computers for analysis of large datasets for 
these experiments. Additionally, the ImageStream® technology does not allow further 
manipulations with cells while conventional flow cytometry offers the option of cell 
sorting that can be used in combination with cell culture and other techniques such as 
single cell PCR profiling. Therefore, the ImageStream® technology appears to be 
complementary to conventional flow cytometry and fluorescence microscopy. 
ImageStream® may address many pressing issues in basophil research using 
conventional flow cytometry in CSU. The principle innovation of this technology 
encompasses a new level of informational content of the acquired data (Basiji et al, 2007) 
such as morphological and immunophenotypical data at a single cell level for cells in 
suspension which has not been possible before. Several important questions may be 
answered by the phenotypic and morphometric analysis at a single cell level, such as 
variability in basophil morphology, immunophenotyping of basophil subpopulations, the 
effect of pre-analytical sample handling on basophil morphology and immunophenotype, 
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the selection of an appropriate gating strategy and the choice of basophil surface markers 
for different experimental settings. In basophil research, combined flow cytometric and 
morphometric studies using human basophils are rare (MacGlashan Jr., 2010b), 
laborious, cumbersome and require exquisite technical expertise. Low basophil counts in 
the peripheral blood, high water-solubility of basophil granules, a low threshold for 
basophil activation and degranulation during pre-analytical sample handling are the key 
limitations for the manipulations with human basophils using current research techniques. 
The use of ImageStream® technology may help circumvent these limitations and may 
make the combination of flow cytometric and morphological studies in human basophils 
more accessible.  
Some limitations of imaging flow cytometry may be highlighted in comparison with 
conventional flow cytometry. For example, conventional flow cytometry is more widely 
available, provides rapid analysis and is easy to use for an experienced operator. In 
contrast, imaging flow cytometry is time-consuming for rare cell analysis, more difficult 
to operate and needs tedious optimization that requires expert consultancy at the level of 
highly specialized flow cytometry service. An image resolution similar to a fluorescence 
microscope with 40-60× lenses may be a limitation of the technique for certain aspects of 
cellular analysis. Additionally, data analysis for imaging flow cytometry dictates 
requirements for computer support comparable to that of crystallography.  Therefore, this 
technology resides, at present, in the domain of academic settings of excellence rather 
than being a widely used research technique. 
From clinical perspective, there are several potential applications of ImageStream® 
technology to basophil enumeration or basophil activation tests in the clinical settings. 
Firstly, current flow cytometric approaches have limited accuracy for rare cell counting 
(Cherian et al, 2010; Bjornsson et al, 2008) and the application of ImageStream® 
technology may improve absolute basophil counting through the morphological 
verification of gated basophil subsets combined with the use of volumetric methodology 
and the development of extended multi-parameter panels for basophil identification. 
Secondly, a better phenotypic and morphological characterisation of an activated 
basophil phenotype using ImageStream® technology may help the development of 
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basophil subpopulations as biomarkers for monitoring the clinical course of allergic 
diseases, CSU or haematological malignancies and the effects of various treatments (Ono 
et al, 2010; Grattan et al, 2003; Wimazal et al, 2010; Saini & MacGlashan Jr., 2012). 
Thirdly, ImageStream® technology can be used as a complementary tool for 
standardization of the laboratory protocols for flow cytometry-based assays used for the 
diagnosis of food and drug allergies and for the detection of serum histamine-releasing 
activity in CSU (Shreffler, 2006; Hausmann et al, 2009; Platzer et al, 2005). For example, 
this technology may be used to evaluate the effects of fixative and lysis solutions on 
basophil morphology and phenotype during sample preparation or may inform and verify 
the bioinformatics-based approaches to automated gating (Jaye et al, 2012). Future 
studies may identify further areas for integrating ImageStream® technology in the 
basophil analysis in clinical samples.  
The aims of this study were: 
1 to assess and compare gating strategies for peripheral blood basophils based on dual 
gating for CD203c and CD63 basophil markers and a gating for CCR3 marker.  
2 to assess phenotypic and morphological basophil variation in peripheral blood of 
healthy subjects and to determine its significance for the gating strategies used in our 
study.  
4.3 Methods 
4.3.1 Participants 
Healthy volunteers were recruited from the members of staff at the Dermatology 
Department at the Norfolk & Norwich University Hospital and at the Biomedical 
Research Centre at the University of East Anglia. The study was approved by Norfolk 
Research Ethics Committee for method development as a part of the project 
“Pathophysiological subtypes in chronic ordinary urticaria and their biomarkers: a 
prospective observational study” (Ref. 08/H0310/53). All participants gave written 
informed consent before taking part in the study. In this optimisation study, healthy 
subjects were not tested for atopy.  
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4.3.2 Sample Preparation 
For imaging flow cytometry studies, 35 ml of venous blood was collected from a healthy 
donor into four 9-ml BD Vacutainer tubes with sodium citrate. Basophils were enriched 
by Ficoll density centrifugation using the protocol of Valent and associates (1990) 
modified for our imaging flow cytometry studies. Citrated whole blood was layered over 
Ficoll-Paque PLUS solution (GE Healthcare, UK) with a density of 1.084 g/ml at the 
ratio 1:1 v/v and centrifuged at 1,800 rpm/min without brakes for 30 min at room 
temperature. The whole Ficoll layer was harvested for basophil studies. Samples were 
washed at 1,920 rpm/min without brakes for 10 min in RPMI 1640 (Invitrogen, no 
Phenol Red) with 3% BSA (Fraction V, Fisher Scientific, UK) at 4°C. The second wash 
was carried out at 980 rpm/min, no brakes, for 10 min in RPMI 1640 containing 3% BSA 
at 4°C. 
After washing, cells were stained and counted according to the method of Kimura et al 
(1973). Then, the volume of cell suspension was adjusted by adding RPMI 1640 
containing 3% BSA to achieve a cell density of 3-4x106 cells/ml per tube. Fc receptor 
blocking reagent for human samples (Miltenyi Biotec, UK) was added 10 µl/tube to each 
sample. Surface staining was performed with a 6- colour staining panel for 30 min at 4°C 
in the dark. Antibodies conjugated with fluorochromes used for basophil studies are 
presented in the Table 1 (Figure 2, Appendix 5). After staining, the cells were washed at 
1450 rpm/min, no brakes, for 5 min in RPMI 1640 containing 3% BSA at 4°C. Then, the 
cells were fixed with 0.025% glutaraldehyde solution in PBS by adding 40µl of 0.025% 
glutaraldehyde to 300 µl of cell suspension. Samples were centrifuged at 200g, 4°C for 2 
min and supernatant was swiftly removed. Immediately, the samples were washed in 2 ml 
of RPMI 1640 containing 3% BSA at 200g for 3 min at 4°C and again the supernatant was 
promptly removed. The second wash was carried out in 1ml of RPMI 1640 with 3% BSA 
at 200g for 3 min at 4°C, the supernatant was removed straight away. After this, wash was 
repeated once again in 0.5ml of RPMI 1640 containing 3% BSA at the same settings 
(200g for 3 min at 4°C). Supernatant was removed and samples left overnight at 4°C. 
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Next day samples were washed twice in 1 ml of RPMI 1640 containing 3% BSA for 3 
min at 4°C. Cells were resuspended in 300 µl of RPMI 1640 with 3% BSA. Then Fc 
receptor blocking reagent for human samples (Miltenyi Biotec) was added 10 µl per tube. 
Samples were shipped in temperature-controlled packaging (Cool Logistics, UK) at 4°C 
(with temperature range between 3-8°C) for imaging flow cytometry studies. 
Critical Steps 
To avoid glutaraldehyde-induced autofluorescence, critical factors during sample fixation 
included volumes of the sample and fixative, quick supernatant removal, leaving samples 
overnight in RPMI 1640 with 3% BSA at 4°C and cell washing twice next day before 
data acquisition. Imaging flow cytometry studies required high cell density in the sample 
for optimal rate of data acquisition. To obtain sufficient number of cells from the defined 
volume of venous blood, certain precautions were undertaken for careful supernatant 
removal to avoid disturbing the cellular pellet and the protocol was modified to reduce 
cell losses during washing steps. Furthermore, at high cell density in the sample, 
basophils tended to be included in cellular clumps. Hence, the 3% BSA was added to 
RPMI 1640 at all stages of sample preparation and Fc receptor blocking reagent was 
added at the final steps to reduce cellular adhesion. In our studies, we found important to 
ship samples at 4°C but not on ice. 
4.3.3 ImageStream® Data Acquisition 
Imaging flow cytometry studies were carried out using ImageStreamX imaging flow 
cytometer (Amnis Corporation, USA). About 50,000-200,000 events per sample were 
acquired. To eliminate debris, only events with the minimal area of 20µm2 in the 
brightfield channel were acquired. Cells were excited with a 405 nm laser (125mW), a 488 
nm laser (200 mW), 561 nm laser (200 mW), a 658 nm laser (120mW) and a 795 nm laser 
(1.75mW) (Figure 1, Appendix 5). The brightfield imagery, the darkfield imagery and 
four fluorescence images per each cells were acquired at 40X magnification. Three 
multicolour staining panels were used for basophil studies (Figure 2A, Appendix 5). For 
comparative gating analysis, multicolour staining panel 1 comprised of CellMask™ Deep 
Red plasma membrane stain (Invitrogen, UK) and antibody conjugates anti-CD203c 
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Brilliant Violet 421 (Biolegend, UK), anti-CD63 FITC (BD Biosciences, UK) and anti-
CCR3-PE (Biolegend) as presented in the Table 1 (Figure 2, Appendix 5). For 
immunophenotyping studies, Panel 2 and 3 were used as explained in Figure 2 (Appendix 
5). The summary of the surface cellular markers is presented in the Table 2 (Figure 2, 
Appendix 5). Unfixed and fixed unstained samples were used as controls for 
glutaraldehyde-induced autofluorescence (Figure 4A and B, Appendix 5). Fluorochrome-
conjugated antibodies against surface markers highly expressed on human basophils (anti-
CD123 Brilliant Violet 421 (Biolegend, UK), anti-CD45 FITC, anti-CCR3 PE) and Cell 
Mask™ Deep Red plasma membrane stain (Invitrogen, UK) (Table 1, Figure 2, Appendix 
5) were used for single stained controls (Figure 4, Appendix 5). Single stained controls 
were acquired with the brightfield illumination off to generate a compensation matrix 
(Figure 1B, Appendix 5). Fluorescence minus one (FMO) controls were used to set the 
gates for cells positive for CD203c (Figure 5A, Appendix 5), CD63 (Figure 5D, Appendix 
5) and CCR3 (Figure 5G, Appendix 5) at 99.9% confidence level. Data analysis was 
carried out using IDEAS software 4.0 (Amnis Corporation) (Figure 3, Appendix 5). 
4.4 Results 
4.4.1 Comparison of two gating strategies for human basophils on the 
same Basophil-enriched Ficolled Peripheral Blood Samples 
To compare the basophil yield by different gating strategies for human basophils, we 
applied two gating strategies based on 1) dual expression of CD63+CD203c+ and 2) dual 
expression of CCR3+CD63+ in the same Ficolled peripheral blood sample from a healthy 
subject. The initial gating strategy for human basophils in Ficolled sample of the 
peripheral blood included identification of cells in focus based on Gradient RMS (Figure 
38A; for morphometric glossary – see Table 3, Appendix 5) followed by exclusion of 
cellular aggregates on a bivariate plot of Aspect Ratio versus Area (Figure 38B). After 
this, FMO-based gates for CD203c, CD63 and CCR3 surface markers were applied on 
the corresponding bivariate plots (Figures 38C, D, F). Boolean gates were constructed by 
a combination of CD203c and CD63 gates for dual gating for human basophils based on 
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CD203c and CD63 expression (Figure 38E) and also by a combination of CCR3 and 
CD63 gates for dual gating for human basophils based on CCR3 and CD63.  
 Thus, two gating strategies were applied to the same sample: a dual gating for CD63 and 
CD203c (Figure 38E) and a dual gating for CCR3 and CD63 (Figure 38G). Basophil 
yield between these gating strategies was different: 0.02% of basophils based on dual 
CD203c+CD63+ gating and 0.4% of basophil based on CCR3+CD63+ gating (Figure 
38E and G). The representative imagery of basophils identified by these two gating 
strategies are presented in Figures 38H and 38I.  
4.4.2 Identification and Phenotypic Analysis of Basophil Subpopulation 
with Surface Alterations in Ficolled Peripheral Blood Samples from a 
healthy donor 
The next step of analysis included visual inspection of cells identified by a dual gating 
strategy constructed using a Boolean logic CD63+ OR CD203c in order to identify 
morphologically and phenotypically distinct basophil subpopulations by analogy with 
flow cytometry gating that displayed basophil variation (Ebo et al, 2012). On visual 
inspection, we identified a subset of basophils with surface alterations (n=128 cells per 
sample). In addition, we observed basophil variation in size ranging from large (mean 
diameter 16.7±1.2 µm) to small (mean diameter 11.4±1.7 µm) basophils. This variation 
was considered to be due to a normal distribution of cells, therefore, cell variation in size 
was not considered in further analysis.  
Representative brightfield image for a basophil with surface alterations is presented in Figure 
39D. Basophils with surface alterations were manually tagged using IDEAS® software and 
then were used for comparisons with the remaining single cells in focus in the sample. 
Immunophenotypic analysis of the basophil subpopulation with surface alterations was 
performed using three samples from the same healthy donor labelled with three different 
staining panels (Figures 39A-C; for staining panels – see Figure 2A, Appendix 5). For 
immunophenotypic analysis, the histograms were plotted for basophil subpopulation with 
surface alterations and all single cells in the focus for each sample (Figures 39A-C). On the 
histograms, basophils with surface alterations were displayed as a green cell subpopulation, 
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all single cells in focus in each sample were represented as a black cell subpopulation. The 
histograms for basophil subpopulation with surface alterations in three samples may suggest 
a bimodal distribution for the expression of CRTH2 (Figure 39A), CCR3 (Figure 39B) and 
CD69 (Figure 39C), with higher expression of these markers on basophils with surface 
alterations compared to all single cells in focus per sample although low cell counts of 
basophils with surface alterations should be noted.  
4.4.3 Distribution of basophil subpopulation with surface alterations in 
gating strategies for each basophil surface marker CD203c, CD63 
and CCR3 in the same Ficoll-processed Peripheral Blood Sample 
from a healthy donor 
As the next step of the analysis, peripheral blood basophils selected by gates for each 
basophil surface marker CD203c, CD63 and CCR3 were compared for the yield of basophils 
with surface alterations (Figure 40). For this sample, a total of 128 basophils with surface 
alterations were identified on visual inspection of cells in the Boolean gate constructed using 
a Boolean logic CD203c OR CD63. For CD203c+ basophil gating, only one of 128 basophils 
with surface alterations was identified by CD203c marker. The use of CD63-based gating 
resulted in all 128 basophils with surface alterations identified as CD63-positive cells. Using 
CCR3-based gating strategy, CCR3-positive cells comprised a total of 120 of 128 basophils 
with surface alterations in the sample. Therefore, CD203c-positive cells accounted for 0.78% 
of basophils with surface alterations (Figure 40B), basophils with surface alterations were all 
positive for CD63 surface marker (Figure 40D) and also CCR3-positive cells represented 
93,75% of basophils with surface alterations in the sample (Figure 40F). Thus, CD63- and 
CCR3-based strategies in this sample yielded higher percentages of basophils with surface 
alterations compared to that by CD203c-based strategy. These findings suggest a variation in 
surface marker expression on basophils with surface alterations, with most cells being 
positive for CD63 and CCR3 but not for CD203c. Figure 40 demonstrates representative 
images of basophils with surface alterations yielded by each single basophil surface marker 
CD203c (Figure 40B), CD63 (Figure 40D) and CCR3 (Figure 40F). 
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4.4.4 Platelet-basophil adhesion in basophil studies using Imaging Flow 
Cytometry  
To explore whether CD63 expression can be confounded by platelet-basophil adhesion, 
we used a flow cytometric panel with platelet-specific markers. Platelet-basophil 
adhesion was demonstrated in imaging flow cytometry studies (Figure 41A-B) by 
including antibodies to platelet-specific markers (CD61 and PAC-1) into our multicolour 
staining panels. Co-localisation of CD63 and PAC-1 expression on platelets adherent to 
basophils is presented in Figure 41B. These data demonstrated that cellular interactions 
of platelets with human basophils can be studied using ImageStream® technology and 
platelet-basophil adhesion may contribute to CD63 expression in basophil studies using 
imaging flow cytometry.  
4.5 Discussion 
4.5.1 The relevance of ImageStream basophil studies in healthy subjects 
for the interpretation of flow cytometry studies in CSU patients in this 
thesis 
For this thesis, imaging flow cytometry analysis in peripheral blood basophils was 
undertaken to assess basophil variation in healthy subjects and to provide a putative 
biological interpretation for differences in basophil phenotypes observed in flow 
cytometry studies in CSU patients in Chapter 3 of this thesis.  
Firstly, in our ImageStream® studies we confirmed that different gating strategies yield 
different percentages of peripheral blood basophils, which differ phenotypically on visual 
inspection at a single cell level. In the ImageStream® study, gating strategy based on 
dual expression of CCR3 and CD63 yielded 20 times higher percentage of basophils than 
CD63+CD203c+ gating in the same sample of a healthy donor. These data are consistent 
with the results of our flow cytometric studies in CSU patients (Chapter 3) which also 
demonstrated significantly higher absolute counts of CD63+CCR3+ basophil phenotype 
compared to that of CD63+CD203c+ or CCR3+CD123+ basophils.  
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Secondly, our ImageStream® studies offered several putative biological explanations for 
differences in basophil phenotype and yield depending on the choice of the gating 
strategies. Our data suggested that the contribution of basophils with surface alterations 
varies in the gates for each basophil surface marker: CD203c, CD63 or CCR3. Basophils 
with surface alterations were noted to be included in single marker gating for CD63 or 
CCR3 but not CD203c. Whether or not accumulation of basophils with surface 
alterations is increased in CSU and contributes to higher absolute counts of 
CCR3+CD63+ basophils observed in our prospective study of CSU patients needs to be 
explored in future studies.  
Thirdly, platelet-basophil adhesion is a well-known phenomenon in conventional flow 
cytometry (Boumiza et al, 2005). In basophil research, platelet adhesion is believed to be 
a rare event which does not affect the results of basophil studies using conventional flow 
cytometry. Nevertheless, we could demonstrate platelet-basophil adhesion in Ficolled 
peripheral blood samples from healthy donors using previously described protocol for 
sample preparation (Valent et al, 1990). Of interest, platelet adhesion is thought to be 
increased in activated basophils (Shreffler et al, 2006). We do not know whether this is 
relevant in the context of inflammation in CSU. Taken together in vivo platelet activation 
(Palikhe et al, 2004) and basophil priming (Vasagar et al, 2006) in CSU, it is plausible 
that the formation of platelet-basophil aggregates may occur more frequently in CSU and, 
therefore, may confound the detection of CCR3+CD63+ basophil phenotype in CSU 
patients. By analogy, increased platelet-neutrophil aggregation was shown for activated 
neutrophils in patients with sickle cell disease in ImageStream® studies (Polanowska-
Grabowska et al, 2010). The suggestion of increased platelet-basophil aggregation in 
CSU needs to be confirmed basophil studies using extended flow cytometric panels with 
platelet-specific markers in healthy subjects and CSU patients.  
4.5.2 Novel insights into basophil phenotypic and morphological 
variation in healthy subjects 
In our ImageStream® studies, we identified a subset of basophils with surface alterations 
in basophil-enriched Ficolled peripheral blood samples from healthy subjects. Could it be 
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an activated basophil phenotype? We did not test for this in our in vitro studies. However, 
there is limited evidence that the expression of CCR3, CRTH2 and CD69 is increased in 
basophils with surface alterations compared with all other cells in focus in the sample. In 
the literature, basophils with increased CD69 expression were described in the bronchial 
lavage fluid obtained from patients with asthma (Yoshimura et al, 2002) and also in the 
peripheral blood of CSU patients (Vasagar et al, 2006). This suggests the possibility that 
observed basophil phenotype with surface alterations may represent activated basophils.  
The formation of surface alterations by peripheral blood basophils may have biological 
significance. In the literature, alterations in surface morphology in leukocytes was 
previously reported using transmission and scanning electron microscopy. For example, 
neutrophils, eosinophils and monocytes demonstrated well-developed cytoplasmic 
projections by transmission electron microscopy and ridge-like ruffles by scanning 
electron microscopy (Adachi et al, 2009). In vitro studies demonstrated that leukocytes 
showed a round morphology under static conditions and respond with pseudopodia 
projections and cell spreading to fluid shear stress (Coughlin & Schmid-Schönbein, 
2004). Previous scanning electron microscopy studies also suggested that surface 
morphology of circulating leukocytes was that of roughened spheres whereas leukocytes 
were shown to increase in diameter and to develop cytoplasmic projections after surface 
contact (Michaelis et al, 1971). In our studies we observed the participation of basophils 
with surface alterations in cellular aggregates. Whether the observed basophil 
subpopulation with surface alterations occurs in the context of basophil chemotaxis, 
adhesion and motility is unknown and worth exploring in future studies.  
Imaging flow cytometry studies were performed in leukocytes and lymphocytes before, 
but the shape changes observed in our studies were not described. Using ImageStream® 
technology, neutrophils were described to increase in size with the uptake of bacteria 
during phagocytosis (Ploppa et al, 2011). Also, HIV-1 infected lymphocytes displayed 
the formation of thin filopodium-like protrusions but had the inhibition of ruffle 
formation (Nobile et al, 2010). Future research into basophils with surface alterations 
using an ImageStream® flow cytometer with the capability of higher image resolution 
would enhance our understanding of basophil surface morphology in health and CSU.  
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Certain stimuli such as anti-IgE and fMLP can induce a graded basophil activation: an 
induction of chemotaxis at low-grade stimulation and a degranulation at a high-grade 
stimulation (Suzukawa et al, 2007). Basophil activation is known to be a graded process 
(MacGlashan Jr., 1995) and it is conceivable that basophil chemotaxis and degranulation 
may be distinct steps of a graded process of basophil activation. Also, the fact that a low-
grade anti-IgE stimulation may induce basophil responsiveness to a chemotactic 
stimulation was discussed in the literature (Yamaguchi et al, 2009).  
At present, it is unclear whether basophils with surface alterations may be an activated 
phenotype due to chemotactic stimulation. Basophil chemotaxis occurs within multiple 
chemokine gradients including monocyte chemoattractant protein MCP-1, MCP-2, MCP-
3, MCP-4, eotaxin, eotaxin 2, eotaxin 3, macrophage-inflammatory protein-1α, RANTES 
and IL-8 (Heinemann, 2000). In addition to basophil recruitment in the tissues, 
chemokines can cause basophil activation (Yamaguchi et al, 2009). In addition to CCR3, 
basophils express several chemokine receptors including CCR1, CCR2, CCR5, CXCR1 
and CXCR2 and CXCR4 (Iikura et al, 2001). Among chemokines, MCP-1/CCL2 is 
considered as the most potent stimulus for basophil activatoin (Kuna et al, 1992; Bischoff 
et al, 1992) while eotaxin is the most potent signal for basophil migration (Yamada et al, 
1997). Which chemotactic signals may be relevant in CSU is yet to be established. Given 
that the migration of basophils towards eotaxin is increased by weak FcεRI-crosslinking 
stimulation (Suzukawa et al, 2005), it is worth exploring whether there is a synergistic 
relation between eotaxin and serum histamine releasing activity in CSU in their effect on 
peripheral blood basophils. Extended panels with several chemotactic receptors and 
adhesion molecules may better characterize this basophil subpopulation in the future.  
The important question remains as to whether observed basophil phenotypic variation in 
ImageStream studies represents a distinct subpopulation or a physiological variation 
according to Gaussian distribution. Statistical frequency distribution of fluorescence 
intensity in differential histograms is important in answering this question. It is not 
possible to infer from two replicates whether these data represent heterogeneity rather 
than temporal or population noise. However, two separate peaks in fluorescence intensity 
on differential histograms as opposed to continuous distribution would suggest a separate 
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cellular subpopulation rather than a fraction of overall cell population. Therefore, 
basophils with surface alterations are likely to be a subpopulation while variation in cell 
sizes would represent population fractions according to Gaussian distribution. This 
suggestion is also supported by the fact that two log-decade difference in fluorescence 
intensity between basophils with surface alterations and the remaining cells in the sample 
is greater than the measurement error in flow cytometry studies. The fact that basophils 
with surface alterations demonstrate a separate peak of fluorescence intensity in some 
surface markers would suggest a link between basophil surface morphology and 
immunophenotype. Future studies in generalizability in healthy subjects, various 
diseases, by using different research techniques as well as the demonstration of biological 
function in vivo and in vitro would answer the question as to whether basophils with 
surface alterations represent a separate subpopulation (Prussin et al, 2010). 
At present, the biological significance of basophils with surface alterations is unknown. 
They may represent a dynamic reversible state in response to microenvironmental factors 
as opposed to stable basophil subsets with regards to anti-IgE stimulation as described by 
Vonakis et al (2007). The factors inducing this cellular phenotype may include cytokines, 
epigenetic modifications, circulating pro-inflammatory factors and may affect precursors 
or terminally differentiated cells. This is likely to be a general phenomenon in the 
inflammation for myeloid cells or lymphocytes (Galli et al, 2012).  
It is also unknown whether large basophils in the sample suggest a physiological 
variation during developmental changes. It is plausible in view of previous descriptions 
of immature basophils of larger size (Parwaresch, 1976) and our imagery of KU812 cell 
line with larger leukemic basophil precursors (Figure 7, Appendix 5). However, we 
detected only 20 large basophils in the sample which does not allow any biological 
interpretation.   
Overall, the detection of cellular subpopulation is considered as a starting point for 
experimental analysis (Huang S, 2009). Re-distribution of basophils with surface 
alterations within the overall basophil populations may occur in inflammatory conditions 
(Altschuler & Wu, 2010) including CSU. Further studies into biological relevance and 
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clinical contribution would allow this subpopulation to be developed into a biomarker or 
a therapeutic target.  
4.5.3 Methodological Recommendations for Basophil Studies using 
Conventional Flow Cytometry 
In our study, we confirmed that 1) basophil phenotype depends on the choice of gating 
strategy, 2) basophil subpopulation with surface alterations may contribute to the certain 
basophil phenotypes, 3) pre-analytical handling may increase the proportion of basophil 
subpopulation with surface alterations, 4) platelet-basophil adhesion may confound CD63 
expression in basophil studies. The results of our imaging flow cytometry studies in 
human basophils may have some important insights into sample preparation, a panel 
design and gating strategies in flow cytometry studies. Technical aspects of methodology 
and some observations of basophil biology identified in our preliminary experiments 
were considered worth noting for future studies in peripheral blood basophils using 
imaging flow cytometry.  
An optimal choice of antibody conjugates was shown to be important for protocol 
development for imaging flow cytometry studies in human basophils. During method 
development, several multicolour staining panels for basophil immunophenotyping were 
tried in preliminary studies. For example, signal resolution for CD63 surface marker on 
peripheral blood basophils in our studies was better for an antibody conjugate with FITC 
(BD Bioscience, UK) than with Alexa Fluor 700 (Exbio Praha, Czech Republic). 
Therefore, ImageStream® technology can be used for optimisation studies, in 
combination with conventional flow cytometry, as a visual guide for a rational 
construction of multiparameter flow cytometric panels based on the marker expression 
levels on cells as well as characteristics of both antibodies and fluorochromes.  
Technical aspects of sample preparation for basophil studies such as the effect of sample 
pre-warming can also be addressed by imaging flow cytometry studies. As demonstrated 
in Figures 7A and 7B (Appendix 5), the number of basophils with surface alterations as 
well as their median CRTH2 fluorescence intensity was shown to increase on sample pre-
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warming at 37°C for 30 min (Figure 7B, Appendix 5) compared to pre-analytical sample 
handing at 4°C (Figure 7A, Appendix 5). 
Extended immunophenotyping of basophil subpopulations may provide new insights into 
their function and biological significance. Noteworthy, basophils with surface alterations 
were noted to form cellular aggregates (Figure 8, Appendix 5) whether it suggests 
increased cellular adhesiveness in this basophil subpopulation is unknown and worth 
exploring.  
Our data suggest that variation in pre-analytical sample handling may affect the 
composition of basophil subpopulation and their surface marker expression as 
demonstrated in our studies by effects of sample pre-warming on the percentage of cells 
with surface alterations and their CRTH2 expression. Our data consistent with method 
development studies in flow cytometric research for the detection of chemokine receptors 
on leukocytes (Berhanu et al, 2003) that found maximum expression of chemokine 
receptors after incubation of samples at 37°C for 30 min. 
Based on our data on basophil heterogeneity, the use of extended multicolour panels may 
provide further insights into basophil subpopulations. At present, an addition of CCR3, 
CRTH2, CD69 to CD63 and CD203c may enhance basophil immunophenotyping and 
may help define a chemotactic basophil phenotype.  
Finally, cellular interactions with human basophils can be studied using ImageStream® 
technology. For example, we demonstrated platelet-basophil adhesion by imaging flow 
cytometry studies (Figure 41A-B). In the future, the use of ImageStream® technology for 
studies in basophil interactions with other cells, for example, B-lymphocytes would be an 
important direction for future research.  
4.5.4 Strengths and Limitations of the ImageStream® Basophil Study 
Manual identification of basophil subpopulations, the time scale and the complexity of 
performed analysis do not permit several replicates of these findings and do not allow 
generalization of conclusions. We also cannot exclude that the proportion of basophils 
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with surface alterations was not affected by density gradient centrifugation (Elghetany & 
Lacombe, 2004), pre-analytical sample handling at different temperatures or atopic 
predisposition in the donor and, therefore, these data need to be reproduced in larger 
studies.  
On the other hand, the consistency of certain aspects of analysis across the samples from 
a different donor (an observation of cells with surface alterations in sample pre-warming 
studies using a different donor), the use of fixation controls, single stained controls and 
fluorescence minus one controls gives confidence in the observations and allows the 
discussion of the possible biological significance of some findings. Although the 
limitations of this study do not allow generalization of the findings, there are several 
observations made in the presented basophil studies that may be important for researchers 
whose work is focused on basophil immunobiology. 
4.5.5 Perspectives of Imaging Flow Cytometry Studies in Basophil 
Research 
At present, imaging flow cytometry studies in human basophils are both stimulating and 
challenging. These studies present us with new challenges in analytical approaches to 
basophil research, revealed some limitations of the technology and our incomplete 
understanding of basophil biology. The fact that cells with surface alterations can be seen 
on the brightfield imagery but can not be detected by digital masks might suggest some 
difficulties in a signal-noise resolution on the brightfield image for fine structures such as 
surface alterations. This difficulty may be resolved by further basophil studies using a 
higher magnification. The use of samples with a very high cellular density may be limited 
for basophil research due to the possibility of basophil adhesiveness under certain 
conditions. New imaging flow cytometers (Mark II imaging flow cytometer, Amnis 
Corporation) with higher throughput may allow acquisition of higher cell counts without 
increasing a cell density in samples for rare cell research applications. An analytical 
approach for discriminating basophil subpopulations based on phenotypic and 
morphometric features needs to be developed. More knowledge needs to be accumulated 
on immunophenotyping of basophil subpopulations. This seems to be easier to achieve 
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with conventional flow cytometry and then return to imaging flow cytometry on a new 
level of understanding of basophil heterogeneity. 
In future studies, it would be important to elucidate whether phenotypic and 
morphological features of basophil subpopulation with surface alterations can be 
reproduced in vitro by direct activation with various factors that can induce basophil 
chemotaxis without degranulation including C5a, IL-3, GM-CSF, eotaxin and eotaxin-2 
(Kay & Austen, 1972; Tanimoto et al, 1992; MacGlashan Jr., 2010; Dahinden, 2000; 
Forssmann et al, 1997). Previous work demonstrated that suboptimal FcεRI-mediated 
stimulation leads to CD69 up-regulation in the presence of IL-3 (Suzukawa et al, 2007) 
and increased eotaxin-induced migration (Suzukawa et al, 2005). Therefore, we would 
expect the higher percentages of basophils with surface alterations upon activation with 
chemotactic factors, cytokines and suboptimal FcεRI-mediated stimulation. Additionally, 
it would be important to detect this subpopulation in healthy subjects, who are stratified 
for atopy, and in patients with allergic diseases and CSU in order to understand the 
biological significance and the clinical context in which this basophil subpopulation may 
be relevant. In patients with hay fever, basophil chemotaxis was increased during hay 
fever season compared to nonallergic subjects or the same allergic patients outside hay 
fever season (Hirsch & Kalbfleisch, 1980). Therefore, it is conceivable that basophils 
with surface alterations are likely to be increased during disease exacerbations in CSU or 
allergic diseases. It would be interesting to compare the in vitro findings with clinical 
scenarios of in vivo basophil activation in CSU or allergic diseases. There are limited data 
suggesting the greater magnitude of in vivo up-regulation of CD69 following intentional 
sting challenge in patients on venom immunotherapy compared to in vitro basophil 
activation on incubation with yellow jacket or honeybee venom (Gober et al, 2007). 
Additionally, in asthma patients, basophils recovered by bronchoalveolar lavage had 
higher CD69 expression compared to circulating basophils suggesting enhanced local 
basophil activation in inflamed tissues (Yoshimura et al, 2002). Therefore, future in vitro 
and in vivo studies may help elucidate the experimental conditions required for the in 
vitro induction of basophil subpopulation with surface alterations and to understand the 
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inflammatory microenvironment in CSU or allergic diseases which may lead to the in 
vivo formation of this basophil subpopulation.  
Overall, ImageStream® technology can provide fascinating insights into basophil 
heterogeneity in health and disease. A suitability of imaging flow cytometry for rare cell 
analysis opens up a prospect of clinical applications of this technology in conditions with 
low basophil counts in the peripheral blood such as CSU. From a practical perspective, a 
study protocol and methodology can be further adapted for basophil studies with research 
and clinical applications. 
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CHAPTER 5 
Re-evaluation of Diagnostic Criteria for Chronic 
Spontaneous Urticaria and Urticarial Vasculitis: 
A retrospective study 
“There is no such thing as simple. Simple is hard.” 
—MARTIN SCORSESE 
Abstract 
Background: Urticarial vasculitis (UV) is a rare disease characterized clinically by 
urticarial lesions with histological evidence of leukocytoclastic vasculitis. Sometimes, it 
can be difficult to histologically differentiate UV from acute (ASU) or chronic 
spontaneous urticaria (CSU), possibly, due to the variability in clinical presentations, 
incomplete histological presentations and limitations of routine histological assessments. 
Neutrophilic urticaria is a histological pattern that occurs in several urticarial conditions 
but its link to serum histamine-releasing activity is currently unclear. 
In this thesis, we hypothesize that there is a difference in the density and the composition 
of the inflammatory infiltrate in the dermis between patients with ASU and CSU and 
between those with CSU and UV. We also hypothesize that CSU patients with serum 
histamine-releasing activity may have histological evidence of neutrophilic urticaria in 
lesional biopsy specimens. 
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To test this hypothesis, the aims of this retrospective study were: 
1 to assess clinical characteristics of patients with ASU, CSU and UV, with the focus 
on skin autoreactivity or serum histamine-releasing activity in these groups; 
2 to compare the numbers of eosinophils and neutrophils in the histological skin 
specimens between patients with ASU and CSU and between CSU and UV; 
3 to characterize the subset of patients with neutrophilic urticaria and to explore 
whether there is an association with serum histamine-releasing activity in this group. 
Materials and methods: In the retrospective analysis, patients with ASU, CSU and UV 
were selected based on the histopathological reports of their lesional skin biopsies. Then, 
clinical diagnosis was verified by a review of clinical notes. Selected patients with ASU 
and CSU are likely to represent a more severe phenotype because they underwent a 
lesional biopsy for differential diagnosis with UV on the grounds of atypical 
characteristics of weals, a lack of efficacy of antihistamines or laboratory findings 
suggestive of systemic involvement. Skin biopsy specimens stained with haematoxylin 
and eosin were assessed for total number of eosinophils and neutrophils per HPF using 
digital image morphometry. Neutrophilic urticaria was defined as 25 extravasated 
neutrophils per five HPF in the dermis of lesional skin according to previously published 
criteria (Toppe et al, 2000). HPF corresponded to 0.0326 mm2. Skin biopsy specimens 
were examined by two raters in a single blinded fashion. The two raters had a good 
agreement for eosinophil and neutrophil counts on haematoxylin and eosin staining (ICC 
=0.910) and for neutrophil counts on immunohistochemistry (ICC = 0.984). 
Results: We studied skin biopsy specimens from 6 patients with ASU, 33 patients with 
CSU and 43 patients with UV. The intermediate group of 21 patients was excluded from 
histological analysis in view of discrepancies between clinical and histological diagnoses 
and, therefore, unclear clinico-pathological correlations. In haematoxylin and eosin- 
stained skin biopsy specimens, there were increased numbers of neutrophils per HPF in 
UV patients compared to ASU (Mann-Whitney U test, p=0.062) or CSU patients (Mann-
Whitney U test, p=0.0002). On immunohistochemistry, the number of myeloperoxidase-
positive nucleated cells (neutrophils) per HPF was also higher in skin biopsies from UV 
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patients than in ASU (Mann-Whitney U test, p=0.0027) or CSU patients (Mann-Whitney 
U test, p=0.0001). The numbers of eosinophils per HPF in the histological skin 
specimens did not differ between UV and ASU or CSU. In our study, neutrophilic 
urticaria was noted in 63.6% of CSU patients including two CSU patients with serum 
histamine-releasing activity. 
Conclusions: The density of neutrophilic inflammatory infiltrate in the dermis was 
significantly higher in UV patients compared to those with ASU or CSU. In our study, 
neutrophilic urticaria was a common feature in histological specimens from CSU patients 
who underwent lesional skin biopsy for clinical reasons. 
5.1 Introduction 
5.1.1 Overview of UV 
UV is a rare disease characterized clinically by urticarial lesions with histological 
evidence of leukocytoclastic vasculitis. UV occurs with peak incidence in the fourth 
decade of life (Aboobaker & Greaves, 1986). Characteristic urticarial lesions tend to last 
longer than 24 hours and leave residual bruising and hyperpigmentation on fading 
(Wisnieski, 2000). In some patients, weals in UV are indistinguishable from those in 
CSU. In addition to weals, other cutaneous presentations in UV may include livedo 
reticularis, Raynaud’s phenomenon and very occasionally bullous lesions (Black, 1999) 
Angioedema frequently occurs in UV (Wisnieski, 2000) Patients with UV often present 
with constitutive symptoms such as fever, malaise and fatigue (Soter, 2000). 
If associated with systemic involvement, UV can lead to substantial morbidity. Joint 
involvement is common in UV. It usually includes arthralgia and stiffness of joints and, 
rarely, arthritis or synovitis (Soter, 2000; Aboobaker & Greaves, 1986). Patients with UV 
may present with gastrointestinal features including nausea, vomiting, abdominal pain, 
intestinal bleeding or diarrhoea (Gammon, 1985). Some patients develop transient or 
persistent microscopic haematuria and proteinuria (Mehregan et al, 1992). Pulmonary 
symptoms may include cough, dyspnoea or haemoptysis (Berg et al, 1988). Some 
patients with UV may develop chronic obstructive pulmonary disease (Venzor et al, 
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2002). Other clinical presentations of UV may include adenopathy, splenomegaly or 
hepatomegaly (Soter, 2000). Rare neurological (pseudotumor cerebri, optic nerve 
atrophy) or ocular (episcleritis, uveitis, scleritis, conjunctivitis) manifestations may occur 
(Venzor et al, 2002). Of interest, a few case reports suggested a distinct association of 
cardiac valvulopathy, Jaccoud’s arthropathy with hypocomplementemic urticarial 
vasculitis (Palazzo et al, 1993). 
Severity of UV varies from mild to life-threatening. Patients with only cutaneous 
involvement are considered to have milder disease. Patients with severe UV present with 
hypocomplementaemia, systemic involvement or refractory disease to treatment. HUVS 
is at the very severe end of the spectrum (Wisnieski, 2000). 
Several disease associations with UV have been described in the literature, (O’Donnell 
and Black, 1995) although it remains unknown whether these associations represent 
causality. Common associations with UV are attributed to connective tissue diseases 
including systemic lupus erythematosus (Asherson et al, 1991) and Sjögren’s disease 
(Alexander & Provost, 1983). Chronic hepatitis B and C are frequent associations with 
UV although other infections such as infectious mononucleosis (Wands et al, 1976) and 
Lyme borreliosis (Olson & Esterly, 1990) have been also linked to UV. 
A thorough laboratory work-up is important in patients with UV in view of potential 
systemic involvement and a risk of associated diseases. A spectrum of autoantibodies has 
been observed in UV including antinuclear antibodies, extractable nuclear antigens, 
(Asherson et al, 1991) antiphospholipid (Grotz et al, 2009) and anti-endothelial 
antibodies (D’Cruz et al, 1995). Besides, skin autoreactivity to patient’s serum has been 
reported in UV (Athanasiadis et al, 2006). However, the pathogenic importance of these 
observations is unclear and further research may elucidate their clinical relevance. 
Based on the presence or absence of serum hypocomplementaemia, two variants of UV 
can be differentiated. Normocomplementaemic UV is characterized by a better prognosis 
and no or minimal systemic involvement (Wisnieski, 2000). By contrast, patients with 
hypocomplementaemic UV tend to have a more severe disease associated with systemic 
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involvement, including nephritis (Grotz et al, 2009). It remains unclear whether there is a 
transition between these clinical variants over time (Wisnieski, 2000). Therefore, serial 
testing of serum complement levels over time is important for distinction between 
normocomplementaemic and hypocomplementaemic UV. 
Hypocomplementaemic UV syndrome is a distinct clinical syndrome identified in about 
5% of patients with UV (Wisnieski, 2000) with the following diagnostic criteria: 1) 
biopsy-proven vasculitis; 2) arthralgia or arthritis; 3) uveitis or episcleritis; 4) recurrent 
abdominal pain; 5) glomerulonephritis; 6) decreased C1q or presence if anti-C1q 
autoantibodies (multidisciplinary approach) (Grotz et al, 2009). 
Management of UV includes antihistamines, non-steroidal anti-inflammatory agents, oral 
corticosteroids, antimalarials and immunosuppressive agents. Recently, biological agents 
have been used in the treatment of UV. There was a case report on the use of anakinra 
(IL-1 receptor antagonist) in UV (Botsios et al, 2007). An open-label study demonstrated 
the efficacy of canakinumab (humanized monoclonal anti-IL-1β antibody) in patients 
with UV (Krause et al, 2013). Also, a patient with UV associated with cutaneous lupus 
erythematosus was treated with anti-IL-6 monoclonal antibodies (tocilizumab) with 
favourable outcome (Makol et al, 2012). An integration of biological agents into the 
management protocol for UV in the future may help overcome the issue of toxicity 
associated with the use of conventional treatments for UV. 
5.1.2 Histopathological diagnosis of UV 
Establishing a clinico-pathological correlation between urticarial lesions and biopsy-
proven leucocytoclastic vasculitis is essential for the diagnosis of UV. The classical 
histological definition of UV include leukocytoclasis, fibrin deposition, endothelial 
swelling and red blood cell extravasation (O’Donnel & Black, 1995). UV tends to affect 
postcapillary venules of the subpapillary venular plexus in the upper dermis. 
Leukocytoclasis presents as neutrophil disintegration and a scatter of nuclear dust 
(Venzor et al, 2002). The mechanisms of leukocytoclasis are not completely understood. 
Fibrin deposition is thought to occur due to the endothelial damage in UV which leads to 
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loss of endothelial anti-coagulative properties and, hence, local activation of coagulation 
results in subsequent fibrin deposition. Red blood cell extravasation occurs due to the 
damage of the vessel wall which allows the transit of red blood cells through the wall. 
Endothelial swelling may be caused by several factors including autoantibodies against 
the endothelial cells or complement membrane activation attack. Shrinkage (apoptosis) of 
the endothelial cells is a common feature of UV. However, a combination of these 
definitive features of UV does not occur in some cases (Gammon, 1985). Therefore, a 
concept of minimal diagnostic criteria has been introduced (Black, 1999). Usually, 
minimal diagnostic criteria for UV include leukocytoclasis with or without red blood cell 
extravasaton although there is a great variation in the combination of minimal diagnostic 
criteria between different studies which does not permit meaningful comparisons. 
Therefore, there is a need for re-evaluation and standardization of diagnostic criteria for 
UV. 
5.1.3 Histological presentations of ASU and CSU 
In clinical practice, patients with ASU or CSU do not usually undergo lesional biopsy 
unless there are clinical or laboratory pointers to the possibility of underlying UV. 
Therefore, the knowledge of the histopathological picture of ASU or CSU is limited 
(Stewart, 2002). 
A three-fold increase in mast cells was described in CSU patients compared to healthy 
subjects (Kay et al, 2014). Inlfammatory infiltration in the skin of CSU patients 
comprises increased numbers of basophils, eosinophils, neutrophils, macrophages as well 
as CD3+, CD4+, CD8+, CD25+ T-lymphocytes in skin biopsy specimens from urticarial 
lesions in CSU patients compared to nonatopic healthy subjects (Ying et al, 2002). The in 
previous research by Sugita et al (2000), the extent and the composition of perivascular 
infiltration in CSU patients was assessed quantitatively and a correlation between 
eosinophils and neutrophils was noted in CSU patients. 
Histological examinations of skin biopsy specimens following the injection of autologous 
serum revealed neutrophilic infiltration in CSU patients at the site of skin testing (Grattan 
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et al, 1990). In histological studies in lesional skin, the analysis of lesional biopsies of 
CSU patients with or without serum histamine-releasing activity revealed the 
predominance of eosinophils in the biopsies of CSU patients without serum histamine-
releasing activity (Sabroe et al, 1999). In the study by Ying et al (2002), there was no 
difference in the numbers of infiltrating inflammatory cells or the cytokine pattern in the 
lesional skin biopsies from CSU patients with or without serum histamine-releasing 
activity. 
Neutrophilic urticaria is a histological pattern that occurs in different types of urticaria, 
including ASU and CSU (Toppe et al, 1998). Neutrophilic urticaria is considered to 
represent a more severe disease (Stewart, 2002). Neutrophilic urticaria was assessed 
quantitatively by Toppe et al (1998) who derived diagnostic criteria for neutrophilic 
urticarial of 25 extravasated neutrophils per five HPFs. Neutrophilic urticaria differs from 
UV by the absence of leukocytoclasis or vessel damage. The mechanisms underlying 
neutrophilic urticaria are poorly understood but are thought to be mediated by the 
expression of cytokines (TNF-α and IL-3) in the skin of CSU patients (Toppe et al, 
1998). Both neutrophilic urticaria and CSU associated with serum histamine-releasing 
activity represent a more severe disease, however, the relation of neutrophilic urticaria to 
a subset of CSU patients with serum histamine-releasing activity has not been clarified. It 
is conceivable that these two subsets of CSU patients may overlap. The previous work by 
Sabroe et al (1999) demonstrated the lack of difference in neutrophil counts in skin 
biopsies in CSU patients regardless of serum histamine releasing activity, although the 
stringent criteria for neutrophilic urticaria were not applied in that study. 
5.1.4 Differential diagnosis between CSU and UV 
CSU is the main differential diagnosis in patients with UV. Sometimes, the differential 
diagnosis of urticaria and UV presents challenges in clinical practice for both the 
clinicians and histopathologists (Wisnieski, 2000). Why can it be difficult to differentiate 
between CSU and UV? 
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Firstly, in some patients, weals in UV are indistinguishable from those in CSU. Recent 
evidence suggests that UV may be an underlying process in 20% of patients with clinical 
presentations of CSU resistant to treatment with antihistamines (Tosoni et al, 2009). 
Secondly, UV is characterized by a significant histological variability (Soter, 2000) and 
some of the characteristic histopathological features of UV may not be present in the skin 
biopsies of individual patients, thereby causing diagnostic difficulty in clinical practice. 
Therefore, the minimal diagnostic histological criteria for UV were discussed in the 
literature (Black, 1999). 
Thirdly, the continuum of histological changes between urticaria and UV has been 
recognized (Jones et al, 1983). At the extremes of the spectrum, urticaria and UV 
represent distinct clinico-pathological entities with clearly defined characteristic 
histological and clinical features. By contrast, series of patients with intermediate 
histological features have been reported (Jones et al, 1983; Monroe, 1981). This suggests 
that there may not be a clear-cut histological distinction between these two conditions 
which reflect an existing gap in our knowledge of skin pathology in these two conditions 
and warrants further research. 
Furthermore, urticaria and UV are both dynamic processes which means a series of 
cellular and molecular events during a histological evolution of urticarial lesions in the 
same patient. The knowledge about the development of UV stems from sequential 
histological studies which are difficult to perform due to invasiveness of the procedure 
and ethical considerations, on one hand side, and to practical aspects of defining the age 
of spontaneous weals in urticaria and UV, on the other (Kano et al, 1998; Lawlor et al, 
1989). Histological patterns associated with the development of lesions in the same 
individual would depend on the age of the lesion and on the disease progression. Time 
course analysis of lesions in exercise-induced urticarial vasculitis suggested that 
neutrophil recruitment and eosinophil peroxidase deposition as earlier events at 10 hours 
and leukocytoclasis and the deposition of neutrophil elastase as later events occurring at 
24 hours (Kano et al, 1996). By contrast, timed sequential biopsies in cold-induced 
urticaria showed significant oedema, with no changes in dermal cell populations, 
Chapter 5 Re-evaluation of Diagnostic Criteria for Chronic Spontaneous Urticaria 
251 
suggesting an exudation rather than and infiltration as a predominant mechanism in cold 
induced urticaria (Lawlor et al, 1999). Consistency in clinical approaches to the timing of 
skin biopsy in relation to the onset of the lesion formation as well as patient cooperation 
in timing the age of the lesion could potentially reduce this source of histological 
variability in urticaria and UV (Callen, 1998). Besides, the intensity of inflammation 
varies between the patients from minimal transient extravasation of proinflammatory 
cells to a dense persistent mixed perivascular infiltrate. 
Finally, the detection of some histopathological features of UV may be difficult due to 
the limitations of the existing methodologies. For example, endothelial damage is better 
assessed by electron microscopy but may be challenging to detect on routine histology. 
The use of fluorescent dyes with high affinity to the nuclear material may improve the 
detection of leukocytoclasis in some cases compared to traditional haematoxylin and 
eosin staining. Also, the representation of affected vessels in the skin biopsy section 
depends on the focal plane of the section through the vessel (Carlson, 2010), thus, careful 
examination of several sections from the same biopsy specimen may help detect the 
affected vessels. Therefore, further development of diagnostic approaches may enhance 
the accuracy of the diagnosis of UV in difficult cases. 
5.1.5 Neutrophils and their contribution to the pathophysiology of CSU 
and UV 
Neutrophils are terminally differentiated leukocytes with a short circulating half-life of 
up to 12.5 hours (Kolaczkowska & Kubes, 2013). The distinctive morphological feature 
of neutrophils is multi-lobed nucleus. Neutrophils are known to derive from pluripotent 
CD34+ myeloid progenitors and to mature in bone marrow. In health, neutrophils are 
implicated in host defense against pathogens, although the contribution of neutrophils to 
adaptive immunity is also discussed (Kolaczkowska & Kubes, 2013). Neutrophils are the 
professional phagocytes with the capacity to generate superoxide anions via the 
activation of NADPH oxidase (Bardoel et al, 2014). 
Neutrophils have three types of cytoplasmic granules including primary, secondary and 
tertiary. Primary (azurophilic) granules contain myeloperoxidase and neutrophil elastase. 
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Secondary (specific) granules contain lactopherin, matrix metalloproteinase-8 and 
pentraxin-3. Tertiary (gelatinase) granules contain gelatinase, matrix metalloproteinase-9 
and MT-6 matrix metalloproteinase. Neutrophil activation occurs as a two-step process 
including, first, priming and then followed by activation at the sites of infection or 
inflammation. Upon activation, the granule contents together with ROS are discharged 
into the phagolysosome for bacterial killing. Neutrophils can also exocytose granule 
products into the extracellular environment, this mechanism of neutrophil degranulation 
and release of toxic products has been implicated in the pathophysiology of various 
diseases. Increased numbers of neutrophils in the circulation as well as neutrophil 
accumulation in the tissues were reported as characteristic features of various 
inflammatory diseases (Nemeth & Mocsai, 2012). 
In the skin, neutrophil-derived enzymes may contribute to tissue damage and skin 
remodeling in chronic inflammation. In the skin, neutrophils are recruited in skin 
response to an intradermal injection of autologous serum (Grattan et al, 1990). Lesional 
biopsies from CSU patients showed an increase in neutrophil numbers in some patients. 
In the context of neutrophilic urticaria, neutrophil accumulation in the dermis occurs 
without the evidence of leukocytoclasis or vessel damage. The subset of patients with 
neutrophilic urticaria is thought to have a more severe disease. Neutrophils may 
contribute to chronic urticarial disease via several putative mechanisms including 
neutrophil-mediated oedema and the release of immune regulatory molecules. 
Neutrophils can increase vascular permeability (DiStasi & Ley, 2009) and thereby may 
contribute to the weal formation in CSU. Neutrophil-induced oedema was described by 
Wedmore and Williams (1981). The contribution of neutrophils to the vasculitic process 
in UV may include the damage of vessels and surrounding tissue through the release of 
cytotoxic mediators. In the recent publication by Finsterbusch et al (2014), microvascular 
leakage was hypothesized to occur as a sequence of events including up-regulation and 
release of TNF during neutrophil adhesion and transmigration in response to chemotactic 
stimulation. As a result, TNF effects on endothelial cells involve the phosphorylation and 
endocytosis of VE-cadherin compexes in the junctions (Schulte et al, 2011) and 
actomyosin contraction (Yuan et al, 2002). This leads to the opening of endothelial 
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junctions, increased endothelial cell permeability and microvascular leakage 
(Finsterbursch et al, 2014). Other neutrophil products may also contribute to neutrophil-
mediated microvascular leakage including azurocidin (Gautam et al, 2001). 
Another effector mechanism of neutrophils involves neutrophil extracellular traps 
(Brinkmann & Zychlinsky, 2007). Neutrophil extracellular traps were demonstrated in 
vascular inflammation (Phillipson & Kubes, 2011). NET formation represents a powerful 
method of neutrophil-mediated microbial killing. Upon activation with IL-8 or 
lipopolysaccharide, neutrophils undergo a discharge of nuclear chromatin together with 
cathelicidin antimicrobial agents. Furthermore, in the context of vasculitis, NET 
formation was reported in autoimmune small-vessel vasculitis (Kessenbrock et al, 2009), 
however, it remains unknown whether NET contributes to the development of UV. 
In view of recent developments in neutrophil biology, the role of neutrophils in the 
pathophysiology of CSU and UV represents a promising research area. Given the 
growing interest in the role of neutrophils in autoimmune conditions, we re-examined the 
contribution of neutrophils to the inflammatory infiltrate in ASU, CSU and UV. Research 
into the contribution of neutrophils to the pathophysiology of CSU and UV is important 
in view of potential ramifications for differential diagnosis and therapeutic targeting of 
neutrophils in these two conditions. 
5.1.6 Summary 
UV is a rare disease characterized clinically by urticarial lesions with histological 
evidence of leukocytoclastic vasculitis. The histological presentations in ASU and CSU 
involve a mixed perivascular infiltration of varying intensity. The histological differential 
diagnosis between UV and ASU or CSU may be difficult for these reasons: incomplete 
presentation of histological features of UV, a histological continuum between CSU and 
UV, the limitations of existing methodology. Therefore, there is a need for re-assessment 
of histological features of ASU, CSU and UV in terms of the density and the composition 
of cellular infiltration in lesional skin biopsy specimens in order to evaluate the 
histological differences between these conditions. 
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The correlation between the numbers of neutrophils and eosinophils in skin biopsy 
specimens was demonstrated in CSU (Sugita et al, 2000). In clinical practice, a 
histological pattern of neutrophilic urticaria is thought to be associated with severe CSU, 
it differs from UV by the absence of leukocytoclasis and vascular damage. Additionally, 
CSU associated with serum histamine-releasing activity is linked to disease severity 
(Sabroe et al, 2002) although no characteristic histological features were detected (Sabroe 
et al, 1999; Ying et al, 2002). Furthermore, neutrophil-predominant infiltrate was 
associated with UV (Lee et al, 2007). Therefore, it is plausible that the histological 
differences between UV and ASU or CSU involve the changes in density and, possibly, 
the composition of the inflammatory infiltrate in the lesional skin. 
Neutrophils are important effector cells of inflammation and may participate in the 
pathophysiology of CSU and UV through their putative contribution to the microvascular 
leakage, possibly, skin remodeling and vessel damage. The formation of NETs was 
demonstrated in vascular inflammation in autoimmune small-vessel vasculitis 
(Kessenbrock et al, 2009). Whether NET formation is relevant to the inflammation in UV 
is unknown. 
5.1.7 Hypothesis and aims of the study 
This thesis hypothesizes that there is a difference in the density and the composition of 
the inflammatory infiltrate in the dermis between patients in ASU and CSU and between 
CSU and UV. We also hypothesize that CSU patients with serum histamine-releasing 
activity may have histological evidence of neutrophilic urticaria. 
To test the hypothesis stated above, the aims of this study were: 
1 to assess clinical characteristics of patients with ASU, CSU and UV, with the focus 
on skin autoreactivity or serum histamine-releasing activity between these groups; 
2 to compare the numbers of eosinophils and neutrophils in the histological skin 
specimens between patients with ASU and CSU and between CSU and UV; 
3 to characterize the subset of patients with neutrophilic urticaria and to explore if there 
is any evidence for associated serum histamine-releasing activity in this group. 
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5.2 Materials and methods 
5.2.1 Patient Selection 
The patients were identified from the diagnostic database at the Pathology Department at 
the Norfolk & Norwich University Hospital using the keywords “urticaria” and 
“urticarial vasculitis” in the histological report. Patients with the histological diagnosis of 
urticaria or UV were selected. The clinical notes of the selected patients were reviewed. 
Only patients with a clinical diagnosis of ASU, CSU or UV were included (Figure 42). 
Inclusion criteria for patients with urticaria: 
1 Clinical diagnosis of ASU or CSU in the clinical notes. 
2 Description of urticarial weals in the clinical notes. 
Exclusion criteria for patients with urticaria: 
1 Predominant physical urticarias. 
Inclusion criteria for patients with UV: 
1 Clinical diagnosis of UV in the clinical notes. 
2 Description of urticarial weals consistent with clinical features of UV. 
Exclusion criteria for patients with UV: 
1 Other types of vasculitis 
5.2.2 Specimen staining 
Skin biopsy specimens stained with haematoxylin and eosin from 6 patients with ASU, 
33 patients with CSU and 43 patients with UV were available for quantitative digital 
image analysis. Also, skin biopsy specimens from 5 patients with ASU, 31 patient with 
CSU and 40 patients with UV were analyzed by dual immunohistochemical staining for 
neutrophil myeloperoxidase and Factor VIII-related antigen. 
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Dual immunohistochemical staining for neutrophil myeloperoxidase and Factor VIII-
related antigen was carried out with automated immunostaining. Paraffin-embedded 
sections were dewaxed in xylene and hydrated using graded alcohols to tap water. Heat-
induced epitope retrieval was performed using EDTA-based buffer (BondTM Epitope 
Retrieval Solution 2, pH=9.0) and heat treatment at 100°C for 20 min followed by 
cooling to room temperature. Mouse-mouse sequential double immunoenzyme staining 
for Factor VIII-related antigen and neutrophil myeloperoxidase was used to study the 
migration of neutrophils through the vessel wall. Enzymatic visualization of alkaline 
phosphatase activity in red was performed using Fast Red (myeloperoxidase), 
visualization of horseradish peroxidase activity in brown was carried out with DAB 
(Factor VIII-related antigen). 
Endogenous peroxidase activity in formalin-fixed, paraffin-embedded sections was 
blocked with 3% hydrogen peroxide for 8 min at room temperature. There was one hour 
incubation of primary antibody mouse anti-human monoclonal antibodies against von 
Factor VIII-related antigen (Leica Microsystems). Bond™ Polymer refine detection 
system (Leica Microsystems) was used to prepare biotin-free polymeric horseradish 
peroxidase (HRP)-linker antibody conjuates. After washing with Bond™ wash solution, 
post-primary polymer enhancer containing 10% (v/v) animal serum in Tris-buffered 
saline and 0.09% ProClin tm 950 was applied for 15 min at room temperature to enhance 
penetration of the subsequent polymer reagent. Bond™ wash solution was used as 
washing buffer for all further steps. After washing, polymerpoly-HRP anti-mouse/rabbit 
IgG containing 10% (v/v) animal serum in Tris-buffered saline and 0.09% ProClin tm 
950 was applied for 15 min at room temperature to localize the primary antibody. The 
substrate chromogen, 3’3-diaminobenzidine (DAB) was applied for 10 min at room 
temperature to visualize the complex via brown precipitate. For the second staining, there 
was an incubation with mouse anti-human monoclonal antibody against myeloperoxidase 
(Leica Microsystems) for one hour. Following the same steps with post-primary polymer 
enhancer and polymer poly-HRP anti-mouse /rabbit IgG, Bond™ Polymer AP Red 
detection system was applied to prepare polymeric alkaline phosphatase – linker antibody 
conjugates. The substrate chromogen, Fast Red, was applied for 20 min at room 
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temperature. Double stained specimens were counterstained using 0.02% haematoxylin 
for nuclear staining. Specimens were dried on a hot plate (50°C) and coverslipped with 
VectaMount (Vector). Immunohistochemistry staining for this project was optimized by 
Joseph Goodwill and was performed by Debra Essex at the Histopathology Department, 
Norfolk & Norwich University Hospital. Scanning and analysis of specimens was 
performed by Dr Elena Borzova and Dr Laszlo Igali at the Histopathology Department, 
Norfolk & Norwich University Hospital. 
5.2.3 Digital Image Analysis 
Histological specimens were analyzed using an Nikon Eclipse 80i microscope. Images of 
the perivascular infiltrate around a characteristic vessel in the upper dermis were digitized 
using Nikon DsR1 camera and processed with imaging software NIS-Elements BR 3.0. 
Examples of quantitative image analysis for skin biopsy specimens obtained from 
patients with urticaria and UV are presented in Figure 43. Inflammatory cell counting 
was carried out based on cell morphology using point counting morphometry (Figure 43). 
Cellular composition (neutrophils, eosinophils) of the perivascular inflammatory infiltrate 
was expressed as cell counts in 0.0326 mm2. The microscopic sections from patients with 
urticaria and UV were evaluated by two observers in a blinded fashion to assess the inter-
observer variability. The two raters had a good agreement for eosinophil and neutrophil 
counts on haematoxylin and eosin staining (ICC =0.910) and for neutrophil counts on 
immunohistochemistry (ICC = 0.984). 
5.2.4 Statistical analysis 
Statistical analysis was performed with STATA statistical package, version 11/SE 
(StataCorp LP, USA). The project was approved by the East Norfolk & Waveney 
Research and Governance Committee (Ref: 2006DERM05L (64-04-09)). The project was 
funded by a British Skin Foundation Small Grant Award. We used the Mann-Whitney U 
test to compare the neutrophil counts between two independent groups (ASU vs CSU; 
CSU vs UV). For inter-observer agreement, we employed inter-class correlation 
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coefficient to detect the difference and its statistical significance for the cell counts 
carried out on the same histological specimens by two independent observers. 
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5.3 Results 
5.3.1 Clinical Characteristics of Patients with ASU, CSU and UV 
Patient selection process for this study is illustrated in Figure 42. Clinical and histological 
features of ASU, CSU and UV were analyzed in patients who underwent lesional skin 
biopsy at the Norfolk & Norwich University Hospital between 1989 and 2014. A total of 
301 patient were identified from the diagnostic database at the Histopathology 
Department using keywords “urticaria” and “urticarial vasculitis” in the histological 
report. In total, 158 patients with the histological diagnosis of urticaria or UV were 
selected for clinical record review. Patients with the clinical diagnosis other than urticaria 
or UV were excluded from further study leaving 104 patients: 6 patients with ASU, 33 
patients with CSU, 43 patients with UV and 22 patients indeterminate. 
Clinical data of patients with ASU, CSU and UV are presented in the Table 6. The 
median age of ASU patients was 45 years (range 14-77 years), of CSU patients – 44 
years (range 19-78 years) and of UV patients – 55 years (range 12-83 years). In UV, 
weals were associated with bruising (34.9%), burning or pain (23.3%) and duration over 
24 hours (51.2%). Half had extracutaneous symptoms (arthralgia, abdominal pain, 
diarrhea, fatigue, fever or lethargy), thyroid autoimmunity (18.6%), microscopic 
haematuria (9.3%), abnormal liver function (23.3%), anti-nuclear antibodies (30.2%), 
elevated ESR/CRP (48.8%) and hypocomplementaemia (18.6%). Treatments included 
oral corticosteroids, dapsone, hydroxychloroquine, colchicine and methotrexate. In CSU 
patients, weals were associated with bruising (4.6%), burning or pain (3%) and duration 
over 24 hours (12.1%). All had normal C3 and C4 levels, raised ESR/CRP (39.4%), anti-
nuclear antibodies (6%) and thyroid autoimmunity (24.2%). Treatments included H1-
antihistamines in conventional and high doses, oral corticosteroids, ciclosporin, 
methotrexate and mycophenolate mofetil. 
Of interest, 11 patients with CSU and five patients with UV were investigated by 
autologous serum skin testing or serum-induced BHR. Three of eight patients with CSU 
and three of five UV patients showed a positive autologous serum skin test. Serum-
induced BHR was positive in two of three CSU patients and one patient with UV. As  
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well as clinical overlap between urticaria and UV, there is limited data for skin 
autoreactivity and serum histamine-releasing activity in both groups, raising the 
possibility that they may represent different ends of a clinicopathological spectrum with 
similar pathogenesis. 
5.3.2 Comparison of histological features between ASU and CSU patients 
We found no statistically significant differences in the numbers of eosinophils or 
neutrophils between patients with ASU and CSU (Mann-Whitney U test, p=0.5008) 
(Figures 44A and B). On immunohistochemistry, the numbers of myeloperoxidase-
positive neutrophils did not differ between patients with ASU and CSU (Mann-Whitney 
U test, p=0.8892) (Figure 45A). 
5.3.3 Comparison of histological features between CSU and UV patients 
To compare the histopathological features of CSU and UV, we compared the 
haematoxylin and eosin-stained histological specimens from 33 CSU patients and 43 UV 
patients. We quantified eosinophils in skin biopsies of CSU patients and those with UV 
and but could not detect any difference between the groups (Figure 44A). By contrast, 
histological examination of skin biopsies of patients with CSU and UV demonstrated 
significantly higher neutrophils counts per HPF in the latter group (Mann-Whitney U test, 
p=0.0002) (Figure 44B). These data were confirmed by immunohistochemistry showing 
that the numbers of myeloperoxidase-positive cells (neutrophils) per HPF in lesional 
biopsy are significantly higher in UV patients compared to those with CSU (Mann-
Whitney U test, p=0.0001) (Figure 45A). 
Analysis of histological specimen underwent immunohistochemical staining for 
neutrophil myeloperoxidase revealed different patterns of neutrophil involvement in 
urticaria and UV as illustrated in Figure 46. Histological findings in urticaria included 
neutrophil margination and perivascular infiltration while neutrophil involvement in UV 
was presented by neutrophil margination, neutrophil infiltration of the vessel wall, 
neutrophil perivascular infiltration and vessel destruction. Morphological changes of 
neutrophils in UV include loss of cellular integrity and extracellular deposition of 
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myeloperoxidase (Figure 46B). Notably, extracellular deposition of myeloperoxidase was 
present mainly in patients with UV. 
5.3.4 Comparison between NUV and HUV 
To compare histological differences between HUV and NUV, we compared neutrophil 
counts in histological specimens from patients with NUV and HUV. There was a 
marginal statistical difference in neutrophil counts between these subsets of UV patients 
(Mann-Whitney U Test, p=0.053) (Figure 45B). 
5.3.5 The histological pattern of neutrophilic urticaria in CSU patients 
Applying the histological criteria by Toppe et al (1998), we noted neutrophilic urticaria in 
21 (63.6%) of 33 CSU patients. Of patients with neutrophilic urticaria defined by 25 
extravasated neutrophils in five HPF of skin biopsy specimen, a dense neutrophilic 
infiltrate of more than 40 neutrophils per five HPF was observed in 15 (45.5%) CSU 
patients. 
5.3.6 The histopathology of CSU with serum histamine-releasing activity 
We only partially achieved our aim to assess the histological pattern of CSU with serum 
histamine-releasing activity because there were only two CSU patients with serum 
histamine-releasing activity in our study population. Both patients demonstrated the 
histological pattern of neutrophilic urticaria (Figure 48). Of interest, 
immunohistochemical staining for myeloperoxidase highlighted the extracellular 
deposition of myeloperoxidase in one CSU patients with serum histamine-releasing 
activity (Figure 48A). Whether this suggests leukocytoclasis, neutrophil degranulation or 
NET formation in CSU patient with serum histamine-releasing activity needs to be 
established in future studies. 
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5.4 Discussion 
5.4.1 The density and the cellular composition of the inflammatory 
infiltrate in CSU and UV 
Our data suggest that the density of neutrophilic infiltrate differs between UV and ASU 
or CSU. Patients with UV demonstrate significantly higher numbers of extravasated 
neutrophils in skin biopsies compared to patients with ASU or CSU. A subset of CSU 
patients (63.6%) has evidence of neutrophilic urticaria in lesional biopsies from 
spontaneous weals. There is limited evidence for neutrophilic urticaria in two CSU 
patients with serum histamine-releasing activity but these data needs to be confirmed in 
larger studies. 
Our data suggest the differences in the density and of the inflammatory infiltrate between 
CSU and UV and its variants which is in keeping with previously published findings. The 
composition of the perivascular infiltrate in CSU was studied in the previous work by 
Sugita et al (2000) and Toppe et al (1998). The association of neutrophil-predominant 
perivascular infiltrate with the histological diagnosis of UV was determined in a study by 
Lee et al (2007) using a multivariate analysis. More diffuse neutrophilia was also noted in 
hypocomplementaemic UV compared to normocomplementaemic variant (Davis et al, 
1998). 
Although our data and the previous work in this area suggest the increase in the number 
of neutrophils in UV compared to ASU or CSU, the histological variability within these 
groups has to be recognized. In UV patients, eosinophil-predominant inflammation can 
be occasionally observed in clinical practice. Also, the neutrophil counts in lesional skin 
biopsy in CSU patients with neutrophilic urticaria can be comparable to that in UV. 
These histological changes may apply only to a small patient subset and, therefore may 
not be detected when the whole group of CSU or UV patients is analysed. Further 
research in larger patient populations may provide new insights into histological 
heterogeneity within patient with CSU and UV. 
The use of conventional haematoxylin and eosin staining and immunohistochemical 
detection of neutrophil myeloperoxidase enhances to the differential diagnosis of urticaria 
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and UV which can be applicable in clinical practice. The detection of leukocytoclasis is 
likely to depend on the detection system. The signal to noise ratio may differ between 
conventional haematoxylin and eosin staining, immunohistochemistry for 
myeloperoxidase and, perhaps, immunofluorescence. 
5.4.2 The histological pattern of neutrophilic urticaria in CSU 
Neutrophilic urticaria is known as a histological pattern that occurs in patients with ASU, 
CSU and physical urticarias (Toppe et al, 1998). The frequency of neutrophilic urticaria 
in CSU was reported at 18% (Toppe et al, 1998). In our study, neutrophilic urticaria was 
noted in 63.6% of CSU patients. We used the same diagnostic criteria of 25 neutrophils 
per five HPFs as described by Toppe et al (1998). This is likely to reflect that CSU 
patients who are biopsied for clinical reasons have more severe disease than those in 
research studies. Furthermore, we illustrated that the intensity of neutrophilic infiltration 
may vary in CSU patients with histological evidence of neutrophilic urticaria. Therefore, 
the histological diagnosis of neutrophilic urticaria may depend on the threshold of 
neutrophil counts used as a diagnostic criterion. In our study we demonstrated that 45.5% 
of CSU patients had a dense neutrophilic infiltrate at more than 40 neutrophils per five 
HPFs. Further research into the definition and the diagnostic criteria for neutrophilic 
urticaria can optimize the diagnostic threshold for neutrophilic infiltrate for maximum 
diagnostic accuracy. 
The observed difference in the numbers of extravasated neutrophil in skin biopsy 
specimens from CSU and UV patients raise the question as to whether perivascular 
neutrophilic infiltration and dermal neutrophilia may represent histological stages of the 
inflammatory process in CSU and UV as was suggested in previous publications 
(Winkelmann & Reizner, 1988; Llamas-Velasco et al, 2012; Peters & Winkelmann, 
1985). Clinically, in cutaneous vasculitis, dermal neutrophilia is considered as a risk 
factor for systemic diseases (Carlson, 2010). Whether these associations exist in UV is 
yet to be established. 
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5.4.3 The strengths and limitations of this study 
The strengths of the study include careful clinical selection of patients and a parallel use 
of both conventional haematoxylin and eosin staining and immunohistochemical 
detection of myeloperoxidase in lesional skin biopsies from the same patient. Also, a 
good inter-observer reliability was also a strength of the study. 
However, several limitations of this study have to be acknowledged. Firstly, this study 
includes 43 patients with UV which may not be representative of all patients with UV. 
Therefore, the results have to be validated in larger patient datasets in the settings of a 
specialized dermatological centre, a multi-centre collaboration or using biobank research. 
This would increase the generalizability of the results. Also, patients with CSU and UV 
underwent lesional skin biopsy as a part of clinical care and therefore had only one 
biopsy, with unspecified timing of lesion development, which may have been a source of 
variation in the histological presentations in lesional skin biopsies in our study. A high 
rate of neutrophilic urticaria in CSU patients in our sample is likely to reflect a more 
severe disease in CSU patients who undergo skin biopsies for clinical reasons. Further 
studies in the diagnostic criteria for neutrophilic urticaria in prospective studies with the 
recruitment of consecutive patients is likely to result in more accurate estimate of the 
frequency of neutrophilic urticaria among CSU patients. Secondly, as all retrospective 
studies, this study has its inherent limitations of the incomplete data and a certain degree 
of variability in clinical approaches between the clinicians. Furthermore, we cannot 
exclude a referral bias and a selection bias in this study, further studies in different 
clinical settings would also increase the generalizability of the results. 
5.4.4 Unresolved questions for future histological studies 
This study poses new questions to be addressed in the pathophysiology of UV. Two main 
determinants of the skin inflammation in UV are the vessel damage and a participation of 
neutrophils mediating this damage. Immunohistochemistry staining for neutrophil 
myeloperoxidase employed in our study advances our understanding of the changes in 
neutrophil involvement in the vasculitic process in UV. The histological pattern of early 
leukocytoclastic changes has a definitive thread-like appearance which may suggest the 
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neutrophil extracellular traps as a potential mechanism for these findings (Brinkmann & 
Zychlinsky, 2007). Neutrophil extracellular traps were implicated in the pathophysiology 
of autoimmune small-vessel vasculitis (Kessenbrock et al, 2009) and may be worth 
exploring in UV. Visualizing the neutrophil extracellular traps can be achieved by a 
combined immunostaining for nuclear (histone) and granular (neutrophil 
myeloperoxidase) components (Brinkmann et al, 2010). In our study, the detection of the 
nuclear component of leukocytoclasis was carried out by haematoxylin and eosin 
staining. In future studies, a combination of fluorescence dyes for the detection of DNA 
and an immunofluorescence detection of myeloperoxidase may improve the detection of 
leukocytoclasis in UV. 
Furthermore, vessel changes during the disease progression are of great importance for 
defining UV (Jones & Eady, 1998) and need to be better understood in the context of 
dysregulated neutrophil-endothelial interactions (Hu et al, 2011) as a possible mechanism 
in UV. This can be achieved by combining the immunohistochemistry staining for 
neutrophil myeloperoxidase with endothelium-specific markers (Haller et al, 1998). 
Mechanisms of the persistence of skin inflammation in severe urticaria represent another 
important question of the pathophysiological significance arising from our study. The 
plausible mechanisms for the persistence of the inflammation could be a deficiency in 
TGF-β (Serhan & Savill, 2005), dysregulation of regulatory T cells (Fujio et al, 2012; 
Nathan & Ding, 2010), defective clearance by macrophages (Nathan & Ding, 2010) and, 
possibly, persistent stimulation with functional autoantibodies. The persistence of skin 
inflammation in severe urticaria and UV may result from the persistent stimulation or a 
deficiency in mechanisms of tissue clearance and repair (Serhan & Savill, 2005; Nathan, 
2002). 
In future prospective studies, an introduction of a powerful DNA microarray approach to 
study systems biology in the skin of UV may enhance our understanding of the disease 
pathophysiology. As an example, the potential insight that can be gained by applying 
systems biology research to the skin inflammation has been recently demonstrated by a 
network-based study in late-phase allergic reaction (Bensom et al, 2006). The prospect of 
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using the DNA microarrays to decipher the complexity of the pathophysiological 
pathways in UV is fascinating. 
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CHAPTER 6 
Discussion 
“We shall not cease from exploration, and the end of all our exploring 
will be to arrive where we started and know the place for the first time” 
—T.S. ELIOT 
Experimental work carried out in this thesis contributes to two main aspects of the 
pathophysiology of CSU: biochemical and histopathologic characteristics of the skin 
inflammation and the clinical course of CSU and predictors of disease severity and 
persistence, together with pathophysiological phenotyping based on the presence of 
functional autoantibodies and the aberrations of basophil biology in CSU. The 
experimental data in this thesis were collected as a result of three research projects: 1) 
cutaneous microdialysis studies in CSU; 2) a prospective observational study of the 
pathophysiological phenotypes in CSU and, as a method development part of this project, 
imaging flow cytometry studies in healthy subjects and 3) a retrospective study re-
evaluating the diagnostic histological criteria for urticarial vasculitis. First, the results of 
the microdialysis study suggested an increased histamine concentration in the upper 
dermis of patients with CSU which was shown to correlate with disease activity. There 
was limited experimental evidence indicating a slow low-grade histamine release 
underlying skin autoreactivity in CSU. 
Secondly, in a prospective observational study, the pathophysiological phenotyping based 
on the presence of histamine-releasing autoantibodies and the patterns of basophil 
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releasability revealed three pathophysiological phenotypes in CSU including responders, 
non-responders to anti-IgE stimulation and a subset of patients with total cellular 
histamine below the level of detection by spectrofluorimetry. Patients with the latter 
group had a more severe CSU than responders or non-responders to anti-IgE stimulation. 
In addition, CSU patients were classified on the basis of the presence or absence of serum 
histamine-releasing activity. Patients with serum histamine-releasing activity were 
characterised by a more severe disease. In our study, the clinical course of CSU observed 
in patients included a clinical improvement and a persistent CSU. Baseline UAS7 was 
demonstrated to be a predictor of a persistent course of disease. The use of different 
gating strategies (CCR3+CD123+; CCR3+CD63+; CD63+CD203c+) for flow cytometric 
basophil enumeration in the same sample from each CSU patient resulted in statistically 
significant differences in absolute counts depending on the basophil phenotype. Absolute 
counts for CCR3+CD63+ basophils were significantly higher compared to 
CCR3+CD123+ or CD63+CD203c+ basophil subpopulations in the same peripheral 
blood sample from each CSU patient suggesting that absolute basophils counts depend on 
the gating strategy used to define peripheral blood basophil phenotype in CSU patients. 
Absolute basophil counts measured by microbead technology showed no association with 
disease severity or persistence.  
Following this, imaging flow cytometry studies in healthy subjects demonstrated that the 
differences in the basophil detection between different gating strategies (CD63+CD203c+ 
versus CCR3+CD63+) may arise from biological (basophil phenotypic variation, a 
relative contribution of basophil subpopulation with surface alterations), technical (pre-
analytical handling at different temperatures) reasons as well as effect of confounding 
factors (platelet-basophil adhesion). Basophil subpopulation with surface alterations was 
mostly detected in CCR3- or CD63-based gates. The data from one healthy subject 
suggests that basophils with surface alterations might have higher expression of CCR3, 
CRTH2 and CD69 but these data need to be verified in future studies on healthy subjects 
stratified for atopy.  
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In haematoxylin and eosin- stained skin biopsy specimens, there were increased numbers 
of neutrophils per HPF in UV patients compared to ASU (Mann-Whitney U test, 
p=0.062) or CSU patients (Mann-Whitney U test, p=0.0002). On immunohistochemistry, 
the number of myeloperoxidase-positive nucleated cells (neutrophils) per HPF was also 
higher in skin biopsies from UV patients than in ASU (Mann-Whitney U test, p=0.0027) 
or CSU patients (Mann-Whitney U test, p=0.0001). The numbers of eosinophils per HPF 
in the histological skin specimens did not differ between UV and ASU or CSU. In our 
study, neutrophilic urticaria was noted in 63.6% of CSU patients including two CSU 
patients with serum histamine-releasing activity. 
Finally, in the retrospective histological study, haematoxylin and eosin-stained staining 
revealed increased numbers of neutrophils per high power field in UV patients compared 
to ASU and CSU patients. These data were confirmed on immunohistochemistry, which 
demonstrated higher numbers of myeloperoxidase-positive nucleated cells (neutrophils) 
per high power field in UV patients compared to ASU and CSU patients. Of interest, the 
numbers of eosinophils per high power filed in skin biopsies from UV patients did not 
differ from patients with ASU and CSU. In our study, we showed a high frequency 
(63.6%) of neutrophilic urticaria in lesional skin biopsy in the population of CSU patients 
who underwent lesional skin biopsy for clinical reasons.  
Several questions of pathophysiological significance arose from the cutaneous 
microdialysis study. Firstly, an increased histamine concentration in the extracellular 
space in the dermis of CSU patients was consistent with the concept of the minimal 
persistent inflammation (Figure 49) in CSU. Several factors may account for an 
increased histamine concentration in the dermis including abnormal histamine 
metabolism, increased local blood flow or enhanced cellular releasability of skin mast 
cells and basophils (Figure 50). The fact of correlation between the extracellular 
concentration of histamine and severity scores for itching and wealing based on visual 
analogue scales pointed towards the possible role of the dermal histamine concentrations 
as skin biomarker of underlying inflammation in CSU and therefore, to the potential 
clinical applications of cutaneous microdialysis in CSU. Research into H4 receptors 
suggested a role of histamine in inducing eosinophil chemotaxis through H4 histamine 
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receptors (Ling et al, 2004). It was unknown whether these effects of histamine on the 
influx of proinflammatory cells was relevant in CSU. If proved so, then these 
proinflammatory effects of histamine could be potentially targeted with H4 receptor 
antagonists. 
Furthermore, an observation of a slow low-grade histamine release underlying serum 
autoreactivity in CSU invited several pathophysiological implications. By analogy, 
similar pattern of histamine release was noted in the previous studies in the late- phase 
allergic reactions by using skin chamber technique. The authors noted about the 
possibility of a distinct mode of histamine release in skin mast cells in the late-phase 
allergic reaction (Zweiman, 1998). In the work by Dvorak (1991), two modes of 
histamine release were described for human basophils: anaphylactic and piecemeal 
degranulation (Figure 51). Piecemeal degranulation was known as a feature of various 
inflammatory conditions and was characterized by a gradual vesicle traffic towards the 
cell surface. Therefore, piecemeal degranulation of skin mast cells and basophils could be 
a potential explanation of the observed pattern of histamine release in patients with a 
positive autologous serum skin test. 
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On the other hand, a slow low-grade histamine release may occur in a positive autologous 
serum skin test but was thought to be an unlikely solely mechanism mediating its clinical 
expression as indirectly confirmed by a recent observation of lack of inhibition of serum 
autoreactivity by antihistamines (Asero et al, 2009). Alternatively, serum autoreactivity 
can be mediated by other mediators and cytokines such as, for example, platelet-
activating factor or vascular endothelial growth factor (Kay et al, 2014b). Other cell types 
may also mediate serum autoreactivity in CSU. A positive autologous serum skin test was 
noted to be similar to the late-phase allergic reaction. However, different kinetic of skin 
response to autologous serum suggests other potential explanations. For example, skin 
pathology of a positive autologous serum skin test is suggestive of neutrophil-
predominant reaction (Grattan et al, 1991). Autologous serum is well known stimuli used 
to induce neutrophil chemotaxis (Paulsson et al, 2010, Follin P, 1999). In the work of 
Toppe et al (1998), it was mentioned that neutrophils could mediate some immediate 
manifestations of physical urticarias. It is tempting to suggest that an intradermal 
injection of autologous serum in CSU may induce a neutrophilic response with a time 
course that can be in keeping with the dynamics of clinical signs of a positive autologous 
serum skin test. Neutrophils were known to be capable of regulating vascular 
permeability (Wedmore & Williams, 1981) by causing vessel leakage through release of 
chemokines and reactive oxygen species and the products of arachidonic acid (DiStasi & 
Ley, 2009). 
Furthermore, cutaneous microdialysis research opens up the perspectives for prospective 
studies in CSU looking at skin threshold for wealing (Figure 52) in susceptible individuals. 
Acute wealing to NSAIDs, enhanced skin response to skin testing with codeine or a positive 
autologous serum skin test could precede the onset of urticaria or persist in the remission of 
the disease. Therefore, prospective studies in skin reactivity in patients with urticaria and in 
predisposed individuals may help elucidate the mechanisms predisposing to CSU. 
The results of a prospective observational study in CSU and preliminary imaging flow 
cytometry experiments suggested basophil heterogeneity in health and disease. Basophils 
were known to have a graded response to stimulation with anti-IgE and fMLP, the 
possibility of associated phenotypic changes during this graded response was discussed in 
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the literature. A low-grade anti-IgE stimulation was noted to induce CD69 expression and 
eotaxin-induced migration of human basophils. Taken together with the results of our 
imaging flow cytometry studies, it is conceivable that the subthreshold stimulation via the 
high affinity IgE receptor might contribute to the phenotypic changes in peripheral blood 
basophils (Figure 53). This may have clinical implications in the context of inflammatory 
conditions like asthma or CSU. Subthreshold stimulation may render basophils 
chemotactic while reaching the source of the chemotactic gradient causes them to 
degranulate (Figure 54). Whether the morphology of basophils with surface alterations is a 
feature of their activation needs to be further studied. However, taking into account an 
increased expression of CD69 on peripheral blood basophils (Vasagar et al, 2006) in CSU 
and in basophils in bronchoalveolar lavage in asthma (Yoshimura et al, 2002), the 
contribution of basophil chemotaxis to the pathophysiology of CSU warrants further 
research. Moreover, patients with polymorphism of CRTH2 in CSU were shown to 
require higher doses of antihistamine therapy (Palikhe, 2009). This is another piece of 
evidence that puts the molecules involved in basophil activation, including chemotaxis, in 
the focus of research in further studies. 
Targeted treatment is a cornerstone of personalized medicine. Patient stratification is an 
essential condition for successful development of personalized treatment approaches. 
Studies in this thesis addressed the issue of the patient stratification by the clinical course 
of the disease, the pathophysiological phenotyping in the prospective study in CSU as 
well as histopathological presentations in the retrospective evaluation of 
histopathological criteria for the diagnosis of urticarial vasculitis. The perspective of 
phenotype-guided therapy would facilitate the development of an individual treatment 
plans for patients with distinct abnormalities of basophil releasability, the presence of 
serum histamine-releasing activity or the presentations of neutrophilic urticaria in lesional 
skin biopsies. At present, there is limited evidence for higher efficacy of certain 
treatments (ciclosporin, plasmapheresis) in CSU patients with serum histamine-releasing 
activity (Grattan et al, 2000; Grattan et al, 1992). However, definitive comparative 
studies for immunomodulatory and biological treatments in the defined 
pathophysiological phenotypes would help incorporate the pathophysiological 
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biomarkers into a routine work-up in patients with CSU for an informed clinical decision 
on the phenotype-targeted treatment. 
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An observation of several aspects of abnormal basophil releasability to the stimulation 
with anti-IgE in different pathophysiological subsets in CSU calls for future studies into 
basophil activation by anti-IgE and other stimulu as well as non-specific basophil 
hyperreleasability to delineate the basophil activation pathways affected by the disease. 
Effects of different patterns of basophil pre-stimulation with serum histamine-releasing 
factors in CSU may define basophils responses to the subsequent stimulation. Further 
research into basophil responsiveness to stimuli after a prolonged stimulation with anti-
FcεRIα autoantibodies and other stimuli may provide more valuable information related 
to the pathophysiology in CSU. This data are in keeping with the recent tendencies in the 
research into allergic diseases suggesting the use of prolonged, continuous or repeated 
allergen challenge to model the events occurring in vivo in the natural course of the 
disease (De Bruin-Weller et al, 1999; Schultze et al, 2012; Ong et al, 2005). 
Finally, research into histopathological staging in CSU and urticarial vasculitis brought 
up new questions about the pathophysiology and the natural history of these two 
conditions. It is of paramount interest to look at the mechnanisms underlying 
leukocytoclasis in urticarial vasculitis with the formation of the neutrophil extracellular 
traps (Figure 55) being one of the possibilities. Also, the perspective of targeted treatment 
to the histological presentations in lesional skin biopsies was explored in the work of 
Criado et al (2008) and would highlight the future directions for this histological research 
in CSU and urticarial vasculitis. 
In general, the field of urticaria research and clinical practice is witnessing the advent of 
diagnostic, therapeutic innovations and awaiting personalised medicine. This will 
inevitably re-design our current approaches to patient work-up and management. 
Research into urticaria is on the verge of an introduction of new powerful approaches like 
systems biology, biobank research and pharmacogenetics which will enhance our 
capabilities for identifying and targeting molecular defects in the disease with innovative 
and individualized therapeutic approaches. These changes are on the horizon and make 
urticaria a fascinating area of research and clinical practice for years to come!
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Statistical statement 
For this thesis, the data analysis was applied to three interlinked research projects 
including a microdialysis study in CSU patients and healthy subjects (Chapter 2), a 
prospective observational study in CSU patients (Chapter 3) and a retrospective 
histological study in patients with CSU and UV (Chapter 5).  
Throughout the thesis, data were visualized by scatterplots or individual dot plots and 
summary statistics of the data were presented by medians and interquartile ranges.  
For the microdialysis study (Chapter 2), the research hypothesis stated that weal 
formation, as assessed by an experimental model of ASST, was mediated by circulating 
serum factors, aberrant skin mast cell releasability and altered skin microenvironment. To 
test this hypothesis, we firstly addressed the statistical question as to whether there is a 
difference in the baseline concentrations of histamine, tryptase and IL-6 in skin dialysates 
between CSU patients and healthy subjects. For this analysis, we employed a non-
parametric Mann-Whitney U test to compare the distribution of the variables between the 
two groups. A non-parametric test was chosen due to the non-normality of the 
distributions and the sample size.  Correlation analysis between two variables was carried 
out using Pearson’s correlation coefficient for variables in which a linear relationship was 
demonstrated from the scatterplot and by Spearman correlation coefficient for variables 
with a non-linear relationships.  
To assess the importance of serum histamine-releasing factors, we carried out a subgroup 
analysis of CSU patients stratified by serum histamine-releasing activity (HRA) and 
healthy subjects. For a comparison between three groups (CSU patients with or without 
serum HRA and healthy controls), we employed Kruskal-Wallis test. This test was 
selected as it is a non-parametric ANOVA that can be used to compare a non-normally 
distributed variable between three groups. For variables demonstrated a statistically 
significant difference by Kruskal-Wallis test, we applied Mann-Whitney U test for 
pairwise comparisons to evaluate which two of three groups were different for a given 
variable. We chose Mann-Whitney U test for the reasons given above.  
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 To assess the noise element in this study, we decided to compare the variance in the 
outcome due to the patients, that is the between patient variation, and the variance in 
outcome due to the order of measurement, that is the within patient variation. If the 
measurement is unreliable then a large amount of variation will be the within patient 
variation whereas if the measurement is reliable then only small amount of variation will 
be due to the within patient variation. In order to estimate these parameters, we applied a 
two-way ANOVA to estimate the variability due to the two factors (patients’ ID and the 
order of measurements). This was the most appropriate way to measure the variability 
due to these two factors. In general, two-way ANOVA test is a parametric test which is 
used for the assessment of the effect of two factors on an outcome. However, for our 
study, we chose this test because i) it estimates the parameter of interest; and ii) there is 
no clear non-parametric alternative for the estimation of variability due to each factor. 
Therefore, we appreciate the limitations of this approach, as the assumption of normality 
may not hold for our dataset and hence the p-values may not be correct.  However, the 
definition of the variation terms does not depend on the assumption of normality and is 
can be used regardless of the distribution. The rationale for using this method lied in the 
fact that we were interested in a relative contribution of variance due to the disease 
process or the measurement error rather than an exact variance estimate. The 
interpretation of the results warrants a brief comment that the between-patient variability 
was higher than the inter-patient variability due to the measurement error although the 
exact contribution of each factor cannot be established in the dataset of this sample size.  
For the observational study (Chapter 3), we hypothesized that disease severity and a 
persistent course of the disease in CSU patients are associated with serum histamine-
releasing activity, aberrant basophil releasability to anti-IgE stimulation and phenotypic 
changes in peripheral blood basophils. To test this hypothesis, we first tabulated the 
number of patients according to two parameters (serum HRA and basophil releasability to 
anti-IgE stimulation). For this analysis, we categorized these variables (Serum HRA: 
positive or negative; Anti-IgE-induced BHR: Basophil responder, basophil non-
responder, total cellular histamine below the LOD). We employed a chi-squared test to 
compare the patient distribution between these categories. Following this Kruskall-Wallis 
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test (a nonparametric ANOVA test) was chosen to compare clinical scores and 
biomarkers between CSU patients across the anti-IgE-induced BHR categories because 
this test does not assume a normal distribution of the data and is suitable for comparison 
of three independent groups. For example, we used Kruskall-Wallis test to compare the 
difference in UAS7 score between three groups according to anti-IgE induced BHR 
(basophil responders, basophil non-responders and those with total cellular histamine 
below the LOD). If the difference was statistically significant by Kruskall-Wallis test, 
this justified further use of Mann-Whitney U test for a pairwise comparisons between the 
groups in order to detect which two groups differ for UAS7.  For comparison of UAS7 
between CSU patients with or without serum HRA, we chose Mann-Whitney U test as a 
non-parametric test for comparison of two independent groups based on small sample 
size of the study and, therefore, a non-normal distribution of the data. For analysis of 
longitudinal data, we coded the patients with persistent disease if their UAS7 at visit 3 
was greater or equal than at the baseline visit. Conversely, patients with baseline UAS7 
greater than that at the visit 3 were classified as patients with improving disease. 
Correlation analysis was carried out by Spearman’s correlation coefficient when a linear 
relationship between the variables could not be ascertained.  
Following this, we employed ROC (receiver-operating curve) analysis to estimate the 
cut-off UAS7 score with optimal sensitivity and specificity to differentiate between the 
patients with persistent or improving disease. We appreciate the small size of our sample 
and, therefore, the limitations of this approach such as uncertainty in the cut-point in a 
small sample size. Further comparisons between the patient groups with persistent or 
improving CSU were carried out using Mann-Whitney U test as a non-parametric test for 
comparing numeric variables of non-normal distribution between two independent 
groups. To compare absolute basophil counts in peripheral blood of CSU patients as 
determined by three gating strategies on the same sample from each patient, we employed 
Wilcoxon signed-rank test based on the matched samples (same patient samples) used for 
analysis and a non-normal distribution of absolute basophil counts in the patient group of 
this size. The Wilcoxon test was chosen to account for the fact that the three samples 
were measured on the same individuals. An alternative approach would have been to 
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have used a non-parametric two-analysis of variance (with factors for ID and test used) 
however, this would have tested for any difference between the three tests whereas we 
were interested in how the tests compared to each other.  
The hypothesis of the retrospective histological study (Chapter 5) stated that there was a 
difference in the density and the composition of the inflammatory infiltrate in the dermis 
between patients with ASU and CSU and between those with CSU and UV.  To test this 
hypothesis, we compared the numbers of eosinophils and neutrophils per HPF in the 
histological skin specimens between patients with ASU and CSU and between CSU and 
UV. We used Mann-Whitney U test to compare the neutrophil counts between two 
independent groups (ASU vs CSU; CSU vs UV). The small sizes of patient groups could 
not justify a normal distribution within the groups, therefore, we used Mann-Whitney U 
test for a non-parametric analysis of two patient groups.  
For inter-observer agreement, we employed inter-class correlation to detect the difference 
and its statistical significance for the cell counts carried out on the same histological 
specimens by two independent observers. The choice of inter-class correlation for this 
analysis was made by exclusion of the alternatives such as Kappa coefficient or Bland-
Altman method. Bland-Altman test is used for comparison of two different approaches to 
measurement which is not strictly applicable for our study where we compared the 
performance of two observers using histological samples analysed by the same technique. 
Kappa-coefficient is used for inter-rater agreement for a categorical variables which 
could not be used for numeric variables such as cell counts in our study. Therefore, inter-
class correlation coefficient was used as the appropriate test for inter-rater agreement for 
comparison of numeric variables such as cell counts per HPF in our histological study 
whilst we acknowledge that this assumes a normal distribution of the outcome for 
confidence intervals, the estimation of the ICC itself does not make this assumption.  
Throughout the thesis, the data are presented as medians and interquartile interval.  The 
distribution of the data in our studies was considered non-normal due to small sample 
sizes. The limitations of the small sample size studies were underscored to avoid an over-
statement of the results.  
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Appendix 1B. Table 1. Classification of Urticaria Subtypes as recommended by
EAACI/GA2LEN/EDF/WAO guideline on Definition, Classification and Diagnosis 
of Urticaria in 2009
Types Subtypes Definition
Spontaneous urticaria Acute spontaneous urticaria Spontaneous wheals and/or angioedema < 6 weeks
Chronic spontaneous urticaria Spontaneous wheals and/or angioedema > 6 weeks
Physical urticaria Cold contact urticaria Eliciting factor: cold objects/air/fluids/wind
Delayed pressure urticaria Eliciting factor: vertical pressure
(wheals arising with a 3–12 h latency)
Heat contact urticaria Eliciting factor: localized heat
Solar urticaria Eliciting factor: UV and/or visible light
Urticaria factitia/dermographic urticaria Eliciting factor: mechanical shearing forces
(wheals arising after 1–5 min)
Vibratory urticaria/angioedema Eliciting factor: vibratory forces, e.g. pneumatic hammer
Other urticaria types Aquagenic urticaria Eliciting factor: water
Cholinergic urticaria Elicitation by increase of body core temperature due to 
physical exercises, spicy food
Contact urticaria Elicitation by contact with urticariogenic substance
Exercise induced anaphylaxis/urticaria Eliciting factor: physical exercise
Table 1. The clinical classification of urticaria subtypes was suggested by the EAACI/GA2LEN/EDF/WAO guideline at the 3rd International Meeting on Urticaria Urticaria 2008 which was held as a joint initiative of
the EAACI Dermatology Section, GA2LEN, EDF and WAO (Zuberbier T. et al, 2009). According to this classification, three urticaria subtypes included spontaneous urticaria, physical urticaria and other urticaria
types. Spontaneous urticaria was subdivided into acute and chronic depending on the duration of the disease. Physical urticarias included cold contact urticaria, delayed pressure urticaria, heat contact urticaria,
solar urticaria, urticaria factitia or dermographic urticaria. Aquagenic, cholinergic, contact urticarias and exercise-induced anaphylaxis/urticaria were considered as other urticaria types in the classification. The
guideline referred to some inconsistencies in this classification. For example, physical urticarias, although chronic conditions, they were grouped separately due to eliciting physical factors as opposed to acute
and chronic spontaneous urticarias that occur spontaneously without physical triggers. 
Abbrevations:
EAACI -  European Academy of
Allergy and Clinical Immunology
GA2LEN - Global Allergy and
Asthma European Network
EDF - European Dermatology
Forum
WAO - World Allergy Organization
Appendix 3. Figure 1. Microdialysis Experiment - Patient DPP01
Date: 1/10/2007
Patient: DPP01
VAS for itching/24hrs: 76mm
VAS for wealing: 54mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
2.806 1.794 2.344 1.859 2.385 4.306 10 8.460 2.737 1.474
2.806 1.620 2.502 1.807 3.239 5.086 0.864 5.904 3.404 0.675
2.806 10 3.297 3.033 10 4.518 1.211 4.202 1.278 1.311
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Appendix 3. Figure 2. Microdialysis Experiment - Patient MHP03
Date: 1/12/2007
Patient: MHP03
VAS for itching/24hrs: 18mm
VAS for wealing: 17mm
Microdialysis Sites: Skin Testing
Codeine PBS ASST
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
8.721 8.630 8.561 8.458 8.258 8.225 8.866 8.522 8.431
8.721 8.940 8.161 9.048 8.087 8.333 9.244 8.762 7.927
8.721 10 8.736 8.616 8.301 8.286 8.521 9.174 8.807
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Appendix 3. Figure 3. Microdialysis Experiment - Patient EBP04
Date: 20/02/2008
Patient: EBP04
VAS for itching/24hrs: 19mm
VAS for wealing: 11mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.115 1.189 0.994 1.352 0.855 0.322 1.982 0
0.115 0.087 0.007 1.131 0.297 1.295 3.048 2.374 0.283
0.115 0.654 2.256 2.454 2.266 0.34 2.225 3.123 1.173
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Appendix 3. Figure 4. Microdialysis Experiment - Patient DMP05
Date: 13/02/2008
Patient: DMP05
VAS for itching/24hrs: 48mm
VAS for wealing: 3mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.444 1.367 1.057 0.885 1.188 1.077 1.013 1.269 1.172
0.444 1.268 1.053 10 1.003 0.927 1.121 1.072 0.909
0.444 1.183 1.059 0.649 0.971 0.978 1.432 1.181 1.061
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Appendix 3. Figure 5. Microdialysis Experiment - Patient DBP06
Date: 05/03/2008
Patient: DBP06
VAS for itching/24hrs: 93mm
VAS for wealing: 91mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
2.692 1.528 1.698 1.586 1.372 2.095 2.616 2.675 1.171 0.081
2.692 2.483 1.843 1.413 1.535 1.233 1.460 3.501 2.314 1.076
2.692 10 1.733 2.476 1.213 1.841 1.345 2.161 1.303 0.653
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Appendix 3. Figure 6. Microdialysis Experiment - Patient NMCP07
Date: 31/07/2008
Patient: NMCP07
VAS for itching/24hrs: 80mm
VAS for wealing: 81mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.973 0.593 0.898 0.469 0.956 0.944 0.36 1.444 0.720 1.079
0.973 0.844 1.197 0.258 1.316 0.740 0.285 1.209 0.591 1.441
0.973 10 1.142 0.611 0.722 0.880 0.897 1.298 0.742 1.248
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Appendix 3. Figure 7. Microdialysis Experiment - Healthy Control NLV04
Date: 03/04/2008
Patient: NLV04
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
1.286 7.378 2.246 6.342 5.665 5.323 5.835 6.574 7.570 4.723
1.286 7.378 2.246 6.342 5.665 5.323 5.835 3.277 8.219 4.743
1.286 10 4.332 5.13 5.097 7.278 3.641 11.041 4.456 5.345
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
0.1 -0.10 -0.3 0.3 -0.1 -0.1 -0.1 0.1 0.5 0.3
0.1 1.70 0.70 0.80 -0.50 0.1 0.3 2.80 0.70 0
0.1 7.60 0.90 0.40 0.30 0.80 0.90 1.10 -0.7 -0.3
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Appendix 3. Figure 8. Microdialysis Experiment - Healthy Control RAV05
Date: 28/11/2007
Patient: RAV05
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingEMLA off
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.172 0.675 0.653 0.655 1.081 0.275 0.573 1.887 0.639 0.898
0.172 0.865 0.792 0.484 1.161 0.190 0.384 0.829 0.007 0.573
0.172 4.042 1.261 10 1.602 2.239 0.435 0.569 0.977 0.542
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
2.13 4 2.93 5.07 10.13 3.07 3.73 21.60 15.07 3.33
2.13 4.27 5.87 4.80 3.73 1.73 3.87 5.73 14.67 2.67
2.13 4.4 6.27 4.67 6.53 16.40 6.4 4.13 8.13 3.60
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Appendix 3. Figure 9. Microdialysis Experiment - Healthy Control LCV06
Date: 06/02/2008
Patient: LCV06
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine PBS ASST
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
2.119 3.417 3.984 2.780 2.390 5.903 0.869 6.388 4.128 3.703
2.119 2.707 6.324 2.457 6.631 2.910 3.525 5.232 2.489 3.595
2.119 10 6.027 5.649 5.075 3.374 2.825 9.363 4.293 3.901
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
1.3 1.3 0.9 1.5 1.9 0.8 2 1.7 1.2
1.3 0.7 -0.3 0 0.9 0 2 1.9 1.1 1.9
1.3 3.10 1.1 2.7 1.7 0 2.50 2.8 2 2.1
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Appendix 3. Figure 10. Microdialysis Experiment - Healthy Control APV07
Date: 01/12/2007
Patient: APV07
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
1.367 0.694 1.312 0.935 0.590 0.670 0.263 1.717 3.785 2.254
1.367 1.122 10 1.054 0.970 1.085 1.111 0.661 3.508 3.274
1.367 10 1.473 1.154 1.046 1.059 0.864 1.128 5.125 5.588
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
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CODEINE
0.7 -0.10 0 -0.70 -0.40 0.30 -0.10 1.30 2.40 0.30
0.7 -0.90 -0.30 -0.80 0.50 1.20 0 2 0.70
0.7 5.9 2.10 3.60 1.90 0.50 -0.30 2.40 0.10 0.30
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Appendix 3. Figure 11. Microdialysis Experiment - Healthy Control ASV09
Date: 22/11/2007
Patient: ASV09
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.436 0.651 1.019 0.243 0.465 0.581 0.627 0.772 0.583 0.352
0.436 1.827 0.573 0.526 1.330 0.533 0.196 0.907 1.372 0.492
0.436 10 0.827 0.607 0.855 0.829 0.800 0.822 0.668 0.156
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
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ASST
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0.7 0.4 -0.5 0.8 -1.5 0 -0.3 -0.7 -0.5 -1.3
0.7 1.10 0.30 1.6 -0.5 -0.5 -0.5 -0.4 -0.5 -0.9
0.7 4.70 2 3.70 2.50 2.30 2.3 -0.1 -1.3 -0.5
A B C D E F G H I J
Tryptase Concentration In Skin Dialysates
Hi
st
am
ine
 (n
g/
m
l)  
Tr
yp
ta
se
 n
g/
m
l 
Appendix 3. Figure 12. Microdialysis Experiment - Healthy Control JEV10
Date: 20/11/2007
Patient: JEV10
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.236 0.287 0.846 0.336 0.885 0.504 0.515 1.028 0.906 0.315
0.236 0.603 0.149 0.741 0.356 0.325 1.064 0.886 0.672
0.236 1.768 3.859 0.326 0.940 0.994 0.466 0.748 1.072 0.260
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
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ASST
CODEINE
16.4 -0.7 0.80 0.7 -0.8 0.5 -0.5 -1.1
16.4 -0.30 2.5 0 -0.4 0.7 0.1 0.4 -0.9
16.4 19.2 0.90 -0.30 0 2.40 3.20 -1.10
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Appendix 3. Figure 13. Microdialysis Experiment - Healthy Control AMSV11
Date: 13/12/2007
Patient: AMSV11
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine PBS ASST
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.859 0.892 0.476 0.930 0.983 0.804 0.485 0.960 0.878 0.900
0.859 1.229 0.555 0.776 1.026 0.853 0.632 0.742 0.834 0.723
0.859 10 0.920 0.808 0.805 0.784 0.635 0.951 1.018 0.697
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
0.7 2.40 2 1.30 0.30 0.50 -0.80 2.10 0.70 -0.70
0.7 -0.30 0.30 -1.10 0.10 2.30 -0.80 3.10 0 -0.70
0.7 0.70 3.10 -0.70 0.30 0.10 -0.70 0.50 -0.70 -1.10
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Appendix 3. Figure 14. Microdialysis Experiment - Healthy Control ODV12
Date: 12/04/2008
Patient: ODV12
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine ASST PBS
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
1.264 0.711 1.439 0.901 0.867 0.967 0.734 0.658 10 4.360
1.264 1.182 1.605 0.840 0.126 0.894 0.646 1.106 9.167 2.334
1.264 10 1.337 0.846 0.365 0.954 0.563 0.723 1.236 0.832
A B C D E F G H I J
Protocol 1 - Healthy Control
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
0.7 0 0.8 0.8 -0.1 0.5 -0.7 -0.3 1.1 -0.3
0.7 2.8 2.3 0.7 -0.1 0.9 0.9 0.9 0.7 -0.7
0.7 5.9 4.9 2.1 2 0.4 1.2 1.5 0.8 1.1
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Appendix 3. Figure 15. Microdialysis Experiment - Healthy Control SCV08
Date: 18/11/2007
Patient: SCV08
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
Codeine PBS ASST
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
0.118 0.782 0.693 0.215 0.161 0.284 0.314 0.189
0.118 0.266 0.085 0.309 0.001 0.308 0.239 0.279 0.646
0.118 2.692 0.444 0.726 0.445 0.217 0.421 0.073
A B C D E F G H I J
Protocol 1 - Healthy Control
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Appendix 3. Figure 16. Microdialysis Experiment - Patient NMP09
Date: 04/09/2008
Patient: NMP09
VAS for itching/24hrs: 71mm
VAS for wealing: 35mm
Microdialysis Sites: Skin Testing
PBS ASST Codeine
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
Protocol 2 - Patient
PBS
ASST
CODEINE
0.816 0.420 0.967 0.415 0.796 0.551 0.927 0.906 0.713
0.816 0.603 0.808 0.953 0.5 0.885 1.167 1.088 0.818
0.816 7.799 4.685 2.248 1.130 0.536 1.042 0.516 3.234
0 5 10 15 20 25 30 35 40
Histamine Concentration In Skin Dialysates
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CODEINE
3.47 1.87 2.8 4.13 5.07 1.73 7.20
3.47 2.53 2.8 2.93 4.27 2.27 1.73 4.40
3.47 4.13 4.27 3.20 2.67 4.27 1.87 2
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Appendix 3. Figure 17. Microdialysis Experiment - Patient JKP10
Date: 17/10/2008
Patient: JKP10
VAS for itching/24hrs: 85mm
VAS for wealing: 60mm
Microdialysis Sites: Skin Testing
PBS ASST Codeine
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
Protocol 2 - Patient
PBS
ASST
CODEINE
2.203 10 10 1.054 0.665 0.825 1.091 10 0.956
2.203 4.199 0.663 10 1.230 10 1.181 10 0.713
2.203 10 10 4.815 0.680 10 1.359 0.927 0.513
0 5 10 15 20 25 30 35 40
Histamine Concentration In Skin Dialysates
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ASST
CODEINE
2.40 2.40 2.80 4.27 4.8 2.80 1.73 5.33
2.40 3.47 0.67 4.13 6.67 2.40 7.60 2.80 4
2.40 4 3.52 3.2 1.60 8 4.80 3.07
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Appendix 3. Figure 18. Microdialysis Experiment - Patient JRP11
Date: 15/10/2008
Patient: JRP11
VAS for itching/24hrs: 50mm
VAS for wealing: 32mm
Microdialysis Sites: Skin Testing
PBS ASST Codeine
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
Protocol 2 - Patient
PBS
ASST
CODEINE
2.792 2.400 1.241 1.558 0.989 1.994 3.002 0.850 0.931
2.792 1.178 1.382 2.259 1.431 1.296 1.386 1.635 1.545
2.792 4.485 1.244 1.164 1.716 1.828 1.043 1.939 2.088
0 5 10 15 20 25 30 35 40
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
4.93 1.60 2.67 3.33 1.33 3.73 10.93 2.80 4.13
4.93 3.20 5.33 2.67 3.87 6 2.80 2.93
4.93 3.20 2.40 1.73 2.67 2.67 5.60 3.07 5.47
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Appendix 3. Figure 19. Microdialysis Experiment - Patient NSP12
Date: 15/01/2009
Patient: NSP12
VAS for itching/24hrs: 28mm
VAS for wealing: 27mm
Microdialysis Sites: Skin Testing
PBS ASST Codeine
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
Protocol 2 - Patient
PBS
ASST
CODEINE
9.007 10 8.512 8.461 8.371 8.721 8.708 8.507 7.856
9.007 10 9.109 9.185 8.518 8.615 8.349 8.552 8.324
9.007 10 10 9.296 8.699 8.824 8.757 8.632 8.596
0 5 10 15 20 25 30 35 40
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
2 1.60 -0.30 0.5 1.5 0.70 1.90 4.10 2.5
2 1.10 0.5 0.8 0.8 0.7 3.2 2.7 3.3
2 0 1.5 1.5 0.5 1.1 9.1 3.5 3.5
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Appendix 3. Figure 20. Microdialysis Experiment - Healthy Control CGV02
Date: 23/09/2008
Patient: CGV02
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
PBS ASST Codeine
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
Protocol 2 - Healthy Control
PBS
ASST
CODEINE
1.218 0.546 0.431 0.994 0.33 0.224 1.002 1.610 0.744
1.218 0.757 0.970 0.522 0.451 0.601 0.368 1.085 1.107
1.218 10 5.509 2.584 1.461 2.486 1.55 0.941 0.909
0 5 10 15 20 25 30 35 40
Histamine Concentration In Skin Dialysates
PBS
ASST
CODEINE
3.5 1.60 -0.50 0.90 -0.30 -0.10 0.80 -0.10 7.70
3.5 0.40 -0.80 1.20 -2.40 -0.10 0.90 0.10 1.50
3.5 3.70 6.30 3.50 0.70 1.30 4.50 1.30 2.50
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Appendix 3. Figure 21. Microdialysis Experiment - Patient MLP12
Date: 02/06/2011
Patient: MLP12
VAS for itching/24hrs: 35mm
VAS for wealing: 42mm
Microdialysis Sites: Skin Testing
PBS ASST Codeine
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
2.439 1.565 0.938 1.944 1.486 1.050 0.687 1.776 0.864 0.825 1.458 1.551 2.138 0.760 0.760 1.092 0.566
2.439 4.346 5.591 6.621 3.419 2.104 1.389 1.282 1.110 1.691 1.315 0.825 0.671 0.870 1.342 1.211 0.585
2.439 420.5 78.71 27.440 11.470 5.611 4.834 2.876 1.382 2.173 1.198 1.382 1.558 0.961 0.932 1.302 0.755
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Protocol 3 - Patient
Histamine Concentration In Skin Dialysates (Neat Samples) 
PBS
ASST
CODEINE
1.906 0.553 0.481 1.404 2.028 0.853 1.210 2.041 1.174 0.658 1.416 1.354 2.041 1.186 0.875 2.152 0.658
1.906 2.890 14.540 17.250 10.490 4.293 3.457 1.466 1.879 1.946 1.127 0.134 1.104 0.754 0.605 0.765 1.579
1.906 269.800 100.900 44.160 18.980 11.030 6.689 1.932 1.892 2.365 0.831 0.331 1.416 0.887 1.139 10.210 1.973
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
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Appendix 3. Figure 22. Microdialysis Experiment - Patient RMP20
Date: 21/03/2011
Patient: RMP20
VAS for itching/24hrs: 92mm
VAS for wealing: 91mm
Microdialysis Sites: Skin Testing
PBS ASST Codeine
PBS
ASST
CODEINE
2.759 4.451 1.502 1.964 0.678 0.909 0.263 1.955 1.444 2.048 -0.895 1.12 0.836 0.543 0.396 0.976 1.089
2.759 4.613 3.361 4.294 3.103 2.039 1.697 2.133 2.095 2.650 1.784 1.510 1.837 0.939 1.013 1.611 1.066
2.759 10.430 5.473 3.032 1.910 2.001 2.523 2.481 1.654 1.882 1.510 2.039 1.315 1.174 1.937 1.387 0.954
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Protocol 3 - Patient
Histamine Concentration In Skin Dialysates (Neat Samples) 
3.989 6.324 1.586 2.222 2.042 1.214 1.782 1.162 1.318 1.641 1.214 1.477 1.099 1.344 1.767 0.95 1.998
3.989 3.779 1.188 3.649 4.863 2.376 1.911 2.662 1.214 2.207 0.926 2.268 0.608 1.767 3.217 1.252 1.725
3.989 66.920 29.560 12.190 4.527 2.892 3.969 2.825 1.697 2.727 2.314 3.130 1.998 2.177 1.896 1.954 3.630
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing Time (mins)
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Appendix 3. Figure 23. Microdialysis Experiment - Patient RPP25
Date: 15/07/2011
Patient: RPP25
VAS for itching/24hrs: 78mm
VAS for wealing: 77mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
PBS
ASST
CODEINE
4.573 4.714 2.091 3.35 1.149 1.49 1.576 1.01 1.747 1.407 0.895 1.198 0.971 0.889 1.095 0.067 0.63
4.573 10.87 12.12 18.220 16.590 12.820 9.265 5.769 3.987 3.443 2.506 2.453 2.072 1.198 1.705 0.927 1.143
4.573 34.740 15.170 11.580 7.256 4.238 2.951 2.119 1.537 1.806 1.069 1.490 1.042 0.774 1.219 0.505 0.597
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Protocol 3 - Patient
Histamine Concentration In Skin Dialysates (Neat Samples) 
2.456 4.995 1.643 2.196 2.210 15.3 10.840 8.490 6.104 5.679 3.836 4.115 3.344 2.760 3.674 2.238 3.361
2.456 6.128 24.730 31.260 29.860 19.850 14.30 5.153 6.349 5.936 2.546 1.630 1.960 1.466 1.319 1.478 1.643
2.456 25.120 20.600 13.320 9.197 5.819 3.177 2.838 1.694 2.056 2.471 1.812 2.014 1.503 1.165 1.295 0.712
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing Time (mins)
Time (mins)
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Appendix 3. Figure 24. Microdialysis Experiment - Patient SAP24
Date: 22/09/2011
Patient: SAP24
VAS for itching/24hrs: 56mm
VAS for wealing: 64mm
Microdialysis Sites: Skin Testing
Codeine ASST PBS
PBS
ASST
CODEINE
1.963 2.368 2.197 1.804 1.925 1.013 1.659 1.5 1.94 1.963 2.586 2.265 1.902 2.512 4.901 2.042 2.857
1.963 3.736 2.164 1.638 1.507 1.541 1.146 1.782 1.293 2.123 1.716 3.295 2.468 1.995 4.646 1.723 1.487
1.963 17.55 33.590 25.040 12.220 5.513 2.807 2.748 2.368 1.971 1.917 1.617 2.248 2.058 2.090 2.123 1.811
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Protocol 3 - Patient
Histamine Concentration In Skin Dialysates (Neat Samples) 
2.205 2.219 1.841 1.800 0.929 2.006 1.733 0.884 1.434 1.978 1.706 1.069 0.783 0.987 1.485 0.873 1.992
2.205 6.580 3.021 2.234 1.536 1.069 1.562 1.359 1.733 2.732 1.614 1.950 3.515 1.654 1.359 0.599 1.248
2.205 2.875 135.200 59.730 26.270 8.575 3.858 3.071 1.841 1.261 0.641 0.987 1.8 1.524 1.950 1.397 0.463
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing
PBS
ASST
CODEINE
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Appendix 3. Figure 25. Microdialysis Experiment - Healthy Control AYV15
Date: 12/12/2011
Patient: AYV15
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
PBS
ASST
CODEINE
1.404 8.007 3.410 1.395 1.071 0.969 3.103 1.116 0.879 0.788 1.430 1.567 1.931 1.733 1.194 1.673 0.833
1.404 5.533 2.936 1.226 7.314 1.964 1.309 1.386 0.477 0.482 1.005 1.369 1.693 1.078 0.920 0.660 0.690
1.404 123.9 40.270 16.520 10.890 4.023 5.010 1.041 0.906 2.008 0.833 1.019 0.757 1.012 0.672 0.372 0.294
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Protocol 3 - Healthy Control
Histamine Concentration In Skin Dialysates (Neat Samples) 
1.876 7.330 1.979 0.986 1.647 0.680 1.760 0.929 0.416 1.304 1.710 1.056 1.425 1.535 2.138 4.096 1.103
1.876 4.883 3.363 1.474 4.698 2.923 0.883 1.091 0.929 1.044 1.710 1.535 2.178 2.125 1.316 1.352 0.759
1.876 248.100 33.380 12.030 8.422 3.844 2.138 1.572 1.01 1.15 1.889 1.76 1.34 1.56 1.647 1.850 1.021
Dialysate collection 30 minutes after testingProbes in
Baseline Microdialysis Skin Testing Time (mins)
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Appendix 3. Figure 26. Microdialysis Experiment - Healthy Control IPV14
Date: 14/12/2011
Patient: IPV14
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
PBS
ASST
CODEINE
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Protocol 3 - Healthy Control
Histamine Concentration In Skin Dialysates (Neat Samples) 
0.802 1.154 0.94 1.179 1.429 0.423 0.109 0.646 0.836 0.746 1.106 0.496 0.668 0.570 0.046 1.203 0.668
0.802 2.869 0.701 0.975 0.646 0.940 0.791 0.193 0.371 1.840 0.311 0.592 0.382 0.232 0.723 0.155 0.592
0.802 32.620 25.030 13.510 6.860 3.492 3.440 0.528 0.975 1.455 1.010 1.480 0.193 0.291 1.965 0.679 0.613
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Appendix 3. Figure 27. Microdialysis Experiment - Healthy Control UBV16
Date: 16/12/2011
Patient: UBV16
VAS for itching/24hrs: N/A
VAS for wealing: N/A
Microdialysis Sites: Skin Testing
PBS
ASST
CODEINE
0.315 0.332 0.232 0.518 0.390 0.232 0.215 0.740 0.115 0.846 0.526 0.082 0.684
0.315 1.129 0.323 0.985 2.630 0.124 2.603 2.510 1.298 0.855 0.039 1.431
0.315 72.990 27.840 18.220 8.198 6.458 3.364 2.227 1.389 0.684 0.365 0.837 0.282 0.441
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Protocol 3 - Healthy Control
Histamine Concentration In Skin Dialysates (Neat Samples) 
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Appendix 3. Figure 28. Microdialysis Experiment - Technical Aspects (6)
The definition of non-specific skin reactivity to microdialysis procedures
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Figure 28. Non-specific skin reactivity to microdialysis procedures. In our study, two patients with CSU (Figures 28A-B) and one healthy subject (Figure 28C)
displayed the elevated dermal histamine (Figures 28A-B) or tryptase (Figure 28C) concentration at the baseline comparable to that after skin testing with codeine. This
may suggest that this dermal response may occur as a result of the insertion or the presence of the microdialysis probes in the dermis. It is important to be aware of the
possibility of these reactions in few individuals. Whether this dermal response can be predicted using high resolution laser Doppler perfusion imaging needs to be
established in the future studies. The corresponding time intervals to sampling periods in the microdialysis studies are presented in Figure 28D. 
Abbrevations:
ASST - Autologous serum skin test
CSU - Chronic spontaneous urticaria 
PBS - Phosphate buffered saline
D. Microdialysis Timeline
Skin testing Skin testing Skin testing
Appendix 4. . Pathophysiological Phenotyping in CSU at Baseline
Patient Serum-induced BHR Serum 
(% of total cellular histamine) histamine-releasing activity
KDP01
MHP02
TBP03
RHP04
SRP05
RWP06
MMP07
MLP08
ASP09
ISTP11
MWP12
JHP14
JCP15
DPP16
IHP17
BSP19
GHP20
DMP21
TMP21
DBP23
BHP24
DMP25
41
5
39
9
0
0
0
6
36
11
34
0
0
0
0
47
44
0
0
50
45
0
positive
negative
positive
negative
negative
negative
negative
negative
positive
negative
positive
negative
negative
negative
negative
positive
positive
negative
negative
positive
positive
negative
Abbrevations: 
BHR - Basophil histamine release
CSU - Chronic spontaneous urticaria
LOD - Level of detection
Figure 1. Based on the results of basophil
releasability assays, we could differentiate
three subsets of CSU patients: 
- responders to anti-IgE stimulation (BHR
over 10% of total cellular histamine to
anti-IgE stimulation) (n=7);
- non-responders to anti-IgE stimulation
(BHR below 10% of total cellular
histamine to anti-IgE stimulation) (n=8);
- total cellular histamine below the LOD of
spectronuorimetry (n=7). 
Based on serum-induced BHR assay,
CSU patients were grouped into CSU
patients with (n=8) and without  (n=14)
serum histamine-releasing activity.
Anti-IgE induced BHR from peripheral
blood basophils of CSU patients was
carried out by Dr Bernhard Gibbs at the
Medway School of Pharmacy (Chatham
Maritime, UK). For basophil releasability
assays, cells were stimulated with anti-IgE
antibodies (Sigma-Aldridge, UK) at
0.1ng/ml. Serum-induced BHR was
assessed on peripheral blood basophils
from healthy donors at the RefLab
(University of Copenhagen, Denmark).
For serum-induced BHR assay, a
diagnostic cut-off of 16.5% was used to
detect serum histamine-releasing activity
in CSU patients (Platzer M. et al, 2005). 
Patient Anti-IgE-induced BHR (%) CSU Subset
(% of total cellular histamine)
KDP01
MHP02
TBP03
RHP04
SRP05
RWP06
MMP07
MLP08
ASP09
ISTP11
MWP12
JHP14
JCP15
DPP16
IHP17
BSP19
GHP20
DMP21
TMP21
DBP23
BHP24
DMP25
4.2
7.4
0
-10.3
0.4
58.1
53.9
9.5
0
48
0
-0.7
13.5
55.9
0
14.8
0
68.1
0
0
0
-1.1
non-responder
non-responder 
histamine below the LOD
non-responder
non-responder
responder
responder
responder
histamine below the LOD
responder
histamine below the LOD
non-responder
responder
responder
non-responder
responder
histamine below the LOD
responder
histamine below the LOD
histamine below the LOD
histamine below the LOD
non-responder
. CSU patient classification related to 
basophil releasability to anti-IgE stimulation
. CSU patient classification related to 
serum histamine-releasing activity
Figure 1
Table 1 Table 2
Appendix 4. Disease Course Profiles in CSU Patients
Patient UAS7 Visit 1 UAS7 Visit 3 CSU course profile
KDP01
MHP02
TBP03
SRP05
RWP06
MMP07
MLP08
ISTP11
MWP12
JHP14
JCP15
DPP16
IHP17
BSP19
DMP21
TMP21
DBP23
BHP24
DMP25
17
20
25
2
0
0
32
12
22
20
2
19
16
28
5
24
29
36
27
0
4
35
0
0
0
35
28
3
32
0
25
23
30
0
37
27
44
0
improving CSU
improving CSU
persistent CSU
improving CSU
improving CSU
improving CSU
persistent CSU
persistent CSU
improving CSU
persistent CSU
improving CSU
persistent CSU
persistent CSU
persistent CSU
improving CSU
persistent CSU
persistent CSU
persistent CSU
improving CSU
Abbrevations: 
CSU - Chronic spontaneous urticaria
UAS7 - Urticaria activity score over 7 days
Table 3. Patients with persistent CSU were demned if their UAS7 score at Visit 3 was greater or equal than that at Visit 1. Patients with improving CSU were demned
if their UAS7 score at Visit 3 was less than that at Visit 1. UAS7 with score range of 0 to 49 was used in this study. 
Table 3.
Appendix 4. Figure 2. The Antibody Panel for Basophil Studies in CSU Patients using
Multicolour Flow Cytometry
A. Multicolour Panel used for Flow Cytometry Studies 
at the Norfolk & Norwich University Hospital
Laser  488nm 488nm 488nm 488nm 633nm 633nm
Fluorescent Dyes
Cell Suface Marker
FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-Cy7
CD63 CCR3 CD123 HLA-DR CD203c CD45
Figure 2. For antibody conjugates, a combination of nuorochromes excited by blue and red lasers (Figure 2A) were
selected to ensure a minimal spillover between the channels for BD FACSCanto ™ II instrument conmguration as
demonstrated by BD Fluorescence Spectrum Viewer output in Figures 2B and C (taken from
www.bdbiosciences.com/spectra).  Flow cytometry studies were carried out using BD FACSCanto™  II Flow
cytometer by Miss Cheryl Barker at the Pathology Department, Norfolk & Norwich University Hospital (Norwich, UK). 
B. BD Flourescence Spectrum Viewer - Blue Laser (488 nm) C. BD Flourescence Spectrum Viewer - Red Laser (633 nm)
Abbrevations: 
CSU - Chronic spontaneous urticaria
FITC - Fluorescein isothianate
PE - Phycoerythrin
PerCP - Peridin Chlorophyll Protein Complex
Cy5.5 - Cyanine 5.5
Cy7 - Cyanine 7
CCR3 - Chemokine (C-C motif) receptor type 3
HLA-DR - D-related human leukocyte antigen (related to the D-locus on the chromosome 6)
APC - Allophycocyanin
Appendix 4. Figure 3. Fluorescence-M
inus-O
ne
Gating Controls and Gate Construction for
Peripheral Blood Basophils in Flow Cytom
etric
Studies
A. FM
O control w
ithout CD63 
CD203c-APC
CD63-FITC
CD203c-APC
CD63-FITC
B. FM
O control w
ithout CD203c 
CD203c-APC
CD63-FITC
C. Gate Construction for Dual
CD203c
+CD63
+Gating 
D. FM
O control
w
ithout CCR3
E. FM
O control
w
ithout CD123
F. FM
O control
w
ithout HLA-DR
SSC-A
CCR3-PE
SSC-A
CD123-PerCP-Cy5.5
SSC-A
HLA-DR - PE-Cy7
Figure 3. In this sam
ple experim
ent, nuorescence-m
inus-one
controls were used to identify positive versus negative events and to
optim
ise the gates for peripheral blood basophils. The FM
O gate for
CD203c was demned by peripheral blood sam
ple stained by a full
panel of antibodies (Appendix 3, Figure 1A) except CD203c-APC
(Appendix 3, Figure 2A). The FM
O gate for CD63 was demned by
peripheral blood sam
ple stained by a full panel of antibodies except
CD63-FITC (Appendix 3, Figure 2B). The Boolean gate was
constructed as a com
bination of FM
O gates for CD63-APC and
CD63-FITC for dual positive cells (Appendix 3, Figure 2C). The FM
O
gates for CCR3-PE, CD123-PerCP-Cy5.5 and HLA-DR-PE-Cy7
presented in the Figures 2D-F. The FM
O gates were set at 99.9%
percentile. The data were acquired on a BD FACS Canto II TM
now
cytom
eter by M
iss Cheryl Barker at the Pathology Departm
ent,
Norfolk & Norwich University Hospital (Norwich, UK). Data analysis
was carried out using Kaluza r analysis software Version 1.1.
(Beckm
an Coulter, Inc.).  
Gate A AND F = Gate L
Boolean gate forCD63+CD203c+ basophils 
0.10%
0.10%
0.03%
0.10%
 
0.10%
 
0.10%
 
Abbrevations: 
APC - Allophycocyanin
CCR3 - Chem
okine (C-C m
otif) receptor type 3
CSU - Chronic spontaneous urticaria
Cy5.5 - Cyanine 5.5
Cy7 - Cyanine 7
FITC - Fluorescein isothianate
FM
O - Fluorescence-M
inus-One
HLA-DR - D-related hum
an leukocyte antigen 
(related to the D-locus on the chrom
osom
e 6)
PE - Phycoerythrin
PerCP - Peridin Chlorophyll Protein Com
plex
SSC - Side scatter
Appendix 4. Figure 4. Basophil Identification by Three
Gating Strategies in Flow Cytom
etric Studies in 
CSU Patients
A. SSC vs CCR3 
B. SSC vs CD123
C. CCR3 vs CD123
Abbrevations: 
APC - Allophycocyanin
CCR3 - Chem
okine (C-C m
otif) receptor type 3
CSU - Chronic spontaneous urticaria
Cy5.5 - Cyanine 5.5
Cy7 - Cyanine 7
FITC - Fluorescein isothianate
FM
O - Fluorescence-M
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PerCP - Peridin Chlorophyll Protein Com
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Figure 4. The gates for double-positive cell populations for each gating
strategy were constructed by com
bining FM
O gates for each m
arker
using an AND Boolean logic. To isolate CCR3
+CD123
+cell, a Boolean
gate (Figure 4C) was constructed by a com
bination of FM
O gates for
CCR3 (Figure 4A) and CD123 (Figure 4B) m
arkers. CCR3
+CD63
+cells
were selected by a Boolean gating (Figure 4F) for double-positive cells
for each m
arker (Figures 4D-E). Boolean gating for CD203c
+CD63
+cells
(Figure 4H) was achieved by a com
bination of FM
O gates for CD203c
and CD63 m
arkers (Figure 4G). The data were acquired on a BD FACS
Canto II TM
now cytom
eter by M
iss Cheryl Barker at the Pathology
Departm
ent, Norfolk & Norwich University Hospital (Norwich, UK). Data
analysis was carried out using Kaluza r analysis software Version 1.1.
(Beckm
an Coulter, Inc.).  
Appendix 4. Figure 5. Spontaneous and Anti-IgE-induced BHR in CSU Patient Subsets
Related to Basophil Releasability to Anti-IgE Stimulation
B. Spontaneous BHR across the
pathophysiological subsets in CSU at baseline
A. Anti-IgE-induced BHR across the
pathophysiological subsets in CSU at baseline
Red bar represents median values.
Pairwise comparisons between the pathophysiological subsets in CSU were carried out by Mann-Whitney U test.
UAS7 score ranged from 0 to 49.  
Figure 5. Pathophysiological phenotyping in CSU was carried out based on patient’s BHR to anti-IgE stimulation and serum histamine-releasing activity.
(Appendix 3, Table 1). 
As a result of the pathophysiological phenotyping, we could differentiate three pathophysiological subsets of CSU patients. Seven CSU patients were grouped
into the pathophysiological subset 1 (responders) based on BHR over 10% of total cellular histamine to anti-IgE stimulation (Figure 5A). 8 CSU patients were
assigned to the pathophysiological subset 2 (non-responders) based on anti-IgE-induced BHR below 10% of total cellular histamine (Figure 5A).
Pathophysiological subset 3 included 7 patients and was characterised by total cellular histamine below the detection limit of spectronuorimetry (Figure 5A).
There was no statistically signimcant difference in spontaneous BHR between responders and non-responders to anti-IgE stimulation (Figure 5B). 
Anti-IgE-induced BHR from peripheral blood basophils of CSU patients was carried out by Dr Bernhard Gibbs at the Medway School of Pharmacy (Chatham
Maritime, UK). For basophil releasability assays, cells were stimulated with anti-IgE antibodies (Sigma-Aldridge, UK) at 0.1ng/ml. Serum-induced BHR was
assessed on peripheral blood basophils from healthy donors at Renab (University of Copenhagen, Denmark). UAS7 with the score range of 0 to 49 was used
in this study. 
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Abbrevations: 
CSU - Chronic spontaneous urticaria 
BHR - Basophil histamine release
UAS7 - Urticaria activity score over 7 days
LOD - Level of detection
fMLP - Formyl-Methionyl-Leucyl-Phenylalanine
IL-3 - Interleukin 3
IL-5 - Interleukin 5
Appendix 4. Figure 6. Baseline Characteristics in Subgroups of CSU Patients 
related to the Clinical Course of Disease 
A. Baseline serum histamine-releasing activity
in patients with persistent or improving CSU
C.  Baseline anti-IgE-induced BHR from
peripheral blood basophils in patients with
persistent or improving CSU
B.  Baseline spontaneous BHR in patients
with persistent or improving CSU
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Figure 6. In our study, 19 CSU completed three visits in the
observational study and were included in the longitudinal analysis
of the clinical course of the disease. Of these, 9 patients had
improving CSU and 10 patients had persistent CSU. 
Serum histamine-releasing activity, spontaneous and anti-IgE
induced BHR at baseline did not differ between CSU subgroups in
relation to the clinical course of the disease (Figure 6A-C). 
BHR assays from peripheral blood basophils of CSU patients were
carried out at the Medway School of Pharmacy (Chatham
Maritime, UK). For basophil releasability assays, cells were
stimulated with anti-IgE antibodies (Sigma-Aldridge, UK) at
0.1ng/ml.
Red bar represents median values.
Pairwise comparisons between CSU subgroups in relation to the clinical course of disease was carried out by Mann-Whitney U test. 
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Abbrevations: 
BHR - Basophil histamine release
CSU - Chronic spontaneous urticaria
Appendix 4. Figure 7. Flow Cytometric Basophil Subpopulations in CSU Patient Subsets
Related to Basophil Releasability to Anti-IgE Stimulation 
B. Baseline CCR3+CD63+ cell counts in the
peripheral blood in relation to basophil
releasability subsets in CSU patients
A.  Baseline CCR3+CD123+ cell counts in the
peripheral blood in relation to basophil
releasability subsets in CSU patients
Figure 7. Flow cytometric basophil studies revealed that there was no statistically signimcant difference in absolute basophil counts determined by three gating
strategies across the pathophysiological subsets of CSU patients (Figures 7A-C). In now cytometric analysis, basophil gating was carried out using CCR3+CD123+,
CCR3+CD63+ and CD63+CD203c+ gating strategies on the same sample for each CSU patient. Absolute basophil counts were quantimed using BD Trucount beads.
Flow cytometric data were acquired by Miss Cheryl Barker using BD FACS CantoTM II instrument at the Norfolk & Norwich University Hospital (Norwich, UK). 22 CSU
patients were included in the analysis, 2 patients were excluded for technical reasons related to data acquisition. 
C. Baseline CD63+CD203c+ cell counts in 
the peripheral blood in relation to basophil
releasability subsets in CSU patients
Red bar represents median values.
Pairwise comparisons between the pathophysiological subsets were carried out using Mann-Whitney U test. 
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CSU - Chronic spontaneous urticaria
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Appendix 4. Figure 8. Baseline Absolute Basophil Counts in Peripheral Blood of CSU
Patients in relation to the Clinical Course of the Disease
A. CCR3+CD123+ cell counts in the
peripheral blood of CSU patients in relation
to the course of the disease 
C. CD63+CD203c+ cell counts in the
peripheral blood of CSU patients in relation
to the course of the disease 
B. CCR3+CD63+ cell counts in the peripheral
blood of CSU patients in relation to the
course of the disease 
Red bar represents median values.
Pairwise comparisons were carried out using Mann-Whitney U test. 
Improving CSU Persistent CSU
n=8 n=10
Improving CSU Persistent CSU
n=8 n=10
Improving CSU Persistent CSU
n=8 n=10
Abbrevations: 
CSU - Chronic spontaneous urticaria
CCR3 - Chemokine (C-C motif) receptor type 3
Figure 8. Flow cytometric basophil studies revealed that there was no statistically signimcant difference in absolute basophil counts determined by three gating
strategies between CSU subgroups related to the clinical course of disease (Figure 8A-C). In now cytometric analysis, basophil gating was carried out using
CCR3+CD123+, CCR3+CD63+ and CD63+CD203c+ gating strategies on the same sample for each CSU patient. Absolute basophil counts were quantimed using BD
Trucount beads. Flow cytometric data were acquired by Miss Cheryl Barker using BD FACS CantoTM II instrument at the Norfolk & Norwich University Hospital
(Norwich, UK). 18 CSU patients who completed three visits in the observational study were included in the analysis, one patient was excluded for technical reasons
related to data acquisition.
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Subgroup Analysis of CSU Patients with or without 
Serum Histamine-Releasing Activity
Baseline characteristics CSU patients without CSU patients with p-value*
serum histamine- serum histamine-
releasing activity (n=12) releasing activity (n=8)
CCR3+CD123+ cells/µl 77.63 (66.86,128.12) 145.78 (48.92,277.54) 0.4875
CCR3+CD63+ cells/µl 916.17 (672.45,1890.5) 604.2 (332.42,1011.62) 0.1649
CD63+CD203c+ cells/µl 40.86 (25.39,105.08) 36.95 (23.67,102.41) 0.7576
  Data analysis revealed a statistically signimcant difference in disease severity between CSU patients with and without serum histamine-releasing
activity (Mann-Whitney U test, p=0.0152). Serum histamine-releasing activity was measured by a serum-induced BHR at the RefLab (University of
Copenhagen, Denmark). For serum-induced BHR assay, a diagnostic cut-off of 16.5% was used to detect serum histamine-releasing activity in CSU patients
(Platzer M. et al, 2005). Data analysis for biomarkers was carried out in 22 CSU patients, now cytometry data analysis included 20 CSU patients. Two
patients were excluded from the now cytometry data analysis due to the technical reasons with data acquisition. 
Abbrevations: 
BHR - Basophil histamine release 
CSU - Chronic spontaneous urticaria
IQR - Interquartile range 
UAS7 - Urticaria activity score over 7 days
VAS - Visual analogue scale
Baseline characteristics CSU patients without CSU patients with p-value*
serum histamine- serum histamine-
releasing activity (n=14) releasing activity (n=8)
VAS for itch (mm) 53 (21,59) 39.5 (28,58.5) 0.7326
VAS for wealing (mm) 33.5 (4,52) 43 (37,62) 0.3054
UAS7 14 (2,20) 25.5 (20.5,28.5) 0.0152
Number of weals on examination 2 (0,47) 21.5 (2,33) 0.4442
Serum-induced BHR (% of total cellular histamine content) 0 (0,5) 42.5 (37.5,46) 0.0001
Spontaneous BHR (% of total cellular histamine content) 3.15 (2.4,5.5) 0 (0,6.25) 0.0804
Anti-IgE-induced BHR (% of total cellular histamine content) 8.45 (0,53.9) 0 (0,2.1) 0.2345
Pairwise comparisons were carried out
using Mann-Whitney U test.
Data are presented as median (IQR).
In our study, UAS7 score ranged 
from 0 to 49.
A. Baseline characteristics in CSU patients with or without serum histamine-releasing activity
B. Absolute counts of peripheral blood basophils identified by three gating
strategies on the same same in CSU patients
Figure 9.
Figure 9.
Appendix 4. Figure  . The Relationship between Disease Severity and Basophil
Subpopulations Gated by Three Different Gating Strategies in CSU Patients at Baseline
B. The relation between UAS7 and absolute
counts of CCR3+CD63+ cells in peripheral
blood in CSU patients
A. The relation between UAS7 and  absolute
counts of CCR3+CD123+ cells in peripheral
blood in CSU patients
C. The relation between UAS7 and absolute
counts of CD63+CD203c+ cells in peripheral
blood in CSU patient
Figure 10. Three gating strategies for peripheral blood basophils were applied on the same sample from each CSU patient. These gating strategies
included dual gating based on CCR3 and CD123, CCR3 and CD63, CD63 and CD203c. There was no correlation between UAS7 and absolute
counts of basophil subpopulations selected by three gating strategies in CSU patients (Figure 10A-C). Absolute basophil counts were enumerated
using BD Trucount beads. Flow cytometric data were acquired on BD FACS CantoTM II instrument by Miss Cheryl Barker at the Norfolk & Norwich
University Hospital (Norwich, UK). Data analysis included 20 CSU patients, two CSU patients were excluded from the analysis for technical reasons
with now cytometry data acquisition. 
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Abbrevations: 
CSU - Chronic spontaneous urticaria
CCR3 - chemokine (C-C motif) receptor type 3
Spearman correlation r = 0.09; p=0.6908 Spearman correlation r = 0.27; p = 0.2492
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Appendix 4. Figure . Biomarker Prospective Study - Patient KDP01
WEEK 0 (21.01.2009) WEEK 6 (02.03.2009) WEEK 12 (29.04.2009) SUMMARY
Period of Observation: 21.01.2009 - 29.04.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 12mm
VAS for wealing: 20mm
UAS7: 17
Number of weals: 24
Treatment: Cetirizine 10mg/day
Ranitidine 150mg/day
SERUM-INDUCED BHR: 41%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 809.14
Basophil purity: 0.067%
Spontaneous BHR: 83.3%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 8.3%
FLOW CYTOMETRY STUDIES
Baseline Baseline Baseline 
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 10%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 666.35
Basophil purity: 0.057%
Spontaneous BHR: 5.9%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 5.2%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 4%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 3777.77
Basophil purity: 0.33%
Spontaneous BHR: 5.6%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 2.9%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 157 cells/µL
CCR3+CD63+ basophils - 263 cells/µL
CD63+CD203c+ basophils - 22 cells/µL
CCR3+CD123+basophils - 102 cells/µL
CCR3+CD63+ basophils - 96 cells/µL
CD63+CD203c+ basophils - 22 cells/µL
CCR3+CD123+basophils - 250 cells/µL
CCR3+CD63+ basophils - 252 cells/µL
CD63+CD203c+ basophils - 34 cells/µL
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Appendix 4. Figure 12. Biomarker Prospective Study - Patient MHP02
CD63+CD203c+cells/µL  0.95%
CD63+CD203c+CCR3+ cells/µL
0.29% (30.78%)
Baseline Baseline Baseline
 
WEEK 0 (28.01.2009) WEEK 6 (05.03.2009) WEEK 12 (18.05.2009) SUMMARY
Period of Observation: 28.01.2009 - 18.05.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 15mm
VAS for wealing: 27mm
UAS7: 20
Number of weals: 2
Treatment: Fexofenadine 180mg/day
Montelukast 10mg/day
SERUM-INDUCED BHR: 5%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 16828.57
Basophil purity: 0.78%
Spontaneous BHR: 42.6%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 7.4%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 97mm
VAS for wealing: 86mm
UAS7: 34
Number of weals: 4
Treatment: Fexofenadine 180mg/day
Montelukast 10mg/day
Acrivastine 8mg PRN
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 346.11
Basophil purity: 0%
Spontaneous BHR: 6.1%
Optimal anti-IgE Concentration: 10µg/ml
Anti-IgE induced HR (1µg/ml): 12.3%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 18mm
VAS for wealing: 14mm
UAS7: 4
Number of weals:
Treatment: Fexofenadine 180mg/day
SERUM-INDUCED BHR: 1%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 5034.72
Basophil purity: 0.16%
Spontaneous BHR: 4%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 2.5%
FLOW CYTOMETRY STUDIES
CCR3+CD123+basophils -  92 cells/µL
CCR3+CD63+ basophils -  299 cells/µL
CD63+CD203c+ basophils -  27 cells/µL
CCR3+CD123+basophils -  249 cells/µL
CCR3+CD63+ basophils -  2860 cells/µL
CD63+CD203c+ basophils -  56 cells/µL
Appendix 4. Figure 13. Biomarker Prospective Study - Patient TBP03
Baseline Baseline Baseline 
WEEK 0 (13.03.2009) WEEK 6 (18.05.2009) WEEK 12 (07.09.2009) SUMMARY
Period of Observation: 13.03.2009 - 07.09.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 18mm
VAS for wealing: 36mm
UAS7: 25
Number of weals: 2
Treatment: Cetirizine 10mg BD
Fexofenadine 180mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 39%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): 0%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 83mm
VAS for wealing: 80mm
UAS7: 47
Number of weals: 40
Treatment: Cetirizine 10mg BD
Fexofenadine 180mg 4 tabs per day
SERUM-INDUCED BHR: 39%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): 0%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 52mm
VAS for wealing: 47mm
UAS7: 35
Number of weals: 28
Treatment: Cetirizine 10mg BD
Fexofenadine 180mg 4 tabs per day
Montelukast 10mg/day
SERUM-INDUCED BHR: 46%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): 0%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 57 cells/µL
CCR3+CD63+ basophils - 531 cells/µL
CD63+CD203c+ basophils - 24 cells/µL
CCR3+CD123+basophils -  223 cells/µL
CCR3+CD63+ basophils - 600 cells/µL
CD63+CD203c+ basophils - 46 cells/µL
CCR3+CD123+basophils -  373 cells/µL
CCR3+CD63+ basophils -  714 cells/µL
CD63+CD203c+ basophils -  189 cells/µL
Appendix 4. Figure 14. Biomarker Prospective Study - Patient RHP04
CD63+CD203c+cells/µL   0.67%
CD63+CD203c+CCR3+ cells/µL
0.16% (23.37%)
Baseline 
WEEK 0 (02.02.2009) SUMMARY
Period of Observation: 02.02.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 6mm
VAS for wealing: 4mm
UAS7: 2
Number of weals: 0
Treatment: Fexofenadine 180mg/day
SERUM-INDUCED BHR: 9%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 333.72
Basophil purity: 0.027%
Spontaneous BHR: 26.3%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): 0%
FLOW CYTOMETRY STUDIES
Appendix 4. Figure 15. Biomarker Prospective Study - Patient SRP05
Baseline Baseline Baseline 
WEEK 0 (09.03.2009) WEEK 6 (08.05.2009) WEEK 12 (08.09.2009) SUMMARY
Period of Observation: 09.03.2009 - 08.09.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 26mm
VAS for wealing: 28mm
UAS7: 2
Number of weals: 2
Treatment: No Medication
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 21142.85
Basophil purity: 1.21%
Spontaneous BHR: 4.9%
Optimal anti-IgE Concentration: NR
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: No Medication
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 23888.88
Basophil purity: 3.28%
Spontaneous BHR: 2.2%
Optimal anti-IgE Concentration: NR
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: 
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 30894.84
Basophil purity: 1.65%
Spontaneous BHR: 1.5%
Optimal anti-IgE Concentration: NR
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
NR = Non-responder
CCR3+CD123+ basophils - 61 cells/µL
CCR3+CD63+ basophils - 697 cells/µL
CD63+CD203c+ basophils - 26 cells/µL
CCR3+CD123+basophils -  217 cells/µL
CCR3+CD63+ basophils -  1037 cells/µL
CD63+CD203c+ basophils -  55 cells/µL
CCR3+CD123+basophils - 320  cells/µL
CCR3+CD63+ basophils -  1136 cells/µL
CD63+CD203c+ basophils -  136 cells/µL
Appendix 4. Figure 16. Biomarker Prospective Study - Patient RWP06
CD63+CD203c+cells/µL   1.22%
CD63+CD203c+CCR3+ cells/µL
0.41% (33.25%)
Baseline Baseline Baseline 
WEEK 0 (11.03.2009) WEEK 6 (06.07.2009) WEEK 12 (19.10.2009) SUMMARY
Period of Observation: 11.03.2009 - 19.10.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Fexofenadine 180mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 2265.6
Basophil purity: 0.143%
Spontaneous BHR: 2.4%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 58.1%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Fexofenadine 180mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 27200
Basophil purity: 1%
Spontaneous BHR: 1.1%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 38.4%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Loratadine 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 21988.23
Basophil purity: 1.15%
Spontaneous BHR: 7.7%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 31.3%
FLOW CYTOMETRY STUDIES
CCR3+CD123+basophils -  244 cells/µL
CCR3+CD63+ basophils -  412 cells/µL
CD63+CD203c+ basophils - 65 cells/µL
CCR3+CD123+basophils -  168 cells/µL
CCR3+CD63+ basophils -  454 cells/µL
CD63+CD203c+ basophils - 70 cells/µL
Appendix 4. Figure 17. Biomarker Prospective Study - Patient MMP07
Baseline Baseline Baseline 
WEEK 0 (16.03.2009) WEEK 6 (02.07.2009) WEEK 12 (23.10.2009) SUMMARY
Period of Observation: 16.03.2009 - 23.10.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 20657.14
Basophil purity: 1.45%
Spontaneous BHR: 2.7%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 53.9%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 51000
Basophil purity: 2.5%
Spontaneous BHR: 6.5%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 34.7%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 34000
Basophil purity: 2.3%
Spontaneous BHR: 5.3%
Optimal anti-IgE Concentration: 10µg/ml
Anti-IgE induced HR (1µg/ml): 19.1%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 61 cells/µL
CCR3+CD63+ basophils - 813 cells/µL
CD63+CD203c+ basophils - 48 cells/µL
CCR3+CD123+basophils -  242 cells/µL
CCR3+CD63+ basophils -  1079 cells/µL
CD63+CD203c+ basophils -  41 cells/µL
CCR3+CD123+basophils -  214 cells/µL
CCR3+CD63+ basophils -  568 cells/µL
CD63+CD203c+ basophils -  38 cells/µL
Appendix 4. Figure 18. Biomarker Prospective Study - Patient MLP08
Baseline Baseline Baseline 
WEEK 0 (18.03.2009) WEEK 6 (04.06.2009) WEEK 12 (09.09.2009) SUMMARY
Period of Observation: 18.03.2009 - 09.09.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 87mm
VAS for wealing: 89mm
UAS7: 32
Number of weals: 33
Treatment: Fexofenadine 180mg BD
Ranitidine 150mg BD
SERUM-INDUCED BHR: 6%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 11142.85
Basophil purity: 0.6%
Spontaneous BHR: 5.5%
Optimal anti-IgE Concentration: LR
Anti-IgE induced HR (0.1µg/ml): 9.5%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 56mm
VAS for wealing: 66mm
UAS7: 26
Number of weals: 18
Treatment: Fexofenadine 180mg BD
Ranitidine 150mg BD
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 6676.05
Basophil purity: 0.41%
Spontaneous BHR: 5.1%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 41.9%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 54mm
VAS for wealing: 62mm
UAS7: 35
Number of weals: 32
Treatment: Fexofenadine 180mg BD
Ranitidine 150mg BD
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 17600
Basophil purity: 0.84%
Spontaneous BHR: 6.2%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 38.1%
FLOW CYTOMETRY STUDIES
LR = Low responder
CCR3+CD123+ basophils - 36 cells/µL
CCR3+CD63+ basophils - 1024 cells/µL
CD63+CD203c+ basophils - 24 cells/µL
CCR3+CD123+basophils - 231 cells/µL
CCR3+CD63+ basophils -  1718 cells/µL
CD63+CD203c+ basophils -  68 cells/µL
Appendix 4. Figure 19. Biomarker Prospective Study - Patient ASP09
Baseline 
WEEK 0 (20.03.2009) SUMMARY
Period of Observation: 20.03.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 84mm
VAS for wealing: 70mm
UAS7: 19
Number of weals: 2
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: 36%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 629.33
Basophil purity: 0.078%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 39 cells/µL
CCR3+CD63+ basophils - 1113 cells/µL
CD63+CD203c+ basophils - 30 cells/µL
Appendix 4. Figure 20. Biomarker Prospective Study - Patient ISTP11
Baseline Baseline Baseline 
WEEK 0 (23.03.2009) WEEK 6 (11.07.2009) WEEK 12 (17.09.2009) SUMMARY
Period of Observation: 23.03.2009 - 17.09.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 21mm
VAS for wealing: 39mm
UAS7: 12
Number of weals: 0
Treatment: Cetirizine 10mg BD
SERUM-INDUCED BHR: 11%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 16314.28
Basophil purity: 1.023%
Spontaneous BHR: 17.3%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 48%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 6mm
UAS7: 12
Number of weals: 2
Treatment: Cetirizine 10mg BD
SERUM-INDUCED BHR: 18%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 39666.66
Basophil purity: 2.5%
Spontaneous BHR: 6.3%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 63.8%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 53mm
VAS for wealing: 74mm
UAS7: 28
Number of weals: 22
Treatment: Cetirizine 10mg BD
SERUM-INDUCED BHR: 18%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 14875
Basophil purity: 1%
Spontaneous BHR: 8.8%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 66.5%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 72 cells/µL
CCR3+CD63+ basophils - 1212 cells/µL
CD63+CD203c+ basophils - 90 cells/µL
CCR3+CD123+basophils -  245 cells/µL
CCR3+CD63+ basophils -  2990 cells/µL
CD63+CD203c+ basophils -  101 cells/µL
CCR3+CD123+basophils -  202 cells/µL
CCR3+CD63+ basophils -  857 cells/µL
CD63+CD203c+ basophils - 87 cells/µL
Appendix 4. Figure 21. Biomarker Prospective Study - Patient MWP12
Baseline Baseline Baseline 
WEEK 0 (22.04.2009) WEEK 6 (18.06.2009) WEEK 12 (08.10.2009) SUMMARY
Period of Observation: 22.04.2009 - 08.10.2009 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 38mm
VAS for wealing: 54mm
UAS7: 22
Number of weals: 32
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: 34%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 25mm
VAS for wealing: 38mm
UAS7: 22
Number of weals: 50
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: 46%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 2mm
UAS7: 3
Number of weals: 0
Treatment: Fexofenadine 180mg BD
SERUM-INDUCED BHR: ND
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 22.2%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 19 cells/µL
CCR3+CD63+ basophils - 401 cells/µL
CD63+CD203c+ basophils - 23 cells/µL
CCR3+CD123+basophils -  207 cells/µL
CCR3+CD63+ basophils -  497 cells/µL
CD63+CD203c+ basophils -  47 cells/µL
CCR3+CD123+basophils -  188 cells/µL
CCR3+CD63+ basophils -  2057 cells/µL
CD63+CD203c+ basophils -  95 cells/µL
Appendix 4. Figure 22. Biomarker Prospective Study - Patient JHP14
Baseline Baseline Baseline 
WEEK 0 (16.04.2010) WEEK 6 (05.07.2010) WEEK 12 (30.09.2010) SUMMARY
Period of Observation: 16.04.2010 - 30.09.2010 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 59mm
VAS for wealing: 48mm
UAS7: 20
Number of weals: 51
Treatment: Levocetirizine 5mg/day
Loratadine 10mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 30466.66
Basophil purity: 1.3%
Spontaneous BHR: 2.9%
Optimal anti-IgE Concentration: NR
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 94mm
VAS for wealing: 88mm
UAS7: 49
Number of weals: 25
Treatment: Levocetirizine 5mg/day
Loratadine 10mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 19.5%
Optimal anti-IgE Concentration: NR
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 74mm
VAS for wealing: 76mm
UAS7: 32
Number of weals: 56
Treatment: Levocetirizine 5mg/day
Loratadine 10mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 11941.17
Basophil purity: 0.9%
Spontaneous BHR: 6.7%
Optimal anti-IgE Concentration: NR
Anti-IgE induced HR (1µg/ml): N/A
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 71 cells/µL
CCR3+CD63+ basophils - 646 cells/µL
CD63+CD203c+ basophils - 27 cells/µL
CCR3+CD123+basophils -  134 cells/µL
CCR3+CD63+ basophils -  1221 cells/µL
CD63+CD203c+ basophils - 80  cells/µL
CCR3+CD123+basophils -  146 cells/µL
CCR3+CD63+ basophils -  3794 cells/µL
CD63+CD203c+ basophils -  96 cells/µL
Appendix 4. Figure 23. Biomarker Prospective Study - Patient JCP15
Baseline Baseline Baseline 
WEEK 0 (09.04.2010) WEEK 6 (23.06.2010) WEEK 12 (06.10.2010) SUMMARY
Period of Observation: 09.04.2010 - 06.10.2010 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 59mm
VAS for wealing: 0mm
UAS7: 2
Number of weals: 0
Treatment: Cetirizine 10mg PRN
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 30166.66
Basophil purity: 1.4%
Spontaneous BHR: 2.1%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 13.5%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 68mm
VAS for wealing: 0mm
UAS7: 2
Number of weals: 0
Treatment: Cetirizine 10mg PRN
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 21294.11
Basophil purity: 1.53%
Spontaneous BHR: 3.6%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 10.1%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 41mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Cetirizine 10mg PRN
Acrivastine 8mg PRN
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 26941.17
Basophil purity: 2.5%
Spontaneous BHR: 2.4%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 9.8%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 79 cells/µL
CCR3+CD63+ basophils - 1018 cells/µL
CD63+CD203c+ basophils - 33 cells/µL
CCR3+CD123+basophils - 82 cells/µL
CCR3+CD63+ basophils -  1064 cells/µL
CD63+CD203c+ basophils - 24 cells/µL
CCR3+CD123+basophils -  263 cells/µL
CCR3+CD63+ basophils -  694 cells/µL
CD63+CD203c+ basophils - 161 cells/µL
Appendix 4. Figure 24. Biomarker Prospective Study - Patient DPP16
Baseline Baseline Baseline 
WEEK 0 (29.09.2010) WEEK 6 (13.01.2011) WEEK 12 (06.04.2011) SUMMARY
Period of Observation: 29.09.2010 - 06.04.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 78mm
VAS for wealing: 73mm
UAS7: 19
Number of weals: 47
Treatment: Fexofenadine 180mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 16000
Basophil purity: 1.4%
Spontaneous BHR: 3%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 58.7%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 38mm
VAS for wealing: 43mm
UAS7: 28
Number of weals: 29
Treatment: Fexofenadine 180mg QD
Montelukast 10mg/day
SERUM-INDUCED BHR: 20%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 29687.5
Basophil purity: 1.7%
Spontaneous BHR: 9.5%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 44.9%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 43mm
VAS for wealing: 47mm
UAS7: 25
Number of weals: 25
Treatment: Fexofenadine 180mg QD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 11357.14
Basophil purity: 0.77%
Spontaneous BHR: 1.2%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 29.7%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 152 cells/µL
CCR3+CD63+ basophils - 3659 cells/µL
CD63+CD203c+ basophils - 135 cells/µL
CCR3+CD123+basophils -  218 cells/µL
CCR3+CD63+ basophils -  333 cells/µL
CD63+CD203c+ basophils -  58 cells/µL
CCR3+CD123+basophils -  184 cells/µL
CCR3+CD63+ basophils -  1584 cells/µL
CD63+CD203c+ basophils -  81 cells/µL
Appendix 4. Figure 25. Biomarker Prospective Study - Patient IHP17
Baseline Baseline Baseline 
WEEK 0 (29.03.2010) WEEK 6 (24.06.2010) WEEK 12 (28.09.2010) SUMMARY
Period of Observation: 29.03.2010 - 28.09.2010 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 52mm
VAS for wealing: 52mm
UAS7: 16
Number of weals: 62
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 9912.5
Basophil purity: 0.5%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 38mm
VAS for wealing: 44mm
UAS7: 28
Number of weals: 23
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 10588.24
Basophil purity: 0.94%
Spontaneous BHR: 15.8%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 18.8%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 32mm
VAS for wealing: 42mm
UAS7: 23
Number of weals: 43
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 10000
Basophil purity: 1%
Spontaneous BHR: 2.3%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 18.1%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 78 cells/µL
CCR3+CD63+ basophils - 398 cells/µL
CD63+CD203c+ basophils - 24 cells/µL
CCR3+CD123+basophils -  93 cells/µL
CCR3+CD63+ basophils -  3100 cells/µL
CD63+CD203c+ basophils -  33 cells/µL
CCR3+CD123+basophils - 356 cells/µL
CCR3+CD63+ basophils -  8835 cells/µL
CD63+CD203c+ basophils - 109 cells/µL
Appendix 4. Figure 26. Biomarker Prospective Study - Patient BSP19
Baseline Baseline Baseline 
WEEK 0 (05.10.2010) WEEK 6 (02.12.2010) WEEK 12 (11.04.2011) SUMMARY
Period of Observation: 05.10.2010 - 11.04.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 44mm
VAS for wealing: 42mm
UAS7: 28
Number of weals: 19
Treatment: Cetirizine 10mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 47%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 2000
Basophil purity: 0.14%
Spontaneous BHR: 12.5%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 14.8%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 6mm
VAS for wealing: 11mm
UAS7: 4
Number of weals: 1
Treatment: Cetirizine 10mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 1800
Basophil purity: 0.09%
Spontaneous BHR: 10%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 17.3%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 38mm
VAS for wealing: 44mm
UAS7: 30
Number of weals: 22
Treatment: Cetirizine 10mg BD
Montelukast 10mg/day
SERUM-INDUCED BHR: 21%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 3020.8
Basophil purity: 0.45%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 25%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 258 cells/µL
CCR3+CD63+ basophils - 238 cells/µL
CD63+CD203c+ basophils - 119 cells/µL
CCR3+CD123+basophils -  656 cells/µL
CCR3+CD63+ basophils -  717 cells/µL
CD63+CD203c+ basophils - 365 cells/µL
CCR3+CD123+basophils - 276 cells/µL
CCR3+CD63+ basophils -  1344 cells/µL
CD63+CD203c+ basophils -  274 cells/µL
Appendix 4. Figure 27. Biomarker Prospective Study - Patient GHP20
Baseline 
WEEK 0 (04.10.2010) SUMMARY
Period of Observation: 04.10.2010 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 41mm
VAS for wealing: 38mm
UAS7: 26
Number of weals: 34
Treatment: Fexofenadine 180mg BD
Doxepine 50mg nocte
SERUM-INDUCED BHR: 44%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 4000
Basophil purity: 0.34%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 372 cells/µL
CCR3+CD63+ basophils - 677 cells/µL
CD63+CD203c+ basophils - 324 cells/µL
Appendix 4. Figure 28. Biomarker Prospective Study - Patient DMP21
Baseline Baseline Baseline 
WEEK 0 (12.01.2011) WEEK 6 (07.04.2011) WEEK 12 (18.08.2011) SUMMARY
Period of Observation: 12.01.2011 - 18.08.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 54mm
VAS for wealing: 16mm
UAS7: 5
Number of weals: 0
Treatment: 
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 19125
Basophil purity: 0.93%
Spontaneous BHR: 3.3%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 68.1%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 9mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: 
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 24921.8
Basophil purity: 1.15%
Spontaneous BHR: 2.5%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 47.6%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 49mm
VAS for wealing: 28mm
UAS7: 0
Number of weals: 0
Treatment: 
SERUM-INDUCED BHR: 33%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 14263.15
Basophil purity: 1.3%
Spontaneous BHR: 5.7%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 49.2%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 127 cells/µL
CCR3+CD63+ basophils - 2568 cells/µL
CD63+CD203c+ basophils - 119 cells/µL
CCR3+CD123+basophils - 170 cells/µL
CCR3+CD63+ basophils -  1566 cells/µL
CD63+CD203c+ basophils - 97 cells/µL
CCR3+CD123+basophils -  518 cells/µL
CCR3+CD63+ basophils -  3037 cells/µL
CD63+CD203c+ basophils -  231 cells/µL
Appendix 4. Figure 29. Biomarker Prospective Study - Patient TMP21
Baseline Baseline Baseline 
WEEK 0 (12.01.2011) WEEK 6 (07.04.2011) WEEK 12 (18.08.2011) SUMMARY
Period of Observation: 12.01.2011 - 18.08.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 54mm
VAS for wealing: 51mm
UAS7: 24
Number of weals: 16
Treatment: No Medication
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 6577.61
Basophil purity: 0.3%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 99mm
VAS for wealing: 97mm
UAS7: 42
Number of weals: 108
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 7250
Basophil purity: 0.6%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 40%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 81mm
VAS for wealing: 83mm
UAS7: 37
Number of weals: 51
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 129 cells/µL
CCR3+CD63+ basophils - 744 cells/µL
CD63+CD203c+ basophils - 61 cells/µL
CCR3+CD123+basophils -  266 cells/µL
CCR3+CD63+ basophils -  1939 cells/µL
CD63+CD203c+ basophils -  141 cells/µL
CCR3+CD123+basophils -  365 cells/µL
CCR3+CD63+ basophils -  1211 cells/µL
CD63+CD203c+ basophils -  189 cells/µL
Appendix 4. Figure 30. Biomarker Prospective Study - Patient DBP23
Baseline Baseline Baseline 
WEEK 0 (11.01.2011) WEEK 6 (08.04.2011) WEEK 12 (11.07.2011) SUMMARY
Period of Observation: 11.01.2011 - 11.07.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 38mm
VAS for wealing: 44mm
UAS7: 29
Number of weals: 0
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 50%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 2125
Basophil purity: 0.14%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 73mm
VAS for wealing: 68mm
UAS7: 36
Number of weals: 12
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 38%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 1510.4
Basophil purity: 0.1%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 81mm
VAS for wealing: 78mm
UAS7: 27
Number of weals: 47
Treatment: Cetirizine 10mg/day
SERUM-INDUCED BHR: 46%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 7533.33
Basophil purity: 0.4%
Spontaneous BHR: 33.3%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 296 cells/µL
CCR3+CD63+ basophils - 3652 cells/µL
CD63+CD203c+ basophils - 85 cells/µL
CCR3+CD123+basophils -  192 cells/µL
CCR3+CD63+ basophils -  950 cells/µL
CD63+CD203c+ basophils -  82 cells/µL
CCR3+CD123+basophils -  541 cells/µL
CCR3+CD63+ basophils -  3320 cells/µL
CD63+CD203c+ basophils -  205 cells/µL
Appendix 4. Figure 31. Biomarker Prospective Study - Patient BHP24
Baseline 
WEEK 0 (10.01.2011) WEEK 6 (08.04.2011) WEEK 12 (28.06.2011) SUMMARY
Period of Observation: 10.01.2011 - 28.06.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 73mm
VAS for wealing: 75mm
UAS7: 36
Number of weals: 58
Treatment: Fexofenadine 180mg QD
Piriton 
Montelukast 10mg/day
Ranitidine 150mg/day
SERUM-INDUCED BHR: 45%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 0
Basophil purity: 0%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 67mm
VAS for wealing: 64mm
UAS7: 34
Number of weals: 52
Treatment: Fexofenadine 180mg QD
Piriton 
Montelukast 10mg/day
Ranitidine 150mg/day
SERUM-INDUCED BHR: 45%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 4531.2
Basophil purity: 0.24%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 88mm
VAS for wealing: 74mm
UAS7: 44
Number of weals: 27
Treatment: Fexofenadine 180mg QD
Piriton
Montelukast 10mg/day
Ranitidine 150mg/day
SERUM-INDUCED BHR: 48%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 4250
Basophil purity: 0.3%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 20%
FLOW CYTOMETRY STUDIES
Baseline Baseline 
CCR3+CD123+ basophils - 133 cells/µL
CCR3+CD63+ basophils - 909 cells/µL
CD63+CD203c+ basophils - 43 cells/µL
CCR3+CD123+basophils -  267 cells/µL
CCR3+CD63+ basophils -  883 cells/µL
CD63+CD203c+ basophils -  116 cells/µL
CCR3+CD123+basophils -  741 cells/µL
CCR3+CD63+ basophils - 3037 cells/µL
CD63+CD203c+ basophils -  295 cells/µL
Appendix 4. Figure 32. Biomarker Prospective Study - Patient DMP25
Baseline Baseline Baseline 
WEEK 0 (15.02.2011) WEEK 6 (06.04.2011) WEEK 12 (27.06.2011) SUMMARY
Period of Observation: 15.02.2011 - 27.06.2011 ASST: Positive
CLINICAL ASSESSMENT
VAS for itching/24hrs: 66mm
VAS for wealing: 56mm
UAS7: 27
Number of weals: 54
Treatment: Fexofenadine 180mg TD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 14666.66
Basophil purity: 0.75%
Spontaneous BHR: 5.1%
Optimal anti-IgE Concentration: N/A
Anti-IgE induced HR (1µg/ml): NR
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 38mm
VAS for wealing: 44mm
UAS7: 14
Number of weals: 9
Treatment: Fexofenadine 180mg QD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 2265.6
Basophil purity: 0.39%
Spontaneous BHR: 0%
Optimal anti-IgE Concentration: 1µg/ml
Anti-IgE induced HR (1µg/ml): 25%
FLOW CYTOMETRY STUDIES
CLINICAL ASSESSMENT
VAS for itching/24hrs: 0mm
VAS for wealing: 0mm
UAS7: 0
Number of weals: 0
Treatment: Fexofenadine 180mg QD
Montelukast 10mg/day
SERUM-INDUCED BHR: 0%
ANTI-IGE-INDUCED BHR:
Basophil count/ml of blood: 35789.47
Basophil purity: 2%
Spontaneous BHR: 4%
Optimal anti-IgE Concentration: 0.1µg/ml
Anti-IgE induced HR (1µg/ml): 10.3%
FLOW CYTOMETRY STUDIES
CCR3+CD123+ basophils - 303 cells/µL
CCR3+CD63+ basophils - 5480 cells/µL
CD63+CD203c+ basophils - 173 cells/µL
CCR3+CD123+basophils -  227 cells/µL
CCR3+CD63+ basophils -  3479 cells/µL
CD63+CD203c+ basophils -  89 cells/µL
CCR3+CD123+basophils - 786 cells/µL
CCR3+CD63+ basophils -  17558 cells/µL
CD63+CD203c+ basophils - 227 cells/µL
Appendix 5. Figure 1. Experimental Settings and a Compensation Matrix 
for Imaging Flow Cytometry Studies using ImagestreamX Imaging Flow Cytometer
A. Laser Power Settings B. The Compensation Matrix for a Fluorochrome
Combination: BV421, FITC, PE, CellMask Deep Red
Figure 1.  Data acquisition was performed using five excitation lasers (405nm, 488nm, 561nm, 658nm and 785nm) (Figure 1A). The laser power
adjustment was carried out using single stained controls. The spectral overlap for this multicolour panel is presented in Figure 1B. All samples were
acquired on an ImageStreamX imaging flow cytometer at X40 magnification using INSPIRE software. 
Abbrevations:
FITC - Fluorescein isothiocyanate
PE - Phycoerythrin
BV - Brilliant Violet
Catalogue No. Clone Antibody Conjugates Manufacturer
Appendix 5. Figure 2. Multicolour Staining Panels used in Imaging Flow Cytometry Studies
324611 NP4D6 anti-CD203c Brilliant Violet 421 Biolegend
557288 H5C6 anti-CD63-FITC BD Bioscience
310706 5E8 anti-CCR3-PE Biolegend
C10046 N/A CellMask™ Deep Red Plasma membrane stain Invitrogen
306017 6M6 anti-CD123 - Brilliant Violet 421 Biolegend
345808 2DI anti-CD45-FITC BD Bioscience
120-001-698 BM16 anti-CRTH2-PE MACS Miltenyi
12-0699-71 FN5D anti-CD69-PE e-Bioscience
336405 V1 - PL2 anti-CD61-PE Biolegend
340507 PAC-1 anti-PAC-1-FITC BD Bioscience
Figure 2.  Three multicolour staining panels were used for imaging now cytometry studies in human
basophils (Appendix 4, Figure 3A). Our main panel of antibodies (Panel 1) included anti-CD203c-Brillian
Violet 421, anti-CD63-FITC and anti-CCR3-PE. Panel 1 was used for comparative studies between gating
strategies for peripheral blood basophils. Panels 2 and 3 were used for basophil immunophenotyping
using surface basophil markers outlined in Table 5. Anti-CD123-Brilliant Violet 421, anti-CD45-FITC, anti-
CCR3-PE and CellMaskTM Deep Red Plasma membrane stain were used for generating a nuorescence
compensation matrix. Anti-CD61-PE and anti-PAC1-FITC were used to detect platelet markers (Table 2).
Laser  405nm 488nm 561nm 658nm 785nm
Fluorescent Dyes
Cell Suface Marker
Brilliant violet 421  FITC PE CellMask Deep Red
CD203c CD63 CCR3 SSC
A. Excitation Lasers, Fluorescent Dyes and Cell Surface Markers used in
Flow cytometry Studies for Human Basophils
Table 1. Antibody specificities, clones and suppliers for antibody conjugates
used in imaging flow cytometry studies for human basophils
Panel 1
Laser  405nm 488nm 561nm 658nm 785nm
Fluorescent Dyes
Cell Suface Marker
Brilliant violet 421  FITC PE CellMask Deep Red
CD203c CD63 CD69 SSC
Panel 3
Laser  405nm 488nm 561nm 658nm 785nm
Fluorescent Dyes
Cell Suface Marker
Brilliant violet 421  FITC PE CellMask Deep Red
CD203c CD63 CRTH2 SSC
Panel 2
Marker Biological Family Biological Function
CD203c
CD63
CCR3
CD123
CD45
CRTH2
CD69
CD61
PAC-1
E-NNP3 (family of ectoenzymes)
TM4 family (tetraspanin)
Seven-transmembrane G-protein coupled receptor
IL-3 receptor ƴ-chain
protein tyrosine phosphatase
Seven-transmembrane receptor
Type II transmembrane C-type lectin protein
integrin Ƶ-3
epitope on glycoprotein Iib/IIIa complex of activated platelets
Involved in hydrolysis of extracellular nucleotides
Expressed in late endosomes, role as an intracellular transport regulator 
C-C chemokine receptor for eotaxin, eotaxin 2, RANTES, MCP-2, -3 and -4
Receptor for IL-3, IL-5, GM-CSF
Leukocyte common antigen
PGD2 receptor
Early leukocyte activation antigen, early T cell activation antigen
A cluster of differentiation on thrombocytes
Fibrinogen binding site on activated platelets
Table 2. Surface cellular markers used in Imaging flow cytometry studies 
Abbrevations: 
FITC - Fluorescein isothiocyanate
PE - Phycoerythrin
CCR3 - Chemokine (C-C motif) receptor type 3
CRTH2 - Chemoattractant receptor-homologous molecule 
expressed on Th2 cells
SSC - Side scatter
PAC-1 - Platelet Activation Complex -1
IL-3 - Interleukin 3
IL-5 - Interleukin 5
GM-CSF - Granulocyte macrophage colony-stimulating factor
PGD2 - Prostaglandin D2
TM4 - Transmembrane 4 superfamily (tetraspanin family)
E-NNP3 - Ectonucleotide pyrophosphatase/phosphodiesterase 3 
 
Appendix 5. Figure 3. Data analysis with IDEAS® software for Imaging Flow Cytometry
Figure 3. Data exploration and analysis were carried out using IDEAS® software version 4.0 (Amnis Corporation).
Image 
Gallery
Analysis
Area
Data Analysis with IDEAS® Software
Appendix 5. Figure 4. Fixation and Single Stained Controls for Imaging Flow Cytometry
Basophil Studies in Healthy Subjects 
Fixation Controls
Unstained Unfixed Sample
Unstained Fixed Sample
Single Stained Controls
CellMask
CCR3-PE
CD123-BV 421
CD45-FITC
A
B
C
D
E
F
Figure 4. For the Image Stream studies the samples
were fixed with 0.0025% glutaraldehyde. Fixed and
unfixed unstained controls were used to assess the
background fluorescence of cells due to
autofluorescence or fixation-induced fluorescence
(Figures 4A-B). 
The laser power was set-up using single stained
controls for basophil markers used in our
fluorochrome panel. Spectral compensation matrix
for our four colour- fluorochrome panel was defined
by using single stained controls with the cell surface
markers characterised by marked expression on
human basophils (Figures 4C-F).
Spectral compensation was successfully applied to
single stained control samples (Figures 4C-E).
Enriched basophil preparations were prepared by
density gradient centrifugation using Ficoll-Paque
PREMIUM medium with density of 1.084g/ml (GE
Healthcare, UK). 
Abbrevations:
BV - Brilliant Violet
FITC - Fluorescein isothiocyanate
PE- Phycoerythrin
Appendix 5. Figure 5. FMO Gating for Peripheral Blood Basophils 
in Imaging Flow Cytometry Studies
Unstained
Sample
Unstained
Sample
Unstained
Sample
B
C
D
E
F
G
H
I
Figure 5. Three cellular surface markers (CD63,
CD203c and CCR3) were used for gating for
peripheral blood basophils in CSU patients. The
gates for cells expressing each of these markers
were demned by FMO gating. The gates on the dot
plots B, E and H were set at the 99th percentile of
the intensity of CD203c, CD63 and CCR3 to include
0.1% of cells in FMO gating controls (Figures 5B, 5E,
5F). 
Cells were considered positive for expression of
these markers if they displayed nuorescence
intensity above the level of the 99th percentile of
FMO gating controls. The percentages of positive
cells for each marker were assessed in fully stained
samples (Figures 5C, 5F, 5I) using a 5-colour now
cytometric panel (Figure 10A, Appendix 3). These
gates were also verimed on unstained samples
(Figures 5A, 5D, 5G).
Enriched basophil preparations were prepared by
density gradient centrifugation using Ficoll-Paque
PREMIUM medium with density of 1.084g/ml (GE
Healthcare, UK). 
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Abbrevations:
BV - Brilliant Violet
FITC - Fluorescein isothiocyanate
PE  - Phycoerythrin
FMO - Fluorescence minus one control
SSC - Side scatter
Area Size A measure of the size of the cell in square microns
Width Size Based on a bounding rectangle, the Width is the smaller side and the Height is the longer side of the rectangle 
Thickness Max Size A measure of the longest width of the cell image
Aspect Ratio Shape The ratio of the Minor Axis divided by the Major Axis
Circularity Shape The degree of the cell image deviation from a circle
Shape Ratio Shape The ratio of Thickness Min/ Length features 
Gradient RMS Texture A measure of changes of pixel values in the image to measure the focus quality of an image
Intensity Signal Strength A sum of the pixel intensities in the cell image, background subtracted. 
Appendix 5.Table 3. Glossary of Morphometric Features of IDEAS® Software 
used in Imaging Flow Cytometry Studies in Human Basophils
Feature Feature Category Definition
The Features are demned according to the IDEAS Image Data Exploration and Analysis Software User's Manual (Amnis Corporation, Version 5,0, September  2011). Table 3.
Appendix 5. Figure 6. Imaging Flow Cytometry Studies with KU812 Cell Line
Figure 6. The Image Stream imagery of unstained KU812 cell line fixed with glutaraldehyde. The brightfield (Channel 2) imagery demonstrates morphology of human leukaemic KU812 cell line. KU812 cell line
was derived from a patient with chronic myelogenous leukaemia in 1985 (Kishi K, 1985). In our studies, KU812 cells were used to study autofluorescence (Channels 3-4) induced by glutaraldehyde fixation. 
Appendix 5. Figure 7. Basophil Subpopulation with Surface Alterations in Imaging Flow
Cytometry Studies in a Healthy Subject using different 
Pre-analytical Sample Handling Protocols
A. Pre-analytical sample handling at 40C B. Pre-analytical sample handling at 370C
C
Figure 7. Sample handling protocols: the effects of sample pre-warming. After Ficoll density centrifugation, basophil-enriched leukocyte suspensions were subjected
to different sample handling protocols depending on the type of the experiment. For basophil immunophenotyping, sample handling and staining was performed at
4OC (Figures 7A, C). By contrast, optimal conditions for basophil functional studies include pre-warming of samples at 37OC before in vitro stimulation (Figures 7B,
D). Sample pre-warming at 37OC resulted in the increased percentage of basophil subpopulations with surface alterations which are morphologically identified as
cells with surface alterations. Basophil-enriched samples were prepared for analysis by density gradient centrifugation using Ficoll-Paque PREMIUM medium with
density of 1.084g/ml (GE Healthcare, UK). All samples were acquired on an ImageStreamX flow cytometer at x40 magnification using INSPIRE software. Data analysis
was carried out using IDEAS® software version 4.0 (Amnis Corporation). 
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Abbrevations:
CRTH2 - Chemoattractant receptor-homologous
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Appendix 5. Figure 8. Basophils with Surface Alterations in Cellular Aggregates in 
Imaging Flow Cytometry Studies  
Figure 8. Visual inspection of cellular aggregates revealed enhanced formation of cellular aggregates by basophil subpopulation
with surface alterations. Basophil-enriched samples were prepared for analysis by density gradient centrifugation using Ficoll-Paque
PREMIUM medium with density of 1.084g/ml (GE Healthcare, UK). All samples were acquired on an ImageStreamX flow cytometer at
x40 magnification using INSPIRE software. Data analysis was carried out using IDEAS® software version 4.0 (Amnis Corporation). 
Abbrevations:
CRTH2 - Chemoattractant receptor-homologous molecule expressed on Th2 cells
BF - Brightfield
BV - Brilliant Violet
FITC - Fluorescein isothiocyanate
PE- Phycoerythrin
SSC - Side Scatter
